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Abstract 
 
Medical Emergency Teams and Critical Care Outreach services are used to try to 
improve the care of patients in the ward environment. The limited treatment options 
include oxygen therapy, non-invasive ventilation, intravenous fluid therapy and in 
some institutions, inotropic support. The efficacy of such interventions is unclear.  
Four studies used both lung models and clinical observation to assess oxygen 
therapy. The model demonstrated a deterioration in oxygen delivery for the variable 
flow systems (Hudson mask, Hudson non-rebreather mask and nasal cannulae) as 
minute ventilation increased. Performance was relatively preserved for a venturi 
system and a high flow nasal cannula system (Vapotherm®).  
Peak inspiratory flow rates (PIFR) were assessed in patients with respiratory distress 
and matched controls. This demonstrated a higher median PIFR of 76.5 l.min-1 (IQR 
51.25 l.min-1) in patients when compared with controls, median of 30.00 (IQR 6.00 
l.min-1) (p<0.0001). 
The model was used to assess continuous positive airway pressure (CPAP) and 
showed no deterioration in oxygen delivery with respiratory rate, with or without a 
CPAP valve. When applied clinically in patients with acute respiratory distress, a 
significant increase in mean arterial oxygenation was observed on moving from a 
venturi mask (FiO2 0.6) to CPAP even without the valve, with a mean increase of 
PaO2 of 10.69 kPa (SD 5.14 kPa) p<0.0001 (n=53). The application of pressure with 
the CPAP valve did not increase this value over the 2 hours studied. 
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The use of intravenous fluid resuscitation (IFR) in the ward was audited. Delay in 
fluid administration, a wide range of volume delivered and a lack of monitoring were 
demonstrated. This audit produced the hypothesis that better monitoring of fluid 
therapy in the wards may reduce the volume delivered and incidence of 
complications. The final study thus compared a simple-to-use cardiac output monitor 
(Vigileo Flotrac®) to a dye-dilution system (LiDCO®). The two systems were found to 
have good agreement both in terms of cardiac output (bias positive in favour of the 
LiDCO 0.58 l.min-1). The upper 95% limit is +1.40 l.min-1 and the lower 95% limit, -
0.28 l.min-1). And stroke volume variation (Bias of 0 with 95% limits of +/- 3.3%). 
In conclusion this thesis demonstrates the impact of abnormal ventilation on oxygen 
delivered by some mask systems. It shows the efficacy of a tight fitting CPAP mask 
and high flow generator, but incidentally demonstrates that, at least initially it is the 
mask system rather than the pressure that has a pronounced effect on oxygenation.  
Fluid management in the ward patient appears poorly controlled and often excessive 
so may benefit from improved monitoring. To this end a cardiac output monitor that 
may be suitable for ward use has been shown to be comparable with a more 
established technique. 
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Chapter 1 
Introduction 
 
1.1 Introduction 
Since the turn of the millennium there has been an increasing focus in the delivery of 
intensive care-type management to ward patients. Evidence that sub-optimal care 
prior to death or ICU admission have led to the evolution of practices which demand 
a greater awareness of critical illness, it‟s recognition and treatment. It is believed 
that these developments will lead to better outcomes for acutely ill patients on the 
hospital wards. 
The current strategies in use fall into broadly two types. Firstly, the recognition of 
critical illness or its impending appearance and secondly interventions to attempt to 
treat or avert a deterioration which may prove life threatening.  
 
1.1.1 Recognition 
Recognition is important as it is believed that early intervention will lead to a 
reduction in morbidity and mortality. This belief has lead to the evolution of a variety 
of scoring systems to rapidly detect the acutely unwell patient on the ward.  
 
1.1.2 Intervention 
Acute interventions in this group of patients remain relatively limited. The techniques 
used are intended to stabilise physiology whilst further diagnostic and curative 
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strategies are employed. Essentially they remain oxygen delivery, non-invasive 
ventilatory support, fluid resuscitation, medical investigation e.g. arterial blood gas 
analysis, invasive monitoring and, in some centres, vasoactive circulatory support. 
One less obvious „intervention‟ is the recognition that significant deterioration in 
condition is part of a non-salvageable situation. This leads to discussion and 
completion of a „do not actively resuscitate‟ (DNAR) order. 
 Overseeing the greater part of these practices are the novel Critical Care Outreach 
Teams (CCOTs), Medical Emergency Teams (METs) or Patient-At-Risk teams 
(PARTs). They are the interface between the ICU and the wards and are 
increasingly employed by National Health Service (NHS) hospitals to perform or 
supervise the above.  
The zeal with which the adoption of such strategies has been embraced has little 
strong evidence. The use of these teams has been studied but only in a relatively 
small number of studies. Less attention, almost none has been focused on the 
interventions employed. Most commonly the evidence cited is literature gleaned from 
sources dissimilar to the scenarios commonly seen in ward patients. This produces 
several questions: Are acute interventions used on the wards employed 
appropriately? Does critical illness change their effectiveness? Should such 
interventions be adjusted in this heterogenous patient group? Are there further 
developments which can be employed to improve their delivery? 
The introduction to this thesis will discuss early recognition and means of 
intervention by teams to set the scene for studying what those teams do in practice 
once alerted to a problem. This thesis aims to address the interventions actually 
used in greater or lesser part. To do the subject justice there needs to be context 
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and so firstly the current evidence for initial care of the acutely ill ward patient and 
how this has evolved in recent years will be reviewed. The development of scoring 
systems and then of intervention teams will be discussed. This will lead to the 
questions asked by this thesis which are how the specific interventions then 
employed actually work.  
The null hypothesis is that: “Some of the interventions employed by outreach teams 
in the wards do not work as they are intended”. To achieve this end a series of in 
vitro and in vivo studies examining methods of oxygen delivery and fluid 
resuscitation; how they are delivered; whether the current modes of delivery are 
effective and whether their delivery conveys morbidity that could be improved upon. 
This chapter now summarises the current evidence for assessment and intervention 
in the acutely unwell ward patient. 
 
1.2 Sub-optimal care leads to increased mortality 
1.2.1 Evidence 
It is believed that on admission to ICU, patients referred from the general wards have 
often received sub-optimal care. To look more closely, McQuillan et al. Studied 100 
patients admitted to two intensive care units (ICU) in UK district general hospitals. 
The care received immediately prior to admission was assessed by two independent 
clinicians1.   
Adequacy of the management of airway, breathing, circulation, oxygen therapy and 
monitoring were graded on a linear analogue score. The results demonstrated 
agreement between the two assessors that 20% were well managed and 54% of 
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patients received sub-optimal care prior to admission. More patients received sub-
optimal care before admission to ICU in the intensive care non-survivors group 
(26/37, 70%), than in the survivors group (28/63, 44%) (p=0.04). 39% of patients had 
been admitted late in their clinical course. They concluded that sub-optimal care had 
definitely contributed to morbidity or mortality in 32.5%, probably in 21% and possibly 
in 32.5%. This important study was one of the first to critically appraise the influence 
of pre-admission care on ICU mortality. Other studies have shown similar results. 
Mcgloin et al. performed a similar study and found a highly significant increase in 
mortality in the group receiving sub-optimal care2. It would be fair to say that 
improvements in monitoring and clinical care of ward patients are important. It is also 
possible to hypothesise that such improvements should lead to a reduction in ICU 
admissions and mortality. 
This need for better ward care has led to the establishment of two important 
innovations over the last decade: 
1. Early warning scores to identify the patients at risk. 
2. Critical Care Outreach Teams (also known as METs, PARTs etc.) to 
implement curative activity through a relatively limited panoply of 
interventions.  
 
1.3 Early Warning Scores 
Early warning scores (EWS) are designed to identify and monitor ward patients who 
are, or may become critically ill. They usually summarise objective physiological 
variables, but can allow for subjective assessments such as concern by nursing staff. 
Single scoring values can be weighted appropriately to define a patient as critically 
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unwell. The sum of multiple physiological values can be also be used as such a tool. 
Repeated measurement of a score provides a method of following improvement or 
deterioration in the patient‟s physiology. The key aspect of these scoring systems is 
that they provide a trigger to a predefined response. This response is aimed at 
producing prompt and targeted intervention to prevent further deterioration and to 
effect clinical improvement. 
 
1.3.1 Physiological variables and Outcome 
Physiological abnormality is associated with poor outcomes. Critical care uses a 
variety of physiological models to predict outcome e.g. APACHE II3, Simplified Acute 
Physiology Score4 (SAPS II), Mortality Probability Models5 (MPM II). Highly abnormal 
physiological values when processed through these models predict poor outcome. 
Patients who suffer in-hospital cardiac arrest demonstrate abnormal physiological 
values in the hours prior to the event6, 7. The same is true for those who die on the 
wards8, 9. Goldhill et al. described the physiological values in ward patients over the 
preceding 24 hours prior to ICU admission10. They demonstrated that simple 
physiological markers such as heart rate, respiratory rate, oxygen saturations (SpO2) 
are commonly measured within this period and are often abnormal signifying 
significant critical illness. In subsequent work the same workers described how there 
is a direct relationship between the number of physiological abnormalities and 
mortality11. On a single day they recorded the following physiological markers for 433 
inpatients:  
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 Age 
 Respiratory rate 
 Heart rate 
 Systolic pressure 
 Temperature 
 Oxygen saturation 
 Inspired oxygen. 
 Level of consciousness 
 Urine output for catheterised patients 
They then followed them up for 30 days with death as the primary endpoint. 26 
patients died during the 30 day follow-up period. Of those 26, mortality increased 
with the number of physiological abnormalities. (0.7%: no abnormalities, 4.4%: 1 
abnormality, 9.2%: 2 abnormalities and 21.3%: 3 or more abnormalities, p<0.0001). 
They also observed that those patients that die are older and have been in hospital 
longer than those that survive12. Hospital mortality rose from 47.1% to 67.2% for ICU 
patients admitted after more than 3 days hospital admission. This is intuitive as such 
patients are likely to have clinical reasons for remaining in hospital. Indeed it could 
be argued that these reasons not only puts a patient at greater risk of acute 
deterioration, but also that the potential for recovery is lower.  
The clear relationship between abnormal physiological values and in-hospital 
mortality should permit early detection of incipient deterioration and lead to an option 
to intervene promptly in an attempt to arrest the process. It is rare for patients to die, 
require cardiopulmonary resuscitation or be admitted to ICU as an emergency, 
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without abnormal physiological values. Thus measuring these values, an early 
warning score or can be developed.  
 
1.3.2 History of Early Warning Scores 
Morgan et al first described a physiologically-based early warning score designed to 
identify critically ill ward patients (Table 1.1)13. Variations of this or the Modified Early 
Warning Score (MEWS) are commonly used as scoring systems in the UK. As can 
be seen from Table 1.1, zero points are awarded for normal physiological values. 
More points are awarded to increasingly abnormal variables. The results are totalled 
to give the score. These total scores are then used as triggers to an appropriate 
response. The nature of that response shall be discussed later. 
This early version of an early warning score has been updated and modified by 
various authors, each adjusting their scoring system to incorporate other 
physiological variables and/or varying the emphasis each variable has within an 
aggregate scoring system. Other writers choose a single parameter scoring system, 
where no summation is performed. Of the several stipulated variables, a trigger is 
made when one or more reaches a predetermined „extreme‟. In a recent review by 
the Intensive Care Audit and Research Centre (ICNARC), of 35 papers pertaining to 
early warning scores, 25 different tools were described. 13 utilised a single 
parameter method, 11, aggregate scoring systems and one described a multiple 
parameter method similar to the single tool, but requiring at least two or more 
variables to be abnormal14. It is clear that there are many early warning scores in 
circulation.  
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Table 1.1 Early Warning Score (EWS) after Morgan et al.
13
 
Score 3 2 1 0 1 2 3 
Heart Rate: 
Beats per 
minute 
 ≤40 41-50 51-100 
101-
110 
111-
130 
≥130 
Systolic 
Blood 
Pressure: 
mmHg 
≤70 71-80 81-100 
101-
199 
 ≥200  
Respiratory 
rate: breaths 
per minute 
 ≤8  9-14 15-20 21-29 ≥30 
Temperature: 
oC 
 ≤35 
35.1-
36.5 
36.6-
37.4 
≥37.5   
Central 
nervous 
system: 
AVPU 
   A V P U 
 
 
1.3.3 Validation  
Assessment of these early warning scoring systems is important in order to validate 
their use. They must be sensitive enough to distinguish those that require a 
response, from those that do not. This is not only important from a resources point of 
view, i.e. avoiding inappropriate calls to a patient that has a low probability of 
deterioration or ICU admission, but also avoiding undue confusion or stress to the 
patient concerned. It is interesting that 25 systems have been described, implying 
therefore that not one system is applicable to all. Indeed the emphasis put on each 
of the physiological variables included may differ depending on the nature of the 
patient group or the environment in which they are cared for. However, a recent 
report by the Royal College of Physicians into acute medicine recommends the 
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adoption of one early warning score across the National Health Service (NHS); the 
so-called NHS Early Warning or NEW score15. Interestingly the National Institute for 
Health and Clinical Effectiveness (NICE), whilst endorsing the use of early warning 
scores were unable to recommend either the NEW score or another version for the 
NHS in general16.  
Validation of early warning scores has been undertaken by several authors. 
Hodgetts et al. examined physiological variables of 118 patients who suffered 
cardiac arrest compared to 132 controls and then formulated activation criteria for a 
MET17. This system incorporated the eight variables that had been identified as 
significantly different between the two groups, namely: increased respiratory rate, 
new shortness of breath, low SpO2, abnormal heart rate, chest pain, low systolic 
blood pressure, abnormal temperature and the subjective concern of a doctor or 
nurse.  An expert panel weighted the scores depending on the odds ratio for cardiac 
arrest thus developing the cumulative scoring method to activate the MET. Applying 
this system to the patients in the study, they demonstrated that a score of 8 on their 
scale was associated with a sensitivity of 52% and a specificity of 99% for cardiac 
arrest. Lower scores of 5-7 demonstrated a sensitivity of 84% and specificity of 89%. 
However, they choose not to use this level as an MET activator. It is inferred that 
resource limitations prevented the MET team from attending all such patients, 
though they do not comment on the likely burden that such a commitment would 
have incurred. They chose cardiac arrest as the endpoint, but did not comment on 
ICU admission in both groups. This study was retrospective and of a small number, 
however it was the first attempt to derive a scoring system from clinical data, rather 
than others that have been subjectively derived from clinical experience. Problems 
with this approach are highlighted by the presence of three different aspects of blood 
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pressure change within the scoring system. All „necessarily‟ included as each was 
demonstrated to be independently associated with cardiac arrest; but significantly 
adding to the complexity of scoring in any given patient. Simplicity of assessment, 
calculation and recording are important in the success of these systems in 
stimulating the appropriate response to clinical change. Burdensome complexity is 
likely to lead to poor documentation and reduce the scoring system‟s effectiveness in 
defining those in need. 
Subjective systems have also been assessed for their validity in identifying patients 
who suffer cardiac arrest, are admitted to ICU or die7, 11, 18, 19. Though 
methodologically different, they all reiterate the importance of monitoring 
physiological variables to detect patients at risk of deterioration. The ICNARC 
systematic review of early warning scoring in 2007 looked at datasets obtained from 
31 of 92 UK hospitals that collected data from their early warning scoring14. 15 
systems were identified and the data was analysed based on the composite end 
points of death, admission to ICU, DNAR orders and cardiac arrest – the „presence 
of established critical illness‟. These endpoints occurred between 5.7% and 64.7% of 
patients, depending on hospital. Median sensitivities were low 43% (inter-quartile 
range 25.4-69.2) with median positive predictive values of 36.7% (inter-quartile 
range 29.3 – 43.8%). Median specificity was 89.5% (inter-quartile range 64.2-95.7%) 
with a negative predictive value of 94.3% (inter-quartile range 89.5 – 97.0%). This 
implies that none of the early warning systems achieved the requirements of a level 
1 clinical decision rule. Such a rule is defined as „that which has been validated for 
use in a wide variety of settings with confidence that it can change clinical behaviour 
and improve patient outcomes‟20. This appears disappointing, however the sample 
sizes were small and not all the possible outcomes comprising the composite 
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outcomes were recorded. There is no data on response to a trigger and/or any 
interventions. This would introduce significant bias.  
Nevertheless, most clinicians would agree that early warning scores have value in 
identifying patients at risk. They increase the awareness of critical illness amongst 
clinical staff and permit a closer working relationship between those with appropriate 
skills in the care of such patients. They are thus an advance on what was previous 
practice. Early warning scores are valuable in themselves, but it is their synonym, 
„Track and Trigger Scores‟ that crystallises there clinical use. The appropriate 
response to an abnormal score is their value and the nature of that response is now 
discussed.  
 
1.4 Early intervention improves outcome 
1.4.1  Early Goal Directed Therapy 
Having identified those as critically ill, or at risk of developing critical illness, 
institution of clinical management is the next step. There is now strong evidence that 
early aggressive management of certain patients with abnormal physiological 
variables improves outcome. Almost no work has been published from the ward 
environment. However information can be extrapolated from other areas. The most 
well conducted trial to evaluate this has been conducted in the Emergency Room of 
an American tertiary referral centre. Published in 2001, Rivers et al. recruited 263 
patients with septic shock and randomised them to receive standard care or „early 
goal-directed therapy‟ (EGDT). Septic shock was defined as, two of four criteria of 
the systemic inflammatory response (Table 1.2) and either a blood pressure below 
90mmHg after 20-30 ml.kg-1 crystalloid resuscitation or a blood lactate concentration 
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of ≥4 mmol.l-1. Both groups received arterial and central venous cannulation. 
Thereafter, the standard care group were managed at the clinician‟s discretion, with 
or without critical care consultation and were admitted to the next available inpatient 
bed. The EGDT group had their central venous oxygenation (ScvO2) measured by 
spectrophotometry and were treated for at least 6 hours in the emergency 
department prior to transfer to the intensive care unit under the care of the critical 
care physicians. Their haemodynamics were managed by a strict protocol based on 
measurements of central venous pressure (CVP), mean arterial pressure (MAP), 
Lactate and ScvO2 (Figure 1.1).  
 
Table 1.2 ACCP/SCCM Consensus Conference Definition of the Systemic Inflammatory 
Response Syndrome.
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Variable Criteria 
Temperature ≤ 36oC or ≥ 38oC 
Heart Rate ≥ 90 beats per minute 
Respiratory ≥ 20 breaths per minute or PaCO2 ≤ 32 mmHg 
White Blood Cell Count ≥ 12,000 cells.mm-3 or ≤ 4000 cells.mm-3 or >10 % 
bands 
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Figure 1.1 The Early goal directed therapy protocol (reproduced with permission)
22
 
 
The results showed well matched groups with a predominance of pneumonia and 
urosepsis. The EGDT group demonstrated a more rapid improvement of MAP, 
ScvO2, pH, base deficit, and serum lactate. The appearance of multi-organ 
dysfunction syndrome was less at 72 hours, and most remarkably of all mortality was 
reduced from 61% in the standard care group to 40% in the EGDT group at 28 days 
(RR 0.58 95% CI 0.39-0.87: p=0.01). Mortality was also significantly different at 60 
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days, standard care 70%, EGDT 50% (RR0.67 95% CI 0.46-0.96: p=0.03). The 
patients in the EGDT group received significantly more fluid, red cell transfusions 
and inotropic support during the initial 6 hour period. However in the ensuing 7-72 
hours the standard care group received significantly more fluid, red cell transfusion, 
vasopressor support and a greater incidence of mechanical ventilation. The total fluid 
requirements were similar for the 72 hour period of study from recruitment (p=0.73) 
as was the use of inotropic agents (p=0.15).  
This study has had a large impact on the care of critically unwell patients with septic 
shock. This is interesting as previous studies had not been able to show significant 
benefits of goal-directed therapy in the ICU environment. Gattinoni et al were unable 
to demonstrate a difference in mortality between three groups of general adult 
intensive care patients23. The first group had treatment aimed at a normal cardiac 
index, the second a „supra-normal‟ cardiac index and the third to maintain the mixed 
venous oxygen saturations at >70% (or a difference of <20% with arterial oxygen 
saturation). Whilst this is not a direct comparison with Rivers et al. in methodology or 
patient groups, the mortality rate was similar for the normal cardiac index group. This 
was achieved in 94.3% of patients within 6 hours of randomisation, which was 
encouraged as soon as possible after meeting the inclusion criteria (Simplified Acute 
Physiology Score (SAPS) of >11). This study only adds to the evidence that 
monitoring and aggressive manipulation of the cardiovascular system in critical 
illness to optimise haemodynamic variables can lead to an improvement in survival, 
but the need to increase haemodynamics and oxygen delivery to above normal 
levels does not confer any benefit. A phenomenon also detected by Hayes et al. who 
found supra-normal physiology to be potentially detrimental24. 
40 
 
Physiologically, goal-directed therapy is likely to improve outcome by the restoration 
of oxygen delivery to the tissues via control of hypovolaemia and the restoration of 
appropriate haemodynamics. Early delivery of care prevents the progression of the 
pathological processes involved in shock and aims to head off the associated cellular 
and thus organ dysfunction, whilst curative strategies such as surgery or antibiotics 
facilitate cure. Rivers et al accentuates the need for a rapid response to the 
development of shock, which as an endpoint prior to cardiac arrest can be detected 
and potentially reversed improving survival. However, as shall be seen in section 
1.4.3, there has been a desire amongst the acute medicine community to embrace 
the findings of Rivers et al. and then extrapolate its methodology to all those patients 
with deranged haemodynamics and resultant shock.  
It is important to note that patients were recruited in the emergency department of a 
large tertiary referral hospital soon after hospital admission. The subjects also had a 
specific diagnosis (septic shock) to account for the deranged physiology. The 
interventions are therefore specific to this patient population in a relatively high-tech 
environment. It has not been proved that a similar approach could be extrapolated to 
the care of the ward patient, with a wide range of potential problems particularly if the 
deterioration may occur at any time over several days from admission. Early 
identification, a specific diagnosis, a high concentration of staff and technology are 
all less obvious in the ward. An early warning score may identify the a ward patient 
as suffering similar physiological embarrassment as a subject in the Rivers et al. 
paper, but should it receive the same response? This is not clear. 
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1.4.2 Impact of Critical Care Skills 
In the Rivers et al. study, the patients in the EGDT group were cared for by intensive 
care physicians on an intensive care unit. Whilst it is likely that the benefits of EGDT 
are due to the interventions dictated by the protocol, some benefit may be derived 
from the skills and training of the medical staff.  There is evidence that the 
environment in which septic shock is detected and initially treated affects outcome. 
Lundberg et al. published a small retrospective study of 41 patients with septic shock 
and related their outcome to their location when the shock first developed25. 10/41 
patients developed septic shock on the wards with a mortality of 70% at 28 days. 
12/31 (39%) of the patients developing septic shock in the ICU died (OR 3.76 
p=0.17). Interestingly the ICU patients had higher APACHE II scores and were older 
yet more survived. Though there were large differences in median time to first fluid 
bolus (15 mins ICU vs 27 mins ward), median time to vasoactive support (22.5 mins 
vs 310 mins) and a median delay of 67 minutes for admission to ICU from the ward, 
none of these factors proved to be significant predicators of mortality in univariate 
analysis. The study is clearly flawed by its small size, retrospective nature and also 
the patient groups examined did not reflect common patterns of infection (33% of 
ward patients had fungaemia). However it may suggest that the closer monitored, 
highly skilled ICU environment could confer an advantage in detection and treatment 
of septic shock above that of the ward environment. It is certainly a belief that 
underpins some ICU admissions, though not only those that are suffering septic 
shock: “They‟ll be in a better environment if they go off”. 
It is true that the ICU has physicians and nursing staff skilled in the care of the 
critically ill. There is more frequent monitoring of vital signs and other modes of 
assessment of haemodynamics. In contrast, general ward patients do not receive the 
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same level of such assessments and monitoring. This is likely to result in a 
difference in the time to detection of shock onset. This is crucial as it is established 
that prolonged periods of hypoperfusion of the major organs gives rise to multiple 
organ dysfunction and/or failure with an associated higher rate of morbidity and 
mortality26, 27.  
The common threads of early detection, early goal-directed therapy and appropriate 
environment and monitoring, has bred a desire to develop protocols/guidelines to 
care for all patients at risk or displaying signs of critical illness. They combine the 
evidence for early warning scores and early intervention, most often Rivers et al. as 
a standard of care. Many of the patients for who the guidelines/protocols are 
designed would not fit those described either by the literature surrounding early 
warning scores, or Rivers et al. However as an example I present the most widely 
accepted example to date. 
1.4.3 The Surviving Sepsis Campaign Guidelines28, 29 
These guidelines were published by in 2004 and updated in 2008 following the 
Barcelona Declaration of 200227, 30. This stated the world-wide aim to affect a 25% 
relative reduction of mortality from sepsis in five years. Constructed using the Delphi 
method of categorising scientific evidence and input from consensus conferences, 
professional bodies and expert opinion, it delivers a set of evidence based guidelines 
as „an international effort to increase awareness and improve outcomes in severe 
sepsis.‟ It recognises the significance of severe sepsis on mortality and morbidity; 
that improvements can be made by „protocolisation‟ of care; and though severe 
sepsis is most commonly treated in the ICU, the paper makes the point that „... the 
committee believes that currently, the greatest outcome improvement can be made 
through education and process change for those caring for severe sepsis patients in 
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the non-ICU setting and across the spectrum of acute care...‟. However further 
discussion of what a non-ICU environment is, is sadly lacking. Would this just mean 
other acute care settings such as the Accident and Emergency department, 
operating theatres etc.? Or would it even apply to the longer term inpatient, General 
Practice etc.? 
The recommendations are extensive; however the initial resuscitation phase is 
based entirely on the Rivers et al. data. Within 6 hours a patient needs to have been 
resuscitated with intravenous fluid with or without inotropic support aiming for a 
central venous pressure (CVP) of ≥ 8 mmHg, a MAP of ≥ 65 mmHg and an ScvO2 of 
≥70% and to use dobutamine if the above are not achieved. They also suggest 
considering the use of vasopressors, corticosteroids and activated Protein C as part 
of cardiovascular support. In the sections under diagnosis and antibiotic therapy the 
guidelines recommend that suitable diagnostic cultures should be performed and a 
first dose of antibiotics should be given within the first hour of diagnosis of severe 
sepsis. This recommendation is based predominantly on a study by Kumar et al. in 
which the data from 2731 patients with septic shock were retrospectively analysed31. 
2154 patients received antimicrobial therapy and of those that were given a dose 
within one hour of the onset of hypotension 78.9% survived to hospital discharge. 
Each subsequent hour‟s delay over the following 6 hours conferred a mean increase 
in mortality of 7.5%. There are other recommendations within the surviving sepsis 
campaign, but those highlighted here once again demonstrate the need for early 
detection of severe (critical) illness and its early and appropriately monitored 
treatment. However the paucity of good evidence in this field means that the 
guidelines are limited to one or two trials and significant consensus opinion from 
predominantly intensive care specialists. The guidelines may be valuable, but how 
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applicable to all patients across the spectrum of healthcare is questionable. Yet in 
many UK general hospitals they have been accepted as the standard of care for all 
patients „unwell‟ with evidence of infection and frequently form the basis for the 
resuscitation of other patient groups. Once again this highlights the need to examine 
the specific interventions used in the far less clearly defined circumstances of the 
hospital general ward.  
 
1.5 Medical Emergency and Critical Care Outreach Teams 
If it is agreed that early detection and intervention is beneficial, a method is required 
to deliver this approach. Goldhill et al. demonstrated that the current ward 
environment cannot convey this intensity10. The large resource burden and potential 
hazards of ICUs prevent all patients being admitted to such high level environments. 
Thus novel techniques have evolved; in particular the MET/CCOT model. 
In the UK and most developed nations the intensive care unit is usually centralised 
within a hospital, utilising a great deal of healthcare resource for a relatively small 
number of patients when compared to the total number within the institution. This 
„Ivory Tower‟ concept, in which a salvage team attends from the ICU, removes a 
critical care patient (often in extremis) from the ward, Accident and Emergency 
department etc. and returns to the unit from which they came, is easily recognisable. 
The patient is then cared for and, if they survive, returns to the ward area „fixed‟ with 
little or no follow up or support for either medical or nursing staff. 
 A new „without walls‟ model in which there is transfer of critical care knowledge, 
skills and technology to the general ward environment has evolved over the last two 
decades. This aims to improve the early recognition of critical ill patients and attempt 
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intervention to prevent clinical deterioration and ICU admission. If ICU admission is 
unavoidable then this model aims to ensure timely transfer. This ward-based support 
is in place to oversee the delivery of medical interventions which may be more usual 
in a level 2/3 environment (Table 1.3). What can be achieved on the wards in such a 
model is that which this thesis will attempt to examine more closely.  
 
Table 1.3 'Comprehensive Critical Care' Classification of Critical Care Patients According to 
Clinical Need
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Level of 
Care 
Description 
Level 0 Patients whose needs can be met through normal ward care in an 
acute hospital. 
Level 1 Patients at risk of their condition deteriorating, or those recently 
relocated from higher levels of care whose needs can be met on an 
acute ward with additional advice and support from the critical care 
team. 
Level 2 Patients requiring more detailed observation or intervention including 
support for a single failing organ system or postoperative care, and 
those stepping down from higher levels of care. 
Level 3 Patients requiring advanced respiratory support alone or basic 
respiratory support together with support of at least two organ 
systems. This level includes all complex patients requiring support 
for multi-organ failure. 
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A second aspect of clinical care is post-ICU care to ensure safe discharges and in so 
doing reduce the risk of re-admission to the ICU. Readmission to ICU is associated 
increase in risk of mortality as demonstrated in a systematic review by Rosenberg  et 
al. in 200032. This group demonstrated that the mean readmission rate in both 
Europe and the USA is approximately 7% (range 4-14%) and that mortality in these 
patients is between 2 and 10 times that of patients who survive ICU without 
readmission. This novel approach to critical care outside of the „Ivory Tower‟ is 
commonly referred to as critical care outreach (CCO). 
 
1.5.1 History of Critical Care Outreach 
Historically CCO evolved from the METs developed in Liverpool, New South Wales, 
Australia by Hillman and colleagues from 1989 and more widely distributed through 
Australia in the 1990s34. In this guise a team containing senior medical and nursing 
staff from critical care are available to be called by any member of the hospital staff 
when a trigger is reached, or if they were otherwise concerned. The team will then 
attend and intervene as appropriate. However akin to a cardiac arrest team, the 
team will disperse once the initial crisis has been managed and the ongoing 
responsibility will return to the attending physicians after a joint decision is made as 
to their ongoing care. On the other hand if the patient requires critical care then 
appropriate arrangements are made.  
In the United Kingdom a similar system has evolved, namely the Critical Care 
Outreach Team (CCOT). Born out of the Audit Commission‟s document „Critical to 
Success‟ in 1999, development of CCOTs was recommended as high priority within 
acute hospitals35. The report recognised that there were organisational and 
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economic imperatives for the development of CCOTs in addition to the clinical 
indications. What was not discussed was what these teams should do in the way of 
meaningful intervention.  
 
1.5.2  Evolution of Healthcare Practice 
Changes in working practices and levels of staffing, particularly amongst the medical 
staff, were recognised as contributory to the shortcomings of ward care35. It was 
observed that a junior doctor in 1999 could be responsible for up to 100 ward 
patients and that the care they could expect to deliver would likely be reactive rather 
than proactive. Medical training has changed since that time. The introduction of 
firstly Calman, and subsequently „Modernising Medical Careers‟ run-through training, 
both emphasising shorter training times and earlier specialisation, are believed to be 
compromising exposure of trainee doctors to the acutely unwell and their ability to 
recognise and treat36-40. Furthermore the reduction in working hours required by the 
European Working Time Directive reduces education time, fragments the medical 
team and can lead to organisational difficulties particularly regarding medical 
handover. The potential problems for continuity of care are great and have been 
recognised by both the Royal College of Physicians and the National Institute for 
Health and Clinical Excellence15, 16. 
Hospitals are also evolving driven mainly by economic imperatives. The NHS 
organisation was once many local hospitals, but now there is increasing 
centralisation of acute hospital services within larger communities. Ambulatory care, 
primary care and care in other institutions now takes the greater part of chronic and 
some acute disease management36, 41, 42. This leads to a greater concentration of 
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critically ill patients within the acute hospital requiring greater use of critical care 
services. However the cost of level 3 care is such that enormous expansion of such 
services is not feasible and so other ways of maintaining a level of care for the 
critically unwell needed to be developed. 
 
1.5.3 The UK Critical Care Outreach Model  
The principles of UK CCOTs were laid out in the Department of Health document 
Comprehensive Critical Care: A review of adult critical care services in 200033. CCO 
services had 3 key aims: 
1. To avert admissions by identifying patients who are deteriorating and either 
helping to prevent admission or ensuring that admission to a critical care bed 
happens in a timely manner to ensure best outcome. 
2. To enable discharges by supporting the continuing recovery of discharged 
patients on wards and post discharge from hospital, and their relatives and 
friends. 
3. To share critical care skills with staff in ward and the community ensuring 
enhancement of training opportunities and skills practice and to use 
information gathered from the ward and community to improve critical care 
services for patients and relatives. 
Since that time inclusion of research and audit as well as post-hospital discharge 
care/clinics have also fallen into the remit of CCOTs43. In short by exporting ICU 
capability to the ward, the CCOTs aim is to reverse over-reliance on the ICU team to 
remove a critical care problem. In contrast they attempt to engender a „can do‟ 
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attitude to the general ward staff by supporting, educating and training, as well as 
delivering care for the critically ill patient using their own skills and attributes. 
CCOT development was initially funded centrally, such was the political desire to see 
it introduced. With only the above principles espoused, it was left to individual trusts 
and critical care networks to develop their own services. Guidelines on the 
introduction of CCOTs were published by the Intensive Care Society (ICS) and in 
terms of membership of the CCOT, they recommended that:44 
 Medical input should comprise of sessions by critical care consultants and 
trainee medical cover for critical care with no other responsibilities to the ICU 
itself. 
 Nursing input should consist of critical care nursing staff, with a possible lead 
role for a nurse consultant or clinical nurse specialist, supported by other 
appropriately trained nurses. 
 Physiotherapy and other allied health professions such as Speech and 
Language therapists may also be included in the team. 
The ICS also recommended that CCOTs should operate 24 hours a day as 
emergencies do not respect working hours, but they also recognised that 
recruitment, and funding may prove difficult in the initial stages. 
In 2005, the National Confidential Enquiry into Patient Outcome and Death 
(NCEPOD) published the report „An acute problem?‟  This examined the care of 
acute medical ICU admissions in the UK excepting Scotland40. They identified 261 
hospitals in the England, Wales and Northern Ireland with level 3 adult beds. 226 
hospitals participated in a survey via posted questionnaires. They retrospectively 
looked at the pre-admission care received by all the adults admitted to general ICUs 
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in June 2003. Three questionnaires were sent, one to the referring physician, one to 
the admitting ICU consultant and an organisational questionnaire to each hospital. It 
reaffirmed the appearance of abnormal physiological variables in the hours 
preceding deterioration and whilst 73% of trusts used early warning scores, 
instructions for parameters triggering patient review were rarely documented. 
Consultant involvement, both before and after admission to ICU was low, with 57% 
of ICU referrals being made without a consultant physician knowing. In terms of 
CCOTs, the report documented that 44% of the UK hospitals that responded did not 
provide outreach service and there was geographical inequality in its provision. The 
hospitals failed to show any improvements in early recognition and intervention in 
critically ill patients and there was no difference between hospitals with or without 
CCOTs in the appropriateness or timeliness of admission to ICU or ICU mortality. 
This report is subjective and retrospective, so it is difficult to draw any strong 
conclusions about the results. It did demonstrate that outreach provision had not 
been ubiquitously entertained by all despite its support from both government and 
professional bodies. In 2007, McDonnell et al. published another survey of 
implementation of outreach services in England performed in 200545. They received 
replies from 191/239 (79.9%) hospitals. CCOTs had been established in 72.8% of 
respondents, but interestingly, had been discontinued in 13.7% of the hospitals 
without CCO services. Lack of funding was the prime reason (6/7). The survey 
demonstrated that whilst 33.8% of hospitals with outreach services provided 24 hour 
telephone „hotline‟ advice, only 14.5% provided direct bedside support on the same 
basis. 71.1% of CCOTs had no medical consultant input, generally being nurse-led 
with only 34.9% having a nurse consultant lead and 41% having no H or I grade 
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nurse involvement. Despite this, 62.2% of outreach teams reported independently 
delivering care. The nature of these interventions are summarised in Table 1.4. 
 
Table 1.4 Interventions Performed or Recommended by Critical Care Outreach Staff (after 
McDonnell et al.)
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Critical care outreach activity Perform 
Activity 
Recommend 
activity 
Perform and 
recommend 
activity 
Investigations, e.g. venopuncture, CXR 39.1% 29% 31.9% 
Change in patient position 56.9% 5.1% 38.0% 
Changes in oxygen therapy 54.3% 5.8% 39.9% 
Initiation of noninvasive ventilation 27.1% 48.1% 24.8% 
Changes in fluid management 20.4% 49.6% 29.9% 
Initiation of blood/colloid transfusion 19.0% 66.4% 14.6% 
Initiation of vasoactive infusions 3.4% 86.2% 10.3% 
Adjustment to medication 3.8% 84.7% 11.5% 
Adjustment to feeding/nutrition 9.8% 78.0% 12.1% 
Adjustment to pain management 8.4% 75.6% 16.0% 
Initiation of DNAR decision 8.4% 80.2% 11.5% 
 CXR, Chest X-Ray; DNAR, Do not actively resuscitate. 
 
1.5.4 Outreach Interventions 
It is clear from the table that outreach practitioners frequently perform simple 
adjuncts to clinical care such as improving patient position and applying oxygen 
therapy.  25% appear happy/free to institute non-invasive ventilation and 20% 
change fluid management or administer blood or colloid resuscitation. Advice is 
offered on what could be deemed the more „medical‟ aspects of critical care such as 
vasoactive drugs and adjustments to medication, but no data is provided that 
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comments on the type of patient in whom such advice is offered, their immediate 
requirements for ongoing care and survival. There is also no reference to the types 
of CCOT that appear more „free‟ to administer these more aggressive therapies. For 
example, does this group contain medical personnel within their ranks permitting 
direct institution of therapy without the need for referral to a doctor? These results 
demonstrate the general nature of most CCOTs in the UK in 2005.  They are 
primarily nurse-led with little 24 hour or weekend cover. They perform simple clinical 
interventions independently, but only advise on significant escalation of patient 
therapy. They have a significant role in the care of the patient who is not regarded as 
likely to benefit from increased levels of care as evidence by their input into DNAR 
orders. Indeed the stratification of the ward patient in to those in whom an 
aggressive treatment strategy or a more palliative approach seems to be a major 
input from CCOTs.  
 
1.6  Evidence for Critical Care Outreach 
The enthusiasm for the establishment of CCOTs in UK hospitals, the relatively 
haphazard way in which they were introduced and the large variability in staffing, 
service and function, makes assessment of their utility difficult. It would be almost 
impossible and potentially unethical to begin a randomised controlled trial at the 
point of introduction, and as such most of the studies that have looked at outcomes 
of patients attended by a CCOT have been observational, retrospective with 
historical controls. 
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1.6.1 Reduction in Cardiac Arrest Rate 
Buist et al. were the first to report the effect of the introduction of a MET to teaching 
hospital46. The non-randomised study compared 22847 medical admissions to 19317 
historical controls after the introduction of a MET. The end points were the incidence 
and mortality from unexpected cardiac arrest. They demonstrated that the 
introduction of a MET significantly reduced unexpected cardiac arrest from 3.77 per 
100 admissions to 2.05 per 1000 admissions. Mortality was also reduced from 77% 
to 55%. This constituted an odds ratio for cardiac arrest of 0.50. (95% confidence 
interval (CI): 0.35-0.73). They concluded that in clinically unstable inpatients early 
intervention by a medical emergency team significantly reduces the incidence of and 
mortality from, unexpected cardiac arrest in hospital. However this reduction in 
unexpected cardiac arrest was largely due to the fact that the MET was able to 
anticipate futility and were able to place do not resuscitate orders. The study also 
showed an increase in unplanned admissions to the ICU after the introduction of the 
MET, although the statistical significance of this result was not stated. It is unclear 
what interventions apart from DNAR orders were key to these results. 
 
1.6.2 Reduction in Readmission Rate 
Ball et al. performed a similar study of patients versus historical controls in a UK 
teaching hospital after the introduction of a nurse-led CCOT47. Available only 12 
hours a day and operationally limited to the care of those patients discharged from 
the ICU, they demonstrated a borderline increase in survival to hospital discharge 
following introduction of the CCOT (risk ratio 1.08 (95% CI: 1.00 – 1.18)) and a 
significant reduction in ICU readmission rate (risk ratio 0.48 (95% CI: 0.26 – 0.87)). 
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However it is important to note that this reduction brought the readmission rate back 
to the national average of 8%. 
Garcea et al. also published a retrospective, before and after, study for surgical 
wards48. With a similar remit to the Ball group, they demonstrated a reduction in 
critical care mortality from 14.3% to 9.8% following the introduction of the CCOT as 
well as a reduction in readmission rates. In-hospital mortality also fell from 9.3% to 
4.8%. Though they could not demonstrate a causative factor that had led to the 
improvements seen and tentatively concluded that the introduction of outreach 
teams has a favourable impact on mortality and readmission rates. Thus it would 
appear that nurse-led CCOTs charged with follow-up of patients discharged from 
ICU improve outcomes when compared to historical controls. However these two 
studies say little of those patients referred de novo to the outreach service. Again, 
the interventions themselves are unclear.  
 
1.6.3 Cost-effectiveness 
Bellomo et al. performed a prospective, controlled, before and after trial examining 
the introduction of a MET to a large teaching hospital49. The team evaluated and 
treated any surgical patient deemed to be at risk of developing an adverse outcome 
by nursing, paramedical or medical staff. They concluded that the introduction of the 
MET was associated with a significant reduction in the number of adverse events 
(relative risk reduction 57.8%, p<0.001), post-operative mortality (relative risk 
reduction 36.6%, p=0.018) and mean duration of hospital stay (23.8 to18.9 days, 
p=0.009). This translated to an economic saving with an estimated decrease in 
hospital stay of nearly 12000 bed days per year. The authors acknowledged that the 
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decrease in adverse events was only partly due to the interventions performed by 
the MET, and that increased awareness of the signs of physiological instability by the 
very introduction of the MET had improved care. It is also important to point out that 
these were post-operative surgical patients likely to have less co-morbidity as their 
medical counterparts. 
1.6.4 In-hospital Mortality 
Mortality data in a similar study comes from Bristow et al. This group published a 
prospective cohort comparison between three similarly sized hospitals in Australia50. 
In one hospital the cardiac arrest team was replaced by a MET while it was retained 
at the other two. The study demonstrated a reduction in unanticipated ICU 
admissions in the hospital with the MET team (case-mix-adjusted odds ratios: 
Hospital 1, 1.00; Hospital 2, 1.59 (95% CI: 1.24-2.04); Hospital 3, 1.73 (95% CI, 
1.37-2.16), however there was no difference in cardiac arrest rates or in-hospital 
death rates between the hospitals. This lack of mortality benefit seen in this study 
was different from that of Priestley et al. who studied the phased introduction of a 
CCOT in the UK over a 32 week period51. They demonstrated that the introduction of 
a CCOT in a single institution reduced in-hospital mortality in wards where it 
operated compared to those where it did not (odds ratio 0.52 (95% CI: 0.32 – 0.85). 
 
1.6.5 The MERIT Study 
To date the best available evidence of the effect of outreach services comes from 
the publication of the MERIT study in 200552. In his large multicentre study 23 
hospitals without previous METs or CCOTs were randomised to have a MET service 
introduced (n=12), or to be controls (n=11). Over a period of four months an 
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educational strategy was undertaken to prepare the study hospitals for the 
introduction of the MET. This included educating staff about calling criteria, 
identifying patients at risk and the importance of a rapid response once criteria had 
been met. Reminders continued thereafter. The MET consisted of the equivalence of 
a pre-existing cardiac arrest team with the addition of at least one doctor and one 
nurse from either the emergency department or the ICU. The results were 
disappointing. There were no differences in cardiac arrest (odds ratio 0.94 (95%CI: 
0.79 – 1.13)); unexpected deaths (odds ratio 1.03 (95%CI: 0.84 – 1.28)) or 
unplanned ICU admissions (odds ratio 1.04 (95% CI: 0.89 – 1.21)). There were 
however three main flaws in the study which makes deriving these conclusions 
hazardous. Firstly, the study period was only six months which would mean that the 
study was inadequately powered. Secondly the cardiac arrest team in the control 
hospitals were often called to critical patients and thus acted as an informal MET. 
Even though far more calls were made to the MET team in the study hospital, many 
were felt to be inappropriate, thus not permitting this phenomenon to counter the 
effect of non-arrest calls in the control group. Finally, despite the rigorous education 
programme, the study demonstrated that even in the MET hospitals documentation 
and response to changes in vital signs were not adequate. Half of the ICU 
admissions were not reviewed by the MET team prior to their appropriate admission 
and the MET team was not contacted for 70% of cases that demonstrated MET 
calling criteria greater than 15 minutes prior to a cardiac arrest. This again 
demonstrates the need for appropriate responses to trigger generated by an early 
warning scoring system. The study did however demonstrate the effectiveness of the 
pre-intervention programme. The calling rate was higher in the MET hospitals (mean 
8.7 per 1000 admissions versus 3.1 per 1000 admissions p<0.0001) and the 
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proportion of calls not associated with cardiac arrest or unexpected death was also 
higher in the MET hospitals (84% versus 48% p<0.0001). It can be implied that this 
increase in awareness is a positive effect of the trial, however the inadequacy of 
documentation and calling when there was evidence of physiological abnormality 
suggests that there is still problems with appropriateness of MET referring, and that 
some patients are still being missed. 
 
1.6.6 Further Evidence 
Most recently, Gao et al. published a multi-centre observational study utilising the 
case mix programme database collected by the Intensive Care National Audit and 
Research Centre (ICNARC)53. This was linked to the data from the survey by 
McDonnell et al. above45. They assessed 108 ICUs accounting for 240,884 
admissions over eight years. They demonstrated that admissions from the wards 
had a higher ICNARC physiology score (sicker) and had higher hospital mortality 
46.9% vs 32.6% when compared to all admissions. Introduction of CCOT brought 
about a significant reduction in cardiac arrest for ward patients within 24 hours 
before admission. Also the mean ICNARC physiology score was significantly 
decreased after the introduction of CCOTs. This is the first study to identify this as an 
endpoint, and it is important. It may imply that CCOT involvement may improve 
timely ICU admission or that direct intervention and stabilisation prior to admission 
improves the clinical state of a patient. It may also mean that patients with high 
ICNARC scores in whom critical care is futile are not admitted. However, like the 
MERIT study, there was no reduction in either ICU or in-hospital mortality. 
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Not all studies have focussed solely on patient outcomes. Baker-McLearn et al. 
evaluated the impact of CCOT from a staff perspective54. Performing 100 semi-
structured interviews with hospital staff, they reported the following. The introduction 
of CCOT had resulted in fewer referrals to the ICU and that the ICU felt more able to 
discharge patients to hospital wards. There was also a perceived improvement in 
links between ward nurses and medical teams, and improved morale among ICU 
nurses. Secondly, there was felt to be increased contact on the wards with critical 
care, resulting in more opportunities to share critical care skills. However, there 
remained concerns about the sustainability of improved skills and some respondents 
felt that junior doctors were becoming de-skilled. 
 
1.6.7 Summary of the Evidence 
There is a need for a novel approach to the care of the hospital in-patient who is 
critically ill, is deteriorating or is at risk. The evolution of early warning scores and 
CCO are significant steps to providing this change. However, the current evidence of 
their value and necessity is contradictory. Some of this disagreement may be borne 
out of the patient groups being examined. The greater part of the application of early 
warning scores and CCO is aimed at the care of the ward in-patient, rather than 
those during admission or following major elective surgery. These two groups are 
different. The A&E/surgical patient has a fixed starting point for their critical illness, 
and this point is easily definable. The timescale of the illness is usually short and as 
such more likely to be rapidly fulminant or rapidly reversible with a lower risk of 
mortality. In contrast the ward patient is frequently several hours or days after 
admission prior to CCO involvement. This is much later after the appearance of their 
initial condition and whilst some may become suddenly critically ill, it is likely that 
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they are in fact demonstrating an accelerating course of their initial illness. Either that 
or a second insult has occurred in a patient already weakened by prior illness. A 
sudden late increase in the aggressiveness of their therapy is therefore unlikely 
reverse the longer processes. There is no literature to support observed EGDT in 
critically ill ward patients. It may be that initial resuscitation over a short period such 
as that described by Rivers et al. may be too short, too long or inappropriate for the 
patients attended by a CCOT. A „one-size-fits-all‟ response to a trigger may not bring 
about the desired improvements in outcome and thus protocols and guidelines 
based only on current best evidence may be hazardous.  
Stratification of those patients in to those for aggressive management and those for 
palliation (DNAR) appears to be a strong influence on the outcome of the studies of 
CCO46, 52. This may account for many of the benefits seen i.e. the reduction of 
readmission rates and reduction in unanticipated ICU admissions rates47, 48, 50. The 
lack of reduction in cardiac arrest calls and unexpected deaths would seem to imply 
that the effect of CCO is more complex. While the focus of much of the literature and 
indeed this introduction has been on the efficacy of the teams, there is little 
information on what they do, how it works and whether it is of benefit; so-called 
interventions. 
 
1.6.8 CCOT Interventions 
One element that stands out in arguing for the provision of CCO is demonstrated by 
the ICNARC study reported by Gao et al. This concluded that the involvement of the 
CCOT improved the clinical state of the patient admitted to the ICU53. Enthusiasts for 
CCOT and EGDT might suggest that prior to transfer, it is the immediate intervention 
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under the supervision of appropriately trained CCOT staff that brings about this 
result. This is therefore the key value of CCO to the patient. Indeed the perception of 
a CCOT among ward staff, as reported by Baker-McLearn et al., is of a team that 
performs specialised manoeuvres in addition to their own care. It is these techniques 
which lead to improvement in the patient‟s condition either as part on an ICU 
transfer, or stabilisation if ICU admission is not required54. However, how effective 
CCOT-guided interventions are at reversing acute illness in ward patients is not 
known, nor how they directly affect the outcome. What are these „interventions‟ used 
by CCOT? In general they are remarkably limited (Table 1.4). Retention of trained 
nursing staff, trainee doctor expertise, lack of medical input to CCOT and limited 
level 1 and 2 bed availability all serve to restrict the possibilities. They can be roughly 
divided in to support and monitoring of the respiratory and cardiovascular systems. 
Their intent is to restore normal respiratory and haemodynamic function whilst 
curative therapies such as antibiotics, surgery, endoscopy, interventional cardiology 
etc. facilitate cure. The commonest interventions delivered on the wards at the 
Chelsea and Westminster Hospital are listed in Table 1.5. 
These are simple tools used to improve the physiological variables that become 
abnormal and contribute to early warning scores. As such they are often employed to 
treat investigation results and improve their values in a „because we can‟ fashion. 
Little is known about how these interventions perform in the sphere of ward-based 
critical illness. Do we fully understand the interactions between patients and even the 
simplest supportive measures? How they are deployed in this environment is also 
unclear. Are they being used appropriately in keeping with the evidence that does 
exist? Do they produce only a short term improvement that may delay the institution 
of other therapy?  Do they show evidence of harm which might negate any benefit 
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they may confer? Can further measures be employed to improve upon their likely 
effectiveness? 
 
Table 1.5 Ward interventions used by the CCOT at Chelsea and Westminster Hospital 
Physiological system Intervention type Intervention 
Cardiovascular 
Monitoring ECG 
NIBP 
CVP 
Therapy Fluid therapy 
Low dose Dopamine 
Respiratory 
Monitoring Respiratory rate 
SpO2 
Intermittent ABGs 
Intermittent ScvO2 
Therapy Mask oxygen 
CPAP 
(BiPAP) 
ECG, electrocardiogram; NIBP, non-invasive blood pressure; CVP, central venous pressure; 
SpO2; pulse oximetry; ABGs, arterial blood gases; ScvO2, central venous oxygen saturation; 
CPAP, continuous positive airway pressure (ventilation); BiPAP, bi-level positive airway 
pressure (ventilation). 
 
As an example, the advent of CCOTs has permitted the increasing use of continuous 
positive airway pressure ventilation (CPAP) on the general wards. It is commonly 
used in the treatment of hypoxia that is unresponsive to mask oxygen therapy. How 
the burden of respiratory disease interferes with the function of more common 
oxygen delivery devices in vivo is not well documented in the literature and may play 
a significant role in subsequent hypoxia. The application of CPAP as a response to 
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this phenomenon usually results in improvement in oxygenation, yet it carries risks in 
the ward setting. Is this the only method of achieving such a target without such 
risks? Could it delay the institution of other modes of oxygenation e.g. mechanical 
ventilation?  
Those that champion CCO believe that a major part of its remit is the clinical 
intervention. In other words ICU-style techniques can maintain patients on the ward 
without the need for transfer. A contrary view of the role of CCO is to patrol the 
wards in order to identify those who require ICU and facilitate timely transfer. Those 
not requiring ICU, or in which ICU would be felt to be futile and could be observed. If 
we are to embrace the former, it is important to be sure that the interventions 
delivered to ward patients as part of CCO are valuable. Our understanding of their 
mechanisms of action needs to be clear. Knowledge of current practice needs to be 
documented in order to ensure that delivery of such methods is appropriate with 
minimal risk or associated morbidity. Finally, can other methods be employed to 
improve on the current practice? It is from these concerns that this thesis was 
conceived.  
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1.7 Thesis Aims 
This thesis hopes to examine two of the main interventions performed as part of 
CCO, namely oxygen delivery and fluid management. 
 
1.7.1 Oxygen Delivery 
The aim of the first experimental chapter is to document how the presence of 
abnormal respiratory patterns affects the performance of common oxygen delivery 
devices. 
Chapter 4 aims to document the nature of ventilation in ward patients with respiratory 
distress. It is hoped that this will provide evidence for that some of the hypoxia seen 
in such patients is due to poor interaction between patient and oxygen delivery 
system. 
The subsequent two chapters aim to clarify whether the improvement in oxygenation 
seen with the application of CPAP to ward patients is due to the change in oxygen 
delivery system or secondary to the direct effects of positive airway pressure. 
 
1.7.2 Fluid Management 
Chapter 7 aims to document the current practice for fluid resuscitation in the critically 
ill ward patient and compare it to the EGDT method as a „standard of care‟. 
Chapter 8 concludes the thesis by examining a novel cardiac output monitor which 
may have utility on the general wards. In comparing it to an established method, it 
aims to prove that the data produced is valid enough to permit its use. 
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This thesis could also look at the influence of CCO on DNAR orders, transfer of skills 
and support of ward staff, but it is the physiological aspects of intervention that I 
choose to focus on. It is hoped that the efficacy and mechanisms of these methods 
can be explored and that while answering some basic questions the thesis may 
indicate what other questions need to be asked about the implementation of 
outreach interventions in clinical practice. 
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Chapter 2 
Materials and Methods 
 
2.1 Introduction 
The previous chapter has highlighted the evolution of critical care outreach teams 
and their current roles in hospitals in the United Kingdom. Most of the evidence to 
date summarises the effect of CCOTs on mortality and ICU readmission. Associated 
evidence for their necessity comes from the positive effects of early warning scores 
and the assumption that early intervention should lead to improvements in patient 
care. The increasing use of intensive care techniques on the general wards has not 
been specifically evaluated. It is thought that early „higher level‟ interventions lead to 
better outcomes. However what can be delivered to ward patients, how effective 
such strategies are and how well they are delivered all remain unclear.  
As alluded to previously the actual number of tools available to the Chelsea and 
Westminster CCOT is somewhat limited, namely: The use of early-warning scores to 
identify patients „at risk‟, increasing the level of physiological monitoring, delivery of 
oxygen, the administration of non-invasive ventilation such as continuous positive 
airway pressure (CPAP) or bi-level positive airway pressure (BiPAP), the almost 
ubiquitous administration of intravenous fluid and occasional use of systemic 
inotropes. One further „tool‟ at the disposal of the CCOT is the „do-not-actively-
resuscitate‟ order (DNAR). This thesis is set out to assess some of these 
interventions.  
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It aims to assess the efficacy of common oxygen delivery devices in a model of 
respiratory distress. A clinical study to document the nature of ventilation in patients 
with respiratory embarrassment is also conducted to permit some degree of clinical 
application of the model‟s findings. 
It next aims to describe the effects of oxygen delivery by a high flow oxygen system 
and any additional effects that the application of a CPAP valve may confer. To this 
end the effects of this device were evaluated in a lung model and then audited in 
clinical practice. 
The delivery and effects of intravenous fluid as an intervention is also evaluated to 
see when and how they are used. An obvious issue is the lack of monitoring 
available in the ward environment. Thus the potential use of novel cardiovascular 
monitoring to improve haemodynamic optimisation via fluid resuscitation is included. 
The DNAR order as an „intervention‟ whilst also considered is not included in this 
thesis. 
 
2.2 Oxygen Delivery 
The application of inspired oxygen is a very common intervention. However little has 
been documented regarding the performance of oxygen delivery devices in the 
presence of the respiratory patterns typical of the acute respiratory failure seen in 
acutely unwell patients.  
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2.2.1 Assessment of Common Oxygen Delivery Systems via a Model 
The first study performed as part of this thesis utilises a model of human ventilation 
to simulate these patterns. The model combines a mechanical ventilator with bellows 
to produce ventilation that can be varied. The use of a Laerdal® Airway Management 
Trainer mannequin (Laerdal®, Orpington, UK) to simulate the upper airway and 
trachea will permit the testing of a selection of oxygen delivery devices in common 
use at Chelsea and Westminster Hospital. Measurement of the oxygen content of 
the „inspired gas‟ delivered by the devices is performed. The aim of this study is thus 
to establish the effects that varying the respiratory rate has on the delivery of oxygen 
by the selected devices. This hopes to confirm or refute the hypothesis that with the 
abnormal ventilatory patterns seen in respiratory failure, oxygen delivery devices 
perform less well than at more normal patterns. 
 
2.2.2 Peak Inspiratory Flow Rates in Respiratory Distress 
The previous chapter aims to describe both in vitro the interaction between oxygen 
delivery systems and ventilation in acute respiratory disease. The next study is 
designed to assess whether a likely significant factor in the performance of oxygen 
delivery devices, peak inspiratory flow rate (PIFR), is abnormal in patients with 
respiratory failure. This would develop the thesis that the ward-based methods to 
achieve oxygenation in the critically ill succeed in greater part, due to ventilatory 
physics rather than pulmonary physiology.  
A case-control study will be performed. „Cases‟ are those with acute respiratory 
failure recruited on the wards of Chelsea and Westminster Hospital. „Controls‟ are 
American Society of Anesthethesiology (ASA) grade I or II pre-operative elective 
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general surgical and orthopaedic patients. Measurements of PIFR is performed 
using a Vitalograph 2120® (Buckingham, UK) hand-held spirometer. The subjects 
undergo three maximum voluntary ventilation assessments for 14 seconds each. 
The plot obtained is analysed using GraphClick 2.9.2 (Arizona Software, USA). A 
mean PIFR can be calculated from the maximal gradient differentiated by the 
software. The hypothesis being tested is that patients with acute respiratory failure 
have a higher PIFR than similar normal subjects at rest. It is hoped that with this 
approach a realistic evaluation can be made of how effective commonly used 
systems are in delivering oxygen in vivo and provide an indication of whether, in 
practice, they work in the way that we think. The inspiratory flow rates may provide 
information about a potentially key factor in the efficiency of delivery of oxygen by 
these systems 
 
2.2.3 Continuous Positive Airway Pressure 
The application of CPAP as an intervention to improve oxygenation in acute 
respiratory failure is becoming more common on the general wards. If tolerated it 
usually leads to a marked improvement in oxygen saturation and as such, may 
convey survival benefit in selected patients. What has not been documented is 
whether the improvement in oxygenation is primarily due an improvement in oxygen 
delivery or the direct effect of positive airway pressure. Chapters 5 uses the model 
for oxygen delivery assessment described in Chapter 3 and applies it to a CPAP 
system. Then Chapter 6 provides an audit of patients being treated with CPAP in 
order to evaluate the effects of high flow oxygen and CPAP. 
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2.2.4 Assessment of CPAP via a Model  
The model described in Chapter 3 is used to assess the Whisperflow® 2-60 (Phillips 
Respironics, Pittsburgh, PA, USA) high flow delivery system. This is the system used 
to deliver CPAP at the Chelsea and Westminster Hospital. Clinically it is usually used 
with pressures of 5cmH2O or sometimes 10cmH2O. Changes are made to the 
respiratory rate and the addition of 5cmH2O and 10cmH2O of PAP applied at each 
rate. Measurement of oxygen content is performed on the „inspired gas‟ as a 
reflection of the effectiveness of oxygen delivery by the system. The aim of this study 
is to establish the effects that varying the respiratory rate has on the delivery of 
oxygen by the high flow system with or without CPAP valves. The hypothesis is that 
a high flow system via a sealed mask would not show the same deterioration in 
performance as that seen with other oxygen delivery systems. 
 
2.2.5 Clinical Audit of the Application of CPAP to Patients 
To follow this up in a clinical scenario Chapter 6 is a clinical study. It examines 
patients with acute respiratory failure in whom CPAP therapy is to be initiated due to 
hypoxia on more conventional oxygen delivery devices. The aim is to document 
whether a change to the Whisperflow® oxygen delivery device brings about 
significant improvement in oxygenation and whether the subsequent application of 
5cmH2O and 10cmH2O of CPAP further increases the arterial oxygen content. Thus 
patients are initially treated with oxygen via a venturi system delivering an 
approximate FiO2 of 0.6. After 10 minutes an arterial blood gas is sampled and 
analysed for the partial pressure of oxygen (PaO2) and carbon dioxide (PaCO2). The 
Whisperflow® system is then applied as per the manufacturer‟s instruction without a 
CPAP valve attached. After a further 10 minutes a second blood gas analysis is 
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performed. A 5 cmH2O Accu-PEEP
® (Vital Signs, Barnham, UK) is then applied and 
a further 10 minutes elapsed, whereupon a third blood gas analysis is performed. 
The patient remains on 5 cmH2O for 50 minutes (totalling 1 hour) before further 
blood gas analysis and a subsequent increase in CPAP to 10 cmH2O. Another hour 
elapses before a final blood gas analysis is taken. At each sampling time of the 
experiment, the patient is asked to assess their level of comfort regarding the 
method of oxygen delivery. The hypothesis of this experiment is that changing to a 
high flow oxygen delivery system will markedly improve oxygenation, but that the 
application of two levels of CPAP commonly used on ward patients does not further 
improve oxygenation. This lack of improvement may also be accompanied by an 
increase in discomfort for the patient. 
 
2.2.6 Summary 
It is hoped that these model and patient based evaluations will provide information 
regarding how two of the common methods of ward-based oxygen delivery work in 
the presence of disease. In particular it will test the previously untested hypothesis 
that the benefits in oxygenation from CPAP accrue predominantly from the 
application of pressure. 
 
2.3 Fluid Resuscitation 
The efficacy of oxygen delivery will have been addressed but the other significant 
and common intervention is fluid management. This is an almost ubiquitous 
intervention performed in any patient attended acutely by the CCOT. Many patients 
are treated as hypovolaemic following initial assessment and varying amounts of 
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intravenous fluid is administered. What is not known is how the involvement of a 
CCOT influences this fluid management, both in its timing, its volume and observing 
its treatment effect? The study by Rivers et al. highlighted the use of early well 
controlled fluid resuscitation in septic patients in an Emergency Room environment1. 
This adds to the general belief that early aggressive resuscitation prevents further 
deterioration and should reduce mortality. As an intervention on the general wards, 
nothing similar to the Rivers study has been performed. There is no data that 
documents the use of intravenous fluid in the acutely unwell in terms of timing, 
volume or associated complications.  
 
2.3.1 An Audit of Ward-based Intravenous Fluid Resuscitation 
The study which will be described in chapter 7 audits the current practice of this 
important intervention. The study aims to document the actual practice of fluid 
resuscitation in the general ward patients in whom CCOT involvement was deemed 
necessary. 
To audit this activity realistically requires a reference point and here are no studies 
other than that by Rivers which address this issue. Therefore, while acknowledging 
that there are profound differences between the Emergency Room and the ward, this 
audit used the Rivers criteria as the gold standard by which practice was to be 
assessed. Patients who were attended by the CCOT at Chelsea and Westminster 
Hospital and received at least a 250ml bolus of fluid within an hour are included. 
Data is collected on the timing of fluid administration, the volume and types of fluid 
used, its clinical effect and the appearance of complications associated with fluid 
resuscitation. The results were then compared to the above gold standard. The 
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hypothesis being tested is that in current practice on general wards, intravenous fluid 
resuscitation is often delivered later than ideal, can be excessive in volume and thus 
may contribute to unnecessary morbidity. It is hoped that such information would be 
valuable in improving the delivery of this intervention to acutely unwell ward patients. 
Further evaluation of efficacy is beyond the scope of this investigation but hopefully 
this study will provide the basic information about the delivery of fluid management 
that will enable evaluation of efficacy in the future.  
 
2.3.2 Cardiac Output Monitoring 
To realistically apply effective fluid management requires some form of invasive 
monitoring which currently is difficult in the ward environment. Chapter 7 aims to 
demonstrate the current „state-of-play‟ with regards to circulatory resuscitation of the 
acutely unwell on the wards. In the intensive care unit, such therapy is often 
accompanied by additional monitoring to assess and control similar treatment. The 
dispersion of critical care skills to the general wards is part of the CCOT remit and as 
such it is reasonable to expect that ICU-type monitoring may play an increasing role 
in the care of ward patients. One such mode is that of cardiac output assessment but 
most current techniques such as pulmonary artery catheters and oesophageal 
doppler techniques are difficult or impossible to use in the ward. What is needed is a 
user friendly device that can be safely deployed in the ward. The use of pulse-
contour wave analysis is ever increasing and newer, simpler equipment is available 
which might be suitable. One such „user friendly‟ device is the Vigileo Flotrac® 
(Edwards Lifesciences, LLC, Irvine USA) and its associated MHD8 Flotrac sensor. It 
requires no calibration and thus can be used directly with only the need of an arterial 
catheter. The final study in this thesis compares this monitor with a calibrated pulse-
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contour wave analysis monitor, the LiDCO®. The aim is to decide if the data 
produced by the uncalibrated Vigileo Flotrac® would reproduce that of a calibrated 
system, thus permitting its use in the wider environment.   
The study recruits intensive care patients in whom pulse contour wave analysis is 
deemed necessary by the attending physicians. The LiDCO® is calibrated in the 
standard way and simultaneous readings from both machines were gathered, 
namely: arterial blood pressure, cardiac output, stroke volume variation. Other data 
included fluid administration, inotrope therapy, arterial blood gas analysis and 
plasma lactate concentrations. The hypothesis of this study is that in the critically ill 
patient, the novel uncalibrated Vigileo Flotrac® produces the same results as the 
calibrated LiDCO® system. 
It is hoped that the approach outlined above will provide useful information about 
some of the interventions currently used for some aspects of acute care given to 
patients on the general wards when their condition is severe or deteriorating. Do the 
limited interventions available work well in acute illness? Is their mechanism of action 
fully understood? Is the delivery of such interventions optimum or can they be 
improved upon?  Are there better ways to deliver this care in the ward such as new 
monitoring devices? 
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Chapter 3 
The Performance of Oxygen Delivery Devices at Varying 
Respiratory Rates 
 
3.1 Background 
Oxygen therapy is one of the most common interventions in the ward environment. 
Oxygen is also commonly administered to patients as part of their routine 
management. In the acute situation breathlessness and hypoxaemia recorded by 
pulse oximetry, is often the trigger that attracts attention and hence intervention. The 
intention is to increase the exogenous oxygen supply. Oxygen is fundamental to 
aerobic metabolism. In critical illness, delivery of oxygen to the tissues may be 
compromised, either through the pulmonary or cardiovascular systems or both. This 
thesis is in greater part about the assessment of ward-based interventions commonly 
used to increase or optimise tissue oxygen delivery. Thus it seems reasonable to 
begin with the intervention, the application of supplementary oxygen, which is usually 
the first to be initiated. It is a key therapy used in many hospital situations and is 
mostly delivered by some form of mask applied to the face. The range of available 
masks is wide utilising differing physical characteristics depending on the needs of 
the recipient, be it severity of hypoxaemia (non-rebreather masks), comfort (nasal 
cannulae) or securing respiratory drive (low FiO2 venturi masks). Whilst almost 
ubiquitous in the treatment of critical illness, each type of mask is thought to deliver a 
characteristic amount of oxygen for that mask. The clinician selects the mask on the 
basis of its oxygen delivery in relation to the requirements of the patient. It is 
perceived that the physical performance of the mask may be altered by 
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circumstances and this will result in a different, usually lower, oxygen delivery than 
that intended. The interaction between the patient and the mask system is complex 
and aspects of this interaction may result in compromise of the oxygen delivery; in 
particular changes in respiratory patterns and rate. The question is how much in 
terms of oxygen delivery, is influenced by changing patterns of breathing, or put 
another way how consistent are the masks in the dynamics of clinical practice? 
 
3.1.1 Oxygen delivery  
Oxygen is an important part of routine care of the sick patient1. When used, the 
arterial oxygenation achieved is often described in terms of the concentration 
delivered by the specific mask system. For example a blood gas result may be put in 
context by describing the inspired oxygen as 60% by mask.  There are many devices 
currently available whose performance has been documented in the literature2-9. It is 
usually reported as either the actual delivery from the system4, the resultant inspired 
concentration of oxygen2, 3, 5-10, or the arterial oxygenation achieved10. Mask 
characteristics are usually assessed in physical systems that rarely allow for 
changes in breathing pattern. 
Measurement of the delivered FiO2 in vivo is technically challenging as invasive 
procedures in the airway are required at considerable discomfort to a subject. As 
such, most measurements that have been reported are carried out in normal 
subjects breathing at rest or trained to vary their tidal volumes2-6, 8-19. Several of 
these studies illustrate that there are multiple factors which may compromise the 
performance of these devices and result in an effective FiO2 that is less, or 
occasionally more than that expected5, 8. From a physics perspective the actual 
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concentration of oxygen delivered is determined by the interaction between the 
delivery system and the patient‟s breathing pattern5. The factors that influence the 
concentration actually inspired by the patient are summarised in Table 3.1. One of 
the main factors in determining FiO2 is the relationship between the fresh gas flow 
rate and the peak inspiratory flow developed by the patient. It is likely that as the 
patient gets distressed the flow rates alter and this will influence entrainment. This is 
a physics problem and so the most practical way to assess this is by a physical 
model. 
 
Table 3.1 Factors that influence the FiO2 delivered to a patient by oxygen delivery devices
5
 
Patient Factors Device Factors 
Inspiratory flow rate Oxygen flow rate 
Presence of a respiratory pause Volume of mask 
 Vent resistance 
 Tightness of fit 
 
3.1.2 Difficulties in Measuring FiO2 
There are few studies that have tried to evaluate delivery system performance in the 
adverse circumstances in which they are commonly used20-22. Practical difficulties 
include the instantaneous and simultaneous measurement of FiO2 and gas flow. This 
is compounded by the problems of identifying and accessing a suitable sampling 
site9. The predominant problem is the relationship between the oxygen flow into the 
mask, the size of the reservoir effect of the mask and the peak inspiratory flow rate, 
the combination of which will determine air entrainment and therefore oxygen 
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dilution. An alternative approach is to devise a model that could mimic spontaneous 
breathing patterns and to collect the mixed inspired gas from the model lungs. The 
mixed inspired gas would to a certain degree, represent the final concentration of 
inspired oxygen. This could be described as the „effective inspired oxygen 
concentration‟ (EIOC) as it represents the resultant oxygen concentration in the 
model over the inspiratory phase of ventilation. This avoids many of the 
measurement problems of the previous methods, but remains only a model. As the 
oxygen delivery from these systems is largely determined by the physics of the 
system, the model should lend itself to providing useful information about the relative 
performance of oxygen delivery systems. 
 
3.1.3 Aims 
The aim of the study was to develop a new system from an existing lung model that 
would enable the effective mixed inspired oxygen concentration to be measured.  
Then to test how effective commonly used oxygen delivery devices are at delivering 
predictable concentrations of oxygen at different respiratory rates. 
 
3.2  Methodology 
3.2.1 Study Design 
It would be conventional to measure inspired gas on inspiration. The unique concept 
behind the model devised is that as it uses the expired gas from the model lungs 
which will be, in effect, the same as the mixed oxygen concentration inspired.  
Therefore, if the expired gas could be collected the concentration measured would 
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be the effective overall inspired oxygen concentration. This system is considerably 
simpler than trying to measure simultaneously the oxygen concentration and flow. 
 
3.2.2 The Model 
An experimental rig was constructed as shown in Figure 3.1. A Laerdal® Airway 
Management Trainer mannequin (Laerdal®, Orpington, UK), was used to simulate 
the nasopharynx, larynx and trachea. The mannequin‟s „bronchi‟ where attached via 
a Y-piece to a set of „slave‟ bellows. These were driven by a second set of „driving‟ 
bellows by way of a connecting rod. These driving bellows had been constructed for 
a previous study some years earlier, but their inclusion in this rig with the use of the 
mannequin, and using a ventilator to provide a range of breathing patterns for the 
mannequin was entirely novel. The use of the airway model was included to provide 
a realistic simulation of the upper airway.  
The driving bellows were connected to a Dräger Evita ventilator (Dräger Medical, 
Hemel Hempstead UK), set to deliver a square wave. This relatively sophisticated 
intensive care ventilator would allow changes in respiratory rate, tidal volume, I:E 
ratio and maximum inspiratory flow rate. As the driving bellows expand, a reciprocal 
negative pressure is produced in the slave bellows. This acts as „inspiration‟. Gas is 
thus „inhaled‟ into the slave bellows. Expiration is passive by way of a return spring. 
This spring conferred a more sinusoidal profile to the square wave ventilation 
delivered by the ventilator.  
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Figure 3.1 The experimental rig 
Positive pressure from the Dräger Evita ventilator inflates the first set of bellows and via the 
connecting rod, causes the second set of bellows to open and draw in gas (solid arrows, 
diagram B). The negative pressure derived from the second set of bellows draws gas from the 
mannequin (dashed arrows, diagram B). During the expiratory cycle of the ventilator the gas 
within the second set of bellows is expelled by a return spring (solid arrows, diagram C) into a 
10-l mixing chamber and then out to the environment past a Datex-Ohmeda 5120 Oxygen 
analyser (dashed arrows, diagram C). Direction of gas movement around the apparatus was 
controlled by unidirectional flow valves. 
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Unidirectional valves block gas return to the mannequin and conduct expired gas via 
a T-piece to a 10 litre airtight canister which is intended to allow adequate mixing of 
the „exhaled‟ gas. This mixed gas represents the mean inspired concentration in the 
model and for the purpose of this study is called the EIOC. This gas was then piped 
past a Datex-Ohmeda™ 5120 Oxygen analyser (GE Healthcare, Chalfont St. Giles, 
UK), and oxygen percentages recorded. All connecting tubes were 22mm 
Intersurgical® Elephant Tubing.  
 
3.2.3 Calibration 
Control measurements were performed by intubating the mannequin with a 7.0mm 
cuffed endotracheal tube. Ventilating at a tidal volume of 300 and 500 ml; respiratory 
rate of 10 breaths.min-1; I:E of 1:2 and no Positive End-expiratory Pressure (PEEP), 
the mannequin ‟breathed‟ firstly air and then 100% oxygen via a Mapleson C system. 
The oxygen analyser was thus calibrated to 21% and 100% respectively. The time 
taken to reach saturations of 100% from 21% was assessed and found to have a 
mean of 4:12.3 mins and 3:05.8 mins for 300 ml and 500 ml respectively. Tidal 
volume measures were achieved using a Wright‟s Respirometer inserted in the 
expiratory limb of the slave system. It‟s reflection of inspiratory volume was assessed 
by attaching a second Respirometer to the end of the endotracheal tube. There was 
concordance between the two at tidal volumes of 100, 250, 500, 750 and 1000 ml at 
respiratory rates of 10, 20 and 30 breaths.min-1. 
Oxygen flow rates to the devices used were controlled by a standard BOC Carnét 
ball flowmeter (BOC Healthcare, Manchester, UK) inserted into wall-oxygen via a 
Schräeder valve at 4 bar pressure. The waist of the ball relative to the device‟s scale 
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was used to determine the oxygen flow rate. Three flowmeters were used 
interchangeably during testing. Each was calibrated at the start of each testing 
session (3-4 hours). This was done by way of a Wright‟s respirometer attached to the 
flowmeter by a 30cm piece of connecting tubing. The flowmeter would be set at 5, 10 
and 15 l.min-1, timed for a minute and the number of litres delivered read off the 
Respirometer. All three of the flowmeters had good concordance between their 
dialled up flow rate and that delivered. Gas output from the flowmeters appeared 
stable and constant, but was not specifically verified. A similar method was used to 
test the calibration of the in-built flowmeter of the Vapotherm® system.  
 
3.2.4 Devices 
The devices selected for study are those commonly used for oxygen delivery in our 
institution (Table 3.2). The manufacturer‟s specifications are summarised in 
Appendix 2. It was felt that with the exception of the Vapotherm® system, they 
reflected those mask systems in common use on the wards in National Health 
Service; certainly those institutions in which the author had previously worked. They 
also reflected a variety of different physical attributes of oxygen delivery devices. For 
example, the presence of a reservoir in the case of the non-rebreather bag, or the 
utilisation of the venturi effect using the Ventimask®. Hence while different masks 
may be used in other Institutions the range used here would reflect the range of 
mask characteristics likely to be available in most hospitals.   
The Vapotherm® system (Vapotherm Inc., Stevensville, Maryland, USA) is a new 
method of delivering oxygen by nasal cannulae. It consists of a high flow air/oxygen 
mixer (0-50 l.min-1). It requires connection to oxygen and air supplies by way of 
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Schräeder valves. The gas mix is humidified and warmed as it passes through the 
device and its warmth is maintained by a warm water jacket surrounding the piping 
that delivers the gases to the patient. Data provided by Vapotherm® Inc. suggest that 
the high flow nasal delivery system is better tolerated than conventional nasal 
cannulae (usually up to a maximum flow of 8 l.min-1) because of the warming and 
humidification of the gas mix. It was included in this study as a novel device, which 
operated at significantly higher flow rates than other devices. It was of particular 
interest to see if this difference would convey significant advantage in oxygen 
delivery, not just improved patient comfort and compliance. 
 
Table 3.2 Devices selected for study (manufacturer) 
Variable Performance Devices Fixed Performance Devices 
Nasal Cannula (Teleflex Medical®) Fixed Performance mask with venturi 
inserts (Ventimask®, Flexicare®) Variable Performance Hudson-type mask 
(Teleflex Medical®) 
Variable Performance mask with 
reservoir bag and safety vent.  
(Teleflex Medical®) 
Vapotherm® (Vapotherm Inc.) 
Thermovent T2 HME  (Smiths Medical®) 
(Teleflex Medical®, High Wycombe, UK, Smiths Medical®, Hythe, UK, Flexicare® Ltd., 
Mid-Glamorgan, UK) 
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With each system the flow rates chosen were those in common use in the institution. 
The study sought to look at the performance of masks as used clinically and was not 
seeking to assess the performance of each delivery system under a range of flow 
rates that may not characterise common use.  
The Thermovent T2 HME (Smiths Medical, Hythe, UK) is a novel device designed for 
use with tracheostomy. To examine this device the mannequin was intubated orally 
as we were not permitted to perform a tracheostomy on the mannequin. This device 
was included as an unusual, but still relevant method of oxygen delivery for specific 
patients. 
 
3.2.5 Assessment 
A standard regimen was executed for each of the above devices. The first sets of 
measurements were performed at a measured tidal volume that was fixed at 500 ml. 
The I:E ratio remained constant at 1:2. The value of the inspiratory flow rate 
delivered by the ventilator was set at the minimum required to generate the 
appropriate tidal volume at each respiratory rate and maintain the I:E ratio at 1:2. For 
each change in respiratory rate the mannequin was ventilated for 5 minutes to 
ensure that equilibrium had been reached at the oxygen analyser. On completion of 
each cycle a further period of 5 minutes „washout‟ on air was performed before the 
next alteration in respiratory rate. The maximum oxygen concentrations were 
recorded for the devices at 10, 15, 20 and 30 breaths.min-1. This was thought to 
reflect a reasonable variety of commonly encountered respiratory rates in „health‟ 
and „disease‟ The variable performance devices were tested at oxygen flow rates of 
2, 4, 6, 8, 10 and 15 l.min-1 as delivered by the (calibrated) BOC Carnét ball 
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flowmeter(s). These rates were chosen based on pragmatic clinical experience. 
Nasal cannulae are commonly used at lower rates such as 2 and 4 l.min-1. Hudson 
masks often are operated between 5 and 10 l.min-1, whilst the responses to therapy 
delivered by the non-rebreather type are invariably quoted „at 15 l.min-1‟. It was felt 
that if this study was to have clinical relevance, then inclusion of this spectrum of 
flow rates would be necessary. The fixed performance devices were assessed using 
the oxygen flow rates for the appropriate inserts, as recommended by the 
manufacturer (see Table 3.3 and Appendix 2). The high flow system, the Vapotherm, 
was analysed at two arbitrary fresh gas flow rates, 15 and 30 l.min-1 and four oxygen 
concentrations, 30, 60, 80 and 100%. The other devices were not tested at such a 
high flow rate (30 l.min-1) as the flowmeter by which they were driven only scaled to 
16l.min-1. Most wall flowmeters in current use are similar in range and so it was felt 
that testing at higher flow rates whilst of interest, would lack clinical application.  
On completion of testing at a tidal volume of 500 ml, the whole experiment was 
repeated at 300 ml. This was done as it was felt that in respiratory failure, tidal 
volume may fall as respiratory rate rises. Testing at a lower tidal volume than 
„normal‟ for adults would thus convey more clinical relevance to the model. 
Each device was tested at each respiratory rate, each oxygen flow rate (variable 
performance devices) and both tidal volumes. „Runs‟ of testing were performed on 
different days and at different times. The observer was always the same. Three 
models of each device were tested: two from the same batch of devices, and one 
from a new batch several months later.  
 
91 
 
3.2.6 Statistical Analysis 
For every model of the device, three runs were performed and a mean and standard 
deviation (SD) calculated and examined for inter-device variability by way of an 
analysis of variance (ANOVA). The results for each model of each device were 
combined into a total mean and SD per flow rate, respiratory rate and tidal volume 
(nine runs). This too would reflect significant device variability if it existed. 
Comparisons between EIOCs at different respiratory rates, at the same oxygen flow 
rate (variable performance systems) or FiO2 (fixed performance systems) were also 
analysed by an ANOVA test. Significance was defined as a p value <0.05. 
 
3.3 Results 
Summary data is presented in this result section. 
 
3.3.1 Inter-device variability 
On comparing the inter-device variability, no significant difference between individual 
masks was detected p=0.95). The two different batches of masks did not differ 
significantly across time p=0.9. 
 
3.3.2 Variable Performance Systems 
The variable performance systems that were analysed were the Hudson mask with 
and without the non-rebreathing reservoir bag attachment, nasal cannulae, and the 
Thermovent HME. 
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3.3.2.1 Hudson mask 
The Hudson mask showed evidence of deterioration of performance as the 
respiratory rate increases both at tidal volumes of 300 ml and 500 ml. At a 
respiratory rate of 10 breaths.min-1 the mask delivers a mean EIOC of 94.67% and 
88.33% at 15 l.min-1 oxygen flow rate for tidal volumes of 300 ml and 500 ml 
respectively. This reduces to mean of 75.67% and 63.33% when the respiratory rate 
is raised to 30 breaths.min-1 (p<0.001). The reduction in performance is greater at 
500 ml tidal volume (38.30%) than at 300 ml (20.07%). (Figures 3.2 and 3.3). 
 
3.3.2.2 Hudson non-Rebreathing Mask 
The addition of a reservoir bag and flap valves over the orifices does not improve the 
performance of the Hudson mask. The mean EIOC delivered by the non-rebreather 
system at 15 l.min-1 oxygen flow rate and 10 breaths.min-1 respiratory rate is 85.67% 
and 79.33% for 300 ml and 500 ml tidal volume respectively.  In fact for all oxygen 
flow rates the non-rebreather system fails to perform as well as the standard Hudson 
mask, across all respiratory rates and at both tidal volumes. It also shows 
deterioration in performance as the respiratory rate increases. For example at an 
oxygen flow rate of 15 l.min-1 the mean EIOC falls from 85.67% to 68.33% (20.2%) 
and 79.33% to 59.67% (24.78%) at 300 ml and 500 ml tidal volume. p<0.001in both 
cases (Figures 3.4 and 3.5). 
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Figure 3.2 Hudson mask. Effective inspired oxygen concentration (EIOC) achieved by a 
Hudson Mask at four oxygen flow rates: 2 litres.min
-1
 (), 6 litres.min-1 (), 10 litres.min-1 () 
and 15 litres.min
-1
 (), across a range of respiratory rates at a tidal volume of 300 ml. Error 
bars represent +/- 2 SD. (n= 9.  measurements per plot). 
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Figure 3.3 Hudson mask. Effective inspired oxygen concentration (EIOC) achieved by a 
Hudson Mask at four oxygen flow rates: 2 litres.min
-1
 (), 6 litres.min-1 (), 10 litres.min-1 () 
and 15 litres.min
-1
 (), across a range of respiratory rates at a tidal volume of 500 ml. Error 
bars represent +/- 2 SD. (n= 9 measurements per plot).  
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Figure 3.4 Hudson non-Rebreather Mask. Effective inspired oxygen concentration (EIOC) 
achieved by a Hudson non-Rebreather Mask at four oxygen flow rates: 2 litres.min
-1
 (), 6 
litres.min
-1
 (), 10 litres.min-1 () and 15 litres.min-1 (), across a range of respiratory rates at 
a tidal volume of 300 ml. Error bars represent +/- 2 SD. (n= 9 measurements per plot). 
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Figure 3.5 Hudson non-Rebreather Mask. Effective inspired oxygen concentration (EIOC) 
achieved by a Hudson non-Rebreather Mask at four oxygen flow rates: 2 litres.min
-1
 (), 6 
litres.min
-1
 (), 10 litres.min-1 () and 15 litres.min-1 (), across a range of respiratory rates at 
a tidal volume of 500 ml. Error bars represent +/- 2 SD. (n= 9 measurements per plot). 
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3.3.2.3 Nasal Cannulae 
The Nasal Cannulae achieved the highest EIOC of all the variable performance 
systems. This was maintained across all oxygen flow rates and both tidal volumes. In 
particular, at 15 l.min-1, a respiratory rate of 10 breaths.min-1 and a tidal volume of 
300 ml, the mean EIOC was 97.33%, approaching the holy grail of 100% in a self-
ventilating patient. The cannulae did, however, also demonstrate deterioration in 
performance as the respiratory rate increased at both tidal volumes. At an Oxygen 
flow rate of 6 l.min-1: 87.67% to 69.33% (20.92%) and 81.33% to 54.67% (14.75%), 
300 ml and 500 ml. P<0.001 in both cases (Figures 3.6 and 3.7).  
 
3.3.2.4 Thermovent H2 HME 
 As with the above oxygen delivery systems, the Thermovent system in the intubated 
mannequin showed deterioration in performance at higher respiratory rates. Unlike 
the previous systems, at lower oxygen flow rates the performance was more 
consistent (2 l.min-1 O2 flow rate Vt 500 ml: 10 breaths.min
-1 31.67%, 30 breaths.min-
1 25.67%). This was however still statistically significant (p=0.04). The change in tidal 
volume had less of an influence on the EIOC (4 l.min-1 O2 flow rate 30 breaths.min
-1: 
Vt 300 ml 32%, Vt 500 ml 31.33%) (Figures 3.8 and 3.9).  
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Figure 3.6 Nasal Cannulae. Effective inspired oxygen concentration (EIOC) achieved by nasal 
cannulae at four oxygen flow rates: 2 litres.min
-1
 (), 6 litres.min-1 (), 10 litres.min-1 () and 
15 litres.min
-1
 (), across a range of respiratory rates at a tidal volume of 300 ml. Error bars 
represent +/- 2 SD. (n= 9 measurements per plot). 
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Figure 3.7 Nasal Cannulae. Effective inspired oxygen concentration (EIOC) achieved by nasal 
cannulae at four oxygen flow rates: 2 litres.min
-1
 (), 6 litres.min-1 (), 10 litres.min-1 () and 
15 litres.min
-1
 (), across a range of respiratory rates at a tidal volume of 500 ml. Error bars 
represent +/- 2 SD. (n= 9 measurements per plot).
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Figure 3.8 Thermovent T2 HME. Effective inspired oxygen concentration (EIOC) achieved by a 
Thermovent T2 HME at four oxygen flow rates: 2 litres.min-1 (), 6 litres.min-1 (), 10 
litres.min-1 () and 15 litres.min-1 (), across a range of respiratory rates at a tidal volume of 
300 ml. Error bars represent +/- 2 SD. (n= 9 measurements per plot). 
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Figure 3.9 Thermovent T2 HME. Effective inspired oxygen concentration (EIOC) achieved by a 
Thermovent T2 HME at four oxygen flow rates: 2 litres.min-1 (), 6 litres.min-1 (), 10 
litres.min-1 () and 15 litres.min-1 (), across a range of respiratory rates at a tidal volume of 
500 ml. Error bars represent +/- 2 SD. (n= 9 measurements per plot). 
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3.3.3 Fixed Performance System 
The fixed performance system that was tested was the Venturi mask and inserts 
supplied by Flexicare®. 
3.3.3.1 Venturi System 
The Venturi system showed consistent performance at the lower oxygen 
concentration inserts at both tidal volumes examined. They mean EIOC measured 
was close to that expected by the insert. For example at 30 breaths.min-1 with a tidal 
volume of 500 ml the 24% and 28% inserts delivered a mean EIOC of 23.67% 
(p=0.79) and 26% (p=0.80) respectively. There was, however, some reduction in the 
EIOC at the higher oxygen concentration inserts, particularly at 500 ml tidal volume. 
(Vt 300 ml 60% insert 10 breaths.min-1 59.67%, 30 breaths.min-1 53.33%. Vt 500 ml 
60% insert 10 breaths.min-1 57.33%, 30 breaths.min-1 50.33%. Both were statistically 
significant (p<0.001) (Figures 3.10 and 3.11). 
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Figure 3.10 Venturi Mask. Effective inspired oxygen concentration (EIOC) achieved by a each 
Venturi Mask insert: 24% (), 28% (), 35% (), 40% () and 60% (), across a range of 
respiratory rates at  a tidal volume of 300 ml. Error bars represent +/- 2 SD. (n= 9 
measurements per plot). 
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Figure 3.11 Venturi Mask. Effective inspired oxygen concentration (EIOC) achieved by a each 
Venturi Mask insert: 24% (), 28% (), 35% (), 40% () and 60% (), across a range of 
respiratory rates at a tidal volume of 500 ml. Error bars represent +/- 2 SD. (n= 9 measurements 
per plot). 
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3.3.4 High Flow, High Concentration Systems 
 The High Flow, High Concentration System that was tested was the Vapotherm® 
system. 
3.3.4.1 Vapotherm® 
The Vapotherm system had additional analysis at two gas flow rates 15 and 30 l.min-
1. The oxygen concentration was selected on the dial on the system. In terms of 
consistent performance, this system showed very little reduction in EIOC as the 
respiratory rate. At tidal volumes of 300 ml there was no change in EIOC at all 
oxygen concentrations, as the respiratory rate increased. Doubling of the gas flow 
rate also had little influence on the EIOC. With the tidal volume set at 500 ml, 
however, there was a slight reduction in EIOC at 15 l.min-1 gas flow (FiO2 100%, 10 
breaths.min-1 71.67, 30 breaths.min-1 67.67) and this did not reach statistical 
significance (p=0.10).  This was abolished when the gas flow rate was increased to 
30 l.min-1. Of most interest was that in this model the Vapotherm® is not able to 
deliver the dialled FiO2. For example, at both 300 ml and 500 ml tidal volume the 
maximum EIOC achieved for „100%‟ FiO2 78.67% and 76.67% respectively. 
Increasing the gas flow rate did improve delivery, particularly in the 500 ml 
assessment, but only by a maximum of 7%. (30 breaths.min-1 100% FiO2 Vt 500 ml) 
(Figures 3.12 and 3.13).  
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Figure 3.12 Vapotherm. Effective inspired oxygen concentration (EIOC) achieved by the 
Vapotherm for four different oxygen concentrations at 30 l.min-1 gas flow: 30% (), 60% (), 
80% () and 100% () across a range of respiratory rates at a tidal volume of 300 ml. Error 
bars represent +/- 2 SD. (n= 9 measurements per plot) 
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Figure 3.13 Vapotherm. Effective inspired oxygen concentration (EIOC) achieved by the 
Vapotherm for four different oxygen concentrations at 30 l.min-1 gas flow: 30% (), 60% (), 
80% () and 100% () across a range of respiratory rates at a tidal volume of 500 ml. Error 
bars represent +/- 2 SD. (n= 9 measurements per plot). 
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3.4  Discussion 
The model clearly demonstrates a reduction in the effective inspired oxygen 
concentration (the mixed oxygen concentration from the entire inspiratory phase) 
with the variable performance masks as the respiratory rate increases while at a 
fixed tidal volume. This varied between delivery systems. For example, nasal 
cannulae with an oxygen flow rate of 4 l.min-1, deliver an EIOC from 69.67% to 48% 
when the respiratory rate increases from 10 breaths per minute to 30 and the tidal 
volume is 500 ml.  
With the fixed performance systems, the impact of altered ventilation is substantially 
diminished especially at the lower concentrations. The 24% venturi mask shows no 
reduction in performance. At higher „fixed‟ concentrations there is deterioration. The 
60% mask does deteriorate from 57.33% at 10 breaths per minute and a tidal 
volume of 500 ml, to 50.33% at 30 breaths per minute, behaving increasingly like a 
variable performance system as the venturi orifice diameter increases. 
The Vapotherm®, which is a high flow rate system, shows minimal change across the 
range of respiratory rates. Interestingly changing the gas flow rate from 15 l.min-1 to 
30 l.min-1 only has a minimal effect on EIOC and neither produces the value that is 
selected on the oxygen:air mix dial, particularly at the higher FiO2. The system is 
known to achieve 99% humidification and this would compromise the EIOC, however 
this could only account for a drop of approximately of 5% with fully saturated air.  
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Table 3.3 Manufacturers recommendations for oxygen flow rates and resultant oxygen 
concentrations for the variable performance device
23
 (see Appendix 2). 
Oxygen Delivery Device Oxygen Flow Rate (l.min-1) Resultant Oxygen 
Concentration (%) 
Hudson mask  
(Teleflex Medical®) 
 
5 – 6 
7 – 8 
9 – 10 
40 
50 
60 
Hudson Nonrebreather  
(Teleflex Medical®) 
10 – 12* 
 
80-100 
Nasal Cannulae  
(Teleflex Medical®) 
 
1 
2 
3 
4 
5 
6 
24 
28 
32 
36 
40 
44 
Thermovent® T2 HME 
(Smiths Medical) 
1 – 10 27 – 60 
Ventimask® 
(Felxicare®) 
2 (24%) 
4 (28%) 
6 (31%) 
8 (35%) 
10 (40%) 
15 (60%) 
24 
28 
31 
35 
40 
60 
Vapotherm® 
(Vapotherm Inc.) 
8 – 40 30 – 100  
*May require higher flows. The flow should be adjusted so that the reservoir bag 
does not deflate more than one third during inspiration  
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Table 3.3 summarises the manufacturer‟s recommendations for oxygen flow rates for 
their variable performance devices tested, and the resultant oxygen concentration to 
be expected. The study performed here, in a model, suggests that with many 
currently used oxygen delivery systems this predicted performance is unpredictable. 
 
3.4.1 Clinical Implications 
This has significant clinical implications. Oxygen therapy is often first line treatment 
of those with acute problems in the ward environment and is also a significant part of 
the armament available to the outreach and other ward teams. If the model results 
are extrapolated to the critically ill patient, then knowledge about the impact of 
altered respiratory pattern on the oxygen delivery being achieved will be important in 
deciding which delivery system to use. Furthermore it may well be that in many 
cases where the target of arterial oxygenation, be it SpO2 or PaO2, is not achieved 
because of the performance of the oxygen mask, a simple  increase in the oxygen 
concentration set or alteration of the flow rate delivered to these systems may 
correct the problem. The second issue is that interpretation of results may be 
affected. Lower patient values than expected as a result of predicting a higher 
oxygen delivery than is actually being achieved may influence clinical judgement as 
to the severity of the problem. There may be a lower than desired SpO2, and a 
clinician may thus institute more invasive forms of ventilation such as continuous 
positive airway pressure (CPAP), bi-level positive airway pressure or even 
mechanical ventilation based on this interpretation. Escalating to these more 
sophisticated forms of oxygen delivery may be entirely appropriate and as shall be 
discussed later in this thesis, be desirable for certain specific conditions. However 
unnecessary escalation based on the delivery of lower than expected oxygen 
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concentrations may be counterproductive in terms of comfort and the need for a 
higher intensity environment. Both CPAP and BiPAP may be difficult to deploy and 
are not without complications when used in a ward environment. If this can be 
circumvented by the use of a more effective system then that would be an 
advantage. Comfort in particular is likely to have a significant influence on the time 
any oxygen system stays on the patient. Using or developing more „comfortable‟ 
systems is important as it may provide more reliable continuous delivery, a 
fundamental factor of oxygen therapy. 
If the desired end-point is a „normal‟ SpO2 or PaO2 then predictable and effective 
oxygen delivery is needed. An understanding of what can be achieved by each 
system is not just academic, but vital if unnecessary use of more invasive systems is 
to be avoided. For example, this study demonstrates that at higher respiratory rates, 
the Hudson non-rebreather mask delivers much lower oxygen concentrations that 
many would assume (many clinicians believe it to be able to deliver 100%). A low 
SpO2 in such a situation may be seen as an indication for CPAP or urgent 
mechanical ventilation. However to achieve the desired end-point, maybe a better 
design or mode of oxygen delivery is all that is required, thus reducing the potential 
hazards of more aggressive techniques. Following on from these studies and an 
increased awareness of these issues, there has resulted a proliferation of the use of 
the Vapotherm® system in the ward environment and a reduction in the use of 
CPAP. It subjectively appears to be effective simply by delivering the oxygen 
concentration that is required. This requires further evaluation. 
Another potential benefit may be that most of the masks and delivery systems in 
common use, with the exception of Vapotherm® are relatively old systems that were 
developed years ago. The information from this model may allow a new innovative 
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approach to developing more dependable systems by looking at ways of altering the 
effective reservoirs in the breathing systems as well as altering flow. The model may 
also be of use in testing the efficacy of these systems. 
 
3.4.2 Mechanism of Failure 
The actual FiO2 that is inspired by the patient and reaches the distal airways is 
difficult to predict for several reasons (see Table 3.1). The entrainment of 
environmental air will be influenced by the relationship between oxygen gas flow 
through the system, the inspiratory pattern of the patient, the effective reservoir 
within the mask system itself and to some degree the dead space of the mask and 
pharynx. The single most important factor is probably the relationship between the 
tidal volume, the peak inspiratory flow rate (PIFR), and at what point this exceeds the 
available volume of undiluted oxygen within the mask and pharynx. In sick patients 
the respiratory pattern is often altered and tends towards relatively lower tidal 
volumes at an increased respiratory rate and hence a high PIFR. Respiratory rates in 
excess of 30 breaths per minute are not uncommon and may be associated with 
PIFR‟s of greater than 30 lmin-1 and loss or diminution of the respiratory pause. This 
will increase entrainment of environmental air which combined with rebreathing of 
dead space gases will dilute the inspired oxygen concentration. 
Attempts to measure this in the past have focused upon trying to instantaneously 
measure FiO2 and gas flow
9. This has been hampered by the sampling site, flow and 
oxygen concentration measurement and aligning these electronically. Sampling in 
patients needs to be as far down the airway as possible, which again poses a 
difficult. The accuracy of the pneumotachograph is problematic and its presence will 
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invariably alter the mechanics of the delivery system itself. Rapid real time oxygen 
concentration analysis has been difficult, and even now, when available, would have 
to synchronise with flow measurement to provide the amount of oxygen delivered.  
An alternative approach is this model that mimics spontaneous breathing patterns. It 
may produce a more realistic indication of how these delivery systems function in 
adverse circumstances. This contrasts with most previous models which have 
evaluated the concentration of the oxygen flowing through the delivery system 
without looking at the interplay between delivery and respiratory pattern4.  
 
3.4.3 The Model as a Reflection of Real Life 
There are problems with the model. It is far from a perfect representation of human 
ventilation. The mannequin is synthetic and whilst anatomically correct, does not 
behave as the more pliable human airway. Snug mask fitting on the face is an issue 
although the same can be said for the human subject. The more rigid mannequin 
permits predictable increases in PIFR as the radius of the airway remains constant. 
In vivo, respiratory distress and tachypnoea with a high work of breathing could 
collapse of the upper airway. This would reduce the airway radius, potentially leading 
to increased airway resistance and reduced PIFR. Air entrainment would thus be 
less and so the performances of the oxygen systems may be maintained. The 
respiratory cycle employed in the model may also differ from that seen in vivo. Fixing 
the I:E ration at 1:2 at all the respiratory rates has two potential confounding effects. 
First, the respiratory pause is likely to be maintained at far higher respiratory rates 
than that seen clinically. This serves to maintain mask performance at higher rates in 
the model. Second, the I:E is not constant in respiratory distress. Expiratory time is 
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reduced in vivo, and although it will also decrease at high rates with the model the 
pattern may be different. As with the loss of respiratory pause this would further 
serve to cause a lower oxygen delivery as there would be less time for any reservoir 
to be replenished. 
Models are able to look at the physics of the ventilation and will never really 
approximate the physiology of the lungs. In these studies it is really the physics of 
oxygen concentration during inspiration that is of interest and the model can look at 
these far more easily than physiological studies. The magnitudes of the changes 
seen are large. While they may not be exactly the same as occurs in vivo the 
magnitude of change clearly illustrates the trends one would see clinically and it and 
does fit with the hypothesis that air entrainment changes with increasing respiratory 
rate to the detriment of inspired oxygen concentration.  
Similarly in terms of gas composition, the results obtained from this model are not 
directly applicable to the clinical setting. There is an absence of the contribution that 
carbon dioxide and water vapour (with the exception of the Vapotherm®) make to the 
concentration of oxygen in the inhaled gas. There is no nasopharyngeal 
humidification and no carbon dioxide production in the inhaled gas. Indeed, the 
rebreathing of any exhaled gas is prevented by the effects of the unidirectional 
valves passing „inhaled‟ gas to the oxygen analyser.  
The contribution of the dead space gases to FiO2 can, however, be estimated by 
making an assumption about the proportion dead space contributes to tidal volume, 
oxygen uptake and CO2 production. A relatively simple formula can be derived to 
predict further reduction in the measured EIOC values caused by the presence of 
dead space gases (see Appendix 1). These are however only estimates and cannot 
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accurately predict FiO2 based on this model‟s data, because of the complexity of 
pulmonary physiology. The variation in anatomical and physiological dead space and 
changes in oxygen consumption and CO2 production, particularly in acute illness, 
make the derived values in Appendix 1 only approximations. The model cannot 
mimic physiology but it does illustrate the physics of oxygen delivery by these 
systems and the trends present in the model would be expected to be present in the 
patient.  
In only one of the delivery systems did the model produce an unexpected result. 
When the nasal cannulae are used the effective inspired oxygen was higher than 
with the Hudson mask which was not an intuitive result. In the model the oxygen is 
delivered into the nose of the manikin and even though the mouth was open, it is 
possible that it effectively produces a pharynx full of oxygen resulting in a high 
inspired oxygen value. It is impossible to say if this represents the situation clinically.  
Using this model, an indication of the performance of different oxygen delivery 
systems has been achieved. The variable performance systems, including those with 
a rebreathing bag, appear to deliver lower than predicted mixed inspired oxygen 
concentrations as the respiratory pattern deteriorates with tachypnoea, at least in 
this model. Thus in clinical practice oxygenation assessments assuming an inspired 
oxygen concentration may be quite misleading. The fixed performance systems are 
better, but only up to 60% oxygen, which may be inadequate. The high flow system 
performed well across the circumstances tested. Anxieties about comfort and airway 
drying may be misplaced24.  The results found here indicate not only the changes in 
performance already described but suggest the model could be used to produce 
realistic tables of oxygen delivery system performance across the entre range of 
oxygen delivery systems. 
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3.4.4 Conclusions 
The model demonstrates that as respiratory rate increases, a fall off in performance, 
in terms of the mean inspired oxygen concentration, is observed in most of the 
commonly used oxygen delivery systems used at this Institution. It demonstrates the 
need for an appreciation of the physical capabilities of these systems in the presence 
of abnormal respiratory patterns. It would appear from this study that when higher 
inspired oxygen requirements need to be met in the ward environment, a high flow 
system (e.g. Vapotherm®) may have a more predictable performance.  
If higher intensity ward care is to be meaningfully deployed it would seem 
appropriate to seek better designs to deliver high oxygen concentrations, whilst 
maintaining the simplicity of an easily applicable mask. Based on this data, it is 
reasonable to suggest a trend towards high flow systems as a strategy. As stated 
previously this is a model but the physics should be the same in vivo. A key 
assumption is that a high PIFR occurs in respiratory distress and this is a/the 
significant contributor to the reduction in performance of open mask systems. 
Proving that this occurs in the clinical setting is important to help explain the findings 
of this chapter and if advances are to be made in the delivery of oxygen to patients 
who are critically unwell. The following chapter attempts to demonstrate whether or 
not PIFR increases in respiratory distress. 
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Chapter 4 
Peak Inspiratory Flow Rates in Respiratory Distress 
 
4.1 Background 
4.1.1 The Relationship between Inspiratory Flow and Oxygen Delivery 
The previous chapter concluded that there is a drop off in the performance of oxygen 
delivery systems and postulated that the most likely mechanism by which the 
deterioration in performance occurs is that of entrainment of environmental air due to 
an increase in peak inspiratory flow rate (PIFR). What is not clear is whether this 
phenomenon is present in the clinical setting. As described in Chapter 3, 
demonstration of a significant fall off in performance of oxygen delivery devices is 
technically difficult in vivo. In order to evaluate the different techniques of oxygen 
therapy some form of in the clinical validation of the model is required. It is assumed 
that inspiratory flow rate changes in many disease states but it may be that whilst 
respiratory rate increases in most forms of acute respiratory disease, alterations in 
tidal volume, minute ventilation, respiratory pause time and inspiratory:expiratory 
(I:E) ratio may cause no significant change in inspiratory flow. This should be 
assessed directly as a significant alteration in flow rates would lend some 
circumstantial credence to the hypothesis that entrainment is a key feature of mask 
performance. Any further innovation in oxygen delivery systems, as shall be 
discussed in the following chapters, requires some knowledge of the physical 
interaction between patient and system and elaboration of the mechanisms by which 
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performance is altered. Thus, this chapter aims to evaluate the in vivo inspiratory 
flow rates in health and acute respiratory illness. 
 
4.1.2 Literature Review 
It was anticipated that there would be considerable literature on inspiratory flow rates 
in acute clinical circumstances. In fact there is a real scarcity of literature that 
examines spirometric changes in acute shortness of breath secondary to respiratory 
illness. In the field of sports medicine high levels of exercise and high workloads are 
associated with very high peak inspiratory flow rates1, 2. Other data from the realm of 
high altitude medicine has reported raised inspiratory flow rates in climbers both at 
rest and exercising3. A study by Depledge et al. modified a Wright‟s respirometer to 
measure peak inspiratory flow rate (PIFR) in normal subjects4. Whilst remarking that 
his innovation had potential for ward usage in patients unable to attend formal 
spirometric examination, there is no further literature that this method was ever 
applied in the acute setting. Finally, there is information from studies examining 
inhalational drug delivery that quote values for peak inspiratory flow rates (PIFR). In 
stable patients PIFRs up to 400l.min-1 have been described5-7. In disease, a study by 
Dhuper et al. looked at detecting room air entrainment as an explanation for the 
failure of Heliox treatment in asthma8. They studied acute asthmatics and normal 
controls breathing 70% Heliox. The study demonstrated a significant fall in helium 
concentration at both tidal ventilation and during an asthma attack (46.2% and 
27.5%) this was counteracted by an additional gas supply being piped into the mask. 
Whilst not directly measuring inspiratory flows, they hypothesised that this change 
and its reversibility, was due to entrainment of environmental air. They demonstrated 
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that a flow rate in to a plastic mask of 25 l.min-1 is required to maintain a helium 
concentration of 70%. 
It is easy to comprehend why similar data has not been gathered in the patient group 
with respiratory failure. Static spirometry is cumbersome and potentially hazardous 
for the acutely unwell subject. Hand-held spirometers are in general basic; 
measuring only forced expiratory volume in 1 second (FEV1), forced vital capacity 
(FVC) and peak expiratory flow rates on single vital capacity manoeuvres. Some 
models will document a PIFR following a VC, but not during tidal ventilation. It is 
abnormal tidal breathing that is of interest in order to explain the findings so far. 
 
4.1.3 Hypothesis 
The hypothesis of this study is that PIFRs are significantly higher in patients with 
acute respiratory failure when „at rest‟, compared to similar healthy subjects. 
 
4.1.4 Aims 
The study had two aims. Firstly to document PIFRs in healthy subjects both at rest 
and during exercise. This would permit comparison of the experimental technique to 
the current literature and thus prove its adequacy. Secondly, to measure and 
compare PIFRs in patients with acute respiratory failure to those of similarly matched 
control patient subjects. 
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4.2  Methodology 
4.2.1  Study Design 
Two similar studies were performed. The first using normal subjects and the second 
using patients and matched controls. 
 
4.2.2 Study 1: Normal subjects 
Recruitment of 10 volunteers was achieved from the anaesthetic and intensive care 
staff at the Chelsea and Westminster Hospital. The group consisted of medical staff, 
nursing staff and physiotherapists. Inclusion criteria consisted of physical fitness to 
climb six flights of stairs and verbal consent to participation in the study. Exclusion 
criteria were chronic lung disease with the exception of asthma at British Thoracic 
Society treatment level 1; inter-current upper or lower respiratory illness, pregnancy, 
orthopaedic or rheumatological illness; a history of syncope or arrhythmia either 
spontaneous or exercise-induced9. 
 
4.2.3 Study Equipment 
In order to immediately assess the peak inspiratory flow rate of the subjects during 
non-forced ventilation, a hand-held spirometer was used. The Vitalograph® 2120 
(Buckingham, UK) was chosen as the most appropriate tool. Connected to a laptop 
PC it can record more complex spirometric values using the accompanying 
Spirotrac® 4.24 software. In particular the maximum voluntary ventilation (MVV) 
function produces a graph of volume against time for 14 seconds. This plot can be 
converted to a JPEG file and analysed using GraphClick 2.9.2 (Arizona Software, 
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USA). This software performs a point differentiation, thereby giving a value for flow 
rate. The spirometer was calibrated by Vitalograph® technicians, and was maintained 
in good working order. Use of the spirometer by the subjects required a bacterial 
filter and a disposable cardboard mouthpiece. 
The steps from the basement to the 5th floor of the hospital were used as the 
exercise test. Each flight was 13 steps (26 per floor) and this approximated 9 
metabolic equivalents (METs). 
 
4.2.4 Testing of normal subjects 
The selected volunteers underwent MVV testing using the spirometer both at rest 
and following rigorous exercise. The subjects were required to sit quietly for 15 
minutes. They then performed an MVV test and a single breath vital capacity 
enabling documentation of forced vital capacity (FVC) and forced expiratory volume 
in 1 second (FEV1). Subsequently each of the subjects were asked to walk (not run) 
as fast as possible from the basement to the 5th floor without stopping. As soon as 
they arrived they underwent a second MVV test. The graphs obtained were 
converted to JPEG format and a mean peak inspiratory flow rate was calculated from 
three of the breaths displayed on the graph. Demographic data of age, gender, 
height and weight, were also gathered.  
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4.2.5 Study 2: Patients 
This was an open non-blinded case-control observational study. Patients were 
recruited from the intensive care unit, general wards and emergency department of 
the Chelsea and Westminster Hospital.  
Inclusion criteria were as follows:  
 Age > 16 years 
 Presence of oxygen therapy. 
 Tachypnoea of greater than 20 breaths per minute. 
 Onset of symptoms within 48 hours. 
 Evidence of hypoxia SpO2 ≤92% breathing room air or a partial pressure of 
arterial oxygen (PaO2) of ≤ 8.0 kPa.  
It was important that these values were reversed to an SpO2 of ≥95%, by the 
application of mask oxygen via a Venturi mask delivering a fraction of inspired 
oxygen (FiO2) of 0.6.  
Exclusion criteria were:  
 
 Excessive oxygen requirements as defined by a fall in SpO2 of ≥5% within 30 
seconds of removal of oxygen and/or desaturation below 90% whilst receiving 
oxygen, at any time. 
 Patient refusal. 
 Reduced level of consciousness. 
 Confusion. 
 Inability to tolerate cushioned mask. 
 Vomiting. 
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 Abnormal facies or facial fractures/injuries. 
 Pregnancy. 
 Refusal by attending physicians. 
 
4.2.6 Controls 
Controls of similar age to the patients being investigated were recruited from the 
surgical wards at both Chelsea and Westminster Hospital and Northwick Park 
Hospital. They were studied from prior to elective general and orthopaedic surgical 
procedures and were required to be independently graded as American Society of 
Anesthesiology (ASA) I and II with no history of chronic lung disease (except asthma 
treated to BTS guidelines level 1) or inter-current respiratory illnesses. They were 
required to describe a normal exercise tolerance defined as being able to climb two 
flights of stairs without stopping or experiencing significant shortness of breath. Their 
SpO2 needed to be ≥95% whilst breathing room air. Cigarette smoking was not an 
exclusion criterion unless there was evidence of chronic obstructive airways disease. 
 
4.2.7 Testing of patients and controls 
The patients underwent three measurements of MMV using the hand-held 
spirometer, three to five minutes apart with oxygen re-applied between tests. The 
examination was terminated if desaturation occurred during testing or the patient 
failed to regain an SpO2 of ≥95% for one minute before repeating. The control 
patients underwent exactly the same testing procedure including the use of oxygen 
between tests. They were tested on the ward pre-operatively, prior to any pre-
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medication or medical intervention. Essentially, an in-patient group who were 
otherwise well. 
 
4.2.8 Data Collection  
Measurement of PIFR was performed using the method outlined earlier. 
Demographic data was also collected including the diagnosis made by the attending 
physicians. 
 
4.2.9 Statistical Analysis 
All statistical analysis was performed using SPSS 14.0 (LEAD Technologies Inc., 
USA). In Study 1, a mean PIFR was calculated in order to validate the method with 
previous studies that looked at high workload exercise. For Study 2 comparisons of 
PIFR measurements between the two groups was performed using Mann-Whitney U 
test. Demographic data was analysed using a student t-test for continuous data and 
a Chi2 for categorical data. 
 
4.2.10 Sample Size 
A sample size of 32 patients and 15 controls permits detection of a difference of a 
PIFR of >36 l.min-1 with a power of 80% and a 5% significance. This value is well 
within the values achieved by healthy volunteers, as outlined in the above 
introduction (up to 400 l.min-1). Data from Study 1 detected a mean PIFR at rest of 
30.29 l.min-1 (SD 2.54 l.min-1). Pilot data with 5 patients (included in the overall 
results) detected a median PIFR of 84.66 l.min-1 (IQR 38.4 l.min-1). Thus a value of 
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>36 l.min-1 would represent an approximate doubling of PIFR and approximate the 
pilot data. 
 
4.3 Results 
4.3.1 Study 1: Normal subjects 
Table 4.1 demonstrates the demographics of the normal subjects taking part in the 
validation study. They are all young (mean age of 30.29 (SD 2.54) and all had a 
normal body habitus with normal lung function. One subject smoked approximately 
five cigarettes per day and another require salbutamol therapy as required for mild 
seasonal asthma. 
 
Table 4.1 Demographics of the normal subjects 
Subject 
Number 
Age 
(years) 
Gender Height 
(cm) 
Weight 
(kg) 
FEV1 
(l.min
-1
) 
FVC 
(l.min
-1
) 
FEV1/FVC 
(%) 
1 35 M 185 79 4.82 6.11 78.89 
2 32 M 184 78 4.91 6.23 78.81 
3 29 M 167 74 4.11 4.78 85.98 
4 29 M 188 87 6.22 7.1 87.61 
5 31 F 166 66 3.45 3.93 87.79 
6 28 F 184 75 4.24 4.82 87.97 
7 29 F 159 56 3.1 3.63 85.40 
8 36 M 185 82 4.61 6.16 74.84 
9 26 M 175 78 4.49 5.28 85.04 
10 34 M 182 78 4.62 5.67 81.48 
FEV1, Forced expiratory volume in 1 second; FVC, Forced vital capacity 
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Table 4.2 The mean peak inspiratory flow rates in normal subjects at rest and at peak exercise. 
Subject 
number 
1 2 3 4 5 6 7 8 9 10 
PIFRrest 
(l.min-1) 
27.22 31.48 33.65 26.35 29.16 27.83 30.27 32.93 32.33 31.69 
PIFRexercise 
(l.min-1) 
282.1 290.2 246.4 306.5 211.5 236.7 215.8 241.7 294.9 278.4 
PIFR, peak inspiratory flow rate. 
 
 
Figure 4.1 The change in peak inspiratory flow rate in 10 normal subjects on climbing 6 flights 
of stairs. 
 
Table 4.2 and Figure 4.1 demonstrate the values for peak inspiratory flow rate for the 
10 normal subjects at rest and after 6 flights of stairs. The data was normally 
distributed with a means of 30.29 l.min-1 (SD 2.54) and 260.41 l.min-1 (SD 34.12) for 
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rest and exercise respectively. These values are in keeping with the published 
literature1-4.  
 
4.3.2 Study 2: Patients 
A total of 47 subjects were recruited to Study 2. 32 were patients with the inclusion 
criteria. 15 were enrolled as normal controls. Their demographics are summarised in 
Table 4.3. The actual PIFR data is presented in Table 4.4 and summarised in Figure 
4.2. The distribution of PIFR values in the patient group was non-parametric and 
showed a leftward skew. As such a mean value for PIFR was not able to be 
calculated and a median calculated instead. In the control group, much like the 
normal subjects in Study 1, the distribution of PIFR values was normally distributed. 
The groups were well matched in terms of age and gender and there were significant 
differences in the respiratory rates and the SpO2 values when breathing room air. 
The median PIFR in the patient group was 76.5 l.min-1 (interquartile range 51.25 
l.min-1). This compared to a median of 30.00 (interquartile range 6.00 l.min-1) in the 
control group (p<0.0001).  
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Table 4.3 Characteristics of patients with respiratory failure and controls. 
Characteristic Patients (n=32) Controls (n=15) p value 
Age (yr) +/- SD 62.8 +/- 16.6 59.73 +/- 12.7 p=0.500a 
Male sex n (%) 53.1% 40.0% p=0.401b 
Diagnosis/Surgical procedure 
Bacterial pneumonia 
Pulmonary oedema 
COPD 
Pulmonary embolus 
Acute asthma 
Acute lung injury 
Atelectasis 
Chest trauma 
Haemothorax 
Pancreatitis 
Pneumocystis carinii pneumonia 
Severe sepsis 
Viral pneumonitis 
 
 
Cholecystectomy 
 Herniorrhaphy 
Haemorrhoidectomy 
TKR 
Varicose veins  
Knee arthroscopy 
THR 
 
 
11 
6 
3 
2 
2 
1 
1 
1 
1 
1 
1 
1 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
3 
2 
2 
2 
1 
1 
 
 
Mean respiratory rate (bpm) +/- SD 27.21 +/- 3.75 12.67 +/- 2.12 p<0.001a 
Peripheral oxygen saturation on air 
(%) +/- SD 
90 +/- 1.72 97 +/- 1.69 p<0.001a 
a2-tailed Student t-test p value; bChi-squared test p value; SD, standard deviation; COPD, 
chronic obstructive airways disease; bpm, breaths per minute. 
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Table 4.4 Mean peak inspiratory flow rates and respiratory rates for patients and controls 
Patients RR  
(breaths.min-1) 
PIFR 
(l.min-1) 
Controls  RR 
(breaths.min-1) 
PIFR 
(l.min-1) 
1 21 75 1 11 30 
2 31 83 2 12 31 
3 25 113 3 10 24 
4 21 73 4 10 33 
5 32 69 5 16 25 
6 28 253 6 12 33 
7 26 58 7 13 24 
8 25 66 8 11 30 
9 31 77 9 10 26 
10 23 295 10 15 26 
11 31 103 11 15 27 
12 30 57 12 13 32 
13 28 82 13 16 31 
14 25 134 14 14 33 
15 32 59 15 12 32 
16 21 112    
17 25 99    
18 21 78    
19 32 142    
20 30 192    
21 28 178    
22 27 49    
23 23 76    
24 27 59    
25 23 94    
26 27 65    
27 31 49    
28 26 76    
29 31 56    
30 27 105    
31 34 59    
32 29 36    
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Figure 4.2 A box and whisker plot demonstrating the difference in peak inspiratory flow rates 
between the patients and controls. p < 0.0001 
 
4.4 Discussion 
This small study examining the effect of acute respiratory failure on the peak 
inspiratory flow rate demonstrates that shortness of breath is associated with an 
increase in the PIFR when compared to a control group of similar age healthy 
subjects without acute respiratory disease. It was clearly impossible to select normal 
subjects prior to acute respiratory failure and while the pre-operative group may have 
been different, potentially with less co-morbidity, it did provide an idea of the flow 
rates in similar age groups under normal circumstances. It would be very unlikely 
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that the patients in acute respiratory failure, as a group, would have particularly high 
resting peak inspiratory flow rates.  
The spread of inspiratory flow rates is wide with a maximum value of 293 l.min-1 
achieved by a young man with severe pneumonia. The patient group also had a 
significantly increased respiratory rate. It was not possible with the software used, to 
measure the area under the curve from the MVV traces and obtain tidal volumes. 
However visual examination and comparison with those of the normal subjects 
during exercise implied that the tidal volume had fallen. It is impossible to say 
whether this represented the same minute ventilation at a higher respiratory rate, 
however it does suggest a double-negative effect as far as a patient‟s interaction 
with an open oxygen delivery system. Firstly the high PIFR could cause functional 
failure of the oxygen delivery device as demonstrated by the model in vitro. 
Secondly, falling tidal volume would increase the proportion of dead space 
ventilation with an associated reduction in alveolar ventilation and worsening of 
ventilation perfusion match. Finally, there is clear loss of the respiratory pause in the 
patient group when compared to the controls. This too would compromise oxygen 
delivery. 
 
4.4.1 Clinical Implications 
If the change in peak inspiratory flow is the cause of entrainment then there may be 
methods of circumventing the problem. This could be achieved by using systems 
that provide a method for matching the PIFR at all times or by providing a suitable 
and adequate reservoir throughout the inspiratory phase of ventilation. For example, 
continuous positive airway pressure (CPAP) systems either run at high flow rates 
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(140l.min-1) or have reservoirs so that peak flows can be easily met. Thus no 
entrainment as evidenced by deteriorating delivery, is seen with these systems. 
According to the data presented here, these technologies should perform well 
enough to match the PIFR in most cases. It also helps explain why in a few cases 
closure of the CPAP valve can occur in inspiration despite full fresh gas flow in the 
system. This phenomenon has been reported by Glover et al. who also used 
developed a model of abnormal ventilation. They used it to assess the mask 
pressure achieved by a CPAP flow generator10. They found that at high inspiratory 
flow rates this pressure could reach atmospheric leading to valve closer, a potentially 
hazardous event for the patient. The flow generators that incorporate a reservoir, 
e.g.Dräger® CF800, are less likely to encounter this problem, and they may yet prove 
a better system than the less bulky non-reservoir flow generators. 
This study was made deliberately simple in order to minimise the risk to the patient. 
However it has several weaknesses. Firstly it was unblinded and this could lead to 
observer bias or even lead-time bias when the patient will participate only when 
feeling improved. Secondly the use of peak inspiratory flow rate rather than mean 
inspiratory flow rate (MIFR) is a potential criticism. PIFR occurs in the midpoint of 
inspiration and is brief. This is usually the time of peak flow so that the area under 
the curve is large. So although the period of air entrainment into an oxygen mask is 
likely to be short, it is unlikely to be offset by a longer time within the inspiratory time 
period when inspiratory flow rate is much lower.   
It could be argued that the nature of the surgery that the control group were to 
undergo was particularly unlikely to have an impact on their respiratory function (e.g. 
herniorraphy, varicose vein excision). This potential selection bias could lead to an 
unduly significant result when compared to the patient group. However, with the 
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exception of the three patients with established COPD (only one of which could be 
described as severe), all the patient groups would have fulfilled ASA I or II status 
prior to their acute illness. As such it is probably reasonable to use these controls as 
a comparison group. Finally the control group were not directly matched. Mean ages 
were comparable, but gender, whilst non-significant appears different. Closer 
matching would prove logistically more difficult in a single centre and would not be 
likely to significantly change the results obtained. Indeed, in an observational study 
such as this, it is questionable if the need for a control group is required at all. 
 
4.4.2 Conclusions 
In conclusion, this study demonstrates in vivo that there is indeed a marked increase 
in PIFR in patients in acute respiratory failure when compared to similar patients 
without acute respiratory illness. As such it confirms the findings reported in Chapter 
3 and could be considered as providing support and some associated clinical 
validation of its findings. This study is a further contribution to proving the hypothesis 
that hypoxia seen with some oxygen masks may be in part due to failure of the 
system. As is studied in the following two chapters, the beneficial effects of more 
sophisticated oxygen systems not studied in Chapter 3 may be due to the physics of 
delivery demonstrated here, rather than physiological effects they are believed to 
convey.  
In the clinical environment the use of oxygen as a major intervention in hypoxia is 
necessary and vital. These first two chapters have demonstrated that persistent 
hypoxia that can be seen with simple oxygen delivery systems is due to a mismatch 
in the mask-patient interface. This is convincingly abolished by the use of CPAP. In 
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the ward environment the advent of MET/CCO has increased the use of CPAP as a 
method for achieving the goal of appropriate oxygenation of the arterial blood. 
However, how much of this is physical and how much is physiological is unclear and 
is examined in the following two chapters. 
 
 
.  
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Chapter 5 
Continuous Positive Airway Pressure 
 
5.1 Background 
The previous two chapters have examined the interaction between the delivery of 
oxygen and the respiratory pattern of the patient. As stated at the start of Chapter 3, 
the delivery of oxygen to critically unwell patient is often an urgent intervention, and 
in such a setting. The actual oxygen delivery has been shown to be unpredictable 
using some of our standard oxygen delivery methods. The data suggest that in 
respiratory distress, the use of common mask systems often leads to a deterioration 
in oxygen delivery just when it would be desired to be optimal. Clinically, as the 
patient with ongoing hypoxaemia is at risk, recourse to more intensive interventions 
is warranted. The clinical situation may require endotracheal intubation and 
mechanical ventilation, but often continuous positive airway pressure (CPAP) or non-
invasive ventilation may be attempted in a bid to prevent immediate or unnecessary 
escalation to this very major intervention. The easiest method to apply in the ward is 
CPAP. The object of this strategy is not to ventilate the lungs, rather to maintain the 
patency of and/or recruit respiratory units which in turn should help preserve 
functional residual capacity. The net effect should be enhanced oxygen delivery and 
uptake. A more sophisticated approach is non- invasive ventilation by Bi-level 
positive airway pressure (BiPAP), where there is ventilation of the lungs by the 
application of two levels of positive pressure. This may be patient triggered or 
mandatory in nature and is also delivered via a tightly sealing cushioned mask. 
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BiPAP is, in this Institution, usually applied in high dependency areas and as such is 
not really a ward based intervention yet and so is beyond the remit of this thesis.  
CPAP is an increasingly common intervention used to deliver oxygen in the ward 
environment. Previously it was the reserve of a higher dependency area such as an 
intensive care or coronary care unit.  It used to be delivered under the supervision of 
respiratory physiotherapists, but now CPAP is very much within the repertoire of the 
general wards and is commonly delivered by nursing staff. Its benefits in congestive 
cardiac failure are well described as well as in some other forms of respiratory failure 
where reduction of the work of breathing may be helpful but its use has been 
extrapolated to a wider range of respiratory failure where the evidence is poor or 
non-existent. The reason for this is that it can be easily applied and it is often 
effective in improving oxygenation.   
There is no doubt that CPAP commonly achieves its goal of increasing patient 
oxygenation in acute respiratory failure, but what remains relatively unclear is which 
aspects of this technique leads to this result. Is it the effect of positive airway 
pressure on the lower respiratory tract, or is it more an effect of the method of 
oxygen delivery? The following two chapters aim to explore this question. 
 
5.1.1 History 
Continuous positive airway pressure (CPAP) was first described as long ago as 1936 
by Poulton, who treated a pulmonary oedema patient with high flow oxygen via an 
anaesthetic mask1. He constructed the oxygen generator by reversing the flow on a 
domestic vacuum cleaner. It was subsequently developed for use in children by way 
of head-boxes, and came into adult practice as a clinical intervention, in the late 
140 
 
1970s2-5. Its use has now diversified into a wide range of clinical situations. In the 
acute setting this is invariably for the treatment of hypoxia from many causes. 
Chronic domiciliary CPAP use is increasingly common for the treatment of 
obstructive sleep apnoea and other disorders associated with sleep and obesity. 
This chapter will not cover this indication further. 
 
5.1.2 Mechanism of Action 
It is said to have a clinical effect in several ways. It improves oxygenation but is also 
believed to have intrinsic benefits to the mechanics of breathing and as such 
reduces the work of breathing. This has the secondary effects of reducing the 
breathing rate and improving efficiency as seen by increased inspiratory force and 
larger tidal volumes. This is achieved through alterations in compliance as the 
relatively small positive pressure results in increased lung volume, possibly with 
either some recruitment or avoidance of de-recruitment, thereby a better position on 
the pulmonary compliance curve6-8. The net effect may be to minimise alveolar 
collapse, improve compliance, decrease the work of breathing and improve 
ventilation/perfusion matching9.   
 
5.1.3 Clinical Uses of CPAP 
The clinical uses of CPAP have been studied widely in many situations where 
pulmonary function is impaired. As stated above the main goals of CPAP treatment 
are to minimise alveolar collapse, improve compliance, decrease the work of 
breathing and improve ventilation/perfusion matching9. This improves oxygenation. 
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The most enthusiasm for CPAP has come from treating acute cardiogenic pulmonary 
oedema (ACPO).  
Bersten et al. demonstrated that the use of CPAP rather than oxygen therapy alone 
reduces the respiratory rate, improves oxygenation and acid-base status at 30 
minutes in 39 patients with ACPO10. There was a significant reduction in the rate of 
intubation and mechanical ventilation in the CPAP group. Interestingly, however 
these indices returned to parity at 24 hours, and there was no differences in mortality 
between the groups, although this was a small study not powered to detect mortality. 
Subsequent studies have confirmed the findings of rapid resolution of symptoms and 
hypoxia, particularly if applied early11. Indeed one study looked at application of 
CPAP by a mobile intensive care unit, prior to hospital admission12. They 
demonstrated significant improvements in oxygenation, respiratory rate, heart rate 
and systolic blood pressure. The trial was however retrospective, and thus it was not 
possible to compensate for other therapies delivered in the pre-hospital environment 
such as glyceryl trinitrate or morphine.  
These smaller studies have shown physiological improvements and reductions in 
intubation rates in ACPO, but there still remains controversy as to whether CPAP 
confers a mortality benefit for this condition. Park et al. published a study of 80 
patients randomised to receive either oxygen by face mask, CPAP or BiPAP13. They 
also documented improvements in symptoms and physiology, but in addition 
demonstrated a significant reduction in mortality for the CPAP and BiPAP patients at 
15 days when compared to the patients who received oxygen alone. This was not 
persistent and mortality was similar at 60 days. The study was prospective, but with 
small numbers in each group. A meta-analysis by Peter et al. looked at 23 trials that 
compared CPAP to oxygen therapy or BiPAP14. They concluded that in ACPO, 
142 
 
CPAP reduces the need for mechanical ventilation and mortality when compared to 
oxygen therapy alone (relative risk 0.59, (95% CI 0.38-0.90, p=0.015)). It failed to 
demonstrate a superiority of BiPAP over CPAP.  
Following this and other work15, the use of CPAP for ACPO as an additional therapy 
has become commonplace. However a recent large multi-centre study by Gray et al. 
was unable to demonstrate a mortality benefit in ACPO16.  They randomised 1069 
patients with ACPO to receive either oxygen therapy, CPAP or BiPAP. They found 
no difference in mortality at 7 days between the groups. They were also unable to 
demonstrate a reduction in intubation rates, improvement in oxygenation at 1 hour or 
respiratory rate between the groups. Only an improvement in a dyspnoea score and 
arterial pH proved to be significantly different. This paper is of major interest. It was a 
well conducted trial with a large study population. It could not show any mortality 
benefit in the specific condition of ACPO with either mode of non-invasive ventilation 
(NIV).  
Much of the theorising that had occurred prior to this publication had focussed on a 
cardiovascular benefit by the application of PAP. Raising intrathoracic pressure 
would reduce cardiac preload, and by reducing the work of breathing, reduce 
myocardial stress17, 18. There is also echocardiographic data of patients receiving 
CPAP for ACPO that supports a reduction in end-diastolic left ventricular volume 
compared to patients on oxygen alone17. Despite this evidence, the paper by Gray et 
al. does not demonstrate that this transfers to a survival benefit 
CPAP has also been shown to convey benefit in the treatment of post-operative 
atelectasis and hypoxia. Squadrone et al. performed a multi-centre randomised 
controlled trial of 209 patients with post-operative hypoxia following major elective 
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abdominal surgery19. Patients were either assigned to receive oxygen by face mask, 
or CPAP. They reported a lower intubation rate  (relative risk (RR), 0.099; (95% CI, 
0.01-0.76; p=0.005)) and had a lower occurrence rate of pneumonia (RR, 0.19; 95% 
CI, 0.04-0.88; p=0.02), infection (RR, 0.27; 95% CI, 0.07-0.94; p=0.03), and sepsis 
(RR, 0.22; 95% CI, 0.04-0.99; p=0.03) in the CPAP group as compared to the 
oxygen group. Whilst other studies have not reported such a significant reduction in 
post-operative pulmonary complications, they have demonstrated a significant 
improvement in radiographical evidence of atelectasis20-22. A recent meta-analysis of 
CPAP use in post-operative hypoxia concluded that „although the effect on mortality 
remains to be evaluated in larger studies, CPAP decreases post-operative 
pulmonary complications (sic), atelectasis, and pneumonia;  supporting its use in the 
clinical practice‟23. 
The benefit of CPAP in other forms of respiratory failure such as pneumonia, asthma 
and chronic obstructive pulmonary disease (COPD) is less clear. Despite its 
widespread use for the treatment of other the common causes of acute respiratory 
failure, there are few studies that examine its benefits in conditions other than 
ACPO. There is evidence that it may confer a survival benefit in the treatment of 
pneomocystis carinii pneumonia associated with HIV infection24, although the 
treatments for HIV have changed immeasurably since this small trial was performed 
in 1992. Delclaux et al. have performed the only substantial clinical trial into the use 
of CPAP to treat all-cause respiratory failure25. They randomised 123 patients with a 
PaO2/FiO2 of <300 mmHg with a normal PaCO2 to receive either oxygen therapy 
alone or CPAP. Approximately half had pneumonia, and one third cardiac disease. 
After 1 hour of treatment, oxygenation was improved in the CPAP group (PaO2/FiO2  
203 mmHg, (95% CI: 45-431) vs PaO2/FiO2 151 mmHg  (95% CI: 78-432) p=0.02). 
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No other differences in respiratory indices were observed between the groups. 
Treatment with CPAP failed to reduce the endotracheal intubation rate, hospital 
mortality or ICU length of stay and it was associated with a higher number of adverse 
events 18 vs 6; p=0.01). This trial demonstrated that which is commonly observed: 
the immediate improvement in oxygenation in all-cause respiratory failure. 
 
5.1.4 Complications of CPAP 
CPAP in the acute setting is not a benign therapy. Whilst many of the trials described 
above have not shown significant complication rates, there are many case reports of 
the complications of CPAP listed below in table 5.126-32. In particular those that give 
the greatest concern to clinicians are the failure to tolerate as this leads to failure of 
oxygen delivery; cutaneous effects, or effectively damage from the tight fitting mask, 
which can limit the time that CPAP can be used and has been reported as requiring 
surgical treatment. Impairment of cough as this could potentially lead to retention of 
secretions and bronchial obstruction, communication difficulties which can make 
management difficult for both patient and clinician. The advent of the CPAP helmet 
has gone some way to improving some of these problems. They remain a relatively 
new method, and there is no evidence that they convey any treatment benefit over a 
mask system, although they may be better tolerated33, 34. Outside of the diagnosis of 
ACPO the evidence of benefit of PAP in terms of mortality is weak, but the 
improvement in oxygenation is documented25.  
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Table 5.1 Recognised complications of CPAP 
Complication 
Failure to tolerate 
Cutaneous damage 
Impairment of cough 
Communication difficulties 
Haemodynamic disturbances 
Pneumothorax 
Pneumocephalus  
Pneumopericardium  
Otorrhagia  
Increased in physiological dead space 
 
Many of the important complications associated with CPAP in acute respiratory 
failure occur because of the mask. In the community where CPAP is applied either 
nasally or via a full face mask, the mask complications are negligible, but not 
unreported35, 36. Yet in the hospital environment they are appreciable. Why this 
should be is subject to conjecture. Community delivered CPAP masks are 
technologically sophisticated and are patient-applied with a high degree of 
supervision by specifically trained practitioners. They are commonly only applied at 
night with the daytime for recovery. The patient group is usually otherwise well and 
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highly motivated. In contrast, the patient with acute respiratory failure has the mask 
applied by less experienced attending staff, has little input into the choice and fitting 
of the mask and in general, the masks lack the sophistication of their community 
counterparts. The CPAP masks still used in the acute setting are cheaper disposable 
type with little facial contouring and a fixed air pressure within the seal. They remain 
applied as continuously as tolerated with little break for tissues at risk to recover. 
Over-tight application of such masks, in a bid to prevent gas leak, may explain the 
higher incidence of cutaneous injury. This complication is common and is directly 
due to the need to seal the airway to the system to provide the perceived benefit of 
positive airway pressure (PAP). Whilst the use of more improved mask designs 
which reduces the need for such a tight fit is ever increasing, cost implications in 
particular are likely to limit their widespread introduction in most hospitals. For 
example a Respironics® ComfortGel mask costs approximately £110, whereas the 
Intersurgical® CPAP mask is priced at under £1.00 if ordered in bulk. 
There has been little or no basic assessment of how CPAP masks work in terms of 
oxygen delivery. They will deliver what is required as entrainment is impossible. 
Improvement seen when a patient is changed from a standard mask to CPAP is 
usually attributed to the physiological benefits from CPAP but this has not been 
studied. It is possible that a large proportion of the improvement seen with CPAP is 
due to the improvement in oxygen delivery above that of an open mask potentially 
interfacing poorly with a patient‟s respiratory pattern. A sealed system with high flow 
oxygen has little to no capacity for entrainment of environmental air and delivers the 
FiO2 set on the flowmeter. The high gas flow rate or presence of a compliant 
reservoir negates those effects of high inspiratory flow rates seen in the previous 
chapter, with a few exceptions37. Could it be that as an intervention, the influence of 
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CPAP on oxygenation is mainly due to improved oxygen delivery compared to open 
oxygen systems, rather than the more physiological explanations related to the 
PAP? If so would better open mask design achieve similar physical properties 
without the potential complications associated with CPAP in the acute setting? 
 
5.1.5 Aims 
The following two chapters seek to examine the first of these questions. Firstly by 
employing the model used in Chapter 3 (see Figure 3.1) we aim to demonstrate that 
a CPAP system does indeed maintain its oxygen delivery in a predictable manner 
across the same ranges of respiratory rates and tidal volumes as with the open 
oxygen systems. Secondly in Chapter 6, to examine the effect of a staged 
introducing a CPAP system to patients in respiratory failure. Thus the aims of the 
following two chapters are: 
1. To demonstrate the effect of varying respiratory rate and tidal volume on 
oxygen delivery of a high flow CPAP system. 
2. In patients with respiratory failure, to describe the effect on arterial 
oxygenation of changing from an open mask system to a closed CPAP 
system and the subsequent application of increasing PAP. 
 
5.2 Methodology 
The same model system as Chapter 3 was used to test a standard CPAP high flow 
system. The lung model was set up and calibrated in the same way as for testing the 
oxygen delivery devices. The CPAP system used was the same that is used 
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clinically at the Chelsea and Westminster Hospital, both on the ICU and the general 
wards. This consisted of a flow generator (Whisperflow® 2-60. (Philips Respironics, 
Pittsburgh, PA, USA) connected to the wall oxygen supply at 4bar. The flow 
generator was then connected to a t-piece via a specific CPAP circuit of 22mm 
corrugated tubing (Intersurgical, Wokingham, UK), passing over a water bath 
humidifier (Fisher & Paykel, Maidenhead, UK). The t-piece inserted into a cushioned 
size 4 CPAP mask (Intersurgical, Wokingham, UK). The third limb of the t-piece had 
a further 100cm of corrugated tubing attached. Two levels of CPAP valve were used 
+5 cmH2O and +10 cmH2O (Accu-PEEP, Vital Signs, Barnham, UK). The CPAP 
mask was applied to the mannequin using the standard harness. All other elements 
of the model were as outlined in the previous chapter. Two flow generators were 
used at different times. They were maintained in good working order. Calibration of 
the oxygen analysers was performed by Philips Respironics technicians and as per 
the manufacturer‟s instructions (see Appendix 2). 
The model with the CPAP system attached was tested in the same way as 
previously. The flow rate on the generator was set to deliver at maximum (140 l.min-1 
according to the manufacturer‟s specifications – Appendix 2).  
Calibration of the driving ventilator and the oxygen analyser within the test rig was 
performed as outlined before. The experiments were performed at two FiO2 settings 
on the generator 0.6 and 1.0. Trails were run at both a Vt of 500mls and 300mls, and 
the respiratory rates were varied from 10, 15, 20 and 30 breaths.minute-1. Each 
respiratory rate was examined three times and a mean EIOC and standard deviation 
were determined. 
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In addition to the reproduction of the methods of Chapter 3 applied to the CPAP 
system. An assessment of pressure within the system was performed. This was 
measured using a 14G Abbocath® inserted in both the inspiratory and expiratory 
limbs of the system. Pressure was assessed using a standard vascular pressure 
transducer set (Tru-wave®, Edwards Lifesciences, Newbury, UK) and a Hewlett-
Packard Merlin ICU monitor (Hewlett-Packard,Bracknell, UK). Measurements of 
pressure were taken in the inspiratory and expiratory limbs in both inspiration and 
expiration. The mannequin was ventilated at 10 breaths.min-1 with a tidal volume of 
500 ml. The flow generator was set to deliver 100% oxygen at a flow rate of 140 
l.min-1 Assessments were made with the system without a CPAP valve and with 5 
cmH2O attached. The process was performed on three separate occasions for each 
of two identical flow generators, using new tubing and valves on each occasion. The 
mean pressures were calculated for each limb in both of the ventilatory movements. 
 
5.2.1 Statistical Analysis 
All data was analysed using SPSS 14.0 (LEAD Technologies Inc. USA). As in 
Chapter 3 comparisons between EIOCs at different respiratory rates and FiO2 were 
analysed by an analysis of variance. Significance was defined as a p value <0.05. 
The null hypothesis was that there was no difference in EIOC between the different 
respiratory rates at the same FiO2. A comparison between the EIOC of a venturi 
mask system and the CPAP system without the valve at the same minute ventilation 
and FiO2. This was done by way of an unpaired two-tailed t-test. 
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5.3 Results 
The CPAP system tested in this model showed no deterioration in performance as 
the respiratory rate increased, either at a Vt of 300 ml or 500 ml (p=0.89 & 1.0 
respectively). The CPAP system delivered oxygen at the expected FiO2. There was 
no change in EIOC at either FiO2 examined and the addition of 5 cmH2O or 10 
cmH2O PAP made no difference to the EIOC detected (p=0.95 & 0.90 respectively) 
(Figures 5.1 to 5.4). 
The results of the pressure measurements within both limbs demonstrated a non-
significant ΔP across the mask. With no valve attached the mean inspiratory 
pressure was 1.4 cmH2O and 1.2 cmH2O for the inspiratory and expiratory limbs 
respectively (SD 0.3 cmH2O) p=0.75. With the 5 cmH2O valve attached this rose to 6 
cmH2O and 5 cmH2O respectively (SD 0.4 cmH2O) p=0.56. Similar results were 
found in expiration. Without the valve the mean pressure in both limbs were 1.6 
cmH2O and 1.3 cmH2O (SD 0.3 cmH2O) p=0.83. Attachment of the 5 cmH2O valve 
resulted in pressures across the mask of 6.2 cmH2O and 5.4 cmH2O (SD 0.4 
cmH2O) p= 0.78 (Figure 5.5).  
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Figure 5.1 Effective inspired oxygen concentration delivered by the CPAP system at 3 PEEP 
settings, across a range of respiratory rates Tidal volume of 300ml. FiO2 0.6. (n=6 
measurements per plot) p=0.89 
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Figure 5.2 Effective inspired oxygen concentration delivered by the CPAP system at 3 PEEP 
settings, across a range of respiratory rates Tidal volume of 500ml. FiO2 0.6. (n=6 
measurements per plot). P=1.0 
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Figure 5.3 Effective inspired oxygen concentration delivered by the CPAP system at 3 PEEP 
settings, across a range of respiratory rates Tidal volume of 300ml. FiO2 of 1.0. (n= 6 
measurements per plot). P=0.95 
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Figure 5.4 Effective inspired oxygen concentration delivered by the CPAP system at 3 PEEP 
settings, across a range of respiratory rates Tidal volume of 500ml. FiO2 of 1.0. (n=3 
measurements per plot) p=0.90 
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Figure 5.5 Mean pressures within the inspiratory and expiratory limbs of the CPAP system 
when attached to the model ventilating at 10 breaths.min
-1
 with a Vt of 500ml. (n= 6 for each 
data point) Error bars represent +/-2SD. 
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5.4 Discussion 
This very simple experiment has demonstrated that the high flow CPAP system 
attached via a sealed mask, delivers an FiO2 as expected to a model of human 
respiration. Changes in respiratory rate and by virtue, minute ventilation have no 
effect on this delivery. This is true for two tidal volumes.  
The most likely mechanisms at play in this experiment are a combination of high 
oxygen flows that can match the inspiratory flow rates even at high minute 
ventilation, and the lack of entrainment of environmental air achieved by sealing the 
airway with a close fitting mask. Also, the contribution of the 100 cm of 22 mm 
corrugated tubing in the expiratory limb of the CPAP system is notable. This was 
included even though many systems only require the application of the CPAP valve 
directly to the mask itself. One major reason was that this was a precursor study to 
the audit of the effect of CPAP in the patients treated at Chelsea and Westminster 
Hospital described in Chapter 6. The use of such a limb had evolved historically and 
was formally summarised in the CPAP protocol particular to this institution. The 
protocol was also the reason for the selection of 5 cmH2O and10 cmH2O as the 
values for PAP in this study and that in the following chapter. Indeed most studies 
use between 5 cmH2O to 15 cmH2O as their settings and most institutions that 
publish their protocols online start at 5 cmH2O
10, 16, 38, 39. Direct reproduction of the 
clinical technique used at this institution was important in allowing conclusions to be 
drawn about the in vitro and in vivo results. In addition, the efferent limb in a high 
flow system, in effect adds an additional reservoir which, combined with the flows, 
preclude rebreathing. The wide diameter of the tubing also precludes a significant 
increase in resistance and hence is unlikely to increase intrinsic pressure in the 
system (Figure 5.5).  
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It could be argued that a CPAP system without an expiratory limb or a CPAP valve 
may permit the entrainment of air through the mask port. This study cannot provide 
such data, however based on the data from Chapter 4 with a median PIFR of 
75l.min-1, a high flow system delivering 140l.min-1, this seems unlikely for most 
subjects. However the same may not be true for CPAP systems that utilise a 
reservoir such as the Dräger‟s CF800 system. It may be that if the use of a high flow 
oxygen delivery device without a valve is to be advocated, then the inclusion of an 
expiratory limb may be warranted.  
 
5.4.1 Clinical Implications 
In clinical practice it is desirable to set the oxygen flow rate at such a level as to 
maintain a small leak of air through the valve during inspiration. This optimises the 
function of the valve in delivering positive airway pressure, but the recognition that 
sealing the face to prevent entrainment of air is not new. This phenomenon was 
recognised during World War Two in oxygen delivery systems for pilots where a tight 
fitting mask was essential to maintain oxygen concentrations at altitude. Also in 
combat conditions the respiratory pattern of pilots was known to change and so 
entrainment could become an issue if the masks were not well fitting. The same is 
true today in modern fighter aircraft. It is of interest that in commercial aviation, 
oxygen masks for passengers are not designed to fit tightly, and at a standard 2 
l.min-1 oxygen flow rate are ineffective in delivering enough oxygen if decompression 
occurs at the usual altitudes of commercial airliners. However the flight crew do have 
appropriately fitting masks in the cockpit. 
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The high oxygen flow rate used in this experiment is probably the most important 
factor in achieving the results demonstrated. What could also be done is to explore 
the effect of a staged reduction in the flow rate with or without the attached 
expiratory limb. Is there a threshold in this model at which oxygen entrainment 
occurs and how does this compare to open system? If the valve were to be attached, 
entrainment would lead to its closure during inspiration – a potential patient hazard. 
However a system without the valve and an expiratory limb – essentially an Ayre‟s T-
piece – may have significant capacity for flow reduction (2-3 times minute 
ventilation), thus reducing potential detrimental effects of high flow such as airway 
drying and noise. The model would lend itself well to such an examination. 
Figure 5.5 amalgamates data from this study and that of Chapter 3. It demonstrates 
the effect of changing from a venturi system to a CPAP system with no valve 
attached, both set to deliver an FiO2 of 0.6. The respiratory rate (and therefore 
minute ventilation) is high and there is a marked increase in EIOC on changing from 
the venturi to the CPAP system. This is statistically significant (t-test p<0.001) for 
both tidal volumes. It demonstrates, in this model, that the performance of the CPAP 
system is superior to that of the venturi at this relatively extreme of ventilation. It 
further underlines the physical properties of these two systems and, whilst the 
venturi system is the „best‟ of the commonly used open systems, it cannot deliver 
oxygen as predictably as its CPAP counterpart.  
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Figure 5.6 The effect on EIOC on changing from a venturi system to a CPAP system with no 
valve at 2 tidal volumes. FiO2 0.6, Respiratory rate 30 breaths.min
-1
. (n=9 measurements per 
plot for venturi, 6 measurements for CPAP)  Student t-test p<0.001. 
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5.4.2 Problems with the Model 
In general this is a good model to test a CPAP system for oxygen delivery, but not 
for the potential physiological effects of CPAP. The realistic mannequin permits a 
relatively good assessment of „mask-seal‟ although its plastic construction is less 
compliant than the human face. This might mean that a seal is well maintained in the 
model at higher PAP values, when a leak might be expect in real life. As in Chapter 3 
the relative rigidity of the upper airway simulator may not simulate the effect of PAP 
on the human version. Any local effects of enhanced airway pressures in the upper 
airways which may be relevant in some uses of CPAP, for example sleep apnoea, 
would not be seen. Similarly any changes in airway diameter cannot be simulated. 
In other ways the application of PAP in this model was irrelevant as the model has 
no capacity for recruitment of alveoli or alterations in V/Q matching. This was borne 
out by the demonstration that the addition of PAP at 5 cmH2O and 10 cmH2O had no 
effect on the oxygen concentration delivered. However the absence of PAP did not 
reduce the oxygen concentration delivered.  
Again as with Chapter 3, the respiratory patterns generated by the ventilator and 
bellows may be similar to those seen in vivo but will never be identical. However, the 
main features of the patterns are reproducible. What the model offers is a close 
examination of the physics of oxygen delivery not the physiology.  
 
5.4.3 Conclusions 
These two in vitro experiments (chapters 3 and 5) pose the question that is not clear 
from the literature. Is the rapid improvement in patient oxygenation seen with the 
application of CPAP due to the alveolar recruitment, prevention of de-recruitment 
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and improvement of the position on the compliance curve; or is it a physical 
phenomenon achieved by the delivery system itself improving oxygen delivery in the 
place of a failing open oxygen system? The model provides convincing evidence that 
entrainment is an issue with the masks tested and that CPAP has no entrainment. It 
suggests the effects are of some magnitude and may be a part of the explanation for 
the increase in oxygenation seen with CPAP. To test this requires examination of 
these systems in patients with respiratory distress and see if there is an initial 
increase in oxygenation but also to see if oxygenation improves with either time or 
with different levels of pressure on the CPAP. The following chapter describes an 
audit of practice in a patient population with acute respiratory failure starting CPAP 
therapy, in which these questions can be examined from the use of these systems in 
vivo. 
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Chapter 6 
The Effect of Continuous Positive Airway Pressure on Oxygenation 
in Acute Respiratory Failure. 
 
6.1 Introduction 
The issue being described in the previous chapters is that the set inspired 
concentration of oxygen in a mask system may be different from that actually 
received by the patients during different breathing patterns. The previous chapter 
demonstrated in a model of human ventilation, that a CPAP system maintains its set 
oxygen delivery regardless of the minute ventilation, or pattern of breathing. As such 
it performs better than the other systems tested in Chapter 3. With the exception of 
the Vapotherm® and the Venturi system at low FiO2 settings, all other systems show 
deterioration in function as minute ventilation rises. The venturi system used at a 
higher FiO2 shows decreased FiO2 in the model with increasing minute ventilation as 
its physical characteristics come to match those of a variable performance system. 
The Vapotherm® showed good maintenance of oxygen delivery as the respiratory 
pattern changed, but the delivered values of FiO2 within the model were not the 
same as the settings on the oxygen:air mixer. Thus of the systems tested, only a 
CPAP system delivers the desired FiO2 across a range of respiratory patterns in this 
model. This is likely due to the complete prevention of the entrainment of 
environmental air by the sealed mask and hence the delivery of oxygen to the lungs 
at suitably high flow to match the ventilatory pattern in abnormal ventilation.  
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6.1.1 Physiological Effects of CPAP 
The effect of CPAP on oxygenation in the clinical setting has physiological as well as 
physical characteristics. The model with no lung tissue was unable to demonstrate 
the physiological effects CPAP may confer, and it may be that the bulk of the 
improvement in oxygenation seen in humans is due to an improvement in lung 
physiology. There is experimental evidence of the potentially beneficial physiological 
effects of CPAP in the literature summarised in Table 6.1.  
 
Table 6.1 Beneficial physiological effects of CPAP 
Physiological Effect  
Minimising alveolar collapse 
Improving pulmonary compliance 
Decreased work of breathing 
Improved ventilation: perfusion matching 
Reduces extra-vascular lung water 
 
Abboud et al demonstrated that the administration of CPAP of both 5 cm H2O and 11 
cmH2O significantly improved mean total lung capacity, functional residual capacity, 
and residual volume in healthy volunteers1. Closing capacity remained unchanged. 
The differences between 5 cmH2O and 11 cmH2O were small. Anderson et al. 
experimenting with excised human lung reported superior re-inflation of simulated 
atelectasis with the application of CPAP compared to simulated normal breathing2. 
They also commented that collateral non-bronchial channels had a significant role in 
the re-inflation of the lung and postulated that „this route of re-expansion also has a 
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potential secretion clearing effect in that pressure is built up distal to an obstruction‟. 
The lungs used were post-mortem and structurally normal. How much these 
suppositions can be applied in vivo remains conjecture. 
Work by Roseler et al in intubated patients after major gastrointestinal surgery 
demonstrated that CPAP of 11 cmH2O significantly improved blood oxygenation and 
reduced the work of breathing3. This study strongly implies a physiological effect as 
the possibility of entrainment had been eliminated by intubation. However these were 
post operative elective surgery patients and as has been described previously do 
often have some atelectasis, contributing to shunt, which is more likely be improved 
by the application of CPAP. A further detail is that ventilation in the intubated patient 
bypasses some of the physiological PEEP engendered by the upper airway. This 
could in theory, increase the probability of CPAP being beneficial. Another  
consideration when discussing the use of CPAP in post-operative patients both in 
this study and that by Squadrone et al. referenced in the previous chapter is the use 
of Nitrous oxide (N2O) as part of the anaesthetic management
4. Nitrous oxide is 
more soluble in blood than nitrogen, and by replacing nitrogen in the alveoli is 
thought to lead to more extensive „absorption atelectasis‟5. The literature suggests 
that N2O does not lead to greater atelectasis than using nitrogen, but may produce a 
more rapid onset6-9. At termination of anaesthesia dissolved N2O rapidly comes out 
of solution into the alveoli, displacing the other gases, namely nitrogen, oxygen and 
to a lesser extent carbon dioxide. This „third gas‟ effect reduces the concentration of 
the other alveolar gases especially oxygen, leading to arterial hypoxia. This 
phenomenon can be circumvented by maintaining a high FiO2, but at the risk of 
worsening atelectasis. 
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Preventing atelectasis may be more effective than reversing atelectasis with positive 
pressure.  It is likely that recruitment manoeuvres using far higher pressures than 
standard post-op CPAP (5-10 cmH2O) is required to overcome the surface tension 
forces of collapsed alveoli. Subsequent application of CPAP might then be expected 
to maintain alveolar patency. This may be why the data from Pasquina et al. 
suggests a superiority of non-invasive pressure support ventilation to CPAP in 
improving radiological evidence of post-operative atelectasis, although it did not 
convey any other clinical benefit10. However, a recent randomised controlled trial of 
recruitment manoeuvres and CPAP versus neither in patients undergoing elective 
surgery was unable to demonstrate a difference in terms of alveolar to arterial 
oxygen gradient11. Whether or not CPAP is of real use in the treatment of post-
operative atelectasis remains a subject of debate but it is clear that upper 
gastrointestinal, cardiac or thoracic surgery will continue to present a significant risk 
of causing atelectasis so methods of preventing atelectasis are important.  
Several studies have demonstrated that CPAP reduces the inspiratory work of 
breathing by offloading the inspiratory muscles. However there is little data that 
describes the effects of expiratory work of breathing12-17. Anecdotal reports suggest 
breathing out „feels‟ more difficult in volunteers and may involve an active 
component. This is usually a passive function, and though reductions in inspiratory 
work of breathing may reduce symptoms of breathlessness, there is no evidence that 
this reduces oxygen consumption (VO2). Indeed one study suggested that the 
application of CPAP in respiratory failure increases VO2
18. Whether this could be 
detrimental is unclear. 
The physiological phenomena, described in Table 6.1, are likely to improve 
oxygenation but are unlikely to have immediate effects. Yet the improvement in 
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oxygenation seen when a patient is transferred from mask oxygen to CPAP is almost 
instant. It is thus reasonable to hypothesise that at least part of the improvement in 
oxygenation in acute respiratory failure is due to a physical effect such as an 
improvement in oxygen delivery.  
 
6.1.2 Aims 
It is obvious that after the application of CPAP in the ward situation, oxygenation 
often improves. The protocol of instituting CPAP at the Chelsea and Westminster 
Hospital is standardised but has never been audited. The aims of the following audit 
were to see if auditing standard practice could demonstrate when the application of a 
high flow sealed oxygen system improves oxygenation in acute respiratory failure 
patients already receiving oxygen via a 0.6 FiO2 venturi mask? Does the addition of 
standard practice CPAP valve to that system further improve the oxygenation 
achieved by the high flow system alone? 
 
6.2 Methodology 
An unblinded observational audit was performed as part of the institution of a new 
protocol for the delivery of CPAP in patients with non-hypercarbic respiratory failure. 
The study was carried out both on the ICU and general wards at the Chelsea and 
Westminster Hospital. It was an observational audit conforming to the written 
Hospital protocol for the introduction and monitoring of CPAP in the ward 
environment and is summarised in Table 6.2 and Figure 6.1. This had been 
developed jointly by the intensive care unit and the critical care outreach team. 
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Table 6.2 Summary of the Chelsea and Westminster written protocol / guideline for the 
introduction of continuous positive airway pressure for the treatment of acute non-hypercarbic 
respiratory failure. In the final column is detailed the measurements made during the study for 
each stage of the protocol. 
Stage Ventilation Mode FiO2 Time Samples 
1 Venti-mask  0.6 10 minutes ABG, RR & Comfort 
score 
2 CPAP system: 0 cmH2O 0.6 10 minutes ABG, RR & Comfort 
score 
3 CPAP system: 5 cmH2O 0.6 10 minutes ABG,RR & Comfort 
score 
4 CPAP system: 5 cmH2O 0.6 50 minutes  ABG, RR & Comfort 
score 
5 CPAP system : 10 cmH2O  0.6 60  minutes ABG, RR & Comfort 
score 
 
Ethical approval was given but did not require written consent as it was deemed part 
of „acute‟ care. Verbal permission was sought.  
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Figure 6.1 Sequential change in oxygen delivery device delivered to the participating subjects 
(as per Hospital protocol/guideline). (A = Venti-mask system, B = CPAP system with no PEEP 
valve – T-piece, C = CPAP system with PEEP valve applied (pressure 5 or 10 cmH2O) 
 
  
A 
B 
C 
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Patients were recruited if they fulfilled the following inclusion/exclusion criteria: 
6.2.1 Inclusion criteria: 
 Adults >16 years 
 Acute (<48 hours)  Type I respiratory failure: 
o PaO2 < 8.0 kPa when breathing room air. 
o PaCO2 <6.0 kPa (not deemed suitable in the presence of CO2 
retention). 
 A decision to apply the CPAP system had been made by the attending 
physicians. 
 Maintenance of SpO2 >93% when breathing oxygen via a Ventimask with an 
FiO2 insert of 0.6. 
 
6.2.2 Relative exclusion criteria were those for applying CPAP in the ward: 
 Patient delirium or low conscious level 
 Evidence of clinical suspicion of raised intracranial pressure. 
 Vomiting 
 Facial injury or abnormality preventing good mask fitting. 
 Imminent endotracheal intubation. 
 Patient refusal. 
 Refusal by the attending physician. 
 
All clinical decisions relating to the patient‟s ongoing care were made by the 
attending physicians. The study observer had no influence on the delivery of CPAP, 
nursing care or any medical decisions.  
Patients were given the option of separate arterial blood gas (ABG) measurements 
or insertion of an arterial catheter under local anaesthetic. In some cases a catheter 
was inserted by the medical team, or was already in situ. All patients were monitored 
with SpO2, non-invasive or invasive (if arterial line in situ) blood pressure and single 
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lead electrocardiography. The subjects were either seated in a chair or in bed. 
Additional monitoring such as central venous catheterisation was dictated by the 
nature of the clinical condition and preferences of the attending medical staff. Once 
the timescale outlined in Table 6.2 had been completed, the care and further 
management was returned to the medical team. 
 
6.2.3 Data collection 
At each stage in the protocol three measurements were made: 
1. An arterial blood gas (ABG) sample recording PaO2 and PaCO2. 
2. An enquiry as to their level of „comfort‟ on a scale of 1 to 10 where 10 is very 
comfortable and 1 is extremely uncomfortable. A comfort score. 
3. Respiratory rate. 
In addition to the ABG, comfort score and respiratory rate data, patient 
demographics, the clinical diagnosis made by the attending physicians and the Acute 
Physiology and Chronic Health Evaluation II (APACHE II) score were documented19. 
 
6.2.4 Statistical analysis 
All data was analysed using SPSS 14.0 (LEAD Technologies Inc. USA). Where 
appropriate the data was analysed on an intention-to-treat basis. To detect statistical 
significant differences in oxygenation and respiratory rate between the different 
stages of the protocol, a two way analysis of variance was performed with a 
Bonferroni correction to allow for multiple testing. Assessment of the ordinal data of 
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the comfort score was performed using a Kruskal-Wallis test. Detection of location of 
differences was performed using repeat Mann-Whitney U tests. Analysis of 
demographic data, diagnosis and APACHE II score was performed using a Student‟s 
t-test for continuous data and a Chi2 test for categorical data. Repeated Measures 
analysis of variance was carried out as part of a sub-group analysis to look at 
whether age, gender, diagnosis or APACHE II score had additional influence on 
oxygenation. A p value of 0.05 was taken to represent a significant finding. 
 
6.2.5 Sample Size 
Although this was a audit it was assumed, from experience, that CPAP would 
improve oxygenation and a power analysis was performed. A sample size of 53 
patients was required to detect a 2.5 kPa increase in PaO2 with a significance of 
0.05 and a power of 80% (assuming a common σ of 6 kPa). 
 
6.3 Results 
53 patients were audited. Their demographic data is represented in Table 6.3. They 
were a heterogenous group of patients with a variety of pulmonary causes for acute 
respiratory failure. The age range was 22-93 years (mean 61 SD +/- 20 years). 2 of 
the patients were intolerant of CPAP prior to completing the 1 hour (stage 4 – see 
Table 6.3). 1 patient became intolerant to the mask at 10 cmH2O (stage 5). 1 further 
patient deteriorated on treatment and was intubated and ventilated prior to 
completion of stage 5. The results are presented in Tables 6.3 – 6.8 and figures 6.2 
– 6.5. Stage 5 is not always appropriate and so there are fewer patients (n=31), and 
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3 of this group had already either become intolerant of CPAP, 2, or required 
intubation, 1.  
Table 6.3 Baseline characteristics of the patients 
Characteristic Value (n=53) 
Mean Age (yr) 60.89 (+/- SD 20.36) 
Male Gender 26 (49.1%) 
Apache II score 17.74 (+/- SD 4.58) 
Mean PaO2 recruitment criterion (kPa) 7.87 (+/- SD 0.76) 
Mean PaCO2 recruitment criterion (kPa) 4.86 (+/- SD 0.71) 
Respiratory rate (breaths.min-1) 29 (+/- SD 6) 
 
 
Table 6.4  Clinical diagnoses of aetiology of acute respiratory failure in audit subjects 
Diagnosis n (%) 
Pneumonia (%) 22 (41.5%) 
Cardiogenic pulmonary oedema 11 (20.9%) 
Atelectasis 7 (13.2%) 
Pulmonary oedema (hypervolaemic) 3 (5.7%) 
Chronic obstructive pulmonary disease 2 (3.8%) 
Asthma 2 (3.8%) 
Obstructive sleep apnoea 2 (3.8%) 
Haemothorax 1 (1.9%) 
Anaphylaxis 1 (1.9%) 
Viral pneumonitis 1 (1.9%) 
Pneumocystis carinii pneumonia 1 (1.9%) 
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Table 6.5  Mean PaO2 in patients with respiratory failure 
Oxygen system  Venturi 
 
T-piece 
 
CPAP 
5cmH2O 
CPAP 
5cmH2O  
CPAP 
10cmH2O 
FiO2 0.6 0.6 0.6 0.6 0.6 
Time 10 min 10 min 10 min 50 min 60 min 
Mean PaO2 (kPa) 10.37 21.06 21.13 21.16 19.56 
Range (kPa) 7 -22 11.05-44.05 10.76-42.92 10.98-36.6 11.1-32.67 
St Dev (kPa) 2.83 7.067 7.53 6.54 5.98 
 
 
 
Figure 6.2  Mean PaO2 in patients with respiratory failure at each stage of the CPAP protocol. 
Error bars represent +/- 2SD (n=53 up to CPAP 5 cmH2O, n=31 for CPAP 10 cmH2O). P<0.001 
(ANOVA) 
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Table 6.6  Mean PaCO2 in patients with respiratory failure 
Oxygen system  Venturi 
 
T-piece 
 
CPAP 
5cmH2O 
CPAP 
5cmH2O  
CPAP 
10cmH2O 
FiO2 0.6 0.6 0.6 0.6 0.6 
Time 10 min 10 min 10 min 50 min 60 min 
Mean PaCO2 (kPa) 4.86 4.93 4.91 4.93 5.04 
Range (kPa) 3.45-6.20 3.51-6.47 3.43-6.31 3.54-6.55 3.73-6.38 
St Dev (kPa) 0.71 0.75 0.76 0.72 0.66 
 
 
 
Figure 6.3  Mean PaCO2 in patients with respiratory failure at each stage of the CPAP protocol. 
Error bars represent +/- 2SD (n=53 up to CPAP 5 cmH2O, n=31 for CPAP 10 cmH2O). P=0.87 
(ANOVA) 
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Table 6.7  Median respiratory rate in patients with respiratory failure 
Oxygen system  Venturi 
 
T-piece 
 
CPAP 
5cmH2O 
CPAP 
5cmH2O  
CPAP 
10cmH2O 
FiO2 0.6 0.6 0.6 0.6 0.6 
Time 10 min 10 min 10 min 50 min 60 min 
Mean Resp. Rate 
(breaths.min
-1
) 
29.4 29.1 28.9 26.6 25.5 
Range (bpm) 14-40 16-40 16-39 15-39 12-32 
St Dev (bpm) 6.05 5.86 5.89 5.16 4.71 
 
 
 
Figure 6.4  Mean respiratory rates in patients with respiratory failure at each stage of the CPAP 
protocol. Error bars represent +/- 2SD (n=53 up to CPAP 5 cmH2O, n=31 for CPAP 10 cmH2O). 
P=0.04 (ANOVA) 
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Table 6.8 Median comfort scores for patients with respiratory failure 
Oxygen system  Venturi 
 
T-piece 
 
CPAP 
5cmH2O 
CPAP 
5cmH2O  
CPAP 
10cmH2O 
FiO2 0.6 0.6 0.6 0.6 0.6 
Time 10 min 10 min 10 min 50 min 60 min 
Median Comfort 
score 
9 7 6 5 4 
Range  6-10 2-9 1-9 1-8 3-8 
IQR  1 1.75 2 1 2 
 
 
 
 
Figure 6.5  A box and whisker plot of the comfort score expressed by patients with respiratory 
failure at each stage of the CPAP protocol. (n=53 up to CPAP 5 cmH2O, n=31 for CPAP 10 
cmH2O). P<0.001 (Krukal-Wallis). 
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The results of this audit in patients with acute type 1 respiratory failure demonstrate 
a significant improvement in PaO2 on changing from the Ventimask
® to the CPAP 
system (mean change 10.69 kPa (SD 5.14 kPa)). The addition of the PEEP valve 
either at 5 cmH2O or 10 cmH2O did not result in an increase in the mean PaO2. The 
mean value of PaCO2 was unaffected by either the change from Ventimask to the T-
piece or on the application of the PEEP valve at either 5 cmH2O or 10 cmH2O. 
(p=0.87). However, there was statistically significant difference in the respiratory 
rate, a decrease, on the application of the 5 cmH2O PEEP valve (p=0.04). Further 
increases in the value of the PEEP valve did not significantly reduce the respiratory 
rate. 
 
The comfort score was significantly reduced on the application of the CPAP system 
from the Ventimask®. (p=0.047). However, though the reduction in the comfort score 
across the whole protocol was statistically significant (p<0.001, Kruskal-Wallis test), 
differences between the subsequent stages were not apparent. 
The diagnosis was considered albeit in a small number of patients. The general 
pattern of early improvement in oxygenation was seen throughout. In the11 patients 
with a diagnosis of cardiogenic pulmonary oedema the pattern appeared the same. 
 
6.4 Discussion 
In patients being put on CPAP for a range of causes of acute respiratory failure there 
is a significant increase in oxygenation on changing from a Ventimask® to a CPAP 
system despite no change in the fractional inspired oxygen. The subsequent addition 
of pressure of either 5 cmH2O or 10 cmH2O appears to have no immediate further 
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benefit in terms of an increase in oxygenation over the following hour, or two hours in 
the patients followed for that time period. It should be noted that the respiratory rate 
did fall on CPAP.  
This audit of the oxygenation of a heterogenous group of patients in respiratory 
failure, being treated with CPAP had some interesting findings. On changing from 
the Ventimask® to the CPAP system it appears that a significant improvement in 
oxygenation occurs during instigation when there is no CPAP valve and hence 
negligible system pressure (the intrinsic pressure in the open CPAP system at these 
flow rates, measured on a lung model, is between 1.2 and 1.6 cmH2O). There then 
appears to be no further improvement in oxygenation on application of the CPAP 
valves to produce positive airway pressure (PAP), either 5 cmH2O or subsequently 
10 cmH2O. There was however a gradual reduction in respiratory rate over the two 
hours on CPAP (p= 0.027). The changes after one hour are not significant although 
this may reflect relatively small numbers.     
The implication is that the immediate improvement in oxygenation is rapid, 
independent of pressure and probably reflects a higher inspired oxygen 
concentration with a closed system than with the Ventimask®.  As the effect occurs in 
a heterogenous group of patients it suggests a physical characteristic of the system 
rather than anything related to any specific disease process. The subsequent 
application of pressure has no further immediate effect on oxygenation, even at 1 
hour, although 5 cmH2O did appear to result in a decrease in respiratory rate. This 
latter effect implies an improvement in the pattern of breathing which could be 
because of better oxygenation. Alternatively it may be due to a physiological effect 
such as a change in the work of breathing, altered compliance or increased FRC but 
this is conjecture. The patients were also undergoing treatment for their condition in 
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parallel to these observations and this cannot be excluded from interpretation of this 
observation.   
It is hard to align the decrease in respiratory rate with the potential for further 
improved oxygenation when no further improvement in oxygenation is seen albeit 
over a limited time period. It is therefore possible the rate effects are due to the initial 
oxygenation effect and not related to more complex physiological corrections such 
as recruitment or changes in ventricular function which one might expect to see by 
one hour. One argument might be that these high flow systems generate their own 
intrinsic pressure but this was measured, on a model, and is only approximately 1.4 
cmH2O which seems highly unlikely cause such impressive effects. 
There was no obvious effect on the carbon dioxide which is reassuring. Comfort has 
always been an issue with CPAP systems and so this simple comfort score was 
used as a very basic assessment tool. It has always been known that patients find 
CPAP uncomfortable and this simple score appears to confirm that.  
 
6.4.1 Critique of the Audit 
The numbers are too small to draw any conclusions from the diagnostic categories. 
Albeit post priori, the differential diagnoses were evaluated. It was the younger 
patients with pneumonia that appeared to have the greatest improvement in 
oxygenation and this was borne out statistically. While it had been expected that the 
patients with congestive cardiac failure would show dramatic improvement with the 
application of pressure, this was not obvious. In such patients the initial improvement 
in oxygenation with CPAP was without any pressure as with the patients with other 
diagnoses. The argument has long been that CPAP benefits congestive failure 
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through the effects of the positive pressure. The oxygenation effect seen in this audit 
occurs before the pressure is applied and so seems to be pressure independent. If 
the physiological effects are genuinely important in terms of oxygenation then, as 
some of these patients were followed for two hours, a hypothesis needs to be 
generated to explain when one might expect to see the benefits of these effects. The 
current literature does not suggest a timescale for the effects of PAP to act on the 
lung. The surrogate approach of detecting when the maximal improvement in 
oxygenation occurs would suggest a one to two hour period20-24. This was part of the 
reasoning behind limiting the audit to two hours. The other was more pragmatic. It 
was felt that continuous therapy with CPAP was most likely to detect the influence of 
PAP on the primary endpoint, oxygenation. Maintaining continuous therapy without a 
break is difficult much beyond two hours, thus a 2 hour limit was set to try to evaluate 
the immediate effects of CPAP. Only two of the 53 patients found CPAP intolerable 
within those two hours and it might be that the audit could have been continued 
longer without significant drop-out. The use of sophisticated masks may improve 
comfort and compliance with treatment, but have a significant cost implication. This 
needs to be formally studied and a future study could attempt longer periods of 
assessment, such as four or six hours. As a final point, it is interesting that the 
respiratory rate was significantly decreased after the application of CPAP even within 
this short time-scale, although it did take longer to become apparent than in the 
literature. Summaries of the mechanical aspects of the physiological rationale for 
non-invasive ventilation (including CPAP) imply an almost immediate effect. Thus 
work of breathing, pulmonary compliance and FRC all improve early in treatment 
which is reassuring when drawing conclusions from the observations reported 
here25. 
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There are several other limitations to this audit. It is observational nature and the 
attention of the team and the nature of the equipment may affect these results. A 
study randomising patients to a T-piece or CPAP would improve the quality of this 
data but this poses dilemmas in consent in patients who are clinically at risk.  
A further issue is that this is a relatively small audit with a wide distribution of data. 
An endpoint of a 2.5 kPa increase in PaO2 between the different stages of the 
protocol would be considered a significant change and this value is  based on the 
literature from studies in ACPO when CPAP is introduced following mask oxygen 
therapy.24 Would such an increase be expected by introducing a CPAP valve to the 
open CPAP system be reasonable? Clinically such an increase would be desirable, 
as for example, an improvement in PaO2 of 7.9 kPa to 10.5 kPa would be viewed by 
most clinicians as an effective, but moderate intervention. In the future bigger 
numbers may allow greater confidence in the information and permit any data from 
subgroups such as diagnosis to become more obvious. Indeed, whilst the 
heterogeneity of the subject‟s pathology makes this data more easily applicable to 
clinical practice, it may hide signals specific to certain patients groups.  
It could be argued that CPAP was not the appropriate treatment for the respiratory 
failure in some of these patients. If this were the case, and it is clearly a matter of 
opinion, then it shows that even in this relatively small group of patients, CPAP is 
being used successfully for patients with evidence of significant hypoxia regardless 
of cause. This is an issue which played a significant part in the inception of this audit. 
If one were to limit the audit to conditions where there is strong evidence from the 
literature of CPAP being of benefit e.g. ACPO or possibly post-operative atelectasis, 
then whilst more scientifically acute, the results would not reflect its use in the 
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medical community, making the results much less applicable. A large prospective 
trial is needed.  
The trigger for consideration for CPAP was a clinician deciding it was needed and 
was dependent on a clinician led diagnosis. This may have added a degree of 
subjectivity. Maybe a more formal assessment of the diagnostic data by independent 
clinicians would allow for greater diagnostic accuracy in a future trial.  
There was a low rate of endotracheal intubation when compared to the literature 
(1.89%). These were mainly ward patients and the decision to use CPAP was 
entirely in the hand of their clinicians and the Outreach team. Though blinded to the 
presence of audit when deciding to institute CPAP, this may reflect earlier 
intervention in this institution.  
 
6.4.2 Clinical Implications 
This audit demonstrates that the CPAP system, with or without pressure, is clearly 
superior in delivering oxygen to the available open mask system. However as 
mentioned in the introduction and as demonstrated by the findings with the comfort 
score, it is uncomfortable for some patients. If its main effects are in fact secondary 
to physics rather than physiology, there is an argument for improving the 
performance of non-sealed mask systems. One can postulate that the seal of CPAP 
system is only required because the reservoirs of commonly used oxygen masks are 
insufficient. Without the necessity of being able to pressurise the system it would be 
easier to design far more comfortable oxygen delivery systems that enable better 
coughing and physiotherapy and even drinking and eating without detriment to 
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oxygenation. It is therefore very important that the mechanism of oxygenation in 
CPAP is investigated further. 
 
6.4.3 Conclusions 
In patients in acute respiratory failure, CPAP  achieved a higher inspired oxygen 
concentration than a Ventimask®  at the same set inspired oxygen fraction but the 
main changes occur prior to the application of the valve and hence the pressure. In 
this simple observational audit it appears the immediate effects of CPAP on 
oxygenation in patients is pressure independent. This challenges existing concepts 
on how CPAP works in the critically ill. This needs urgent examination in a formal 
study. 
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Chapter 7 
An Audit of Fluid Resuscitation of Ward Patients 
 
7.1 Background 
The means by which the ward outreach services can intervene in the ward are 
limited and to this point the main focus has been on oxygen delivery to the patient. 
The other significant area of intervention is fluid management and dealing with „on 
the ward‟ fluid resuscitation.  
A very common problem is haemodynamic disturbance and in particular 
hypotension. Goldhill et al. demonstrated that ward patients have a higher mortality 
with critical illness than patients presenting to the emergency department or via the 
operating theatre1. The emphasis was on detecting problems early, the implication 
being that earlier implementation of treatment may avert deterioration and should 
improve outcome. Hence the advocacy for track and trigger scores. The Critical Care 
Outreach Team (CCOT) and the ward based staff are in the ideal position for early 
identification of fluid management issues and therefore well placed for early 
intervention. To date the areas that have been investigated have been either the 
means of early detection and development of early warning systems, or the efficacy 
of the team approach2-7. This includes CCOT and MET (Medical Emergency Team) 
and has focused on dealing with ward problems using early warning systems linked 
to team management and then hard outcomes such as cardiac arrest. There is very 
little or no information about specific interventions such as when and what  fluid 
management is instituted and whether it is effective, even though it is a significant 
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part of the interventions that are likely to be instituted. The study by Rivers et al. 
where they applied early goal directed therapy in the emergency department and 
demonstrated improved outcomes seems to be a good potential model for ward 
intervention8. While clearly this is a very different environment, it seems intuitive, that 
early intervention elsewhere such as the ward should also be beneficial. The earlier 
the better is not dissimilar to the concept of the „Golden Hour‟ so familiar in the 
treatment of trauma9. In practice this has not yet been shown in the ward 
environment.   
This chapter is intended to provide an idea of what is happening currently in one 
institution to try to develop a picture of fluid management as a ward based 
intervention.  
 
7.1.1 Hypotension and Early Circulatory Failure 
The intervention of fluid administration is hard to define. In the ward environment a 
patient may become unwell for a wide range of reasons. The early warning signs of 
tachycardia, hypotension, alterations in perfusion and tachypnoea may be indicators 
of hypovolaemia or relative hypovolaemia. Depending on the cause and its natural 
history this may, if left untreated, progress towards a shock state. Shock is defined 
loosely as failure of the circulation to adequately meet the body‟s metabolic 
demands. It classically comes in several guises outlined in Table 7.1.  
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Table 7.1 Physiological classification of circulatory shock
10
 
Type of Shock Examples 
Distributive Sepsis 
Anaphylaxis 
Cardiogenic LV failure 
Severe valvular disease 
Hypovolaemic Haemorrhage 
Heat stroke 
Obstructive Pulmonary embolism 
Cardiac tamponade 
 
Once established it may require relatively sophisticated interventions to treat shock 
including invasive cardiovascular monitoring to guide fluid and inotrope management 
which may necessitate Intensive Care and is not feasible in the ward. Paradoxically 
early simple interventions in the wards, before shock becomes established may be 
relatively more effective than late intervention in Intensive Care. Therefore in the 
ward environment, focusing on the clinical events that may be a clue to evolving 
shock is probably more useful in terms of intervention than once shock has become 
established and more aggressive measures will almost certainly be needed. The 
evidence that exists currently demonstrates beyond reasonable doubt, that failure to 
deal with these problems early is associated with poor outcome and that early 
warning systems do detect the problems earlier3, 11, 12. As yet hard data confirming 
that early intervention in the ward is effective is lacking. As mentioned few, if any, 
studies address the specific interventions being used and tend to focus on the 
systems being employed such as CCO or MET6, 13, 14.  
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The techniques currently available to treat or support early signs of circulatory 
insufficiency in the ward are limited to intravenous fluid resuscitation in various 
forms. Some ward areas permit low dose inotropes (e.g. Dopamine), but in general, 
the initial resuscitation of the acutely shocked patient is limited to the administration 
of fluids. These may be in the form of crystalloid, colloid and/or blood products. The 
monitoring available is also very limited with central venous monitoring often 
unavailable in the early stages when the CCOT is called. 
 
7.1.2  Intravenous Fluid Resuscitation 
 In the ward situation, with limited facilities fluid resuscitation is commonly the first 
approach to improving the circulation. While it is simple and rapid and is often 
beneficial it is not innocuous. In resuscitation, it has long been associated with 
problems although the literature tends to come from resuscitation environments or 
from management of the critically ill. In 1977 Lucas et al. demonstrated that high 
volumes of fluid resuscitation in trauma (mean of 9.3 litres blood and 17.4 litres of 
crystalloid) lead to a syndrome of hypertension and a raised cardiac output with 
respiratory insufficiency in 18 of the 35 patients studied15. Further information 
suggesting the potential negative effect of excessive fluid administration comes from 
a study by Wiedemann et al. this time in patients with acute lung injury16. In the very 
sick, a conservative fluid strategy in cardiovascularly stable patients reduced 
intensive care stay and time of mechanical ventilation and suggested liberal fluid 
management may be detrimental in the critically ill with pulmonary complications. 
There is no doubt that in these scenarios excess fluid administration is hazardous 
but can it be extrapolated to the ward? The work of Goldhill and others suggest that 
some patients on the ward are becoming critically ill and need early intervention and 
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so, while the studies are not available, it is reasonable to assume that while the ward 
situation may be different the dilemma as regards fluid administration is the same. 
The lesser severity of illness may be balanced by the paucity of monitoring.  
Under these circumstances the mode in which fluids are administered is unclear. 
Generally it takes two forms. In the dehydrated patient who may be considered to be 
behind on fluid, a general increase in fluid administration may be indicated which is a 
relatively minor alteration in the management already in place. This would be very 
hard to detect as a step wise intervention, in an audit. Alternatively if the patient is 
considered hypovolaemic, through changes in blood pressure perfusion or urine 
output, the administration of boluses of fluid may be initiated. Defining a bolus is 
complex. In studies a „bolus‟ is usually defined in terms of both volume and rate of 
administration. In the ward there is no set definition and circumstances may dictate 
both the size and rate of administration of a bolus. This makes it difficult to define 
what constitutes a bolus.  
A reasonable broad encompassing definition might be, “An incremental volume of 
fluid being given far more rapidly than would be usual for normal intravenous fluid 
administration and being given for a specific indication.” 
In the studies that have been published such as those of Rivers et al. in the 
emergency setting or those in the high risk surgical population, the environments 
allowed invasive monitoring. This included monitoring of central venous pressure, 
lactate concentration and the ScvO2 in the Rivers study and the use of central 
catheters and cardiac output monitors with high risk surgical patients17-19. In those 
studies it is clear that the use of intravenous fluid to resuscitate the shocked patient 
needs to be timely, appropriate and well monitored if the goals of resuscitation are to 
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be achieved with the least associated morbidity. In the ward environment these 
monitors are not readily, if ever available and in patients found by early warning 
systems, would need to be initiated rather than being in place. While a ubiquitous 
practice, it would seem after an extensive search of the literature, that the use of fluid 
resuscitation on the wards of a general hospital has never been studied. It has 
certainly not been studied in the manner in which it is currently used by CCOTs as 
one of the few interventions available to them.  
This is the context in which a preliminary audit to assess the accessibility of this 
intervention to study, was established. In this Institution CCO services are functional 
and are called to the ward to assess and institute early intervention which often 
involves fluid management. The aim of the audit was to acquire a general picture of 
current practice with regard to fluid intervention for haemodynamic instability in the 
ward environment. There was no obvious comparator at the time of this audit but it 
was considered wise to use a comparator, a „gold standard‟. The nearest approach 
is that by Rivers et al. using the early goal directed therapy guidelines albeit in a very 
different environment where patients are seen de novo and management instituted 
rapidly, often with fluids. At the time of this audit Rivers protocol for early goal 
directed therapy was being considered for implementation in the ward environment.  
Although there are clear limitations to the comparison it theoretically provided a 
known standard against which the audit could be compared and had the potential 
advantage of looking at the practicality of its implementation. 
.  
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7.2 Methodology 
This was a prospective audit of the use of fluid intervention for haemodynamic 
instability in the ward and was observational in nature. The observer had no 
influence on clinical care and decision making. The audit was carried out on the 
general wards of the Chelsea and Westminster Hospital. The population of patients 
audited were identified by the following criteria: 
 
7.2.1 Inclusions 
 Adults >16 years 
 Entry to the audit was triggered by referral to CCOT for opinion about the 
management of a predefined haemodynamic abnormality or „target‟ (Table 
6.2).This was required to be either: 
o  A new referral. 
o A minimum of 5 days since a previous review by ICU/CCOT. 
o A minimum of 5 days after discharge from ICU. 
 The need for fluid resuscitation. 
 They had to be ward based in-patients with a duration of admission > 24 hour, 
i.e. not new admissions 
 
7.2.2 Exclusions 
Patients from level 2 and 3 beds were excluded, as well as patients attending the 
emergency department. It was felt sensible to exclude patients in the maternity or 
paediatric departments and those suffering cardiac arrest. 
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7.2.3 Definitions  
Intravenous fluid resuscitation: A bolus was loosely defined as: “An incremental 
volume of fluid being given far more rapidly than would be usual for normal 
intravenous fluid administration and being given for a specific indication.” 
For the purpose of this audit and to be inclusive, intravenous fluid resuscitation (IFR) 
was defined the use of a bolus as an intake of greater than or equal to 250ml of 
intravenous fluid in 60 minutes as an individual and specific intervention separate 
from the prescribed fluid administration.  
Target (feature of haemodynamic instability): In each situation the indication for 
IFR was recorded, the „target‟ was haemodynamic instability necessitating 
intervention. An assessment made of whether treatment of the target was 
satisfactory (reversed) by the administration of intravenous fluid. This did not 
necessarily mean that the indication chosen had returned to „normal‟ but rather that 
its ongoing treatment with IFR was not required further. 
Complications: The detection of complications of intravenous fluid was attempted 
by recording variables associated with predictable complications of hypervolaemia20. 
These were new signs of peripheral oedema, rales on auscultation. New chest x-ray 
signs of infiltration consistent with oedema and with no other cause. Lastly, a CVP 
greater than 15 mmHg. 
Comparison with goal directed therapy. Data was also gathered, where possible, 
on targets sought in the ward which were comparable to those described by the 
study by Rivers et al. on EGDT, as evidence of systematic goal-directed treatment8.  
This could be used as a comparator albeit from a different environment.  
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7.2.4 Practical Application of the Method 
A patient from the ward was included on referral to the CCOT. The admission 
criterion to this study was the need for fluid to treat haemodynamic instability as 
outlined above.  
The time from the first appearance in the patient‟s documentation of the target 
abnormality was recorded. The time of the institution of IFR was documented to 
assess the response time after the appearance of the target. The time from its 
appearance to calling the CCOT was also documented.  
If IFR was required already, on the advice or the direct action of the CCOT, an 
assessment of the specific indication for IFR was made. This then became the target 
and its reversal an endpoint, as was its failure to effect reversal. This was used to 
define success or failure of the IFR. The definitions of target are summarised in 
Table 7.2. Each patient was reviewed at 6, 24, 48 and 72 hours. A range of other 
available physiological data pertaining to the perceived success of IFR was also 
gathered on each occasion. The baseline data recorded and the subsequent review 
data are summarised in Table 7.3. 
Time 0 was defined as the time of the first fluid bolus. When two or more 
measurements of infrequently sampled variables e.g. pH by arterial blood gas 
analysis (ABG) were present within a time interval, the sample closest to the review 
time was recorded. Complications of fluid management were sought by the 
assessment of the variables thought to be indicative of fluid overload (Table 7.3).  
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Figure 7.1  The Early goal directed therapy protocol (reproduced with permission)
8
 
 
Some measurements from the early goal directed therapy (EGDT) protocol as 
described by Rivers et al. were chosen as a standard with which to compare the 
results in the audit. Thus data was gathered to detect adherence to the protocol 
published in the New England Journal of Medicine8 (Figure 7.1). This took the form 
of examining, at 6 hours, measurements obtained from central venous catheters 
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(CVC) and their subsequent use of ScvO2 and the maintenance of a haematocrit 
above 0.3.  
The use of vasoactive agents was not relevant as this was almost impossible in the 
ward environment. Other patient endpoints were defined as ICU admission, death 
and the initiation of a „Do not actively resuscitate‟ (DNAR) order. Data collection was 
ceased if the patient was admitted to the ICU, died or was transferred to another 
institution. Death in hospital was recorded. 
 
Table 7.2  Definitions of targets for IVR 
Target Definition 
Low mean arterial pressure (MAP) MAP < 65 mmHg 
Increased heart rate (HR) HR > 100 beats.min-1 
Low urine output (UO) UO < 0.5 ml.hr-1 
Raised creatinine Creatinine > 120 μmol.l-1 when thought to 
be previously normal 
Worsening acidosis pH < 7.36 and unacceptable to the 
attending team 
Abnormal base deficit (BE) BE < -2 and unacceptable to the 
attending team 
Abnormal lactate Plasma lactate > 2 mmol.l
-1 and 
unacceptable to the attending team 
Other Any other cause thought by the attending 
team to require IVR. 
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Table 7.3  Data recorded during audit at baseline and reviews at 6, 24, 48 and 72 hours. 
Baseline data recorded Review data recorded 
Demographics Age (yr) 
Male gender 
DOA (days) 
Diagnosis 
APACHE II (0-71) 
MMODS (0-20) 
IVR Fluid volume 
administered (ml) 
Fluid type(s) used 
Fluid balance (ml) 
MMODS (0-20) 
Target achieved? (Y/N) 
Target and response Target 
Time of abnormality 
(hr) 
Time of response (hr) 
Time to call CCOT (hr) 
Complications New bilateral rales 
(Y/N) 
New CXR infiltrates 
(Y/N) 
New clinical oedema 
(Y/N) 
CVP > 15mmHg (Y/N) 
RRT for fluid overload 
(Y/N) 
Cardiovascular HR (beats.min
-1
) 
MAP (mmHg) 
CRT (s) 
CVC (Y/N) 
CVP (mmHg) 
ScvO2 (%) 
Use of inotropes (drug 
and dose) 
Haematocrit 
Cardiovascular 
 
HR (beats.min
-1
) 
MAP (mmHg) 
CRT (s) 
CVC (Y/N) 
CVP (mmHg) 
ScvO2 (%) 
Use of inotropes (drug 
and dose) 
Haematocrit 
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Table 7.3 (contd.) Data recorded during audit at baseline and reviews at 6, 24, 48 and 72 hours. 
Baseline data recorded Review data recorded 
Respiratory Respiratory rate 
(breaths.min
-1
) 
Oxygen therapy (Y/N) 
NIV/CPAP (Y/N) 
FiO2 
SpO2 (%) 
ABG? (Y/N) 
PaO2 (kPa) 
Respiratory Respiratory rate 
(breaths.min
-1
) 
Oxygen therapy (Y/N) 
NIV/CPAP (Y/N) 
FiO2 
SpO2 (%) 
ABG? (Y/N) 
PaO2 (kPa) 
Metabolic pH 
BE 
Lactate (mmol.l
-1
) 
Metabolic pH 
BE 
Lactate (mmol.l
-1
) 
Renal Urinary catheter (Y/N) 
UO (ml.kg.hr
-1
) 
Creatinine 
Renal Urinary catheter (Y/N) 
UO (ml.kg.hr
-1
) 
Creatinine 
 Outcomes On ward? (Y/N) 
ICU (Y/N) 
Died (Y/N) 
DNAR (Y/N) 
IVR, intravenous fluid resuscitation; DOA, duration of admission; APACHE II, acute physiological and 
chronic health score
21
; mMODS, modified multi-organ dysfunction score
22
; CCOT, critical care 
outreach team; CXR, chest X-ray; CVP, central venous pressure; RRT, renal replacement therapy; 
CVC, central venous catheter; ScvO2, oxygen saturation of central venous blood; NIV, non-invasive 
ventilation; CPAP, continuous positive pressure ventilation; FiO2, fraction of inspired oxygen; SpO2 
pulse oximetry oxygen saturation; ABG, arterial blood gas; PaO2, partial pressure of arterial 
oxygenation; BE base deficit; UO, urine output; ICU, intensive care unit; DNAR, do not actively 
resuscitate order. 
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7.2.5 Statistical analysis 
Descriptive statistics are presented as mean +/- standard deviations (SD) for 
continuous data and median and inter-quartile range (IQR) or range for non-
parametric data. Testing of relationships between different time intervals for fluid 
balance and rate of administration was performed using a Kruskal-Wallis test. 
Differences between separate time intervals were assessed using multiple Mann-
Whitney U tests. All statistical analysis was performed on SPSS v14.0 (LEAD 
Technologies Inc. USA).  
 
7.3 Results 
7.3.1 General observations 
84 non-consecutive patients were identified as suitable for entry to the audit over the 
study period of 12 months. Only those referred for haemodynamic instability were 
included. Complete documentation of medical observations, blood results, blood gas 
results etc. were sought. These were found to be deficient due to a variety of 
problems such as nursing documentation, lost samples, absence of CCOT cover at 
night, in 30 of the eligible patients and so these patients were excluded. This 
resulted in a cohort of 54 patients. 
The indications for fluid resuscitation are summarised in Figure 7.2. The two most 
frequent indications were a urine output below 0.5 ml.kg-1.hr-1 or a mean arterial 
pressure of less than 65 mmHg.   
A summary of the admission duration of the subjects is displayed in Figure 7.3. 
Median length of stay was 3 days (IQR 7 days). The baseline characteristics of the 
patients in the study are summarised in Table 7.4. The range of diagnoses was large 
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reflecting the heterogeneity of the disciplines that the CCOT cover. Diagnoses 
including such diversity as a ruptured ectopic pregnancy, massive epistaxis, 
Addisonian crisis and metformin overdose, preclude a readable table of diagnoses. 
The reasons or indications for fluid therapy are described in Table7.1 and Figure 7.4.  
All patients received at least 6 hours IFR with one exception where the patient was 
transferred out to another institution for specialist care. 39 patients had not reached 
a final end point (ICU admission, death or discharge) point at 24 hours, 35 by 48 
hours. By 72 hours this decreased to 26 patients remaining in the audit, the rest 
having reached a final endpoint.  
Figure 7.2  The indications for the institution of IVR – the Target. (UO, low urine output; MAP, 
low mean arterial pressure; BE, abnormal base defecit; HR, abnormal HR; pH, abnormal pH; 
azotaemia, rising creatinine; lactate, raised lactate. Criteria defined in Table 7.2). 
 
206 
 
 
Figure 7.3  Length of stay for the patients prior to the institution of IVR 
 
Figure 7.4  Causative pathophysiology underlying the conditions of the patients in the audit. 
1 
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Table 7.4  Baseline characteristics of the patients. 
Characteristic Value (n=54) 
Mean Age (yr) +/- SD 57.9 +/- 18.3 
Male gender (%) 44.4 
Mean Heart rate (beats.min-1) +/- SD 108.4 +/- 16.7 
Mean arterial pressure (mmHg) +/- SD 59.96 +/- 15.2 
Capillary refill time of <2 seconds (%) 46.3 
Mean Respiratory rate (breaths.min-1) +/- SD 23 +/- 6.4 
Mean SpO2 (%) +/- SD 96.98 +/- 2.4 
Median APACHE II Score (IQR) 20 (12.8) 
Median mMOD Score (IQR) 4.5 (5.8) 
SpO2, pulse oxygen saturation; APACHE II, acute physiological and chronic health score
21
; mMODS, 
modified multi-organ dysfunction score
22
. 
 
 
7.3.2 First involvement of the CCOT 
Figure 7.5 summarises in a box and whisker plot the timeline from the first 
appearance of the target abnormality and the initial delivery of IFR (delineated by the 
box and whisker on the left). Median time was 3 hours (IQR 3 hours). The plot on the 
right records the timescale of the involvement of the CCOT with the appearance of 
an abnormal physiological target. Median time for referral to the CCOT is 5 hours 
(IQR 4 hours).  
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Figure 7.5. Response times from first appearance of target abnormality. 
(Time IVR = Time delay to the initiation of IFR after appearance of the target abnormality; Time 
CCOT = Time delay before contact with the CCOT after appearance of the target abnormality). 
X axis = timeline Y axis = time in hours.  
 
7.3.3 Ward patients compared to those in the Rivers EGDT study. 
In this group of ward patients approximately 35 patients (64%) would have been 
eligible for consideration in the Rivers trial. However there were also three cases of 
gastrointestinal haemorrhage, two of status asthmaticus and two of acute pulmonary 
oedema, which were exclusion criteria in the original study. It was intended to use 
the Rivers trial as a comparator to have some standard for comparison. The issues 
being evaluated can be summarised as follows; 
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Treatment of the Problem within 1 hour of the Problem Being Recognised  
The evidence is demonstrated in Figure 7.5. It clearly took far longer to identify and 
treat ward patients than those presenting to an emergency department.  
 
Administration of Oxygen and/or Intubation 
9/53 patients (16.7%) did not receive supplemental oxygen within the first 6 hours. 
However the SpO2 was with one exception, adequately saturated on breathing room 
air. 
 
Central Venous Catheterisation (CVC) and IFR to a CVP of 8-12 mmHg  
This was rather central to the Rivers study and clearly was easily achieved. The 
ward environment in most general hospitals in the UK is far less conducive to placing 
central venous access. Despite this, 13/53 (24%) patients underwent central venous 
cannulation during the first 6 hours and a further 6/53 patients already had central 
catheters in situ prior to inclusion in the audit.  
In terms of use of these for measurement the situation was unclear. Documentation 
was scarce, and the CVP values were often not recorded, or only every 4 hours. 
There was no evidence of a graded response to the CVP measurement, and its use 
in guiding the fluid management. Where there was a record of the measurement, 
10/19 patients with CVC‟s in situ did not achieve a CVP of 8 mmHg, 6/19 had CVP 
measurements within the range with 3 of these patients above 12 mmHg at 6 hours. 
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ScvO2 Measurement 
5/53 patients had an ScvO2 measurement taken in the first 6 hours. Each had one 
sample taken and none had repeated measurement. All were below 70% (range 59-
69%). No patients went on to receive dobutamine as this was not possible but one 
patient in severe cardiogenic shock did receive adrenaline. 
 
Maintenance of Haematocrit (Hct) above 0.3 to Improve Oxygen Delivery  
19/53 patients had a Hct less than 0.3. Of the patients who received blood, all, 9/9, 
were known to have an acute haemorrhagic condition and be actively bleeding but 
only 5 of these had Hct less than 0.3. 14 of the 19 patients with a haematocrit ≤0.3 
did not receive blood.  
 
7.3.4 Resolution of the Target Indication for Intervention 
The indication for IFR, or target, was assessed for a return to haemodynamic 
normality as defined by the trigger values over the 72 hour period of the patient 
audit. This is summarised in Table 7.5. Of the 54 patients included, 9 had resolved 
their target by six hours, 14 by 24 hours, 5 by 48 hours and 5 by 72 hours. In total, 
33 of the 54 patients had resolved their targets by 72 hours. 4/54 patients had not 
resolved their target at 72 hours, and had not either died or been admitted to the ICU 
(16/54 – see below).  
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Table 7.5  Resolution of target abnormality 
Time interval (hr) 6 24 48 72 Total (%) 
All patients (n=54) 9 14 5 5 33 (62) 
MAP target (n=16) 1 3 2 3 9 (56) 
BE target (n=6) 0 3 0 0 3 (50) 
MAP, mean arterial pressure; BE, base deficit. 
 
Table 7.5 also summarises some sub-group analysis for the targets of MAP <65 
mmHg and BE < -2. 9/16 patients with MAP as their target resolved the problem with 
IFR alone. Of the remainder 4/7 who failed to respond to fluid were admitted to ICU, 
2/7 were palliated and 1/7 died. With regards to BE as a target, 3/6 resolved the 
problem within 24 hours. Of the remainder, 2 were admitted to ICU and 1 was 
palliated. 
 
7.3.5 Poor Patient Outcomes 
21 patients did not have resolution of their haemodynamic problems with fluid 
administration. Of these 13/20 were admitted to the ICU and 1 patient was 
transferred to a specialist centre. 3 patients died on the ward within 24 hours – with 2 
suffering cardiac arrest. 1 patient was made DNAR and palliated. There were a 
remaining 4 patients who did not resolve but did remain on the wards after the 72 
hour interval. One patient with an unresolved target remained actively treated, 
resolved slowly and was discharged home. In the remaining 3 patients the decision 
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was made to go to a DNAR status with appropriate palliation. Therefore 13 patients 
failed to resolve and required further treatment. There is inadequate information to 
assess whether the ward interventions were helpful in preventing further 
deterioration prior to ICU admission. These 13 patients were admitted to the ICU, 11 
were admitted within 6 hours and the remaining 2 within 24 hours. 5/13 died on the 
ICU and 2/13 after discharge to the ward. There were 6 survivors. 
 
7.3.6 Complications associated with fluid administration. 
Potential complications associated with IFR are summarised in Table 7.6.  
Oedema was defined as the subjective presence of new generalised peripheral 
oedema.  Overall almost half the patients had oedema. Rales were defined as 
bilateral inspiratory crepitations typical of pulmonary oedema observed by the 
attending team. 
X-ray changes. New infiltrates were defined as the appearance of bilateral alveolar 
shadowing on any chest x-ray that was taken during the 24 hour period and was not 
thought to be directly related to other pathology affecting the patient.  
A CVP > 15 mmHg was also recorded for the 19 patients who had a CVC in situ or 
inserted during the audit period. The number 15 mmHg was arbitrary; chosen as 3 
mmHg above the recommended target from the Surviving Sepsis Campaign23.  
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Table 7.6  Complication rates and the time of their appearance. 
Time interval (hr) 6 
(n=54) 
24 
(n=39) 
48 
(n=35) 
72 
(n=26) 
Total (%)  
(n=54) 
Rales 18 10 4 0 32 (59) 
CXR changes 14 8 2 1 25 (46) 
Oedema 1 6 11 8 26 (48) 
CVP > 15 mmHg  1 1 3 2 7 (37) 
No Complications (%) 31 (57) 16 (41) 12 (34) 11 (27)  
 
 
Table 7.7  Results for fluid volumes and rates administered over the 4 time intervals. 
Time interval (hr) 6 24 48 72 
Median cumulative 
fluid volume (ml) 
[Range] 
2000 
[500 - 7406] 
4800 
[1500 - 8100] 
8025 
[2500 - 11100] 
9847 
[7506 - 13660] 
Median fluid balance 
(ml)  [range] 
1160 
[100 - 3940] 
2863 
[770 - 6940] 
4375 
[110 - 9594] 
5730 
[1150 - 11419] 
Median rate of fluid 
administration 
(ml.hr
-1
)  [range] 
300 [83 - 667] 200 [63 - 338] 120 [42 - 167] 102.8 [63 - 148] 
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7.3.7 Volumes and Rate of Fluid Delivery 
The volumes, rate of delivery and balance of fluid administered are summarised in 
Table 7.7. The median amount of fluid administered to those who remained on the 
wards for the duration of the audit was 9847 ml [range 7506-13660 ml]. There was 
also a statistically significant rise in fluid balance for the time intervals 24, 48 and 72 
hours (p<0.001). The initial volume of fluid in the first 6 hours is 2000 ml, but 
delivered at a median rate of 300ml.hr-1. Both volume and rate reduced over time (p< 
0.001). 
 
7.4 Discussion 
7.4.1 Summary 
This audit sought to describe fluid interventions by the CCOT in patients in the ward 
environment. It proved an extremely difficult subject to audit and highlighted a large 
number of difficulties in investigating this type of ward intervention and indeed of 
assessing the efficacy of a ward based CCOT.   
The range of patient diagnoses was too large to easily demonstrate in a table and 
this illustrates the breadth of the remit of a ward based CCOT. In this audit the 
median APACHE II score was 20 which is high for a ward environment and may 
suggest that ICU admission is likely. 
The specific findings were as follows: 
The response time from target trigger to initiation of fluid resuscitation was a median 
of 3 hours (IQR 3 hours) while the median time to referral to the CCOT was 5 hours 
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(IQR 4 hours) suggesting that fluid resuscitation was often instituted before the 
arrival of the CCOT.  
Of the patients receiving fluid therapy as an intervention, 34/54 were successful but it 
is hard to pin point the cause of failure in the remainder.  
The cumulative amount of fluid given over 72 hours to those that remained on the 
wards was 9847 ml [7506 – 13660 ml]. The cumulative fluid balance at 72 hours was 
a median value of 5730 ml [1150 – 11419 ml]. 
Potential complications were common with the appearance of oedema of the lungs 
and tissues in approximately 50% of the patients. The pulmonary complications 
appeared early phenomenon. 
 
7.4.2 Comparison with the EGDT Protocol of Rivers et al 
As an audit, the comparison with the Rivers et al. study is problematic and will be 
discussed below needs to be discussed. The decision to use the Rivers study as a 
comparator was clearly erroneous creating more problems than it solved.  
For example, from the point of inclusion in the study the entry trigger was referral to 
the CCOT but IFR was often initiated prior to referral to CCOT as can be seen by the 
time delays so that the use of CCOT referral as a method of selecting patients 
clearly excluded some patients. This was not comparable to the Rivers study where 
each patient in a casualty department is assessed on admission and so is seen 
immediately. This contrasts with ward patients who present randomly in a wide range 
of ways and the specific illnesses are not usually de novo primary illnesses. In the 
ward patients there was a delay in the institution of IFR and in the involvement of the 
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specialist team. This could really only be assessed against other ward based 
environments but there are no such studies.  
Oxygenation was not a primary goal in this audit while it was central to the Rivers 
study. Most patients did not have oxygen therapy instituted rapidly. At the review of 
the diagnosis the target abnormality was invariably haemodynamic to be included in 
this audit rather than respiratory. The SpO2 was with one exception, adequately 
saturated on breathing room air. This therefore was not a helpful endpoint to 
consider. 
The use of CVP measurements was far less in the ward patients. This information is 
interesting but not helpful. In the Rivers study it was perceived that a target CVP 
value was essential and hence all have that monitoring. In the ward environment the 
CVP could have been used diagnostically but it is unlikely with such a wide range of 
patients that a specific CVP for all patients is either a realistic or even sensible goal 
for management.  However this part of the audit does indicate that CVP is used more 
than was probably expected although it casts no light on how it is used.  
This use of ScvO2 is of interest because it was a novel interventional measurement 
at the time. Although only 5 patients had such data recorded, it at least demonstrates 
an awareness of its potential value. There was no written evidence of how it was 
used if at all. More interesting is more recent work by Rupert Pearse (personal 
communication) showing that the range of normal ScvO2 is wide and although 59% 
may be outside the normal range for Rivers, the patients may have fallen within a 
normal range. Reliance on ScvO2 as a sole measurement without the clinical 
background is probably fraught with difficulty.   
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In the Emergency department the focus on haematocrit is almost certainly 
appropriate but in the ward environment protecting a haematocrit of 0.3 is difficult in 
the context of a restrictive transfusion policy. While many would argue that in any 
acute illness a higher haematocrit is both safe and sensible the evidence is not yet 
there. Hence in both ICU and the wards a haematocrit less than 0.3 might even be 
perceived as good practice. In any event it makes comparison impossible.  
These were the main comparators used and it clearly demonstrates the difficulties in 
using values or criteria from a rather specific trial in a very different environment. As 
a comparator it is useless but it did clearly illustrate some issues that might not 
otherwise have been aired, such as the use of haematocrit and of ScvO2.  
Of interest is the severity of illness. The APACHE score in the audit had a median 
value of 20. This does suggest the severity of illness of patients in the ward 
environment is in some respects comparable with that in a published trial albeit from 
an emergency department. It needs to be mentioned that this was not the way in 
which the APACHE score was originally described but it does still provide some 
indication of severity of illness. It may not be the optimal score for such an audit in 
future and possibly the SOFA score might be more appropriate. 
 
7.4.3 Response Time 
The response time is important. The delay in the response time to the institution of 
IFR is disappointing especially when compared to the study by Lundberg et al. 
whose ward patients had a median time to delivery of fluid of only 27 minutes24. In 
this audit, the difference between the time of initiation of treatment and the time to 
referral to the CCOT imply that start of therapy was by the attending team. This 
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study was performed before the introduction of the Chelsea Early Warning Scoring 
System (CEWSS), so one might have assumed that awareness would now be higher 
and responses faster. Nevertheless a median of 3 hours from appearance of the 
problem to the first bolus of fluid is disappointing. It is probably relevant to consider 
the targets that triggered a response. A MAP of 52 mmHg in a 24 year old man (a 
defined target in this audit) is probably judged differently from the same value in a 76 
year old. A BE of -10 may is more likely to trigger a rapid response than a UO of 20 
ml.hr-1. This is an area that needs to be addressed.  
 
7.4.4 The Efficacy of the Intervention  
This audit shows that this relatively simple intervention was effective in reversing the 
problem much of the time. If one excludes those patients in whom the intervention 
resulted in a change of management, such as palliation it would appear that the 
majority of those with hypotension responded, 9/14. Those who failed either died, 1, 
or were admitted to ICU indicating the magnitude of the problem was greater than 
could be averted in the ward. Using base excess as an indicator with the same 
exclusions, then 3/5 responded to fluid. This would suggest in a limited series that 
these interventions are actually successful in a significant number of patients. It 
implies that IFR is an effective treatment for a significant number of patients with the 
defined targets. However for those that do not respond, how much of this is due to 
delays remains unknown.  
Of those that later needed admission to intensive care this raises a series of 
questions about the ward interventions. It is presumably important to know whether 
the interventions allowed ICU admission and prevented further deterioration or even 
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death in the wards but detailed analysis of these cases would be needed to make 
this assessment. The ICU admission rate was similar to that of the MERIT study7 
with an ICU mortality rate similar to that of Goldhill et al. This data would suggest 
that CCOT involvement in fluid management will be ineffective in some patients who 
are likely therefore to need ICU. It would be of value to know if they were genuinely 
considered salvageable at the time of admission to Intensive Care. It would also be 
useful to know the nature of the underlying problem and the degree of genuine 
reversibility. It is important to appreciate that more patients did respond to treatment 
than did not and that in those that did not their failure to respond may be an 
indication of severity of illness. It is interesting that 11 patients admitted to ICU were 
transferred within 6 hours of the institution of IFR. With no easily identifiable control 
group as a comparison, it is difficult to say whether or not this relatively brisk 
resolution of a problem is related to the input of the CCOT.  
6/54 patients died during this audit. 2 suffered cardiac arrest, but 4 had a new DNAR 
order applied as a consequence of the need for IFR, when it and other measures‟ 
were observed to be failing. Whilst struggling for improvements in mortality is an 
important role of CCOT, the recognition of inevitable failure and appropriate 
withdrawal of „critical care‟ is potentially as valuable, but harder to define and 
measure. 
 
7.4.5 Fluid management 
Table 7.7 is interesting. Firstly the cumulative amount of fluid and the fluid balances 
certainly confirm the assertion made earlier that most practitioners err on the side of 
more rather than less fluid. For those that remained on the ward for the full 72 hours 
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a fluid balance of up to 10 litres is of concern, particularly in view of the 
complications documented. Secondly the median rate of fluid administration seems 
lower then might be expected, particularly in the first 6 hours. This may be due to a 
more cautious approach by non-CCOT personnel or by the affect of the 9 patients 
that reversed their target in the first 6 hours with only small amounts of fluid.  
 
7.4.6 Complications of Fluid Management 
 Overall this appears to be high.  It was the complications in part that that inspired 
the inception of this audit. It is important to break down the complications as they 
were assessed. Oedema was common and increased with time. The difficulty in this 
sign is that while it is associated with fluid administration it is also associated with 
severity of illness and the two cannot be easily separated. The same is true of 
pulmonary rales. Both are suggestive, neither is definitive. The presence of new 
pulmonary oedema on a chest X-ray may be a slightly harder endpoint and this was 
also substantially increased.  
The use of a high CVP value was taken as an objective sign of fluid overload and 
used because it was part of the Rivers study. Its value in assessing potential 
complications is very limited. As can be easily seen those with high values which 
should be a positive feature in the Rivers study yet potentially a negative feature 
here , are very small in number.  
Overall one would have to comment that there is circumstantial evidence of some 
fluid overload. The appearance of pulmonary congestion appears to be greatest 
early in the resuscitation period with the greater proportion of clinical and 
radiographical evidence documented with in the first 48 hours. In this audit no patient 
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had an overt clinical complication from fluid overload but clearly there is potential for 
this to happen. As a large number of patients did resolve their haemodynamic 
problems the apparent cost benefit lies in favour of fluid administration. 
Nevertheless, although it cannot be directly stated from the results, it would seem 
obvious that most of this fluid administration is done without monitoring and this 
presumably increases the potential risk. There is a place for trying to improve 
monitoring in the ward environment to facilitate fluid management.   
 
7.4.7 Limitations of the Audit 
This was an over-ambitious project aimed at providing information about a common 
ward intervention about which there is currently no in evidence at all. An audit of this 
type covers a large number of wards and a wide range of patients. The intention was 
to focus on fluid intervention. It is difficult to capture these incidents. The use of 
referral to CCOT seemed the only realistic way of approaching the problem but it is 
quite clear that most interventions were initiated before the CCOT were involved. 
This was in contrast to the study of CPAP in Chapter 6 where only the CCOT and 
ICU were able to implement CPAP, so intervention was limited to those two teams. 
While using the referral as a trigger allowed those interventions to be found and 
tracked, inevitably an unknown but almost certainly large number of minor 
interventions with no referral were lost. It is also a major consideration that at the 
time of the audit the CCOT functioned during an extended day but overnight and 
weekend events could easily be missed. Documentation was generally very poor 
and made this audit difficult in particular determining why an intervention was 
initiated. Follow up also posed problems over the time period of the audit and after 
wards.  
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Another major issue is that this audit makes the assumption that fluid therapy is the 
appropriate treatment for the targets outlined. These were chosen as signs of 
circulatory insufficiency. The administration of fluid as a treatment for these signs 
supposes that fluid will reverse the problem. Clearly that is not true in practice. The 
treatment of the underlying condition is intricately associated with the likelihood of 
success of supportive measures. Some patients were destined to fail because of the 
severity and nature of the condition and the effectiveness and rapidity of its specific 
treatment. Defining success of CCOT or fluid resuscitation by fluid management 
alone is a large weakness in this study.  
The use of the Rivers study as a comparator has already been discussed and while 
at the outset it seemed not only a reasonable standard but also the only standard 
that had been evaluated it became clear most aspects of the study were not 
comparable. It should be mentioned that at the time of planning CCOT were 
discussing trying to implement Rivers approach in the ward environment in part.  
The numbers appear small but belie the logistical difficulties of collecting the data. 
 
7.4.8 Conclusions 
In summary this audit was a difficult project to do, and as such should be considered 
a pilot study that has highlighted a number of difficulties that should lead to better 
methodology. It identified the problems of studying the efficacy of interventions 
performed on a large, very diverse group of patients. More importantly it clarifies why 
there has been on effective study of interventions commonly used in almost every 
hospital ward. This must be addressed. 
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It is difficult to define end points for interventions. Reducing mortality and ICU 
admission represent just the tip of the iceberg when describing the role of CCOT. 
Indeed of the patients who died, three quarters had a new DNAR order. This too is a 
valuable intervention. Looking only at the response to a single intervention not 
usually curative in its own right, ignores the influence of treatment of the underlying 
condition. In the Surviving Sepsis Campaign, antibiotics are to be given within 1 
hour. In this diverse group of diagnoses such a requirement would be difficult to 
enshrine. 
This audit does demonstrate slow response times and potentially excessive amounts 
of poorly monitored fluid administration. Better ways of improving response to a 
trigger still need to be sought even in this era of track and trigger. More robust 
methods need to be developed to measure the effect of CCOT on ward patient‟s 
treatments. Trying to delineate the effect of one supportive intervention on outcome 
has proved very difficult and the data produced does not permit significant 
conclusions to be drawn. Expanding studies into other interventions and looking for 
positive effects of CCOT may prove difficult and expensive but as it constitutes such 
a large part of daily ward based practice and as the outcomes are of such 
consequence it does deserve attention. 
Fluid therapy in the wards is common, is performed in a range of ways for diverse 
reasons and seems to be effective in a high proportion of cases but with the potential 
for complications. In those in whom it fails the mortality is high. There has been no 
significant work on these interventions and their efficacy. In other environments fluid 
management is guided by monitoring but this is rarely the case in the wards. One 
area that urgently needs evaluating is whether user friendly monitoring systems are 
available that would be helpful in the ward environment for fluid administration. 
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Chapter 8 
The Comparison of an Uncalibrated Cardiac Output Monitor with a 
Dye Dilution Pulse Contour Method 
 
8.1 Background 
The previous chapter which considered fluid administration included the observation 
that fluid was often given as a treatment, but monitoring of how much was needed 
was a problem. A cardiac output monitoring system would presumably assist those 
in the ward environment but at present these techniques, which are invasive and 
complex are restricted to higher dependency areas. A simple user-friendly technique 
for use in the ward which is reliable in terms of correlation with more invasive 
methods both in accuracy and consistency could be a useful adjunct to ward 
management.  
 
8.1.1 Oxygen Delivery 
The need for disciplined cardiovascular support is increasingly important in the care 
of the critically ill. A stable circulation permits the effective delivery of oxygen and 
nutrients to the tissues, whilst permitting removal of the waste products of 
metabolism. The delivery of oxygen is vital for aerobic cellular metabolism. This 
efficient mode of cellular energy production is desirable. More cellular energy 
presented as adenosine tri-phosphate (ATP), is produced per molecule of glucose 
than by anaerobic metabolism (36 molecules of ATP to 2). Cellular integrity is energy 
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dependent, especially membrane potential maintenance and acid-base control. 
Failure of oxygen (and nutrient) delivery obliges cells to convert to anaerobic 
metabolism compromising energy production and thus risking cellular integrity and 
function, which in turn can impair organ and thus whole body function. In critical 
illness there is a need to maintain delivery, particularly of oxygen, to the tissues. This 
function is for the greater part served by the circulation. Consisting of the heart as 
the pump and the vessels as the conduits, oxygen is carried to the cells. The 
majority is carried bound to haemoglobin. Put simply, Oxygen delivery (DO2) is 
dependent of the amount of oxygen contained in the blood (CaO2) and the circulation 
propelling it to the tissues – reflected as the cardiac output (CO). Indeed DO2 is 
calculated as CO x CaO2. What DO2 is required to maintain normal homeostasis in 
critical illness is an important question? It was thought reasonable to match the DO2 
to the consumption of oxygen (VO2). This can increase markedly in conditions such 
as severe sepsis. Matching DO2 to VO2 would be physiological and that increasing 
cardiac output to achieve this, or even exceed this target would improve outcome. 
However as outlined in Chapter 1 the studies of Gattanoni and Hayes did not 
demonstrate this to be a beneficial strategy1, 2. Indeed it can be argued that this 
technique ignores a much more complex reality both at a circulatory and cellular 
level. Looking at the global effects may be considered simplistic as in illness, 
regional blood flow is often disordered, but from a pragmatic viewpoint the 
maintenance of an adequate circulation to optimise at least a normal DO2 is still seen 
as an important part of critical care. It is likely that the earlier it‟s restoration, the 
greater the likelihood of a favourable outcome3. 
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8.1.2 Interventions to Improve DO2 
Manipulating DO2 can be achieved by intervention at most points on the oxygen 
cascade. Oxygen delivery to the alveoli has been discussed and examined already 
in this thesis. The concentration of haemoglobin needed in critical illness remains 
debated but is a component of oxygen delivery and is important to survival4, 5. 
Optimising the cardiac output is also a key strategy employed. This is commonly 
achieved by either fluid or inotropes or both. Fluid management is a simple 
intervention deliverable on the ward. It has been demonstrated to be both life saving 
if given appropriately, but also detrimental if given in excess3, 6. As demonstrated in 
the previous chapter, control of fluid management is very variable when delivered to 
patients on the ward. Yet the simple clinical end points assessed on the wards such 
as peripheral skin temperature, jugular venous pressure and base deficit are 
themselves surrogate and prone to misinterpretation. Grissom et al. demonstrated 
associations with physical examination findings and cardiac output measurements, 
but they correlated poorly7. Vincent et al. demonstrated that whilst peripheral 
temperature is of use in low cardiac output states, it correlates poorly with cardiac 
output in septic shock. A recent review by Schey and Williams concluded that skin 
temperature assessment of cardiac output is at least equivocal8. The insertion of a 
central venous catheter is time honoured, but often of questionable value and more 
recently the use of central venous oxygen saturation (ScvO2) as a guide to 
circulatory adequacy is widespread but is also contraversial7, 9, 10. More invasive 
devices such as the pulmonary artery catheter are inappropriate in the ward are not 
without risk11, 12. If DO2 is a sensible end-point to be assessed in order to control fluid 
management, then would it not be better to assess the end-point – cardiac output 
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more formally, than other markers? The issue is then, which monitors are available 
and which can be used on the ward?  
 
8.1.3 Cardiac Output Monitoring 
Cardiac output monitoring devices have been in common use for many years in the 
intensive care unit. The high nurse to patient ratio and the highly skilled nature of the 
critical care nurse enables these techniques to be used in a relatively safe 
environment. Methods currently employed to measure cardiac output and other 
haemodynamic parameters are outlined in Table 8.1. 
In the ICU, cardiac output monitoring has been used in a variety of ways and 
attention has focussed on its overall impact on outcome. In that respect its use for 
monitoring fluid administration is subsumed in its general use. Despite its frequent 
use in the intensive care unit, the case for monitoring cardiac output remains 
unclear. Any monitor that can be considered of use will need to demonstrate that the 
treatments initiated by the results it produces, convey a benefit. In critical care this 
will invariably require a benefit in mortality. As yet this has not been demonstrated in 
a large trial. The PAC-Man trial of 2005 is the largest to date and focussed on the 
pulmonary artery catheter (PAC)13. Concern over the safety of the device had been 
raised by the publication of a cohort study by Connors et al. which demonstrated an 
excess mortality for ICU patients treated with the aid of a PAC (odds ratio 1.24 (95% 
CI 1.03 – 1.49)12. The PAC-Man study enrolled 1041 patients and randomised them 
to receive a PAC or not. The study was unable to demonstrate an excess mortality or 
an increased survival and the authors concluded that further studies are required to. 
„Ascertain whether management protocols involving PAC use can result in improved 
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Table 8.1  Current methods of measuring cardiac output in patients. 
Method of measurement Comments 
Transthoracic echocardiography Non-invasive. Requires high technical expertise. 
Intermittent 
Transoesophageal 
echocardiography 
Invasive. Requires high technical expertise. Risk 
of upper GI complications 
Pulmonary artery catheter Invasive. Thermodilution technique. Intermittent. 
Remains gold standard 
Transthoracic bolus injection 
(PiCCO, LiDCO, Modelflow) 
Requires central and arterial access. Thermo/dye-
dilution technique 
Pulse contour wave analysis Continuous, Most require calibration. May require 
special catheters 
Oesophageal doppler Invasive. Continuous. Simple to use, but can be 
difficult to focus. 
Aortovelography Non invasive. Questions over accuracy. 
Intermittent.  
Thoracic bioimpedence Non invasive. Low signal to noise ratio. Reflects 
changes rather than absolute values. 
Fick principle (NICO) Non- invasive. Requires mechanical ventilation. 
Problems in conditions with V/Q mismatch. 
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outcomes in specific groups if these devices are not to become a redundant 
technology.‟  
Connors and PAC-Man examined the impact of one type of cardiac output monitor 
on survival of heterogenous ICU patients. More specifically, there is data supporting 
its use in early goal-directed therapy high risk surgery. Pearse et al used a lithium 
dye dilution method to goal direct a DO2 of 600 ml.kg.min
-1 in high risk post operative 
patients admitted to the ICU. The results were a significant reduction in post-
operative complications and hospital length of stay, but no mortality benefit14. Boyd 
et al. using a PAC demonstrated a 75% reduction in mortality for high risk surgical 
patients (5.7% vs 22.2%; p=0.015) by maintain the same DO2 with dopexamine
15. 
Gan et al. used and oesophageal Doppler monitor in major surgery to guide fluid 
management. They demonstrated a significantly higher CO in the study group and a 
shorter hospital length of stay16. Fenwick et al. confirmed that the use of CO 
monitoring to optimise patients undergoing major surgery was cost-effective17. In 
general these trials in pre and post-optimisation are examples of goal directed 
therapy. The CO monitor has no direct therapeutic value, but guides the controlled 
use of fluid and pharmacology. Early goal directed intervention has been discussed 
at length in the last chapter and its relevance to ward patients questioned, but the 
use of this type of monitoring as an aid to fluid administration is slightly different from 
the more aggressive goal-directed approach. In either case it is intuitive to intervene 
as soon as possible. Gattinoni showed that increasing DO2 after 12-36 hours after 
the onset of shock conferred no benefit in patients admitted to the ICU1. This is 
different from early fluid management, but nevertheless if CO monitoring is to have 
an impact in guiding therapy, then early deployment is likely to be necessary.  
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8.1.4 Stroke Volume Variation 
The studies outlined in the previous section describe the use of CO monitors to 
guide the optimisation of DO2. This involves the use of fluid, blood and inotropic 
agents usually in high dependency areas. In the ward simple fluid management still 
remains the simplest and most fundamental cardiovascular intervention at the 
disposal of the ward physician. The detection of fluid depletion and appropriate fluid 
use to correct the deficit can be a difficult challenge if excess fluid use is to be 
avoided. When to conclude fluid resuscitation and move to other modes of 
circulatory support such as inotropes remains difficult. In low output states, a poor 
CO response to fluid may be seen and more may given in the belief that the 
circulation remains empty. This may worsen the situation. Conversely in sepsis, a 
high CO and the desire to generate a higher mean arterial pressure may lead to an 
earlier use of inotropes or vasopressors before appropriate amounts of fluid have 
been given – Rivers et al. It is known that central venous pressure (CVP) as a guide 
to fluid status has poor predictive value, as has pulmonary capillary occlusion 
pressure (PAOP); and 50% of patients will not respond to a standard fluid challenge 
in terms of increasing their cardiac output18, 19. Thus the CO and its response to fluid 
may not tell the whole tale of fluid status, and other methods of assessing fluid 
responsiveness may also need to be utilised.  
In ICU patients undergoing positive pressure ventilation, an increase in intra-thoracic 
pressure during the inspiratory cycle leads to an increase in right atrial pressure. If 
venous pressure is low, this leads to a reduction of right ventricular (RV) filling and 
output and by virtue of the circulation, left ventricular (LV) filling and output. This 
cyclical change in LV output is translated to the arterial tree. CO monitors analysing 
this waveform can thus detect changes in stoke volume – stroke volume variation 
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(SVV). This has been shown to be highly predictive of fluid responsiveness. For 
example an SVV of >10% is predictive of a 15% increase in cardiac output on 
delivery of 500ml of fluid20, 21. SVV relies on constancy within the thoracic cavity. 
Hence changes in beat-to-beat heart rhythm such as atrial fibrillation or varying 
ventilatory patterns when spontaneously breathing, will affect the sensitivity of this 
variable to predict fluid status. The value of SVV as a predictor of fluid 
responsiveness in the non-ventilated has only been described in animals22. It thus 
remains of interest, but its role in the fluid management of the ward patient needs 
assessment. 
 
8.1.5 Cardiac Output Monitoring of Ward Patients 
There is no data to date that expounds the virtues of CO monitoring in the 
resuscitation of ward patients. It may be an area where cardiac output monitoring 
could also have an impact. This may not be solely in terms of mortality, but as with 
the high-risk surgical patients, a reduction in length of stay or nosocomial 
complications; possibly a reduction in ICU admission. If time is of the essence, then 
CO monitoring on the ward even as part of pre-ICU resuscitation could have value. 
Inadequate or excessive fluid management based on clinical findings or blood gas 
results may compromise patient outcome. This may be especially true if there is 
evidence of pulmonary oedema or inflammation6.  
We have seen in the previous chapter that in one institution the fluid management of 
the acutely unwell could be improved upon. This could take several guises, better 
protocols and guidelines, greater education in to the prompt treatment of shock, 
increased use of central venous catheters and ScvO2 or a more direct involvement of 
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the ICU via the CCOT. If the use of some form of monitoring either for simple fluid 
management or RGDT is to be advocated it will require cardiac output monitoring. A 
simple device with few complications would be required for use in a ward based 
environment.  
 
8.1.6 Pulse Contour Wave Analysis 
Table 8.1 demonstrates the available range of techniques. Of those that give 
continuous data of haemodynamics, many are invasive with incumbent risks. The 
use of the arterial waveform derived via an arterial catheter is most attractive in 
terms of simplicity and ongoing care. This is pulse contour wave analysis. 
The two most common systems that are in use in the UK are calibrated by 
thermodilution (PiCCO®) or dye dilution (LiDCO®). Both have been compared to a 
PAC as a gold standard and found to produce similar data23, 24. However both have 
the disadvantage of requiring regular calibration (approximately eight hourly). The 
PiCCO requires a specialised arterial catheter, in a large artery, with a thermistor 
and ideally, central venous cannulation. LiDCO can function with a normal arterial 
catheter, but has expensive disposables and is not recommended for use with 
neuromuscular blocking agents. A novel monitor has appeared on the market which 
is simpler in its operation. The Vigileo Flotrac® (Edwards Lifescience, LLC, Irvine US) 
is a pulse contour analysis monitor which is uncalibrated.  It uses a software 
algorithm to determine the aortic compliance from the demographic data of the 
patient (gender, age, height and weight). The algorithm was developed using data 
collected from a wide variety of clinical situations involving patients and healthy 
volunteers. It contains a correction factor that alters the value of SV by using a 
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mathematical model based on the kurtosis of the arterial waveform. This derives a 
correction factor (χ) which is calculated every 60 seconds to allow for dynamic 
changes in vascular tone. It is thus simple to use requiring only a standard arterial 
cannula and no central catheter. It produces calculations of SV based on the arterial 
waveform; these are transferred in to cardiac output and cardiac index (CI) by 
multiplication of SV and heart rate to give CO, then division by body surface area 
derived from the height of the patient. It also assesses the SVV of the derived SV. 
The Vigileo Flotrac® (VF) has been compared to PAC, PICCO and transoesophageal 
echocardiography in previous studies. Many were performed in surgical patients with 
mixed results 25-28. In the ICU population, two studies in haemodynamically unstable 
patients have been reported. Compton et al studied 25 patients requiring fluid 
resuscitation and/or vasopressors29. They compared the cardiac index data from the 
VF to a PICCO. The bias between PICCO and VF was found to be 0.68 l.min-1.m-2 
with a high percentage of error 95% limits of agreement 1.94 l.min-1.m-2. Sakka et al 
found similar results in cardiac output for 24 patients with septic shock, quoting a 
bias of 0.5 l.min.-1 when compared to a PiCCO, but again with a wide percentage of 
error (SD 2.3 l.min-1). Despite these concerns, a recent meta-analysis of the VF 
concluded that the recent improvements in software have developed the VF into a 
monitor that has good agreement with intermittent thermodilution in stable situations, 
and that though it may not perform as well in rapidly changing haemodynamics, the 
authors agree that its use in early goal directed therapy maybe it‟s „niche‟30. One 
thing is true, it‟s simplicity of use via a standard arterial catheter make it very 
attractive for use in lower „tech‟ environments such as the general ward. If it can be 
agreed that CO monitoring can form part of the fluid management or goal directed 
therapy required in acutely unwell ward patients, then the VF seems particularly 
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attractive. To be of value, it has to reflect the data that is collected by monitors in 
established use. Much of the work by Pearse et al. in a similar patient group, high-
risk surgical patients, was performed using the LiDCO system. It is also the standard 
CO monitor at the Chelsea and Westminster Hospital. There is no data comparing 
the performance of the VF to the LiDCO.  
 
8.1.7 Aims 
The previous chapter described problems with fluid management on the wards. It is 
thought that this could be improved upon by the use of a simple CO monitor to guide 
fluid resuscitation and inotrope management, even in the ward or prior to ICU 
transfer. On this assumption, this study aims to compare the performance of the 
novel VF CO monitor to the established LiDCO monitor. If comparable in terms of 
accuracy and precision, then a case could be made for its inclusion in the initial 
management of the acutely unwell ward patient with circulatory shock. 
 
8.2 Methodology 
8.2.1 Study Design 
This was a partially blinded observational study using patients as their own controls. 
It was performed on the intensive care unit at Chelsea and Westminster Hospital 
using a heterogenous group of patients admitted with haemodynamic instability in 
which CO monitoring was initiated during the first 24 hours of admission.  
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Inclusion Criteria: 
 Adults >16 years 
 Patients in whom the attending physicians desired cardiac output monitoring 
as part of the patient‟s ICU care. 
 Less than 24 hours after admission. 
 
Exclusion criteria: 
 Refusal of consent if alert. 
 Contraindications to arterial or central venous cannulation. 
 Use of neuromuscular blocking agents. 
 Severe aortic regurgitation. 
 Pregnancy 
 Refusal by attending physicians. 
 Not expected to survive >24 hours. 
All procedures and therapies were performed as part of routine patient care under 
the instruction of the attending physicians. No interventions were initiated for study 
purposes. The physicians were able to use the LiDCO monitor freely and all clinical 
decisions based on haemodynamic data were derived from the LiDCO monitor. The 
VF was placed at the back of the ICU bed spaced, turned to face the wall, and thus 
not in the view of either medical or nursing staff. 
Radial artery access was achieved using a standard radial artery catheter chosen by 
the operator (usually a 20G Abbocath®). The catheter was connected to the MHD8 
Flotrac sensor which permits continuous monitoring of arterial pressure. This was 
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linked to the MHM1E Vigileo monitor with the up-to-date 1.07 software, and the 
arterial pressure transduced separately to the ICU monitor.  The pressure transducer 
was zeroed to the mid-chest level.  
The LiDCO was calibrated according to the manufacturer‟s instructions. 0.15 – 0.3 
mmol of lithium chloride is injected rapidly into a central vein and blood drawn 
continuously from the arterial catheter across the electrode sensor. This produces 
the decay curve upon which the pulse contour wave analyser is calibrated. The 
LiDCO was calibrated 8-12 hourly, in keeping with the manufacturer‟s instructions. 
The arterial pressure waveform is obtained from the monitor and thus there is only 
need for one arterial catheter to run both CO monitors.  
The study was run for the first 24 hours of the patient‟s admission. Values for hourly 
cardiac output, stroke volume variation and arterial blood pressure were obtained 
from both machines. Patient demographics, fluid and inotrope therapy were recorded 
and blood gas values for base excess and plasma lactate concentration. A fluid 
challenge was defined as a bolus of crystalloid or colloid greater than 250mls within 
an hour. 
 
8.2.2 Statistical Analysis 
Statistical analysis was performed using SPSS 18.0 (LEAD Technologies Inc. USA) 
Microsoft Excel (Microsoft® Inc.USA) and GraphPad Prism 4.0 (GraphPad software 
inc. USA) software. For the comparison of CO measurements and agreement 
between the two techniques, the Bland–Altman method was applied. Statistical 
advice was sought as the use of Bland-Altman plots to assess levels of agreement 
for cardiac output monitoring has been questioned in the literature by Myles et al31. 
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Limits of agreement were defined by 95% limits. The agreement would be 
considered adequate if the 95% limits were within 30%. In order to establish if the VF 
reflects SVV response as well as the LiDCO, the differences in SVV pre and post 
fluid bolus were calculated and then expressed as a Bland–Altman plot for the first 
fluid bolus each patient received. Other data is presented as a mean (SD) for 
continuous data and median (IQR) for non-parametric data. 
 
8.2.3 Sample Size Calculation 
Based on the previous literature comparing CO monitors, an agreement of less than 
0.3l.min-1 was considered appropriate32, 33. There is no statistical literature for power 
calculations of equivalence testing for a repeated measures analysis, only repeated 
measures power calculations (up to 8 repeats). Thus the sample size calculation was 
based on this technique. As such for a significance of 0.05 and a power of 80% a 
sample size of 25 patients was required. 
 
8.3 Results 
25 patients were recruited. The patient characteristics are summarised in Tables 8.2 
and 8.3. All were emergency admissions except for one elective post-operative 
patient. All patients had baseline cardiac output data within 6 hours of admission. A 
total of 572 cardiac output measurements were recorded in the 25 patients. 
Episodes of no measurement occurred in 4 patients. 2 required transfer to the 
operating theatre for urgent surgery, 1 patient required transfer to the CT scanner for 
diagnostic purposes. 1 patient unexpectedly arrested and died within 8 hours of 
admission.  
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23 of 25 patients received vasoactive infusions during measurements and the mean 
doses are displayed in Table 8.2. 
As an example, data gathered for cardiac output measurement at 1hour, 6 hours, 12 
hours and 24 hours for each patient is summarised in Table 8.4. Visual assessment 
suggests that the VF measures a lower value for CO at the same time point when 
compared to the LiDCO. This appears to be especially true when the cardiac output 
is high.  
Table 8.2  Baseline characteristics of the patients at recruitment 
Patient characteristic Value (n=25) 
Mean age (yr) (+/-SD) 63.9 (15.0) 
Male gender (%)  16 (64) 
Mean APACHE II (+/-SD) 23.24 (4.3) 
Mechanical ventilation (%) 24 (96%) 
Mean mean arterial pressure (kPa) +/- SD 62.6 (12.9) 
Vasoactive drugs (median dose μg.kg-1.min-1 (IQR)) 
Norepinephrine (0.13 (0.18)) 
Epinephrine (0.44 (0.42)) 
Dobutamine  (5 N/A) 
None 
 
17 (68%) 
5 (20%) 
1(4%) 
2 (8%) 
SD, standard deviation; IQR, inter-quartile range  
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Table 8.3 Clinical diagnosis of participating subjects 
Diagnosis N (%) 
Cardiogenic shock 6 (24) 
Pneumonia 6 (24) 
Abdominal sepsis 3 (12) 
Acute renal failure 1 (4) 
Aortic stenosis (post-operative) 1 (4) 
Hepatic cirrhosis 1 (4) 
Hypertensive encephalopathy 1 (4) 
Major trauma 1 (4) 
Neutropenic sepsis 1 (4) 
Pancreatitis 1 (4) 
Pulmonary embolus 1 (4) 
Urinary sepsis 1 (4) 
Oesophageal variceal bleeding 1 (4) 
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Table 8.4 Cardiac output measures for LiDCO and Vigileo at 4 time points (l.min
-1
) 
Time 1 hour 6 hours 12 hours 24 hours 
Patient No. LiDCO Vigileo LiDCO Vigileo LiDCO Vigileo LiDCO Vigileo 
1 2.3 2.1 3.6 3.2 4.1 4.3 4.2 4.1 
2 6.8 6.5 10.6 9.8 10.5 9.5 12.1 9.8 
3 5.4 5.3 7.5 7.3 7.6 7.4 7.4 7.0 
4 4.6 4.4 6.4 6.2 6.2 5.9 6.4 5.8 
5 6.8 6.0 7.5 7.2 8.7 8.0 9.0 8.2 
6 2.4 1.9 4.1 3.3 3.2 1.9 4.7 3.9 
7 7.7 6.8 7.9 6.4 8.2 7.3 7.3 6.7 
8 8.3 8.2 12.3 10.7 11.9 10.9 10.7 9.7 
9 5.3 7.5 8.2 7.7 7.3 7.0 5.7 5.2 
10 4.2 4.0 5.6 5.3 6.1 4.5 6.1 5.1 
11 2.3 1.8 2.5 1.8 2.7 2.2 2.5 2.4 
12 2.9 1.9 N/A N/A 4.3 3.0 4.6 4.2 
13 4.1 4.2 5.2 5.1 4.9 4.9 5.2 4.7 
14 6.7 5.9 6.5 5.7 7.5 6.6 8.4 8.5 
15 4.3 3.5 4.5 3.9 4.7 4.1 3.9 3.8 
16 2.3 2.1 5.3 5.1 5.3 5.1 4.8 4.5 
17 10.5 9.6 10.5 8.9 12.7 10.2 10.3 9.4 
18 2.3 2.1 3.4 3.3 N/A N/A N/A N/A 
19 4.5 4.1 4.8 4.4 4.9 4.6 4.0 4.0 
20 5.6 4.9 9.8 9.1 10.1 9.5 9.5 8.6 
21 2.2 2.3 4.3 4.3 3.8 3.6 4.0 4.1 
22 6.4 6.3 8.5 8.1 10.6 9.7 11.1 9.9 
23 5.6 5.4 7.1 6.4 N/A N/A 5.7 5.3 
24 9.5 9.0 9.7 9.0 8.7 7.9 11.0 8.2 
25 6.8 6.0 5.4 5.1 7.8 6.9 6.4 5.9 
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A Bland-Altman plot is presented as a graphic representation of the level of 
agreement between the two systems. The control lines are based on the within 
subject sum of squares, which produces a model which compensates for the effect 
of repeated measures.31 The bias is positive in favour of higher readings by the 
LiDCO and has a value of 0.58 l.min-1. The upper 95% limit is +1.40 l.min-1 and the 
lower 95% limit, -0.28 l.min-1 (Figure 8.1) 
 
Figure 8.1 Bland-Altman Plot of the difference between Flotrac and LiDCO derived cardiac 
outputs against the mean cardiac outputs in the 25 patients in the study. The within-subject 
variance is estimated by a random effects model which includes the mean measurements of 
the two methods for each measurement occasion. Bias = 0.58 l.min
-1
, Upper 95% limit = 1.40 
l.min
-1
, Lower 95% limit -0.28.  
 
23 of the 25 patients received at least one fluid bolus. All 23 received a minimum of 
500 ml of fluid as their first bolus, and this was sampled generating 46 
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measurements for Bland-Altman analysis. This is summarised in Table 8.5 and 
Figure 8.2. The agreement between the change in SVV before and after the fluid 
bolus (ΔSVV) was high with bias of 0 and 95% limits of agreement of +3.32% and -
3.32%. 
 
 
Figure 8.2  Bland-Altman plot for ΔSVV after a fluid challenge. (Bias = 0; Upper 95% limit of 
agreement = 3.32%; Lower limit of agreement = -3.32%. SD Bias =1.69%) 
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Table 8.5   Δ SVV after a fluid bolus for the LiDCO and Vigileo systems 
Patient Number LiDCO (%) Vigileo (%) 
1 4 3 
2 6 6 
3 5 4 
4 5 5 
5 4 7 
6 8 7 
7 7 4 
8 4 4 
9 5 5 
10 10 8 
11 7 7 
12 2 1 
13 2 0 
14 -1 1 
15 2 2 
16 2 3 
17 2 2 
18 -1 0 
19 4 4 
20 -1 2 
21 1 1 
22 -2 2 
23 2 0 
24 1 0 
25 4 3 
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8.4 Discussion 
8.4.1 Cardiac Output 
In this chapter a pulse contour analysis device was tested against an established 
system for continuous CO monitoring. LiDCO has previously been validated against 
thermodilution techniques using a PAC, although the patient group was that of 
hyperdynamic hepatic transplant candidates23. The results of this study show that the 
performance of the Vigileo Flotrac® system was comparable in the reporting of 
cardiac output measurements with the LiDCO in a heterogenous group of ICU 
patients. The bias of 0.58 l.min-1 combined with narrow limits of agreement (-0.28 
l.min-1 and +1.40 l.min-1) could be argued as clinically acceptable as the SD 
difference from the mean CO is less than the 30% limit suggested by Critchley et 
al.34 However the sample size calculation was determined supposing that the 
systems would record cardiac outputs of less than 0.3 l.min-1 difference. Clearly a 
difference of 0.58 l.min-1 could be very significant at lower CO states, but 
interestingly, the plot maintains close association to zero at cardiac outputs below 6 
l.min-1 and it is at the higher end of CO that the two systems diverge in terms of 
agreement. Not surprisingly the VF has good agreement with the „gold standard‟ 
LiDCO at normal cardiac output values. The VF value is derived from a mathematical 
model based on predominantly normal physiology and responses in healthy 
subjects. When the physiology becomes significantly deranged at high levels, the 
algorithm appears to be less able to compensate for its lack of calibration with the 
abnormal circulation and fails to reflect the CO detected by the LiDCO. In practice 
this may be of little clinical significance. For example, the difference between a 
LiDCO CO of 12.4 l.min-1 and a VF CO 11.4 l.min-1 is unlikely to be important in 
clinical management. Conversely differences of 0.5 l.min-1 at the opposite end of the 
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spectrum could be the difference between alterations in management and no action. 
The findings suggest that the VF system reasonably reflects the CO as measured by 
LiDCO in critically ill patients.  
These findings are different from two previous studies comparing the VF with other 
techniques of pulse contour wave analysis CO monitoring29, 33.  Both these studies 
concluded that the VF system could not replace more invasive CO monitoring 
systems in ICU patients. Compton et al detected a systematic under-reading of 
cardiac output measurements by the VF when compared to a PiCCO thermodilution 
technique. Sakka et al reports a bias to over-reading the cardiac output, although 
they omit to quote a bias. Both studies demonstrated the deterioration in agreement 
when the values of cardiac output are high similar to this study. The Compton data is 
also magnified by the use of CI rather than CO bias 0.68 l.min-1.m-2 to 0.76 l.min-1.m-
2. We chose to use CO as a closer reflection of the true measurement of the system 
without a further conversion.  
Explaining the differences between this and the other two studies in critical illness is 
difficult. The patient groups appear comparable from their demographics excepting 
that the patients in other studies had higher abnormal physiological scores, were on 
higher doses of vasoactive medication and had higher mean arterial blood 
pressures. The range of CO/CI measured in the other two studies was also higher. 
Both studies actively sought haemodynamically unstable patients. The patient‟s 
inclusion in this study was only dependent on the need for CO monitoring as decided 
by the clinicians, although haemodynamic instability was the most common 
indication. This study enrolled 2 patients not on inotropes and 3 further subjects on 
doses of norepinephrine less than 0.10 μg.kg-1min-1. Other studies of surgical 
patients with more stable haemodynamics have found good agreement between 
249 
 
PiCCO and VF32, 35, 36. It could be an influence of these less unstable subjects on the 
results. 
Methodologically, the two above trials compared PiCCO to VF. We used LiDCO. 
Both have been validated against the „gold standard‟ PAC, however the LiDCO has 
no data supporting its agreement with PAC or PiCCO in these types of patients. It 
may be that our chosen comparator does not agree well with PiCCO in ICU subjects 
and that this is where the difference lies. Thermodilution has significant pitfalls to 
operator variation, patient pathologies, and the indicator used. Techniques 
independent of thermal influences such as dye-dilution may represent a better 
technique for calculating CO in these patients. From a pragmatic point of view the 
use of LiDCO to measure CO is the standard on the ICU at Chelsea and 
Westminster Hospital. Medical decisions are based upon its information. Thus if a 
new monitor is to be considered for use in this single institution, it needs to reflect 
current practice. LiDCO uses dye-dilution calibration which makes it likely that it is a 
good reflection of changes in CO, if not the absolute value. 
The arterial access used in Sakka et al was femoral for both the systems, utilising 
the same PiCCO catheter. The VF recommendations are for radial artery access, 
and the difference in waveform between femoral and radial artery may have 
influenced the results. Compton et al. used two arterial catheters PiCCO in the 
femoral and VF in the radial. Whilst appropriate to manufacturer‟s instructions the 
actual waveform being analysed is different and possibly subject to differences with 
use of vasopressors. Indeed they admit that the peripherally derived radial arterial 
pressure significantly underestimated the central arterial pressure and that a 
pressure difference of >5mmHg was associated with significant increases in bias. In 
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the observations reported here, the same arterial waveform was used for both 
monitors permitting the same arterial waveform to be analysed. 
Finally, the use of all time samples for all patients being analysed in the same graph 
is statistically unsound, and both of the previous studies were guilty of this analysis. 
When repeated measures data are available, it is desirable to use all the data to 
compare the two methods. However, the original Bland–Altman method was 
developed for two sets of measurements done on one occasion and so this 
approach is not suitable for repeated measures. To compensate, Compton analyses 
one measurement series, and finds a similar large bias with wide limits of 
agreement. We used a modification of the statistical model developed by Myles et 
al.31. This adjusts for the mean CO value for the individual over time and the mean 
measurement between the two methods. It provides a statistically more sound 
representation of the level of agreement between the two systems. 
 
8.4.2 Stroke Volume Variation 
With regards to the agreement of the two systems to detect changes in SVV to a 
fluid challenge, there was excellent agreement, bias 0, with narrow limits of 
agreement (+/- 3.32%). No previous studies have compared these two monitors for 
agreement in SVV as a measure of response to fluid challenge. However both have 
been validated as predicting fluid responsiveness based on the SVV22, 37. It is 
therefore exciting that even if the CO values may differ (particularly at the upper end 
of the spectrum) between LiDCO and VF, the ability for them to agree that a patient 
is likely or unlikely to respond to fluid may be very useful in maintaining a disciplined 
fluid resuscitation strategy. This result is useful only in the ventilated ICU patients 
251 
 
and is included here for completeness. The role in the ward environment in 
spontaneously breathing patients needs clarifying.  
The results found here are encouraging, but cannot be immediately extrapolated in 
to the ward environment. Despite good agreement with LiDCO, the ICU patient 
group does not reflect the ward patient. Further work is now needed to assess 
haemodynamic parameters seen in acutely unwell ward patients and to assess the 
impact of spontaneous breathing on the accuracy, but possibly more importantly, the 
precision of the two systems. Secondly, the introduction to this chapter outlined a 
desire that a simple CO monitor could aid in guiding fluid therapy on the ward. These 
observations provide a suggestion that this monitor in particular, may be helpful in 
the ward, but needs assessment in the target population. The close agreement of 
SVV is in ventilated patients alone.   
The pragmatic aspect of the clinician controlled fluid management used in this study, 
means that analysis of the response to fluid administration is observational. The 
criterion of a fluid bolus defined as a volume of >250 ml within an hour takes no 
account of the patient size or clinical state but is the standard ICU practice. It was 
chosen as a pragmatic volume that reflects interventional fluid administration above 
that expected as maintenance fluid. It equates to approximately 3.5 ml.kg-1 for a 70 
kg patient and most trials which examine fluid responsiveness, use a 250 ml to 500 
ml boluses or up to 15 ml.kg-1 as the volume delivered although often in a shorter 
time period.38-40 The Surviving Sepsis protocol suggests 1000 ml of crystalloid or 300 
ml - 500 ml of colloid over 30 minutes.41 Thus our definition was quite conservative 
as a threshold. 
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There is a clear need for a trial looking at the response of the CO or even SVV in 
ward-based fluid resuscitation. Indeed the use of the VF versus more established 
monitors of fluid balance both clinical (heart rate, blood pressure, urine output, skin 
temperature, passive leg raising, mental state etc.) or technical (CVP, ScvO2, Base 
deficit etc.) would be very valuable.   
The VF requires arterial access. This is currently not common practice on the wards, 
but environments such as the emergency department, CCU and medical admission 
units (and even labour ward) are increasingly „high tech‟ level 1/2 bedded areas. It is 
not unreasonable to expect the growth of arterial catheter use as a standard of care 
for the acutely unwell in these places. It is a part of the role of the CCOT to transfer 
skills form the ICU environment to the ward. Care and monitoring of an arterial 
catheter would seem a reasonable skill to develop in the ward. This would be useful 
for fluid administration, but the more complex issue is whether ward patients receive 
inotropes? However if it can be established that ward-based CO parameters and 
ensuing treatments improve outcome, reduce ICU admission and reduce length of 
stay, then it may be something that evolves, again with the aid of CCOT. 
 
8.4.3 Conclusions 
An assumption was made that some form of cardiac monitoring may assist in the 
fluid administration in the ward environment, but most systems are considered 
unsuitable for ward use. The Vigileo Flotrac® is potentially usable in that environment 
if it were shown to be accurate and consistent. The observations reported here 
suggest that this monitor compares favourably with the LiDCO system in the ICU and 
can be considered as a useful tool in assessing cardiac output and SVV over a wide 
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range of cardiac output values. Its relative failings at the higher values of cardiac 
output may only be of academic rather than clinical relevance, but even at low output 
states it appears to agree with the LiDCO system. It does require arterial access, but 
is an easier technology to use than the LiDCO system and would have the potential 
for ward use if arterial catheters could be used there. Further work is needed to 
validate its use in patients breathing spontaneously. If this were to confirm its 
efficacy, then it can be considered for ward use. It has pragmatic advantages over 
other available monitors.  
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Chapter 9 
Thesis Conclusions 
 
9.1 Review of Thesis 
This thesis sought to investigate the methods used and effectiveness of, ward based 
interventions for the care of the critically ill. The advent of critical care outreach 
teams (CCOT) has brought enhanced care into the wards but with limited means of 
treatment available. It is important to know the efficacy of these treatments. While 
there are an increasing number of studies evaluating the overall effect of the teams 
and their treatments, there is almost no information on the efficacy of the individual 
treatments commonly employed. The two most common interventions employed in 
the ward by CCOT are oxygen delivery and fluid administration and it is these two 
areas that have been addressed in this thesis. 
 
9.1.1 Performance of Oxygen Masks 
Oxygen therapy remains a key part of acute intervention. Despite their widespread 
use, the interface between patient and mask system is not well documented in the 
presence of abnormal breathing patterns. The model designed to mimic such 
conditions demonstrated a significant fall off in performance of several of the 
commonly used systems when respiratory rate and thus minute ventilation 
increases. 
This finding has significant clinical implications as outlined in Chapter 3, but is worth 
re-iterating. At present in many situations the condition of the patient in terms of 
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oxygen saturation is at the bedside seen on the context of the set oxygen delivery. 
Yet it is shown here that the set oxygen delivery and the actual delivery may be very 
different. This may mean that the condition of the patient may be misinterpreted and 
their oxygenation perceived to be far worse than it is in reality. Furthermore if the 
respiratory pattern influences the efficacy of an oxygen delivery system then 
knowledge of the effect could be important and useful in deciding which delivery 
system to use in a patient with a high respiratory rate or at least to understand that 
the actual oxygen delivery may fall short of that expected under those 
circumstances. Elucidating the physics of the delivery systems potentially permits 
some stratification of their application to patients with differing disease severity. A 
poor response to increasing oxygen flow via some of the more predictable mask 
systems may indicate that less oxygen is being delivered due to the respiratory 
pattern and may be an indication to change system. It may even suggest the need 
for a change to a more effective intervention such as CPAP or non invasive 
ventilation. The chapter also demonstrated that some systems performed more 
consistently than others.  
The relatively predictable performance of the Vapotherm® (high-flow nasal cannulae) 
encourages the realistic prospect that oxygen delivery can be improved without the 
need for a sealed mask. Further research in this area could be directed towards 
more „comfortable‟ yet efficacious systems. New designs of oxygen delivery systems 
or rediscovery of old ones, that have suitable „reservoirs‟ removing the need for tight 
fitting masks and loud high flow systems could be developed and tested. Hoods 
helmets and tents should (and are) being evaluated. 
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9.1.2 Peak inspiratory flow rates in respiratory distress 
Chapter 4 used a simple hand-held device to measure peak inspiratory flow rates 
(PIFRs) in patients with evidence of respiratory distress and compared their values 
to those of a control group of hospital in-patients. The major finding was a significant 
difference in PIFR between the groups with the patient group exhibiting much higher 
values. Essentially in patients with respiratory distress the peak inspiratory flow is 
often greatly increased and taken in the context of the previous chapter‟s findings, 
suggest that this could significantly influence the potential for air entrainment. This 
would result with deteriorating oxygen delivery as the pattern changes and peak flow 
rises. The implication is that sick patients paradoxically will have more air 
entrainment and lower oxygen delivery. This very simple assessment contributes to 
the findings detected in Chapter 3 and gives a clue that the findings in the model 
may be transferable to the clinical environment. As a study it can be criticised 
regarding the comparability of the two groups and how closely they were matched, 
but it is reasonable to regard the data as demonstrating a phenomenon that is highly 
likely to influence the performance of mask systems, especially with regards to 
mixing of delivered oxygen and environmental air. As with the model in Chapter 3, 
the data obtained in this study could be integrated into further research in to oxygen 
delivery systems. Analysis of the true nature of the respiratory patterns seen in a 
variety of ventilatory disorders would be valuable in determining features of novel 
systems such as reservoir volume, oxygen flow rate etc. These two chapters provide 
some basic information about a factor affecting mask performance and also the 
variability of commonly used masks at least in this Institution. It provides some 
quantification of the performance of oxygen delivery systems. When masks fail 
CCOT escalate to CPAP and this was investigated in the next section.  
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9.1.3 Continuous Positive Airway Pressure 
The use of CPAP for the ward treatment of acute hypoxia has become ubiquitous, 
but has several documented problems. It is the method often used when ordinary 
masks fail and is the next escalation in oxygen delivery. Chapters 5 and 6 
investigated the likely mechanisms for its perceived superiority over open mask 
systems as an intervention for improving oxygenation. We demonstrated that in a 
model of ventilation, the high flow CPAP system predictably delivers the desired 
concentration of oxygen regardless of the pattern of ventilation. This was in stark 
contrast to the performance of the some of the open oxygen masks in the Chapter 3. 
In considering the reasons for this obvious difference the hypothesis was generated 
that the mode of delivery of oxygen when using CPAP prevents entrainment of air 
and, to some extent, this is the way in which it works. From this the consideration 
was raised as to the relative contributions of the application of positive airway 
pressure (PAP). Using the standard protocol for initiating CPAP in the ward it was 
shown that in a moderately sized group of heterogenous patients with respiratory 
failure, the greatest, and probably only, large increment in oxygenation occurs on 
changing from mask oxygen to a T-piece (CPAP without a valve) to CPAP. Though 
this was a relatively short period of observation of up to two hours, there is the 
inescapable observation that at least in this setting, the addition of PAP contributes 
little more in terms of oxygenation, than the CPAP system, without pressure. 
This finding is likely to be contentious. There are certainly several considerations. 
Was enough PAP used to justify the above conclusions?  Only 5 cmH2O and 10 
cmH2O were used and this may have been inadequate but in practice in this and 
many other Institutions those are the values commonly employed by CCOT and so 
they are relevant values.   
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Was the length of time of observation long enough?  It was impressive that the 
changes seen were immediate and sustained, yet the addition of PAP did not 
contribute further in the time period. Certainly over a longer period the contributory 
effects of PAP may have appeared but firstly this was not seen in the time period 
and also this is the time period of early active intervention when oxygenation 
improvements are being sought. A study for a much longer period would be useful 
and needs to be done.   
Was the patient group a fair reflection of those that were likely to benefit from the 
application of PAP?  They may not have been as they were a heterogenous 
population including only a few patients with conditions where the PAP component is 
„known‟ to be effective. In some respects the observations here are therefore a self-
fulfilling prophecy, as applying PAP to patients in whom there is no literature to 
support its use is likely to show no benefit. This was found, but the application of 
CPAP without pressure did improve oxygenation across the entire population. More 
importantly the population represented that in which this intervention is commonly 
used in many Institutions. Thus the criticisms may be valid in terms of study design, 
but not in terms of current practice in a hospital that is reflective of many in the UK. 
Further research should be devoted to answering the critique above more fully. 
Larger numbers in specific diagnostic categories would elucidate any particular 
conditions that would show true benefit from PAP, rather than improved oxygen 
delivery. Acute cardiogenic pulmonary oedema is the condition said to benefit from 
CPAP. Such a study might finally define the benefit of PAP in acute cardiogenic 
pulmonary oedema above and separate from other causes of acute respiratory 
failure..  
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One consideration derived from these findings is that if the PAP element of CPAP is 
relatively unimportant then designing oxygen delivery systems that not only deliver 
the oxygen required but are comfortable and user friendly may be feasible released 
from the constraints of pressurised systems. It is an important area that needs to be 
clarified. 
Combining the findings of the four chapters examining oxygen delivery as a ward-
based intervention it is clear that the higher flow systems (CPAP and Vapotherm®) 
improve oxygenation across a range respiratory patterns. They appear superior to 
their „older‟ and less sophisticated counterparts. It would be very interesting to 
conduct a randomised control trial of the two methods in specified groups of 
respiratory failure patients. Outcomes would need to exceed improvement in 
oxygenation and include morbidity, mortality, endotracheal intonation rates as well as 
patient acceptability. Other designs for either high-flow, or large reservoir oxygen 
systems could also be included in such a study. The main aim of such studies would 
be to demonstrate that oxygenation could be achieved safely with similar outcomes 
as CPAP, without the disadvantages of a closed mask system. 
 
9.1.4 The Efficacy of CCOT in Delivering Fluid Resuscitation on the Wards 
The other area that is key to the activities of CCOT is the use of fluids for 
cardiovascular intervention. This is a crucial part of the CCOT armamentarium for 
dealing with hypotension in a wide range of circumstances. Again there is little or no 
evaluation of either its use or its efficacy in the literature, yet it is widely used.  
Chapter 7 did not directly follow on from the studies conducted previously. It audited 
the use of intravenous fluid resuscitation as an intervention to treat evidence of 
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circulatory deficiency. It was an interesting and useful exercise. As an audit, probably 
its greatest achievement was demonstrating how difficult it is to examine such a 
strategy in the ward environment. As such its inclusion in this thesis could be 
questioned. However, this thesis set out to assess the interventions performed as 
part of the care of the acutely unwell ward patient and like oxygen therapy, fluid 
treatment is ubiquitous. Prompt and disciplined fluid management has been shown 
to improve outcomes in other environments of clinical medicine and is being 
championed as a gold standard of care in the ward environment1-3. Whilst this audit 
was not controlled in order to apply similar conclusions to its findings, it was 
designed to demonstrate a „state-of-play‟ in a UK general hospital.  
To try to provide a measurement stick for comparison, as there were no direct 
comparators, the guidelines for goal directed resuscitation in the emergency 
department were used. This was in retrospect far less „fit for purpose‟ than was 
realised at the outset. Yet there were some interesting findings: There were 
important delays in initiating fluid therapy following the appearance of a problem. 
This was followed by delay in the referral to a CCOT for expert advice and support.  
Both of these delays were exaggerated by comparison with an emergency 
department because of the unpredictable and sporadic appearance of problems in a 
ward environment. Nevertheless the difficulties of picking up problems and then 
dealing with them were clearly shown. 
When implemented, fluid management was liberal and often associated with 
evidence of significant morbidity, such as fluid overload. This was in part because of 
the lack of means of assessment and of monitoring of what was being administered. 
Monitoring of fluid therapy in a group of sick individuals was poor or non-existent and 
raised the question what modalities of monitoring could or should be applied in the 
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ward environment and by whom? In contrast to these findings the apparent success 
rate was high in that 35/54 patients neither died nor went on to require critical care. 
As a measure of success where intervention was needed this would suggest benefit 
although clearly there could be no comparison with no treatment.  
There is a considerable amount of further research that should be done as a 
response to the findings of Chapter 7. Why is the response to signs of circulatory 
failure so slow, especially when an early warning scoring system is in place? A study 
could be designed to evaluate this. More interestingly perhaps would be examining 
the implementation of a „Rivers-esque‟ protocol for care of ward patients with 
evidence of septic shock. Could the application of aggressive management with 
ScvO2, Dobutamine, lactate measurements etc. substantially improve the 
management of ward patients and convey the same level of benefit as alleged for 
those in an emergency department? As discussed in Chapter 1, the context of the 
established ward patient is very different from the A&E admission and application of 
the same technique of resuscitation, though intuitive, may not be correct. Indeed this 
may lead on to further examination of the part of the „Do not actively resuscitate‟ 
order in the management of the ward patient who demonstrates circulatory 
insufficiency, an aspect of COOT that has not been examined in this thesis. This 
section obviously raised more questions than answers but it has highlighted an 
important and large area of practice in many Institutions that to date has not been 
investigated and where it is suggested there could be improvement.  
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9.1.5 The Comparison of a Novel Cardiac Output Monitor with a Standard 
In seeking to improve care for ward patients, one of the principles of CCOT is to 
export critical care skills and technologies. This study looked at the ability of a 
simple-to-use cardiac output monitor (Vigileo Flotrac®) to reproduce the results of the 
standard ICU monitor (LiDCO) in use at Chelsea and Westminster Hospital. The 
results confirmed an acceptable degree of agreement between the two systems in 
terms of tracking changes in cardiac output. However, the absolute values differed, 
but within acceptable limits. Agreement between the two monitors regarding the 
stroke volume variation (SVV) was also studied and was found to be highly 
concordant.  
This study and the audit of Chapter 7 suggest that further research into this field. AS 
outlined above, there is no data that defines the need for more invasive monitoring in 
the acutely unwell ward patient group. Thus a study suggested above incorporating a 
strict resuscitation protocol with criteria for necessary monitoring, timing of insertion 
and result-response algorithms, targeted at ward patients would be valuable. This 
could include, or be followed by study of the value of a CO monitors in general, or 
specifically the Vigileo Flotrac® in the management of such subjects. It remains 
questionable whether CO monitors will make the leap from ICU to the wards, but in 
the author‟s own working lifetime nurse administered intravenous antibiosis, 
continuous CVP monitor transduction, CPAP, BiPAP and low dose inotropes have all 
transferred across to the ward environment. With appropriate training and 
safeguards, should the arterial catheter and an associated simple CO device not 
make a similar crossing? The studies so far have been in the critically ill and its 
clinical use in ward scenarios and it actual benefits in that environment need to be 
elucidated first. 
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9.2 Limitations of the Thesis 
The major limitations of each study are discussed in their relevant chapters. 
However the environment and numbers require special mention. The work done on 
this thesis was single centre, single observer and whilst all the studies in which a 
sample size calculation was performed, reached the defined numbers, there are 
several aspects of the studies that could be improved by increasing the numbers 
recruited. 
The CPAP system study is probably the first to look at the actual oxygenation effects 
of CPAP at these values including zero, and clearly needs significantly greater 
numbers to confirm these findings and to resolve two further issues. Firstly, the study 
was too small to detect changes between the T-piece system and the CPAP system. 
At present there appears to be no difference between the two. A much larger study 
(probably multi-centre) would be required to have sufficient power to detect a 
difference. Secondly, the heterogeneity of the study population was such that 
deciding if particular patient groups may benefit from CPAP was not possible by sub-
group analysis. Differences in response to CPAP by varying causes of respiratory 
failure would require a much larger study population, or ideally separate studies for 
separate conditions. Similarly the study looking at peak inspiratory flow could be 
given more credence if greater numbers could be recruited and again, subgroup 
analysis may further expand the physiological knowledge base of oxygen delivery in 
different patient populations. For commonly used techniques such as these it is 
important the fundamental aspects of delivery are properly elucidated. 
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9.3 Recommendations for Clinical Practice 
9.3.1 Oxygen Therapy 
If the delivery of oxygen is one of the most important aspects of care for the acutely 
hypoxic patient this thesis has shown that the delivery systems commonly used have 
deficiencies of consistency of delivery that are predictable. The target the clinician 
wishes to set for his patient may therefore not be achieved using standard systems 
and more complex variants such as CPAP may be employed. The thesis raises the 
question that a significant component of the efficacy and consistency of oxygen 
delivery is dependent on the airtight design of the system rather than the PAP. If this 
is correct it may allow a new approach to the design of delivery systems 
unconstrained by the technical requirement for pressurisation. In this author‟s 
opinion it is oxygen in the blood that matters and while an effective delivery system is 
required it should also conform to the tenet prima non nocere and in this regard there 
are aspects of CPAP that fail. It can be harmful, it is uncomfortable and its use in the 
treatment of respiratory failure has moved from a specific indication, cardiogenic 
pulmonary oedema, to any cause of respiratory embarrassment. It often takes time 
to initiate when specialist teams are involved. The advent of CCOT is likely to mean 
its use will continue to proliferate and reliance on its efficacy may paradoxically lead 
to potentially hazardous delays in necessary mechanical ventilation. This would be 
akin to that expressed by Keenan et al. in their recommendations on not persisting 
with non-invasive ventilation following failed extubation4. It is of interest that since the 
CPAP study was presented, the Chelsea & Westminster CCOT have independently 
reduced their use of CPAP in favour of the Vapotherm® system which as a high flow 
system performs well in terms of oxygen delivery and patients prefer it.  This also 
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needs further investigation. Delivery of oxygen needs to be effective, be it by 
designing better comfortable mask systems or by mechanical ventilation.  
 
9.3.2 Critical Care Outreach 
At the start of this project it was hoped to demonstrate the efficacy of CCO in 
delivering care to the ward-based critically ill patients. This was overoptimistic and 
the scale and difficulty of the task was underestimated. It has identified that there is 
an enormous amount of work still to be done. Chapter 7 would suggest that despite 
CCOT, there are still significant problems with the ward care of patients with signs of 
circulatory shock. This is disappointing in that most of the problems directly linked to 
CCOT stem from logistics rather than capability. A 24 hour service needs to be 
mandatory to help prevent delay. The Chelsea and Westminster CCOT is nurse led 
and operates relatively independently of the ICU medical staff. As such they have 
limited power in prescribing new therapy, deploying monitors such as central 
catheters, ordering sophisticated interventions and generally carrying enough clinical 
weight to mobilise the system rapidly for the patient‟s benefit. This was highlighted in 
the audit by the uncontrolled and possibly excessive use of fluid. This is not a 
criticism of the clinical skills of a group of highly motivated, highly trained individuals, 
more an assessment of the limitations put upon their skills by national and local 
rules. I believe that a CCOT should have a medical presence, suitably trained to 
assess, investigate and deliver critical care. I would hope that this could reduce 
delays, promote rapid institution of ward interventions, and a smoother transfer to 
ICU if required. Evidence for this does not lie in this thesis, but further work could be 
done to investigate this additional input. It will of course cost more. 
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Even though the use of the Surviving Sepsis Campaign protocol is problematic when 
considering the resuscitation of patients from all causes of circulatory failure, it is 
being championed for ward based sepsis. Direct implementation of it as a tool for all 
other causes is almost foolhardy, but it does have some virtues which need to be 
identified and the protocol modified accordingly. The impetus placed on timeliness 
and monitoring is laudable and a focus on reassessment rather than a „fire-and -
forget‟ approach is important. Development of guidelines both local and national 
should be undertaken to improve the prompt controlled delivery of initial treatments. 
A study as outlined above could really add weight to such an argument. 
 
9.3.3 Cardiac Output Monitors 
The use of pulse contour analysis cardiac output monitors to guide the resuscitation 
of the circulation has yet to be proved in general critical care patients. However in 
surgical patients they do convey some benefit and have been shown to be superior 
to central venous catheters, in assessing fluid status and responsiveness1, 5, 6. It 
would be pointless trying to introduce a complex, hi-tech system into the ward 
environment and any device has to be simple , safe, easy to use, reliable,  „plug-in 
and go‟ and provide easy-to-understand usable information or it will not be deployed. 
With appropriate support and staffing, a system like the Vigileo Flotrac® could be 
used on a ward to aid in the assessment and delivery of resuscitation. Much work is 
required in this field.  
 
271 
 
9.4 Recommendations for Future Research 
Potential research projects have been outlined in each of the chapter summaries. 
This thesis set out to appraise the interventions delivered to acutely unwell ward 
patients. What appeared initially simple grew into something very complex. Whilst it 
appears the number of „interventions at the disposal of the ward-based clinician 
seem few, the evidence for their use, their method of delivery, their clinical benefit 
and actual current delivery have all yet to be elucidated. Attempting to assess such a 
broad church may have been folly, and if starting again it may have been more 
prudent to focus on just one intervention. The oxygen delivery systems could have 
been taken further forward with attempts to perform the Vapotherm® vs CPAP study 
and this stands out as a significant follow-up piece of research that could be done. In 
addition, developing novel system designs and subjecting them to model and then 
clinical trial might have produced a more succinct and directed thesis.  
If I was to start over then this would probably have been a better tactic. However the 
desire to detect and observe the other aspects of the immediate care received by 
critically ill patients is strong. Does what we do to ward patients have a bearing on 
their outcome? Is the CCOT in its current guise useful? Which patients benefit from 
aggressive intervention and which may not? Can we improve on the monitoring and 
management of such patients? This thesis only scratches at the surface of these 
questions. Thus further work could include: 
 The demography. CCOT works in a very varied and busy environment. What 
is the true nature of the work in terms of how many patients are treated and 
for which conditions? This probably cannot be defined, but some population 
statistics would be helpful.  
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 CCOT carries an instruction to educate and disseminate skills and information 
and the effectiveness of this deserves study. How effective are training 
courses such as ALERT on preparing staff for their interaction with critical 
illness? What impact does ward based teaching have on the critical care skills 
of the tutee? Six months later do trainees use what they were taught and do 
they turn reactive to proactive? 
 One very important element that came out of the audit and has been reported 
previously, is the ability of CCOT/MET to make decisions which may mitigate 
against aggressive therapy and provide a framework for the limitation of 
treatment7. It would be interesting to look at the incidence of this phenomenon 
and how it affects both the patient group and ward staff. 
Non-specific interventions which include aspects of infection control, rehabilitation, 
management of post ICU patients both in the hospital and in the community, all need 
to be addressed. 
 
9.5 Final Conclusions 
While there is still significant focus on what happens once a patient arrives in an ITU 
there remains very little information on what happens before, yet we know how 
important that is8-11. In starting with the basics of demonstrating the mechanisms of 
action of a commonly available ward based intervention, this thesis established that 
not all CCO interventions are as well understood as first thought and that there is 
scope for major improvement. Evidence that 3 years after the introduction of a 
CCOT, the appropriate tracking, triggering and timely intervening on the general 
wards is still poor, could question the constrained efficacy of CCOT in its current 
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guise. It is important to temper negativity with the observation that the majority of 
patients do not go to ITU or die and that there is clear benefit in terms of ward 
management although hard to quantify. Critical care outreach is here to stay and it 
needs to remain. It may be difficult to show benefit in trials, but it is the author‟s 
contention that removal of CCOT would clearly and rapidly demonstrate significant 
detriment. It will evolve and change as with all medical specialities, but in doing this 
needs to become standardised and critically assessed to ensure that it can deliver 
that which was desired at its inception. Goldhill et al. started by evaluating scoring 
systems12. This thesis makes the next step which is evaluating commonly employed 
methods. These are two steps of a long and difficult road.  
„The first step towards amendment is the recognition of error’.   Seneca (5-65 A.D.) 
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Appendix 1 
Mathematical Derivation of the Possible Contribution of Dead 
Space Gases to the EOIC 
 
A.1 Introduction 
The mechanical model permits the application of simple physical principles to allow 
the estimation of the possible further detriment the inclusion of dead space gases 
and vapours might have to the EIOC obtained from measurement. For this 
mathematical formula we have selected the Hudson mask as the example, although 
the calculations could be used with data from any of the oxygen delivery systems 
tested. 
 
Derivation of Formula for EIOCcorr 
Tidal volume (Vt) in an average 70kg male  500 ml1 
Dead space (both anatomical and physiological) (VD) 30% of Vt
1 
Oxygen Consumption      250 ml.min-1[1] 
Respiratory Quotient (R)     0.81 
The data that we have derived from the model requires correction factors for the 
effect of dead space to be added in.  
 
277 
 
A.1.1 Carbon Dioxide 
For each breath, at the end of expiration we can assume that VD contains gas from 
the alveolus (VA). The oxygen concentration of VA at end expiration (VA[O2]) is the 
original oxygen concentration at end inspiration (Vi[O2]) minus the proportion of 
oxygen consumed and is reflected in the value of EtO2. If R is assumed to be 0.8, 
then it can be assumed that the 80% of the difference between Vi[O2] and VD[O2] is 
made up of CO2. Resting oxygen consumption is approximately 250 ml.min
-1, thus 
CO2 production is:  
0.8 x 250 = 200 ml.min-1.  
At a respiratory rate of 10 breaths.min-1, the contribution of CO2 per breath would be:  
200 ÷ 10 = 20 ml.  
This CO2 would be distributed in a VA of: 
VA = Vt-VD 
= 500 – 150 = 350. 
The CO2 would contribute (20 ÷ 350) x 100 = 5.7% of the value of VD gas at end-
expiration.  
The value contribution of CO2 at a respiratory rate of 30 would have a value of 
approximately 2% assuming a constant O2 consumption, Respiratory quotient, Vt 
and VD:VA ratio. These assumptions may not be applicable in pathology that results 
in such a high respiratory rate. 
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A.1.2 Water Vapour 
Fully saturated air contains water vapour at a partial pressure of 47 mmHg1. If 
atmospheric pressure is assumed to be 760 mmHg, then water vapour will 
contribute: 
(47 ÷ 760) x 100 = 6.18% 
So this could be added as a correction factor to the EIOC as the model results for 
the non-humidified systems (all except the Vapotherm®) 
If it is assumed that both inhaled and exhaled gases are fully saturated and that the 
water vapour is distributed evenly through all gases, then the correction required for 
the oxygen concentrations as a percent is: 
= 0.0618 x EIOC 
e.g. for an EIOC of 40% we must subtract: 
= 0.0618 x 40  
= 2.47% 
The additional contribution of CO2 between approximately 2% and 5.7% would mean 
between approximately 8% and 13% of the VD would contain water vapour and CO2. 
 
A.1.3 Dead Space 
If we assume that VD contributes 30% to the value of Vt, and that the EtO2 reflects 
the concentration of oxygen in the dead space then it can be said that the 
contribution of this gas to Vi[O2] is: 
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= 0.3 x EtO2 
i.e. 30% of the gas inhaled has an oxygen concentration of the EtO2 
This is added to the concentration of oxygen delivered by the oxygen system in the 
rest of Vt (70%).  
= 0.7 x EIOC 
= (0.3 x EtO2) + (0.7 x EIOC) 
Now add in the contribution of water vapour for a final formula that approximates the 
FiO2 for VD of 30% 
EIOCcorr = [(0.3 x EtO2) + (0.7 x EIOC)] – (0.0618 x EIOC) 
 
A.2 Examples 
From the data for a Hudson Mask: 
Vt    500 ml 
RR   10 breaths.min-1 
Oxygen flow rate  2 l.min-1 
Assuming the EtO2 is 30% and a VD of 30% 
EIOCcorr  = [(0.3 x 30) + (0.7 x 42)] – (0.0618 x 42) 
  = 35.80% 
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The estimation of the EtO2 and proportions of VD and VA, make this method only an 
approximation of the contribution of dead space to the EIOC derived from the model, 
but it does allow the plotting of families of curves for both increasing VD at the same 
tidal volume, as well as variation in the EtO2 (see below). 
 
A.2.1 Example 1: Hudson Mask 500 ml. Effect of Varying Proportion of Vt that is VD 
Table A.1 shows the EIOC measured for the Hudson mask across the range of 
respiratory rates when the Vt was set at 500 ml. We can calculate the EIOCcorr for a 
VD:VA ratio of 30:70 by putting the values of EIOC into the formula and assume that 
the EtO2 remains fixed at 30%: 
EIOCcorr = [(0.3 x EtO2) + (0.7 x EIOC)] – (0.0618 x EIOC). 
This results in Table A.2.  
 
Table A.1 Effective inspired oxygen concentration (EIOC) values for a Hudson mask at a tidal 
volume of 500 ml. 
Oxygen Flow 
Rate (l.min
-1
) 
Respiratory rate (breaths.min
-1
) 
10 15 20 30 
2 42.00 35.00 33.00 30.00 
4 59.33 50.67 44.67 40.33 
6 65.33 56.67 50.33 44.67 
8 74.33 65.00 58.00 51.33 
10 82.00 71.33 63.67 55.67 
15 88.33 79.67 72.67 63.33 
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Table A.2 EIOCcorr for a Hudson mask at 500 ml assuming an EtO2 of 0.3 and a VD:VA ratio of 
30:70. 
Oxygen Flow 
Rate (l.min
-1
) 
Respiratory rate (breaths.min
-1
) 
10 15 20 30 
2 35.80 31.34 30.06 28.15 
4 46.87 41.34 37.51 34.74 
6 50.70 45.16 41.12 37.51 
8 56.44 50.48 46.02 41.76 
10 61.33 54.52 49.63 44.53 
15 65.37 59.84 55.38 49.42 
 
There is increasing reduction in EIOCcorr as the oxygen flow rate and respiratory rate 
increases. This is in part to the assumption that the EtO2 is fixed at 30% and 
therefore has a greater influence on the EIOCcorr at higher EIOC‟s. Estimation of 
EtO2 is difficult in vivo as it is dependent on oxygen uptake which can vary 
significantly, particularly in respiratory pathology. 
If we consider only the EIOCcorr for the Hudson mask at Vt 500 ml and oxygen flow 
rate of 4 l.min-1. We can use the derived formula to approximate the effect of altering 
the ratio of VD and VA assuming that EtO2 is maintained at 30%. This is summarised 
in Table A.3 and shown graphically in Figure A.1.  
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Figure A.1 The effect of varying the VD:VA ratio  on the EIOCcorr for a Hudson mask delivering 
oxygen at 4 l.min-1 to a Vt of 500 ml with an assumed EtO2 of 30%. 60:40 (), 50:50 (), 40:60 
(), 30:70 (), 20:80 () and no correction (). 
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Table A.3 The Hudson mask with oxygen flow rate of 4 l.min
-1
 and a Vt of 500 ml. The effect on 
EIOCcorr of altering the VD:VA ratio assuming a constant EtO2 of  30%. 
VD : VA Ratio 
Respiratory rate (breaths.min
-1
) 
10 15 20 30 
 
No Correction 59.33 50.67 44.67 40.33 
20:80 49.80 43.40 38.97 35.77 
30:70 46.87 41.34 37.51 34.74 
40:60 43.93 39.27 36.04 33.71 
50:50 41.00 37.20 34.57 32.67 
60:40 38.07 35.14 33.11 31.64 
 
The calculations results confirms that introduction of a correction factor further 
reduces the EIOC that the mask delivers. Also increasing the contribution of the 
dead space gases and vapours by increasing the proportion of Vt that is VD reduces 
the EIOC still further. This simplistic view of mixing of gases in the model relies on 
significant assumptions and the values derived for EIOCcorr can only be viewed as a 
guide for the real mask performance in vivo. 
 
A.2.2 Example 2: Hudson Mask Vt 500 ml. Effect of varying the value of EtO2 
The derived formula for calculating EIOCcorr to allow for the effect of dead space 
gases and vapours relies on an approximation of EtO2 as a reflection of oxygen 
consumption and carbon dioxide production. The value of EtO2 is predominantly 
dependent upon the FiO2 and oxygen consumption. Oxygen consumption can vary 
widely in pathology and so for the purpose of this example we present calculations 
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based on a spectrum of possible EtO2 values. This represents the best and worse 
case scenarios depending upon the value of EtO2 as a representation of oxygen 
consumption, and its contribution to the concentration of oxygen in the dead space 
gases. 
Using the Hudson mask again at 500 ml and 4 l.min-1 oxygen flow rate. The EIOCcorr 
values obtained with the EtO2 varying between 40% and 15% are represented in 
Table A.4 and Figure A.2.  
 
Table A.4 Hudson mask at 500 ml delivering 4 l.min-1 oxygen flow rate. Effect of varying the 
EtO2 on the EIOCcorr if the VD:VA ratio is constant at 30:70 
EtO2 (%) 
Respiratory rate (breaths.min
-1
) 
10 15 20 30 
No Correction 59.33 50.67 44.67 40.33 
15 42.37 36.84 33.01 30.24 
20 43.87 38.34 34.51 31.74 
25 45.37 39.84 36.01 33.24 
30 46.87 41.34 37.51 34.74 
35 48.37 42.84 39.01 36.24 
40 49.87 44.34 40.51 37.74 
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Figure A.2 The effect of varying the EtO2 on the EIOCcorr for a Hudson mask delivering 
oxygen at 4 l.min-1 to a Vt of 500 ml with an fixed VD:VA ratio of 30:70. 0.15 (), 0.2 (), 0.25 
(), 0.3 (), 0.35 (), 0.4 () and no correction (). 
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The table and figure also confirm that assuming a lower oxygen concentration in the 
expired gas will produce a further reduction in delivery by the oxygen systems, and 
that the greater the difference between the oxygen concentration delivered and the 
EtO2 results in a lower corrected EIOC. Once again we caution that the above 
calculations represent true values in vivo, as their derivation depends upon 
assumptions about EtO2 and VA:VD ratio, both of which are potentially extremely 
variable in the patient population. However, the above tables and figures do 
demonstrate the possible effects of the dead space on the delivery of oxygen to the 
alveoli and how that would further undermine the performance of the mask in reality 
as opposed to this bench model. 
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Appendix 2 
Manufacturer’s Data for Equipment Tested 
        
Non-Rebreathing Mask
Adult Child Estimated Oxygen Concentrations
Oxygen Flow (l/min) Oxygen Concentration*
10 - 12 80 - 100%
        
Medium Concentration Mask
Adult Child Estimated Oxygen Concentrations
Oxygen Flow (l/min) Oxygen Concentration*
5 - 6 40%
7 - 8 50%
9 - 10 60%
        
Nasal Cannula
Adult Child Estimated Oxygen Concentrations
Oxygen Flow (l/min) Oxygen Concentration*
1 24%
2 28%
3 32%
4 36%
5 40%
6 44%
May require higher flows. the flow should be adjusted
so the reservoir bag does not deflate more than one third
during inspiration.
Recommended Flow Rate - 
        
Nebuliser Kit
Adult Child Recommended Flow Rate
6-8 lpm
Non-Rebreathing Mask
CHILD
41058L
Non-Rebreathing Mask
ADULT
1059L
Medium
Concentration Mask
CHILD
41042L
Medium Concentration Mask
ADULT
1041L
Nasal Cannula
ADULT
1104L
Nebuliser Kit
CHILD
41894L
Nebuliser Kit
ADULT
41893L
Teleflex Medical and Hudson RCI’s oxygen therapy products are identified by a unique colour-coded system to enable 
you to select the right product first time.
Teleflex Medical  Stirling Road  Cressex Business Park  High Wycombe Buckinghamshire HP12 3ST
Tel: 01494 532761  Fax: 01494 524650  Freephone 08000 197347  info.uk@teleflexmedical.com  www.teleflexmedical.com
HUDSON RCI  OXYGEN THERAPY PRODUCTS
*Oxygen concentrations are estimates only and may vary significantly, depending on the patient’s respiratory rate, tidal volume, the oxygen flow into the system, the amount  
..of room air entrained, and the mask fit.
®
Moisture Output
25mg 1-1 H2O @ 15 breath/min
-1 Tidal volume 500ml
Resistance to Flow
0.3 hPa (cmH2O) at gas flow rate 0.5l/sec
-1 (30l/min) [0.6cm H2O 1
-1 sec-1]
0.7 hPa (cmH2O) at gas flow rate 1.0l/sec
-1 (60l/min) [0.7cm H2O 1
-1 sec-1]
1.2 hPa (cmH2O) at gas flow rate 1.5l/sec
-1 (90l/min) [0.9cm H2O 1
-1 sec-1]
O2 l/min 1 2 3 4 5 6 7 8 9 10
O2 % 27 33 37 42 45 47 53 54 57 60
Simple opening port allows quick 
and easy access for a suction catheter
to aid the removal of secretions.
Integrated oxygen 
port that can provide
up to 60% oxygen
concentrations 
to the patient via 
the simplest of
connections.
Original Portex Thermovent T paper
media provides high level performance
heat and moisture exchange to patient.
Clear housing gives 
an aesthetic appearance
and allows visualisation
of contamination.
Dead Space
11ml
Inspired Oxygen Concentration (%)
15 breath/min
Tidal volume 500ml
The New Portex Thermovent® T2 HME
providing a clear choice
AIRWAYMANAGEMENT
THE DETAILS GIVEN IN THIS LEAFLET ARE CORRECT AT THE TIME OF GOING TO PRESS. THE COMPANY RESERVES THE RIGHT TO IMPROVE THE EQUIPMENT SHOWN.
Smiths Medical International Ltd
Hythe, Kent CT21 6JL UK 
Tel: +44 (0)1303 260551 Fax: +44 (0)1303 266761
www.smiths-medical.com
Smiths Medical - a part of Smiths Group plc
For further information please call your local Smiths Medical distributor or Smiths Medical on +44 (0)1303 260551
Portex, Themovent and Smiths design mark are trademarks of Smiths Group plc.
Literature No. LIT/AM2593
THE NEW PORTEX THERMOVENT® T2 HME
Ordering information
Description Product Code
Portex Thermovent® T2 Heat & Moisture Exchanger 100/570/022
Smooth, rounded edges
aids patient comfort.
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The New Portex 
Thermovent® T2 HME
providing a clear choice
AIRWAYMANAGEMENT
1 2
4 5 6 7 8 9
The device should be orientated with the oxygen port on its underside when placed
on the 15mm connector of the tracheostomy tube. The suction port should remain
closed when not in use. 
Insert the suction catheter and
commence suctioning. Take care not to
scrape secretions onto the port door.
If supplementary oxygen is required, tubing from a suitable oxygen source should be
connected to the oxygen port. The oxygen flow should be controlled according to the
patient’s requirements.
The Portex Thermovent® T2 device should be removed from the tracheostomy tube prior
to disconnecting the oxygen line to avoid the risk of decannulation.
When suctioning is complete, remove the
suction catheter and close the suction
port door.
When suctioning is required, open the suction port door to allow insertion of the suction catheter.
Description
• Sterile, single use heat and moisture exchanger. 
• Provides effective humidification for spontaneously 
breathing patients whose upper airways are bypassed
by a tracheostomy tube.
• Device can be used for a maximum period of 24 hours.
Indications for use
• For use on adult and paediatric patients with a tidal 
volume more than 70ml.  
• Reduction of heat loss through the broncho pulmonary tree.  
• Helping to prevent thickened secretions and changes 
in lung function.
• Supplying additional oxygen when required.  
• Facilitating the removal of secretions.  
• Preserving humidity and minimising damage to 
tracheal epithelial cells.  
For more detailed information, please refer to the instructions for use.
3d3c3b3a
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- Controlled Oxygen Therapy
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History Examination plus Blood Gas Analysis
Low minute Volume
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ventilation)
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The Only Clinically Proven Fixed Performance Oxygen Mask 
Oxygen therapy devices for the spontaneously breathing patient fall into two categories, Variable 
Performance and Fixed Performance.
1. Variable Performance
These devices administer uncontrolled oxygen therapy, because the patient creates the inspired mixture 
by the act of breathing. Examples of these are nasal catheters, nasal cannulae and mask shells with or 
without a rebreathing bag (see pictures below). Various factors cause unpredictability in knowledge and 
control of inspired oxygen concentration when using these devices. Firstly, because the oxygen  ow is 
less than the patient’s inspiratory  ow, the patient obtains some oxygen and some air, but in unknown 
proportion because normal breathing has an irregular pattern:
The resulting oxygen concentration varies not only on a breath by breath basis, but also from patient to 
patient. Secondly, the size of the mask, size and placement of the vents and  t of the mask to the face will 
cause variation in inspired oxygen concentrations.
2. Fixed Performance
These devices allow controlled (known,  xed and selectable) oxygen dosage. They create a constant 
proportion of air/oxygen mixture in excess of patient inspiratory  ow rate and are independent of patient 
factors or  t to the face. With gas  ow constantly in excess of patient demand and with enhanced CO2 
washout, rebreathing is virtually eliminated.
To work e  ciently and to prevent air dilution a  xed 
performance device should incorporate: a) A large 
volume face piece (not less than 280ml), b) Gas mixture 
 owing directly towards the nose and mouth, c) Vents 
positioned well away from the patient airway. Fixed 
performance devices are sometimes referred to as 
venturi or air entrainment masks.
The disadvantage of using a variable performance device is that blood gas values cannot be easily 
interpreted since they only re ect performance variation of the mask/patient interface rather than a true 
change in the condition of the lungs under treatment.
Normally, a reduction in arterial oxygenation is compensated for by an increase in cardiac output to avert 
tissue hypoxia. When this ceases to be adequate, tissue hypoxia is accompanied by acidosis, a fall in 
standard bicarbonate and pH. Oxygen therapy becomes necessary when the arterial oxygen tension 
lies on the steep part of the oxyhaemoglobin dissociation curve i.e. below 50mm Hg. The objective of 
oxygen therapy is to increase arterial oxygen tension, so that normal O2 delivery to the tissue is restored. 
The essential aim in respiratory disorders is to keep out of the shaded zones and prevent further clinical 
deterioration. Patients rarely remain viable with arterial blood values in the red area - 25mm Hg or below. 
(see graph on page 3)
Rationale for controlled oxygen therapy
Excess oxygen can be harmful. Like many drugs, oxygen can be associated with toxicity and excess oxygen 
can be harmful to the lungs (pulmonary endothelium). The use of inspired oxygen greater than 60% should 
be avoided if possible. Decreasing the amount of supplemented oxygen at the earliest possible time 
should be routine practice.
1. Irrespective of the cause, hypoxia should be treated using a Ventimask which gives an appropriate  
   dosage, to bring oxygen tension and saturation to near normal.
2. When acute ventilatory failure exists, indicated by CO2 retention, then O2 therapy is only indicated, if  
    there is a concomitant hypoxia. Examples would be: CNS depression, Guillian-Barre syndrome and  ail 
    chest, all of which require treatment by IPPV if severe.
3. When chronic ventilatory failure and CO2 retention occur such as in chronic bronchitis and emphysema, 
    patients rely on hypoxia to drive respiration. Excess Oxygen dosage in such patients will thus cause 
    respiratory depression and narcosis. However, they will bene t from a small increase in inspired 
    Oxygen. 24% and 28% Ventimasks are appropriate under these circumstances and will produce 
    dramatic improvement in saturation and levels of consciousness.
4. Where there is excess shunting of venous blood without CO2 retention, as in infective pneumonia, 
    direct lung trauma or contusion, shock lung, acid aspiration syndrome or chronic congestive cardiac 
    failure, higher oxygen concentrations (35%-60%) are often required and can be administered safely. 
    Monitoring of arterial oxygen while Ventimasks are in use will indicate whether the lungs are improving 
    or deteriorating. When parenchymal lung failure is so severe that 60% inspired oxygen is not su  cient 
    to achieve satisfactory blood oxygen levels, IPPV is indicated even if alveolar ventilation assessed by CO2 
    measurement is adequate. In the  ow chart below, selection of the appropriate Ventimask is related to 
    the various types of respiratory disorder.
Objective of 
Oxygen Therapy  
Oxygen  
Administration 
Methods  
Variable Performance Devices:
Fixed Performance Devices:
The Flexicare Oxygen Therapy Range   
Humidity Adaptor
Normally, enough moisture is present in ambient air entrained into a venturi barrel to provide su  cient 
humidi cation. Patients however, with thick mucous secretions in the airway, undergoing controlled oxygen 
therapy may require additional humidi cation.
To provide this a humidity adaptor has to be attached to the venturi barrel, 
with the open end away from the mask and connected to either a large 
volume nebuliser or humidi er. When oxygen is delivered at a  ow rate 
of 1-4 l/min by mask, nasal cannula or nasal catheters, the oropharynx 
or nasopharynx provide adequate humidi cation. At a higher  ow rate 
or when oxygen is delivered directly to the trachea, humidi cation is 
necessary.
Ultimately it might be necessary to increase the moisture content of the 
inspired gases in order to prevent the possible detrimental e ect of dry 
gases on the airway structure. The humidity adaptor  xes over a venturi 
barrel as normal.
The adaptor has a 22mm arm which is connected to a humidi er via 22mm 
corrugated (elephant) tubing. Humidi ed air is transported from the 
bubble humidi er or heated humidi er to the humidity adaptor, then it is 
mixed with  xed concentration oxygen. This is the most accurate method 
of giving Fixed Concentration Humidi ed Oxygen to the patient.
Humidity Adaptor 
Oxygen  ows into a 
jet to entrain air 
through apertures in 
the venturi barrel
The resultant air/oxygen 
mixture containing the 
prescribed O2 concentration 
 ows into the face piece for 
patient breathing
Surplus gas leaves the mask 
through the holes to  ush out 
expired CO2
B) Calculating total gas mixture  ow rates
In most clinical situations the minimum recommended oxygen  ow rate will entrain su  cient air to 
provide a gas mixture  ow rate to match or exceed the patients inspiratory  ow rate. If a patient is known 
to be hyperventilating it may be necessary to increase the oxygen  ow rate to generate a greater gas 
mixture  ow to ensure this is in excess of patients demand. Using the mixture graph below, the total gas 
 ow rate available to the patient can be assessed.
Example
24% Ventimask:
At the minimum O2  ow rate of 2 litres/min, this mask will generate a total  ow rate of 52 litres/min. To 
calculate the total  ow rate from the same mask if O2  ow is increased to say 4 litres/min, simply look for 
the 4 litres/min on the vertical axis of the graph and follow the horizontal line where it intersects the 24% 
line. At this point of the intersection look to see what air  ow rate on the horizontal axis is appropriate. In 
this case it is 100 litres/min. Add O2  ow rate for the  nal mixture  ow rate. 100 (air entrained) + 4 (oxygen 
 ow) = 104 litres/min.
Similar calculations can be carried out for the remaining mask concentrations at varying O2  ow rates.
How a Fixed 
Performance Mask Works
A) Principles of operation
A  xed performance device utilises the HAFOE principle (High Air Flow with Oxygen Enrichment). 
O2  ows into a jet to entrain air through apertures in the venturi barrel. The resultant air/oxygen mixture 
containing the prescribed Oxygen concentration  ows into the face piece for patient breathing. Surplus 
gas leaves the mask through the holes to  ush out expired CO2.
In Summary, note that the increasing O2  ow rate maintains the O2 concentration but delivers it at a 
higher  ow rate.
Medium Concentration Mask
The Venticaire Medium Concentration Mask is a small capacity, variable performance mask. At a  ow rate of 6-8 litres/minute the Venticaire MC mask delivers an oxygen 
concentration of 40% to 50% depending on the patients breathing rate and tidal volume.
Non Rebreathing Mask
The Non Re-breathing Mask provides a high concentration of oxygen and the reservoir bag allows for adequate oxygen to be available to meet the unpredictable patients 
breathing pattern and tidal volume. 
Ventimask
Clinically Proven... “only Ventimask is able to provide a  xed and predictable oxygen concentration with changing and variable breathing patterns” 1. Ventimask is the 
accepted standard for controlled oxygen therapy for exact oxygen concentration delivery, optimum clinical performance with greater patient acceptability.
FOR MORE INFORMATION ON OUR FULL RANGE OF OXYGEN THERAPY PRODUCTS, PLEASE CONTACT OUR CUSTOMER SERVICES TEAM.         +44 (0)1443 474647  
Nasal Cannula 
Nasal Cannulae are used for their simplicity and patient convenience. There is entrainment of ambient air through the nostrils. The FiO2 achieved is proportional to a) the  ow 
rate of oxygen (1-6 l/min), b) the patients tidal volume, inspiratory  ow rate, and c) the volume of the nasal pharynx.
! ? 2
Flexicare Medical Limited. Cynon Valley Business Park, Mountain Ash, Mid Glamorgan. CF45 4ER UK.  Phone: +44 (0)1443 474647  Fax: +44 (0)1443 474222
www. exicare.com
2000i 
Operating Instruction Manual
Section 1 Indications and Contraindications 
Primary Indications:
Used to warm and humidify breathing gases, generally prescribed during oxygen therapy where concentrations 
of oxygen greater than ambient air are utilized to treat symptoms and manifestations of hypoxia including:
•	 Documented	hypoxemia:	decreased	Pa0
2
 in blood below normal range
•	 Acute	care	in	which	hypoxemia	is	suspected
•	 Severe	trauma
•	 Acute	myocardial	infarction
Secondary Indications:
•	 Managing	hypothermia
•	 Treating	bronchospasm	caused	by	cold	air
Contraindications:
General:
•	 Any	situations	in	which	humidification	is	contra-indicated	(see	AARC	Clinical	Practice	Guidelines)
Specific	to	Nasal	Cannula:
•	 Patients	with	occluded	or	defective	nares	should	not	use	the	system.
Section 2 Definitions,	Warnings	and	Cautions
2.1 Definitions
A	WARNING	indicates	that	a	potentially	harmful	situation	may	occur.
A	CAUTION indicates a condition that may lead to equipment damage, malfunction, or 
inaccurate	operation.
A	NOTE	indicates	a	point	of	emphasis	to	make	operation	more	efficient	or	convenient.
ASEPTIC TEChNIqUE is practices and procedures performed under carefully controlled conditions with 
the	goal	of	minimizing	contamination	by	pathogens.	Specifically	with	respiratory	equipment,	especially	
with	reference	to	the	Vapotherm	2000i,	this	includes	proper	hand	washing	and	avoiding	direct	hand	
contact	with	connection	points.
Please	take	the	time	to	familiarize	yourself	with	the	definitions,	warnings,	cautions	and	notes	listed	in	this	
manual.	They	cover	safety	considerations,	special	requirements,	and	regulations.
The	user	of	this	product	assumes	sole	responsibility	for	any	malfunction	due	to	operation	or	maintenance	
performed	by	anyone	not	trained	by	Vapotherm™	staff	or	official	training	documentation.	
When	handling	any	part	of	the	Vapotherm®	2000i,	always	follow	hospital	infection	control	guidelines	and	
Standard	Precautions.	Vapotherm	recommends	that	users	follow	the	disinfection	procedure	found	in	this	
manual.	Vapotherm	also	recommends	that	users	follow	the	Centers	for	Disease	Control	(CDC)	publications:	
Guidelines for Maintenance of In-Use Respiratory Therapy Equipment and Guidelines for Prevention of 
Nosocomial Pneumonia. 
2.2 General Warnings
•	 Federal	Law	(U.S.)	restricts	the	sale	of	this	device	to,	or	by	the	order	of	any	physician.
•	 This	is	a	humidification	device	generally	used	for	providing	continuous	flows	of	breathing	gas.
	 The	Vapotherm® 2000i	is	not	a	ventilatory	device	and	should	not	be	used	as	life	support.	
•	 This	device	will	not	operate	without	flow.
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Section 2 Warnings	and	Cautions
General Warnings (cont.) 
•	 The	Vapotherm®	2000i	must	be	disinfected	between	each	patient	use	and	after	30	days	of	use	on	the	
same	patient.
•	 Gas	flow	delivered	by	this	device	is	limited	to	40	liters	per	minute.	Maximum	operational	flow	rate	
should	not	be	exceeded.
•	 Prior	to	use	machine	should	be	positioned	and	secured	to	a	sturdy	IV	pole.	
•	 The	system	includes	several	disposable	elements	that	are	labeled	as	single	patient	use	only:	do	not	
attempt	to	sterilize	or	reuse.	Follow	all	local	and	federal	regulations	for	disposal.	
•	 Oxygen	supports	combustion;	this	device	should	not	be	used	near	or	around	open	flames,	oil,	grease	
or	any	flammables	or	anesthetics.
•	 Performance	verification	must	be	performed	prior	to	use.
•	 Service	on	the	device	should	be	performed	by	qualified,	certified	service	technicians	ONLY.
•	 To	prevent	injury	do	not	attempt	to	perform	any	service	to	the	Vapotherm	2000i	while	a	patient	is	
connected	to	the	device.
•	 If	the	device	is	damaged	or	not	working	properly	do	not	use.	Contact	Vapotherm	or	your	authorized	
Vapotherm	representative.
•	 Do	not	operate	if	power	cord	is	damaged.	
•	 The	device	should	not	be	turned	on	and	left	unattended.
•	 Do	not	use	the	Vapotherm	2000i	in	or	around	water	other	than	the	water	bag	that	feeds	the	system.
•	 Failure	to	utilize	sterile	water	supply	or	clean	gas	supply	may	increase	risk	of	bacterial	contamination.
•	 The	Vapotherm	2000i	utilizes	warmed	water	and	can	pose	a	risk	for	colonization	of	bacteria	and	
patient	infection	if	disinfection	procedures	are	not	followed.	
•	 Gas	flow	is	external	to	the	Vapotherm,	but	the	care	giver	should	confirm	the	integrity	of	all	respiratory	
gases	utilized	to	ensure	they	are	free	of	contamination.
•	 Gas	supply	must	be	made	of	clean	dry	medical	grade	gas	to	prevent	harm	to	the	patient	and	prevent	
damage	to	the	Vapotherm	2000i.
•	 An	oxygen	analyzer	with	alarms	must	be	used	when	the	delivered	concentration	level	is	critical.	The	
Vapotherm	2000i	does	not	provide	oxygen	concentration	analysis	capability.
•	 To	reduce	any	potential	transmission	of	contaminated	water	from	the	system,	all	assembly	and/or	
disassembly	of	the	unit	should	take	place	outside	the	primary	care	areas.
•	 The	2000i	is	not	a	Continuous	Positive	Airway	Device	(CPAP).	There	are	no	controls	to	deliver	or	
monitor	airway	pressure.	The	2000i	humidifies	breathing	gases	that	are	delivered	externally	through	
standard	air/oxygen	blender	and	flowmeter.	The	2000i	should	not	be	used	to	deliver	pressure	in	a	
closed	system.
2.3 Cautions
•	 Verify	that	the	power	source	is	compatible	with	the	electrical	specifications	shown	on	each	component. 
For	proper	grounding	reliability,	connect	the	2000i	power	cord	only	to	a	properly	marked	hospital	grade	
receptacle.	DO	NOT	USE	EXTENSION	CORDS.	If	any	doubt	exists	as	to	the	grounding	connection,	DO	NOT	
operate	the	device.
•	 Do	not	immerse	the	Vapotherm	2000i	in	water.	Do	not	steam	or	gas	sterilize	the	Vapotherm	2000i.
•	 Read	and	understand	this	manual	prior	to	operating	the	system.
•	 The	Vapotherm	2000i	must	be	disinfected	if	the	water	circuit	is	opened	up	by	removing	or	replacing	a	
component.
•	 Aseptic	techniques	(including	proper	hand	washing	and	avoiding	direct	hand	contact	with	connection	
points)	and	Standard	Precautions	should	always	be	followed	when	handling	medical	equipment.
•	 Standard	Precautions	should	always	be	followed	when	coming	in	contact	with	patients.
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Section 2 Warnings	and	Cautions
2.4 General Inspection
When	unpacking	the	Vapotherm	2000i	system	,	ensure	that	the	unit	is	inspected	for	damage	before	use.	
Report	any	damage	or	missing	parts	immediately	to	your	authorized	Vapotherm	distributor.
When	renting	a	Vapotherm	2000i,	customers	should	require	the	rental	service	to	provide	a	certification	
that	the	machine	has	been	disinfected	before	accepting	delivery.
Section 3 About	the	Vapotherm	2000i	and	2000h
The	Vapotherm™	2000h	for	home	use	consists	of	the	combination	of	a	2000i	unit	and	the	“Home	Care	
Compressor	Kit	(Part	number	HCK200-M)”.		The	HCK-200	Kit	consists	of	an	HS-100	Stand,	a	5060A	
Room	Air	Compressor	and	Flowmeter	assembly.
1.	A	Vapotherm	authorized	Durable	Medical	Equipment	(DME)	Supplier	is	responsible	for	the	following:
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2.	The	user/home	care	provider	is	responsible	for	the	following:
•	 Assembling	the	2000i	unit	and	the	kit	components 
•	 Instructing the user in their responsibilities for operating the system 
•	 Providing	1000	ml	sterile	water	bags	as	needed 
•	 Routine	servicing	of	the	system 
•	 	Removing,	replacing,	and	disposing	of	the	disposable	components	(Vapor	Transfer	Cartridge,	
Vapotherm	Spike	Set	-1	&	Delivery	Tube)	every	30	days 
•	 	Disinfecting	of	the	2000i	unit	every	thirty	days	following	the	procedure	found	in 
Section	8.1	–	8.6	of	the	2000i	Operating	Instruction	Manual
•	 Change	nasal	cannulas	when	soiled	or	excessively	wet	from	secretions.	Dispose	of	properly. 
•	 Installing and replacing the sterile water bag 
•	 Avoid	liquid	spills	on	the	components 
•	 Do	not	attempt	any	repairs.	If	you	have	any	problems	with	your	Vapotherm	2000i	device 
notify	the	DME	provider	immediately
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Section 4 Set-up
4.1 The 2000i Unit
1.		 The	back	of	the	2000i	has	an	IV	pole	clamp	that	 
enables	IV	pole	attachment.
2.	 The	unit	should	be	mounted	on	a	sturdy	IV	pole	 
approximately two feet from the top of the  
pole to facilitate ease of access and proper 
flow	from	sterile	water	system.
3.		 If	using	an	oxygen	blender,	mount	the	blender	 
above	the	Vapotherm	2000i	on	the	IV	pole.	
4.	 Connect	blender	hoses	into	both	air	and 
oxygen	wall	connections.
5.		 Plug	Vapotherm	power	cord	into	a	hospital 
wall	power	outlet.
WARNINGS: 
Aseptic technique (including proper hand washing  
and avoiding direct hand contact with connection  
points) should always be followed when setting up  
and operating the Vapotherm 2000i.
The medical gas source is external to the Vapotherm  
2000i. Always verify the integrity of the medical gas  
source and utilize bacterial filters if necessary.
Closed system components (VSS-1, Vapor Transfer  
Cartridge and Patient Delivery Tube) should not be  
opened in patient care area.
4.2 Selecting the Vapor Transfer  
Cartridge
Vapotherm	provides	both	a	high	flow	cartridge	 
(VT01-AS)	and	a	low	flow	cartridge	(VT01-BS).	
•	 The	high	flow	cartridge	(VT01-AS)	should	be 
used with the pediatric cannula with an  
operational	flow	range	of	5–20	liters	per	minute	 
(lpm)	or	with	adult	sized	cannula	with	an	 
operational	flow	range	of	8–40	lpm.	
•	 The	low	flow	cartridge	(VT01-BS)	should	be 
used with the neonatal, premature, infant, or  
intermediate sized cannula with an operational  
flow	range	of	1–8	lpm.
WARNINGS: 
Do not exceed maximum operational flow rates of 40 lpm 
for the high flow cartridge (VT01-AS) and 8 lpm for the low flow cartridge (VT01-BS).
Ensure that the correct cartridge is inserted before operating.
Section 3 About	the	Vapotherm®	2000i
The	Vapotherm	2000i	warms	and	humidifies	flows	of	air,	oxygen	or	medical	gas	blends	for	delivery	to	a	
patient,	by	nasal	cannula	or	Vapotherm	approved	interface.Warming	and	humidification	of	breathing	gas	
occurs	in	a	Vapor	Transfer	Cartridge,	where	air	and	water	are	separated	by	a	membrane	permeable	to	
water	vapor.	The	membrane	consists	of	microtubules	constructed	of	polysulfone	material.	The	membrane	
meets	HIMA	(Health	Industry	Manufacturers	Association)	standards	on	filters	for	sterilizing	liquids	and	has	
been	shown	to	effectively	exclude	bacteria	from	crossing	from	the	water	circulation	to	the	gas	flow.
The	warmed	humidified	gas	stream	reaches	the	patient	via	a	patented	triple	lumen	Patient	Delivery	Tube.	
Humidified	gas	flow	is	delivered	through	the	center	lumen.	The	outer	lumens	contain	water	which	is	
warmed	via	an	internal	heater	and	propelled	through	the	system	via	an	internal	pump	(See schematic, 
fig. 1).	This	maintains	breathing	gas	temperature	and	minimizes	condensation.	The	final	patient	interface	
is	a	Vapotherm	nasal	cannula	or	approved	interface	configured	to	minimize	resistance	and	heat	loss.	
NOTE: The water circuit and gas circuit of the Vapotherm 2000i do not come in contact with each other.
Respiratory	gases	are	supplied	to	the	Vapotherm™	2000i	from	an	external	gas	supply,	typically	through	a	 
standard	wall-mounted	flow	meter	connected	to	the	hospital	medical	gas	supply.	Gas	flow	rate	is	controlled	 
by	the	external	flow	meter	or	medical	gas	blender.	There	are	no	flow	controls	on	the	Vapotherm™	2000i.	
Connections	for	gas	flow	and	water	are	made	via	the	rear	panel.	All	Vapotherm	2000i	controls	are	on	the	
front	panel	of	the	device.	
WARNING: Use of patient interfaces not recommended by Vapotherm may cause safety concerns or 
affect the performance of the device. 
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Section 4 Set-up
4.5 Vapotherm Spike Set (VSS-1): for  
connecting Sterile Water Bag
1.	 Hang	a	sterile	water	bag	from	IV	Pole.
2.	 Connect	VSS-1	to	the	water	inlet	port	on	back	of	unit	and	make	 
sure	it	locks	into	place	(Fig.	5).
3.	 Ensure	the	VSS-1	is	clamped	then	remove	spike	cap.	Wipe	spike	 
with	disinfectant	wipes,	70-90%	isopropyl	alcohol.
4	 Firmly	insert	spike	into	sterile	water	bag	while	avoiding	direct	 
hand	contact	with	the	spike	tip	and	water	bag	septum.
5.	 Leave	VSS-1	spike	set	clamped	until	ready	to	fill	unit.
WARNINGS: 
The VSS-1 is single patient use item and should be changed with 
each patient.
If the VSS-1 is removed from the Vapotherm device for any reason 
the Vapotherm 2000i should be disinfected following the routine  
disinfection procedure before being returned to service.
CAUTION: Never leave the VSS-1 unclamped when the system is not  
running.
NOTE: Removing an empty sterile water container does not constitute  
opening the closed system. New sterile water containers can be spiked  
using the same VSS-1 without removing the device from service  
following the procedure above.
4.6 Connect To A Gas Source
1.	 Connect	a	source	of	air,	oxygen	or	medical	gas	blender	to	the	gas	 
inlet	port	of	Vapotherm	2000i	(Fig. 6).	Gas	inlet	connection	is	a	 
hose	barb	that	accepts	female	fitting	on	a	standard	1/4”	 
(6.35mm)	oxygen	tube.	
NOTE: Vapotherm will not operate unless there is gas pressure at gas  
inlet. With no flow/pressure sensed, a “System Failure” alarm will  
sound.
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Section 4 Set-up
4.3 Inserting the Vapor Transfer Cartridge
1.		 The	Vapor	Transfer	Cartridge	(VT01-AS	or	VT01-BS)	attaches	to	 
the	unit	by	two	water	and	two	air	connections.
2.		 When	facing	the	unit,	access	is	via	a	hinged	cover	on	right	side.	 
The	cartridge	may	be	fitted	in	either	direction.
3.		 Date	the	cartridge.
4.		 Remove	protective	caps	from	luer	side	ports	of	cartridge (Fig. 1).
5.		 Attach	lower	air	tube	from	Vapotherm	2000i	to	lower	end	of	 
cartridge.
6.		 Insert	projecting	side	ports	into	matching	connections	in	unit. 
Press	cartridge	firmly	into	place	(Fig. 2).
7.	 Attach	upper	air	tube	from	Vapotherm	2000i	to	top	of 
cartridge (Fig. 3).	Make	sure	tubing	is	not	kinked.
8	.		 Close	hinged	cover.	If	it	does	not	close	easily,	check	that	cartridge	 
is pressed fully into place and that air tubes are not interfering  
with	cover.
WARNINGS: 
The cartridge must be changed between patients and discarded 
after each use.
If the cartridge is removed, the unit should be disinfected.
If the cartridge is dropped, it should be discarded.
NOTE: Do not remove cartridge from the Vapotherm 2000i 
without first draining the machine.
4.4 Inserting the Patient Delivery Tube
1.	 Insert	Patient	Delivery	Tube	into	lower	portion	of	the	unit	by	 
aligning	blue	tabs	on	tube	with	notches	on	bottom	of	unit.
2.	 Firmly	press	into	place	(Fig. 4, see next page).	Blue	lip	on	tube	 
must	be	flush	with	the	bottom	of	unit.
3.	 Rotate	1/4	turn	clockwise	and	pull	slightly	downwards	to	lock	into	 
place	(Fig.	4,	see next page).
WARNING: The Patient Delivery Tube is a single patient use item 
and should be changed with each patient.
If the Patient Delivery Tube is removed from the device for any reason  
the Vapotherm 2000i should be disinfected following the routine 
disinfection procedure before returning to service.
CAUTION: Unit will not operate correctly if the Patient Delivery Tube 
is inserted improperly or not locked into place. 
Section 5 Operation	of	The	Vapotherm™	2000i
5.5 Setting the Temperature and Warm-Up
1.	 The	Vapotherm	2000i	displays	the	actual	temperature	of	the	circulating	water.	Press	and	release	the	
up	or	down	arrow	on	the	front	of	the	unit	to	display	temperature	setting	for	3	seconds.
2.		 To	adjust	the	temperature	setting	of	the	Vapotherm	2000i,	press	and	hold	the	up	or	down	arrow	
until	the	desired	temperature	is	displayed	in	the	LED.
NOTES:  
The Vapotherm 2000i always defaults to previous set temperature at power up.
The temperature can be set between 33 and 43˚C.
5.6 Connecting to Patient
1.	 Wait	for	desired	operating	temperature	to	be	reached	BEFORE placing the cannula on the end of 
the	Patient	Delivery	Tube.
2.	 Check	water	level,	temperature	display	and	gas	flow	rate.
3.	 Size	cannula	to	patient	by	ensuring	that	nasal	prongs	do	not	fit	tightly	into	nares.
4.	 Attach	properly	sized	cannula	that	is	designed	to	function	with	the	cartridge	installed	in	the	machine	
onto	the	delivery	tube.	Adjust	the	flow	to	the	desired	rate	and	place	the	cannula	on	the	patient.	
5.	 Some	condensation	of	moisture	around	nose	is	possible.	In	addition,	high	moisture	level	may	
mobilize	mucus	from	nose	and	sinuses.	Make	sure	patient	has	a	supply	of	tissues.
Cartridge Cannula Type Operational Flow Rates
High Flow (VT01-AS) Adult 8 – 40 lpm
High Flow (VT01-AS) Pediatric 5 – 20 lpm
Low Flow (VT01-BS) Premature, neonatal, infant, intermediate  1 – 8 lpm
WARNINGS:  
Always follow aseptic technique (including proper hand washing and avoiding direct hand contact with 
connection points) when setting up the Vapotherm 2000i and Standard Precautions when placing on  
a patient.
Cannula should not obstruct the nares of the patient.
Change nasal cannulas when soiled.
After start-up, during the normal purging of the Patient Delivery Tube, air will release and appear as 
bubbles in the bubble trap of the VSS-1. If the Patient Delivery Tube is filled and a stream of continuous 
bubbles appear in the bubble trap, it may indicate a problem with the cartridge or Patient Delivery Tube 
and both should be checked or changed.
NOTE: 
If using a low flow cartridge (VT01-BS) the flow cannot be decreased below 5 lpm until an appropriate 
cannula has been attached to the delivery tube
Droplets of condensation may appear at the end of Patient Delivery Tube while unit is warming up. This 
is normal and will stop within a few minutes when temperature is reached. If this condition continues 
refer to trouble shooting section. If the system operates while not connected to a patient, condensation 
is likely to develop.
Operating Instruction Manual Page 11Operating Instruction Manual Page 10
S
C
Mute
Power
Fig. 2
Fig. 3
Section 5 Operation	of	The	Vapotherm™	2000i
5.1 Prepare for Activating the Unit
1.	 Ensure	that	the	Vapotherm	2000i	power	cord	is	plugged	into	a	 
hospital	electrical	wall	outlet.
2.	 Unclamp	the	Vapotherm	Spike	Set	(VSS-1)	(Fig. 1).
5.2 Turn on Flow
1.	 If	using	the	high	flow	cartridge	(VT01-AS)	flow	should	be	 
started	at	least	8	lpm	for	warm-up.
2.	 If	using	the	low	flow	cartridge	(VT01-BS)	flow	should	be	set	 
to	at	least	5	lpm	for	warm-up.	
3.	 Turn	on	flow.
5.3 Priming the Unit
1.	 Unit	should	be	started	in	CLEANING	MODE	“CL”	to	prime	a	new	 
Patient	Delivery	Tube.
2	 To	place	unit	in	CLEANING	MODE,	press	both	the	power	on	and 
the	ALARM	SILENCE/MUTE	buttons	simultaneously	(Fig. 2).
3.	 The	display	will	show	“CL”	and	LED	next	to	cleaning	icon
S
 
will	illuminate.
4.	 Water	will	begin	to	circulate	and	fill	the	Patient	Delivery	Tube.
5.	 Operate	in	CLEANING	MODE	until	Patient	Delivery	Tube	has	been	 
purged	of	air	bubbles.
6.		 When	air	has	been	purged,	press	POWER	to	stop	system
7.	 Wait	until	display	blanks.
NOTES: 
Pressing both the power and alarm mute buttons will set unit  
in CLEANING MODE, pressing only the power button sets unit in  
NORMAL mode. 
Water is not being heated in CLEANING MODE: the purpose 
of this mode is to fill the outer lumens of the Patient Delivery Tube 
with water.
Gas flow is highly recommended (but not mandatory) during priming.
5.4 Activate the Unit
1.		 Press	the	Power	button	only,	to	start	in	NORMAL	MODE	(Fig. 3).
2.		 If	not	using	the	Patient	Delivery	Tube	with	integrated	cannula, 
do	not	place	cannula	on	the	end	of	tube	until	warm	up	is	complete.
Fig. 1
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Alarm Cause Action 
indication
NOTE: To restart after a system failure, the unit must be reset by a momentary pressure on the Power 
button. Do not hold the Power button. The alarm will shut off after a delay of about a second, and 
the unit can then be restarted normally.
S
S
Water	is	not	filling	system	properly 
 
Low	Water	Pressure 
 
Malfunctioning	Water	or	Gas 
Pressure	Sensor
Make	sure	VSS-1	spike	set	is	open,	and 
the tube is not kinked or blocked by 
air	bubbles.
Make sure gas and water connections are 
open, gas can flow to unit, and air has 
purged from water system: if not, run 
‘CLEANING	MODE’.
Send	in	for	service.
Water low
Insufficient	gas	or	water	pressure. 
 
 
 
Malfunctioning Water	or	Gas 
Pressure	Sensor
Make sure the gas and water circuits are 
open and functional and air has purged 
from the water circuit if the unit is in 
normal	operating	mode.
Run	in	“CLEANING	MODE”.
Make sure there is correct flow for 
cartridge	flow	rates.	If	using	<5lpm	with	a	
low flow cartridge, a nasal cannula must 
be	attached.
If a component failure return the unit 
for	service.
System Failure
Cartridge Water	drops	in	the	circuit	will	
cause	a	cartridge	alarm;	this	does	
not necessarily mean the cartridge 
needs	to	be	replaced.	
Section 6	Alarms,	Trouble	Shooting	and	Component	Change-Outs
6.1 General
1.		 Periodically	check	for	alarm	conditions.
2.		 Unit	will	shut	down	if	there	is	no	gas	flow.	However,	flow	will	not	be	interrupted	if	unit		
shuts	down	or	malfunctions	for	any	other	reason.
3	 Unit	will	shut	down	if	temperature	safety	limits	are	exceeded,	or	if	water	level	is	low	for		
more	than	4	mins.	However,	unheated	gas	flow	will	continue.
NOTE: Should a malfunction occur, indicators on the front panel will light and an alarm will sound. 
If the actions listed here do not correct the problem causing the alarm, the unit should be returned to 
an approved facility for service.
6.2 Alarms and Troubleshooting
Section 5 Operation	of	The	Vapotherm™	2000i
5.7 Operations – General Guidelines
1.	 Check	that	water	is	properly	circulating	through	the	machine	by	making	sure	the	Patient	Delivery	
Tube	is	warm	across	the	entire	length.
2.	 If	good	circulation	cannot	be	confirmed,	check	that	the	water	flow	is	not	obstructed	by	air	bubbles.
3.	 Take	precautions	to	minimize	cooling	of	the	unheated	cannula	by	trying	to	maintain	contact	with	
the	patient’s	skin	and	insulating	the	exposed	portion	of	the	cannula	with	bedding.
4.	 Cartridge	door	should	be	closed	during	operation.
NOTE: Condensation in the cannula may occur at low flow rates. To minimize condensation, these 
general guidelines should be followed:
•	 If using flow rates less than 5 lpm, do not set the temperature higher than 34ºC.
•	 The	Vapotherm	unit	should	not	be	in	a	position	where	it	is	cooled	(eg.	by	an	air	conditioning	outlet).	
CAUTION: DO NOT EXCEED flows of 8 lpm for VT01-BS and 40 lpm for VT01-AS cartridge. 
DO NOT SET flows below 1 lpm for VT01-BS.
WARNING:
Never occlude the nares with cannula.
NOTES:
It may become necessary to disconnect the cannula from the Patient Delivery Tube for short periods, such as 
when moving a patient out of a radiant warmer. At flow rates less than 5 lpm, cannula disconnection will 
activate a system failure alarm, requiring a reset. To avoid this alarm, briefly turn off unit by pressing the power 
key once. The display will show two bars. Disconnect the cannula from Patient Delivery Tube and move the 
patient, reconnect the cannula, then press the power key once more to restart the unit.
A SYSTEM FAIL (88) alarm will activate if there is insufficient gas pressure in the manifold. If no cannula is fitted, 
flow rate at startup should be at least 5 lpm. The minimum flow rate for operation is 1 lpm if a neonate, infant 
or premature-sized cannula is fitted, 5 lpm with a pediatric cannula, and 8 lpm with an adult cannula.
Cannulas are single use patient items, dispose of as necessary or according to your institution’s guidelines or  
when visibily soiled or excessively wet from secretions. Weekly change out is recommended to avoid any 
hardening of nasal prongs.
An air lock can develop at the pump, preventing normal water flow. Try restarting the unit in 
cleaning mode.
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Section 6	Alarms,	Trouble	Shooting	and	Component	Change-Outs
6.3 Component Change Outs
WARNINGS: 
The vapor transfer cartridge, patient delivery tube, and VSS-1  
spike set are all single use only and should be discarded after  
removal from the Vapotherm 2000i.
The Patient Delivery Tube, VSS-1 and Vapor Transfer Cartridge  
should not be changed or replaced in the patient care area. 
The system must be disinfected any time the Vapor Transfer  
Cartridge, VSS-1 or Patient Delivery Tube are removed.
NOTE: The cannula and sterile water source can be replaced without  
disinfecting the system. As with all respiratory equipment, proper 
hand washing techniques should be followed before contacting 
or replacing any patient interfaces.
6.3.1 Replacing Vapor Transfer Cartridge
1.	 Power	off	unit.	Disconnect	gas	flow.
2.	 Close	clip	on	VSS-1.	(Fig. 1)
3.	 Open	hinged	cover.
4.	 Disconnect	air	tubes	from	cartridge	ends	by	pressing	tubing	away	 
from	cartridge.	
5.	 Remove	cartridge	by	pulling	straight	outwards.	(Fig. 2)
6.	 Proceed	to	Section	8.0	and	disinfect	the	Vapotherm®	2000i	device	 
before	returning	the	device	to	service.		
7.	 For	set-up	please	refer	to	Section	4.3	of	the	manual.
CAUTION: Do not grip cartridge tubing with sharp instruments.
6.3.2 Replacing the Patient Delivery Tube
1.	 Power	unit	off.	Disconnect	gas	flow.
2.	 To	remove	tube,	push	base	of	tube	upwards,	rotate	1/4	turn	 
counter	clockwise	and	pull	downward.	(Fig. 3)
3.	 Proceed	to	Section	8.0	and	disinfect	the	Vapotherm®	2000i	device	 
before	returning	the	device	to	service.
4.	 For	set-up	please	refer	to	Section	4.4	of	the	manual.
6.3.3 Replacing the VSS-1 Spike Set
1.	 Power	off	unit.	Disconnect	gas	flow.
2.	 Clamp	VSS-1	and	remove	VSS-1	Spike	Set	from	the	water	inlet 
port	on	the	back	of	the	Vapotherm	2000i	by	releasing	the 
quick	connect	on	the	water	inlet	port.
3.	 Proceed	to	Section	8.0	and	disinfect	the	Vapotherm®	2000i	device 
before	returning	the	device	to	service.
4.	 For	set-up	please	refer	to	Section	4.5	of	the	manual.
Fig. 2
Alarm Cause Action 
indication
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If further assistance is needed please call your clinical product specialist or local distributor representative.
S
S
If	the	Cartridge	Alarm	is	continuous	
and air bubbles are rising into the 
VSS-1	bubble	trap	or	if	a	flow	or	
water	is	visible	in	the	tube	below	
the cartridge, then the cartridge 
has	failed.
If cartridge alarm is intermittent 
and there are no bubbles in the  
VSS-1	bubble	trap	or	no	obvious	
water flow below the cartridge there 
may	be	condensation	in	the	system.
First	disconnect	the	patient	from	the	unit,	
shut down unit, drain unit, disinfect unit, 
replace	cartridge,	VSS-1	and	delivery	tube,	
and	follow	set	up	instructions. 
 
Occasional brief alarms due to 
condensation	are	not	a	cause	for	concern.	
Try	briefly	pinching	and	releasing	tube	
under	cartridge	to	dislodge	the	drops	and/	
or	decrease	set	temperature.
Cartridge
Malfunction	of	Temperature	
Control	System.
Shut	down	system	and	return	for	service.	
NOTE: A momentary High Temperature 
alarm may occur when the unit has 
been switched off and on again. If the 
temperature then stabilizes, no action 
is needed.
High 
Temperature 
Alarm
High	water	or	air	pressure	due	to	
high resistance in water circulation 
or air outlet: or malfunctioning 
pressure	sensor.
Blocked	tube	alarm	due	to	high	
WATER	pressure	will	cause	a	
continuous or intermittent tone 
and	alarm	light.	The	flow	of	
breathing gas continues, but is 
no	longer	heated. 
Blocked	tube	alarm	due	to	high	
GAS	pressure	will	cause	a	5	second	
alarm	tone.	If	the	obstruction	
persists the system will continue  
to	alarm	in	5	sec	episodes.	Water	
circulation continues but the heater 
shuts	off.	
 
 
 
Check	that	delivery	tube	is	correctly	
positioned, rotated clockwise, and pulled 
into	locked	position.	Check	that	water	is	
circulating	within	delivery	tube.	If	alarm	
persists	replace	delivery	tube	and/or	
cartridge.	Disinfect	unit	prior	to	replacing	
components.
Find	and	correct	the	cause	of	obstruction.		
The	most	common	cause	is	a	kink	in	the	
nasal	cannual	or	in	the	prong.	Attempting	
to	run	the	Vapotherm	2000i	at	very	high	
flow through a patient interface not 
approved	by	Vapotherm	may	also	raise	the	
internal pressure sufficiently to trigger a 
Blocked	Tube	Alarm.
Blocked Tube 
Alarm
SSection 6	Alarms,	Trouble	Shooting	and	Component	Change-Outs
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Section 8	Routine	Disinfecting	Protocol
8.1 Disinfection Supplies
1.	 DK-301	(a-e	included	in	kit)	 a.	 Disinfection	Bag	A	 b.	 Disinfection	Bag	B 
	 c.	 Disinfection	Tube	 d.	 Cartridge	Bypass	Tubes 
	 e.	 Y-Spike	Assembly
2.	 Gloves
3.	 Safety	Glasses
4.	 Disinfectant	wipes,	70-90%	isopropyl	alcohol
5.	 Approved	Disinfectant
6.	 1000ml	Sterile	Water	Bag
7.	 Medical	Grade	Air	Source
8.	 Standard	adult	flow	meter	with	oxygen	7ft	tubing	attached
WARNINGS: 
Vapotherm should be disinfected after each patient or every 30 days on a single patient. Do not disinfect in 
an open patient care area.
The DK-301 disinfection kit is a single use item. Operators should open a new disinfection kit for each 
disinfection procedure and discard the components at the end of the procedure.
Disinfection Procedure should be performed in a well ventilated area. Use Standard Precautions and 
aseptic techniques during this procedure. 
The Vapor Transfer Cartridge SHOULD NOT be in place when disinfecting the unit.
The Vapor Transfer Cartridge is a single use disposable and must be discarded after each patient use. 
DK-301 IS NOT designed to disinfect Vapor Transfer Cartridges.
8.2 Pre-Cleaning Process
1.	 After	patient	use,	it	is	recommended	that	the	Vapotherm	2000i	System	remain	attached	to	the	IV 
pole	with	all	the	component	parts	intact.	
2.	 Move	the	Vapotherm	2000i	System	to	a	hospital	approved	 
reprocessing	area	outside	the	patient	care	area.	
WARNING: The water circuit of the Vapotherm 2000i System is not  
sterile and can potentially have bacterial contamination. The water  
circuit of the device should never be opened in a patient care area.  
Transport the Vapotherm 2000i System to an appropriate area for  
draining, cleaning and disinfection.
3.	 Wash	hands	and	put	on	gloves.
4.	 Drain	the	Vapotherm	2000i	System	in	a	receptacle	by	cutting	the	 
delivery	tube.	(Fig. 1)
5.	 Remove	and	dispose	of	the	delivery	tube,	cannula,	VSS-1	spike	 
set,	and	sterile	water	source.
6.	 Remove	and	dispose	of	the	vapor	transfer	cartridge.
WARNING: The water circuit of the Vapotherm 2000i system has the potential for bacterial growth so 
standard precautions should be used to open the water circuit. Disposable components should be disposed of 
in accordance with hospital guidelines and operators should wash their hands after breaking down the device.
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Section 7	Removing	From	Patient	and	System	Shut	Down
1.	 	Remove	cannula	or	other	interface	from	patient.
2.	 	Press	and	release	power	switch	(Fig. 1).	Display	will	show	“--”
3.	 	Close	clip	on	VSS-1	(Fig. 2).
NOTE: The system’s pump continues to run for 1 minute to allow  
heater to cool down.
4.	 After	1	minute,	water	pump	shuts	off	and	numeric	display	is	 
blank.	Unit	may	now	be	disconnected	from	power	outlet.
5.	 Remove	unit	from	patient	care	area	and	proceed	to	disinfection	 
process.
CAUTIONS:  
Avoid disconnecting from power or gas sources while machine is  
operating.
Do not unplug from power source until display is blank.
Section 8	Routine	Disinfecting	Protocol
8.4 Set-up (cont.) 
6.	 Hang	Bag	A	with	200	ml	of	approved	disinfecting	solution	from	IV	 
pole	hook.		
7.	 Wipe	blue	end	of	disinfection	tube	with	an	approved	disinfectant	 
wipe.	Insert	into	bottom	port	of	Vapotherm™	2000i	system.	Press	 
firmly	into	place,	rotate	1/4	turn	clockwise,	and	pull	down	slightly	 
to	lock	in	position.	(Fig. 5)
8.	 Wipe	the	other	end	of	the	disinfection	tube	with	an	approved	 
disinfection	wipe	and	attach	it	to	the	bottom	outlet	of	Bag	A.	 
Lock	into	place.	(Fig. 6)
9.	 Suspend	Bag	B	on	a	separate	hook	on	IV	pole.	Cap	should	be	 
firmly	closed	to	minimize	potential	spilling.
10.	 Attach	Y-Spike	Assembly	by:
a.	 Disinfect	wipe	male	colder	fitting	end	of	Y-	Spike	Assembly	 
and insert it into water inlet port on the back of the  
Vapotherm	2000i	system.	Lock	into	place.	(Fig. 7)
b.	 Disinfect	wipe	the	O
2
 bushing connector end of the 
Y-Spike	Assembly.	Attach	connector	to	the	air	inlet	connector	 
port	on	the	back	of	the	Vapotherm	2000i	system. (Fig. 8)
c.	 Disinfect	wipe	the	spike	end	of	the	Y-Spike	Assembly	and	insert	 
into	bottom	outlet	of	Bag	B	until	it	comes	to	a	stop.
WARNING: If spike is not properly inserted, it may cause disinfectant  
to leak creating a potential safety risk. The spike should be inserted  
into Bag B up to the ridge at the bottom of the spike. Do not insert  
the spike past the ridge at the  
bottom of the spike.
NOTE: If the spike is inserted too  
far into Bag B it will be difficult to  
remove, do not insert the spike  
past the ridge at the bottom of  
the spike. If the spike is hard to  
remove from Bag B rotate the  
spike while removing it to make  
it easier.
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Section 8 Routine	Disinfecting	Protocol
8.3 Pre-Disinfection Cleaning and Decontamination 
1.	 Wash	hands	and	put	on	new	gloves.
WARNING: Always use standard precautions when cleaning and  
disinfecting the Vapotherm 2000i system.
Always use individually wrapped 70-90% isopropyl alcohol disinfectant  
wipes when wiping down the Vapotherm 2000i and disinfection kit  
components.
Always use a new disinfectant wipe taken directly from the package or  
container and ensure that the disinfectant wipe has not dried out  
before using it on the Vapotherm 2000i device.
2.	 Wipe	exterior	casing	including	inside	hinged	cover	with	an	 
approved	disinfectant	wipe.	(Fig. 2)
3.		 Wipe	inside	and	outside	of	the	following	connections	with	an	 
approved	disinfectant	wipe:
a.	 Four	cartridge	connection	ports	inside	hinged	cover 
(Upper	and	lower	cartridge	air	tubes	and	the	water 
connection	ports)	
b.	 Water	inlet	and	air	inlet	connectors	on	rear	of	unit
c.	 Delivery	tube	port	on	the	bottom	of	unit.
8.4 Set-up
1.	 Take	the	4	inch	bypass	tube	with	90°	barb	fittings	(Bypass	Tube	A)	 
and	wipe	the	ends	with	an	approved	disinfectant	wipe.	Press	firmly	 
into	the	inner	cartridge	connection	ports	(water	circuit).	(Fig. 3)
2.	 Take	the	6	inch	bypass	tube	with	straight	barb	fittings	(Bypass	Tube	 
B)	and	wipe	the	ends	with	an	approved	disinfectant	wipe.	Insert	 
firmly	into	outer	upper	and	lower	cartridge	ports	(air	circuit).	(Fig. 4)
WARNING: The By-pass Tubing has been designed to optimize the  
flow of solutions through the Vapotherm 2000i system. Failure to use  
the By-Pass Tubing supplied by Vapotherm™, Inc. could lead to  
improper disinfection and or drying.
3.	 Close	hinged	cover.
4.	 Prepare	200ml	of	approved	disinfectant	solution	and	add	it	to	 
Bag	A	with	slide	clamp	closed	(see	Appendix	A	–	“Disinfection	 
Solutions”	for	approved	disinfection	solutions,	appropriate	 
concentrations,	and	required	hold	times).
WARNINGS: 
Disinfection solutions, concentrations and hold times in Appendix A  
have been verified by independent laboratory testing to adequately  
disinfect the Vapotherm™ 2000i machine when following these  
instructions. Modifying this procedure or using an alternative disinfection solution, concentration, or hold 
time could result in inadequate disinfection thereby increasing the risk of contamination.
Always wear gloves when handling disinfectant solutions, work in a well ventilated area, and use an 
accurate measuring device to ensure the proper concentration of disinfection solution and water.
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Section 8	Routine	Disinfecting	Protocol
8.5 Disinfect Gas and Water Circuits	(cont.)
14.	 Leave	all	DK-301	tubing	connected	to	the	Vapotherm	system.
15.	 Dispose	contents	of	Bag	A	in	accordance	with	all	applicable	regulations	and	institutional	guidelines.
8.6 Drying
1.	 Ensure	that	the	Disinfectant	Tube,	Cartridge	Bypass	Tubes	and	the	 
Y-Spike	Assembly	are	all	in	place.
CAUTION: In order to dry the Vapotherm 2000i system, the  
Disinfectant Tube, Bypass Tubes and the Y-Spike Assembly must all be  
connected to the Vapotherm 2000i system.
2.	 Remove	the	spike	from	the	empty	sterile	water	bag	and	wipe	with	 
an	approved	disinfectant	wipe.
3.	 Insert	spike	from	Y-Spike	Assembly	into	standard	oxygen	tubing.
4.	 Set	flowmeter	to	15	lpm.
5.	 Take	the	Vapotherm	2000i	system	and	position	the	system	flat	on	 
its	side	opposite	the	cartridge	door	for	2	minutes.	(Fig.12) 
6.	 After	2	minutes	attach	the	Vapotherm®	2000i	device	back	on	the	IV	Pole	and	continue	to	dry	at 
15	lpm	for	25	minutes.
7.	 After	a	minimum	of	25	minutes,	disconnect	the	disinfection	tube,	the	cartridge	By-Pass	tubing	and	
Y-spike	assembly	and	close	the	door	to	the	cartridge	area	for	storage.	Discard	all	components	of	the	
DK-301	kit	in	accordance	with	all	applicable	regulations	and	institutional	guidelines.
8.	 Wipe	down	exterior	casing	with	disinfectant	wipe.
9.	 Place	a	sticker	over	the	cartridge	access	door	to	certify	that	the	device	has	been	disinfected.
10.	 Log	the	disinfection	procedure	on	a	Vapotherm	2000i	Disinfection	Log	Sheet	or	in	a	similar	log	
approved	by	your	institution.	Appendix	B	has	a	Sample	Disinfection	Log.	The	Disinfection	Log	can	be	
accessed	and	printed	out	at	www.vtherm.com.
11.	 Place	the	system	in	a	clean	plastic	cover	and	seal	the	end	by	tying	a	knot	or	a	clip.
12.	 The	system	is	now	ready	for	use	or	storage.
CAUTION: Do not set the flowmeter above 35 lpm or start the drying process without the disinfecting 
tube in place. This can cause damage to the pressure transducers in the Vapotherm 2000i system. 
WARNING:
Gram (-) bacteria can grow in moist environments. The Vapotherm 2000i system should not be stored 
with visible water remaining in the device. 
Vapotherm should be disinfected after each patient or every 30 days on a single patient.  
Do not disinfect in an open patient care area.
The DK-301 disinfection kit is a single use item and must be discarded after the disinfection procedure.
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8.5 Disinfect Gas and Water Circuits
1.	 Open	clamp	on	Bag	A.	Disinfectant	will	start	to	drain	from	Bag	A	 
through	the	unit	and	into	Bag	B.	(Fig. 9)
2.	 When	disinfectant	has	stopped	draining	into	Bag	B,	clamp	Bag	A.
NOTE: Not all contents from Bag A will drain into Bag B.
3.	 Start	the	Vapotherm	2000i	system	in	cleaning	mode	by	pressing	 
the	Mute	and	Power	buttons	at	the	same	time	(Fig. 10).	 
Disinfectant	will	circulate	through	gas	and	water	circuits.	 
Run	unit	in	cleaning	mode	for	the	required	hold	time	given	in	 
Appendix	A	for	the	disinfection	solution	used.	
WARNING: Operating the Vapotherm 2000i system in cleaning mode  
for less than the required hold time may not adequately disinfect the  
machine and could lead to contamination of the air and water circuits  
thereby increasing the risk of infection.
4.	 After	circulating	disinfection	solution	through	the	machine	for	the	 
appropriate	hold	time,	turn	the	Vapotherm	2000i	off	by	pressing	the	 
power	button.
5.	 Unclamp	and	lower	Bag	A	and	hang	onto	Vapotherm	i.v.	pole	 
clamp	knob. (Fig. 11)
6.	 The	disinfectant	that	was	contained	in	reservoir	Bag	B,	has 
circulated through the unit, and the circulated disinfectant 
solution	drains	into	Bag	A	for	collection	and	disposal.
7.	 Hang	1000	ml	of	pre-packaged	sterile	water	on	i.v.	pole.
8.	 Loosen	cap	on	Bag	A	to	allow	air	to	vent	out	of	the	bag	as	sterile	 
water	fills	the	bag.
WARNING: The disinfection procedure has been specifically designed  
to use 200 ml of disinfection solution and 1000 ml of sterile water. 
Bag A is designed to hold 1200 ml of solution. Using larger than the  
recommended volumes during disinfection or rinsing could cause a  
spill of diluted disinfection solution.
9.	 Close	the	clamp	on	Bag	B,	remove	the	spike,	and	discard	the	Bag	B	in	 
accordance	with	all	applicable	regulations	and	institutional	guidelines.
10.	 Wipe	spike	with	an	approved	disinfectant	wipe	and	firmly	insert	 
into	the	spike	port	of	a	prepackaged	sterile	water	bag.	Confirm	 
that	water	is	flowing.
11.	 Immediately	start	the	Vapotherm	2000i	in	cleaning	mode	by	 
pressing	the	Mute	and	Power	buttons	at	the	same	time.	(Fig.	10)
12.	 Run	the	cleaning	mode	to	circulate	the	sterile	water	through	the	Vapotherm	2000i	system	until	all	
the	water	has	drained	from	the	sterile	water	bag.	Immediately	turn	off	the	system.
CAUTION: Running the system dry can damage the water pump.
13.	 Clamp	tubing	and	close	cap	on	Bag	A	and	disconnect	the	bag	from	the	disinfectant	tube.
WARNING: Failure to clamp off or close the cap of Bag A firmly before disconnecting it from the 
disinfection tube could cause diluted disinfection solution to spill.
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Section 10 Warranty
Vapotherm,	Inc	warrants	that	the	Vapotherm™	2000i	shall	be	free	of	defects	of	workmanship	and	
materials and will perform in accordance with the product specifications for a period of one year from 
the	date	of	sale	by	Vapotherm,	Inc.	If	the	product	fails	to	perform	in	accordance	with	the	product	
specifications,	Vapotherm,	Inc.	will	repair,	or	replace,	at	its	option,	the	defective	materials	or	part.	This	
warranty	does	not	cover	damage	caused	by	accident,	misuse,	abuse,	alteration	and	other	defects	not	
related	to	material	or	workmanship.
VAPOTHERM,	INC.	DISCLAIMS	ALL	LIABILITY	FOR	ECONOMIC	LOSS,	LOSS	OR	PROFITS,	OVERHEAD	OR	
CONSEQUENTIAL	DAMAGES	WHICH	MAY	BE	CLAIMED	TO	ARISE	FROM	ANY	SALE	OR	USE	OF	THIS	
PRODUCT.	THIS	WARRANTY	IS	GIVEN	IN	LIEU	OF	ALL	OTHER	EXPRESS	WARRANTIES.
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9.2 Definitions and symbols
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Section 9 General Information
9.1 Specifications
Dimensions:	 Height	11”	(280	mm),	width	5.5”	(140	mm),	depth	4.5” 
(114 mm)	excluding	IV	pole	clamp.
Weight:	 Less	than	6	lbs	(2.7 kg)	without	water	reservoir.
Vapotherm spike set:	 Works	with	sterile	water	bags	up	to	2000 ml	bag.
Circulating water volume	 <100 ml.	(excluding	Patient	Patient	Delivery	Tube).
Mounting:	 Rear	mounted	clamp	fits	standard	IV	pole	or	hanger.
Power:	 (US)	115 V,	60 Hz,	250 VA	(warm	up),	approximately	80	VA	(continuous). 
(Other	versions)	220 –240 V, 50–60 Hz,	250 VA	(warm	up),	
approximately	80 VA	(continuous).
Gas source pressure: 4–50 psi.	At	high	pressures	(e.g.	hospital	wall	system)	the	Vapotherm	2000i	
must	be	connected	to	the	gas	outlet	via	a	standard	medical	flowmeter	and	
flow	regulator	with	approved	fittings.
Gas flow:	 Controlled	by	external	flowmeter.	Operating	range	1–40 lpm, dependent 
on	cartridge	type	and	patient	interface	used.
Output gas temperature:	 (US)	33 –43ºC	at	outlet	of	the	delivery	tube,	adjustable	by	front	panel	
settings.	(Other	versions)	33 –41ºC.
Humidification:	 Vapor	phase,	by	transpiration	through	microporous	membrane.	Output	
is	at	least	95%	relative	humidity	at	nasal	cannula	at	a	flow	rate	up	to 
20 lpm,	at	least	90%	at	flow	rates	from	20–40 lpm,	over	the	full	range	
of	operating	conditions.
Vapotherm	2000I	Operating	Instruction	Manual	–	Appendix	A:	Disinfection	Solutions                          Page 25
Vapotherm 2000i Operating Instruction Manual
Appendix A – Disinfection Solutions
This	appendix	lists	approved	disinfectant	solutions	and	the	required	hold	times	necessary	to	
disinfect	the	Vapotherm	2000i	machine	using	the	routine	disinfection	procedure	outlined	in	the	
Vapotherm	2000i	Manual	Rev	B,	Section	8.	The	following	disinfectants	have	been	independently	
tested	by	an	ISO	compliant	FDA	registered	lab	using	“good	laboratory	practices”	(GLP):		
Manufacturer Active Ingredients Trade Name Concentration Hold Time*
Minntech Corporation 
14605	28th	Avenue	North 
Minneapolis,	MN	55447 
(800)	328-3345
Hydrogen 
Peroxide	22% 
and	Peracetic 
Acid	4.5%
Minncare™ 1% 10	minutes 
at	20˚C
Maril	Products	Inc. 
320	West	6th	Street 
Tustin,	CA	92780 
(800)	546-7711
Dimethyl	Benzyl	
Ammonium	Chloride	10% 
and	Dimethyl	Ethyl	Benzyl	
Ammonium	10%
Control 3™ 1% 10	minutes 
at	20˚C
*Section	8	Step	4	of	the	Vapotherm	2000i	Operating	Manual	requires	approved	disinfection	
solutions	to	be	circulated	through	the	device	for	an	appropriate	hold	time	as	outlined	in	this	
column	of	Disinfection	Appendix	A.
WARNINGS:  
These disinfectant solutions are designed to be used to disinfect the Vapotherm 2000i 
machine without the cartridge in place. These disinfectant solutions ARE NOT approved to 
disinfect the cartridge.
Failure to properly prepare the disinfection solution or circulate the disinfection solution 
throughout the machine for the appropriate hold time could result in inadequate disinfection.
Disinfectants must be used at proper concentrations. User must confirm solution has been 
mixed according to disinfectant manufacturers instructions, or used in pre-diluted form.
Solutions must not be used past their expiration dates See disinfectant manufacturer’s 
product labeling for instructions.
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Appendix B – Sample Disinfection Log
Vapotherm 2000i  Hospital ID Disinfection Disinfectant 
Operator
 
Machine Serial No. (If Applicable) Date Solution & 
   Hold Time
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Appendix A – Disinfection Solutions (cont.) 
Dilution Instructions for preparing a 1% solution of Minncare® and Control III™
Supplies Needed:
•	 A	beaker,	graduated	cylinder,	or	container	suitable	for	measuring	and	mixing	200ml	of	
disinfectant solution
WARNING: Components or instruments that are not part of the DK-301 Kit and are used to mix 
or pour disinfectant solutions should be either single use components or glassware that has been 
sterilized, high level disinfected, or pasteurized before use in accordance with your institution’s 
specific disinfection and sterilization procedures. 
•	 10ml	syringe,	or	pipette,	graduated	in	1ml	increments
•	 Concentrate	Disinfectant
•	 Minncare®	Cold	Sterilant	EPA	Reg	No.	52252-4	(22.00%	Hydrogen	Peroxide,	4.50%	
Peroxyacetic	Acid,	73.50%	Inert	Ingredients)
•	 Control III®	Disinfectant	P/N	10006	(10%	n-alkyl	dimethyl	benzyl	ammonium	chloride, 
10%	n-aykyl	ethyl	benzyl	ammonium	chloride,	80%	inert	ingredients)
•	 200 ml of sterile water
WARNINGS:  
Always follow manufactures recommendations for handling disinfectant solutions.
Always wear Personal Protective Equipment when handing disinfectant solution.
Procedure:
1.	 Don	appropriate	Personal	Protective	Equipment:	Safety	goggles,	gloves,	splash	apron.
2.	 Using	an	appropriate	syringe	or	pipette,	draw	up	2 ml of undiluted Minncare® 
(EPA	Reg	No.	52252-4)	or	Control	III®	(P/N	10006)	and	expel	it	in	a	device	appropriate	for	
measuring	200 ml	of	solution.
3.	 Make	up	200 ml	of	solution	by	adding	sterile	water	to	the	measuring	device.
4.	 Close	the	slide	clamp	on	Disinfection	Bag	A	and	pour	disinfectant	solution	into	the	bag.
5.	 Close	the	cap	of	Bag	A	firmly,	to	avoid	spills	and	continue	with	Step	6	in	Section	8.4	of	the	
disinfection	procedure	(Page	18).
6.	 Attach	to	IV	Pole	and	Vapotherm	2000i	according	to	Disinfection	procedure	and	continue	to	
follow	Disinfection	Protocol.
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This information is provided in response to requests from users to elaborate on the role of 
pressure in a high flow nasal cannula system. This educational paper provides summary 
material related to flow and pressure from the respiratory and neonatal literature.   
Material contained herein is not designed to provide clinical practice guidelines and is 
consistent with official instructions for use for Vapotherm, Inc. 
 
Indications for Use for Vapotherm® High Flow Devices: 
 
Vapotherm, Inc. manufactures high flow humidification devices and patient circuits for 
use in respiratory support for neonatal, pediatric and adult patients. These products are 
not intended for use as continuous positive airway pressure (CPAP) devices, but rather as 
high flow systems to deliver conditioned breathing gases. Vapotherm recommends that 
users always maintain an open system, including applying a cannula that does not 
occlude more than 50% of the patient’s nares. 
 
Precision Flow™ 
 
The Precision Flow™ is intended to be used for adding warm moisture to breathing gases 
from an external source for administration to a neonate/infant, pediatric and adult patient 
in hospitals, sub-acute institutions, and home settings. It adds heat and moisture to a 
blended medical air/oxygen mixture and assures the integrity of the precise air/oxygen 
mixture via an integral oxygen analyzer. The flow rates may be from 1 to 40 liters per 
minute via nasal cannula. 
 
Vapotherm 2000i® 
 
The Vapotherm 2000i is designed to add moisture to and to warm breathing gases for 
administration to patients, including neonates/infants, pediatrics, and adults. The flow 
rates may be from 1 to 40 liters per minute via nasal cannula. Environments for use 
include home, hospital, and sub-acute institutions. 
 
 
BACKGROUND ON MECHANISMS OF ACTION IN HIGH FLOW THERAPY 
 
Recent developments in gas conditioning technology introduced by Vapotherm have 
facilitated the expansion in the use of a nasal cannula. No longer restricted to 
conventional flow limitations (≤ 6 L/min in adults; ≤ 2 L/min in infants), nasal cannulae 
are now being used for High Flow Therapy (HFT™). HFT™ refers to the use of nasal 
cannula gas flows that exceed patient inspiratory flow rates such as to: 1) insure that the 
patient will inspire the intended gas composition without entrainment of room air, and 2) 
provide for other physiologic impacts including purging of end-expiratory gas from the 
nasopharynx during expiration and development of mild distending pressure.  
 
In a recent paper by Dysart and colleagues, five potential underlying mechanisms of 
action for HFT™ are identified1: 
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1) Washout of the nasopharyngeal dead space 
2) Reduction in inspiratory resistance associated with gas flow through the 
nasopharynx 
3) Improvement in respiratory mechanical parameters associated with gas 
temperature and state of humidification 
4) Reduction in metabolic work associated with gas conditioning 
5) Provision of mild distending pressure 
 
This paper discusses topics related to the fifth identified mechanism, distending pressure, 
with respect to nasopharyngeal pressure development and including expected pressure 
ranges and safety. Specifically, the scope of this paper will define the relationship 
between pressure in the patient circuit and the nasopharynx, and identify the factors that 
contribute to inadvertent pressure development.   
 
 
KEY DEFINITIONS 
 
High Flow Therapy (HFT™):  Respiratory gas therapy where the flow from the 
external gas source exceeds a patient’s inspiratory 
flow rates, eliminating entrainment of room air 
during inspiration. 
Patient Circuit:    Tubing connecting the gas source to the cannula. 
Nasopharynx:    The body cavity being purged during HFT™. 
Pressure:  The distending force created when a gas stream 
comes in contact with resistance. 
Flow:  The stream or current of respiratory gas through the 
device and respiratory systems, typically quantified 
in liters per minute (L/min). 
Resistance:  A force that tends to oppose flow, resulting in back 
pressure. 
Resistor:  A specific point or region in the flow path that has 
been identified as having relatively high resistance, 
resulting in significant backpressure (i.e. a 
bottleneck).  
 
 
FLOW AND PRESSURE FUNDAMENTALS 
 
HFTTM is intended to be an open system, with flow delivered to a patient via nasal 
cannula, where the cannula prongs do not occlude the nares and where the patient’s 
mouth is not held closed. In this open system, the pressure in each compartment is a 
function of the resistor(s) that lie in series downstream from that compartment. In this 
regard, circuit pressures will always be substantially greater than pressure in the 
nasopharynx*. To explain why circuit pressures will always be substantially greater than 
nasopharyngeal pressure, consider Figure 1. 
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(*NOTE: the exception to this rule would be in the event of a complete or nearly 
complete blockage of flow exiting the patient’s nasal and oral orifices. The Vapotherm® 
Precision Flow™ is designed with the ability to recognize an occlusion and alarm, and 
halt flow until the occlusion has been resolved.)  
  
 
FIGURE 1.  SCHEMATIC OF A HIGH FLOW THERAPY CIRCUIT / PATIENT 
INTERFACE 
 
 
 
R = resistive element; P = pressure compartment impacted by downstream resistance 
 
Figure 1 demonstrates that there are two principle resistors and thus two pressure 
compartments in the circuit / patient interface.  Resistor #1 (R1) represents the nasal 
cannula and therefore pressure compartment #1 (P1) represents the patient circuit.  
Resistor #2 (R2) represents the components resistive to gas exhausting from the patient’s 
nose (around the cannula) and mouth and therefore pressure compartment #2 (P2) 
represents pressure generated in the nasopharynx. For each pressure compartment, the 
established pressure is a result of the total downstream resistance (RT; Equation 1); 
therefore, P1 is always a function of both R1 and R2, while P2 is only ever a function of 
R2. Furthermore, because under normal conditions R1 is dramatically greater than R2, we 
can expect P1 to be much greater than P2.  
 
 
EQUATION 1: DEFINITION OF TOTAL RESISTANCE FOR SERIES RESISTORS 
 
RT = R1 + R2 
Where RT is total resistance and R1 and R2 are individual resistors in series 
 
 
PRESSURE IN THE DEVICE CIRCUIT 
 
The aforementioned principles translate to practical application of HFT™ therapy in the 
following manner. Because a nasal cannula offers such a high resistance to flow, any 
device intended to drive high flow rates through a cannula (defined in respiratory care 
terms as > 6 L/min) must be designed to contain and function under these normally high 
operating patient circuit pressures. Any attempt to relieve circuit pressures via a pressure 
relief valve to protect device components, would naturally result in a reduction of actual 
flow through the cannula thus lessening the intended flow (see Figure 2)2. However, the 
Open to  
Atmosphere 
R1 R2 
P1 P2 
Flow (F) 
Source 
Document#: 3010425 Rev New 
high circuit pressures do not translate to the patient because they are a function of the 
cannula resistance which is upstream to the nasopharynx. 
 
 
FIGURE 2.  IMPACT OF A PRESSURE RELIEF VALVE IN A HFT™ SYSTEM 
 
This figure is reproduced from data presented in Lampland et al2 using a Fisher and 
Paykel® system with and without a pressure relief valve (PRV) set to 45 cmH2O.With the 
pressure relief valve in place, the system does not permit more than 2 L/min to pass 
through the cannula regardless of the flow entering the humidifier. 
 
 
PRESSURE IN THE NASOPHARYNX 
 
Nasopharyngeal pressure (positive airway pressure) is determined by three principle 
factors3:  
1) the flow setting,  
2) the patient’s unique anatomical dimensions, and  
3) the leak out of the nose around the prongs and out of the mouth.   
  
In HFT™, the basic flow setting is meant fundamentally to exceed normal inspiratory 
flow rates so as to eliminate entrainment of room air. Inspiratory flow rates can be easily 
calculated for a patient based on actual or predicted values (Equation 2). For example, if 
an adult patient exhibits textbook values for respiration (tidal volume = 500ml, breathing 
frequency = 12 br/min, inspiratory time fraction is 0.3), then inspiratory flow rate is 
approximately 20 L/min. In this case, a HFTTM flow setting of 25 L/min would ensure 
meeting the definition of HFTTM. At these relatively moderate flow rates only moderate 
nasopharyngeal pressure can be expected, and flow rates can be titrated upward to 
enhance nasopharyngeal washout effects without generating substantial increases in 
pharyngeal pressure. However, Vapotherm emphasizes that during HFT™ pressure is not 
the principle mechanism of action and caregivers should not utilize excessive flows in an 
attempt to generate substantial distending pressures. 
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EQUATION 2: CALCULATION OF HFTTM FLOW RATES FOR PATIENT 
PREDICTED VALUES 
 
VI = (VT x f) / Fti 
Where VI is inspiratory flow in L/min, VT is tidal volume in L, f is breathing frequency in 
breaths/min and Fti is fraction of inspiratory time (typically 0.3) 
  
Anatomical size of the patient at the nares and internally are factors in determining 
distending pressure3, 4 because anatomy largely defines the resistance to flow passing 
through and out of the nasopharynx. However, if flow ranges are determined based on 
predicted normal inspiratory flow rates, then anatomical features are accounted for as 
these computations account for a patient’s size. The relationship between anatomy and 
flow resistance is more clinically relevant with infants as opposed to adults, where in 
some cases just two or three liters per minute of flow may constitute HFT™. 
 
The most critical factor in determining nasopharyngeal pressure development when 
initiating HFT™ is the relationship between internal diameter of the nares and the size of 
the nasal cannula used3, 5, 6. Going back to the original report of pressure development 
with a nasal cannula, esophageal pressure was not recordable when a very small cannula 
was used, but mild pressure was produced when a larger cannula, relative to the patient 
size, was used at the same flow rate5. In a bench model, Kahn and colleagues demonstrate 
that nasopharyngeal pressure development is predominantly a function of the leak around 
the prongs3, thus making the selection of which nasal prong size to use an important part 
of applying the therapy. 
 
Vapotherm recommends selecting nasal prongs that have an outside diameter no more 
than 50% of the inside diameter of the patient’s nares. With this fitting mild distending 
pressure will develop, which will support the other mechanisms of action; however, there 
is still adequate room for leak around the prongs. The leak is necessary to allow for a 
reasonable amount of flush in the nasal cavity to accomplish the actions of dead space 
washout.   
 
 
EXPECTED NASOPHARYNGEAL PRESSURE RANGES  
 
In the adult patient population, caregivers have not often raised concerns about pressure 
development. This is presumed to be because the large anatomical size in the adult is not 
considered conducive to excessive pressure development relative to the airway pressures 
provided by pressure support therapies. However, Bamford and colleagues presented in 
abstract form a study demonstrating oropharyngeal pressures in adults7. These data are 
presented in Figure 3. 
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FIGURE 3:  OROPHARYNGEAL PRESSURES IN ADULTS DURING HFTTM 
 
Reproduced from Bamford et al 20047; Data are means ± SEM for minimum, peak and 
mean oropharyngeal pressures. 
            
In the neonatal community, a significant body of literature has been amassed to describe 
the resultant airway pressures during the application of HFT™. Table 1 reports the 
findings from these studies, which are consistent in agreement that maximum pressures 
are typically not different from a CPAP setting of 6 cmH2O. Note that in a number of 
these studies, the protocols called for a closed mouth and occluded nares in an effort to 
establish greater pressures.   
 
 
CONCLUSION  
 
Pressure in the patient circuit is necessary to drive high flows though a nasal cannula, but 
this circuit pressure is isolated from the patient’s nasopharynx. In individual patients, 
nasopharyngeal pressure during HFT™ is dependent on factors which include flow rate, 
patient’s size and the relationship between cannula prong size and the internal diameter 
of the nares. However, pressure generation has been evaluated in a number of recent 
papers and shown to be moderate.
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TABLE 1. NEONATAL AIRWAY PRESSURE STUDIES USING HIGH FLOW NASAL CANNULA  
Study Journal Year # of 
Infants 
Wt 
Range 
(gm) 
Flow 
Range 
(L/min) 
Conclusions of Airway Pressure Relevant 
Circumstances 
 
Saslow8 
 
J Perinatol 2006 18 580 – 1990 3 - 5 Not more that CPAP of 6 cmH2O 
Esophageal 
manometry referenced 
to CPAP 6 cmH2O 
 
Pyon9 
 
PAS 
(abstract) 2008 8 < 2000 6 - 8 Not more than CPAP of 6 cmH2O 
Esophageal 
manometry referenced 
to CPAP 6 cmH2O 
 
Spence10 
 
J Perinatol 2007 14  Up to 5 Intrapharyngeal pressure was 4.8 ± 0.5 cmH2O at 5 L/min 
Mouth closed and 
nasal catheter 
 
Wilkinson4 
 
J Perinatol 2008 18 534 - 1868 2 - 8 
Mean pharyngeal pressure of  
5.3 cmH2O at 5 L/min 
Nasal catheter 
 
Kubicka11 
 
Pediatrics 2008 27 200 - 3500 1 - 5 
Highest oral cavity pressure recorded 
was 4.8 cmH2O 
Mouth closed with 
snug prongs 
  
Lampland2 
 
J Pediatr 2009 15 1324 ± 424 1 - 6 Similar to CPAP of 6 cmH2O 
Esophageal 
manometry referenced 
to CPAP 6 cmH2O 
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Introduction
The WhisperFlow CPAP System delivers continuous positive airway pressure 
(CPAP) throughout the breathing cycle. It provides CPAP at preset levels 
throughout inspiration and exhalation, independent of the patient's flow rate. The 
WhisperFlow System is intended for use on spontaneously breathing patients.
The variable generator WhisperFlow System allows you to vary fractional inspired 
oxygen (FIO2) from 28% to 100%. The fixed generator WhisperFlow System 
delivers FIO2 from 28% to 33%, depending on the flow and PEEP valve used.
Figure 1. WhisperFlow CPAP System: variable and fixed generators
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The WhisperFlow System may be contraindicated for patients with any of these 
conditions: 
• Fluid retention
• Pneumothorax
• Decreased cardiac output and gastric distention 
• Severe facial injury (noninvasive use)
• Hypotension secondary to hypovolemia.
How it works
The WhisperFlow CPAP System is a precision venturi device that uses an oxygen 
supply in conjunction with entrained air to generate an output flow. The 
WhisperFlow System uses a 60 psi (412 kPa) oxygen supply, and can generate 
flows over 150 L/min. down to 28% fractional inspired oxygen (FIO2). The 
WhisperFlow CPAP valves, which are placed within the circuit, are used to 
maintain preset positive pressure at flow rates from 10 to 150 L/min. 
Setting up the WhisperFlow System
WARNING: Do not use the WhisperFlow System without an oxygen analyzer to 
alert you to a loss of oxygen wall pressure or other system faults.
WARNING: Always ensure that the PEEP valve is correctly connected to the 
patient circuit, and that the exhaust port of the PEEP valve is not attached to 
the circuit.
WARNING: The ON/OFF knob controls a continuous valve. Be sure to turn the 
knob FULLY counterclockwise, one half turn, for the fully ON position.
WARNING: Place a pressure gauge or pressure monitor in-line, between the 
generator outlet and the patient interface by use of an in-line tee. Alternatively, 
pressure can be monitored by attaching pressure monitoring tubing to the 
mask port.
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CAUTION: To avoid damage to the WhisperFlow System by entraining particles 
into the device, always install a filter on the fresh gas intake port.
CAUTION: The WhisperFlow System, as with similar systems from other manu-
facturers, does not include a non-rebreathing valve for use with tracheal tubes. 
If the oxygen supply fails while the patient’s tracheal tube is connected to the 
system, the patient will rebreathe the gas in the supply tubing and may be 
asphyxiated.
1. Select a sealing face mask or endotracheal (ET) tube as the patient 
connection. Ensure that the mask fits comfortably, seals the bridge of the 
nose, and fully covers the nose and mouth. 
2. Choose the PEEP valve. (See the parts list for a complete list of available PEEP 
valve sizes and part numbers.)
3. Assemble the circuit according to Figures 2 through 6, depending on the 
mask, oxygen analyzer, pressure gauge or monitor, and humidifier you are 
using. As you assemble the circuit, please note:
• Use a pressure relief valve to protect the patient's lungs from trauma in the 
event that the PEEP valve becomes occluded. Select a PEEP valve at least 
5 cmH2O higher than the expiratory PEEP valve.
• To ensure accurate measurement of the FIO2 delivered to the patient, use 
an inline oxygen analyzer upstream of the patient connection and 
humidification device (if used).
• To assist in detecting adequate flow from the generator, place a pressure 
gauge, 0-30cmH2O, or pressure monitor, in-line between the generator 
outlet and the patient interface, or attach a pressure monitor line to the 
patient mask. Should the registered pressure decrease significantly during 
patient inhalation, then the flow to the patient needs to be increased.
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• The WhisperFlow System can deliver a minimum FIO2 of 28-29% to the 
patient. However, the longer the tube lengths used, the higher the 
minimum FIO2. (Longer tubing increases the resistance of the patient 
circuit, allowing the generator to entrain less air.)
• The WhisperFlow System's location upstream of the patient and the high 
flows it produces make contamination and resulting cross-infection highly 
unlikely. However, if cross contamination is a concern, attach a 22-mm 
OD/ID filter to the output port of the generator.
WhisperFlow® CPAP System User’s Manual
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Figure 2. Dual-port mask, oxygen probe with integrated tee piece
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Figure 3. Dual-port mask, 15-mm oxygen probe 
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Figure 4. ET tube connection, 15-mm oxygen probe 
CAUTION: The WhisperFlow System, as with similar systems from other manu-
facturers, does not include a non-rebreathing valve for use with tracheal tubes. 
If the oxygen supply fails while the patient’s tracheal tube is connected to the 
system, the patient will rebreathe the gas in the supply tubing and may be 
asphyxiated.
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Figure 5. ET tube connection, oxygen probe with integrated tee piece 
CAUTION: The WhisperFlow System, as with similar systems from other manu-
facturers, does not include a non-rebreathing valve for use with tracheal tubes. 
If the oxygen supply fails while the patient’s tracheal tube is connected to the 
system, the patient will rebreathe the gas in the supply tubing and may be 
asphyxiated.
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Notes to Figures 2 through 5
The notes below apply to Figures 2 through 5 above:
• Figures 2 through 5 show how to assemble the WhisperFlow system and 
WhisperFlow accessories. The WhisperFlow unit should only be used with 
the accessories supplied by the manufacturer, Respironics, or its 
authorized agent. In particular, the face mask has an integral one-way 
valve, which prevents exhalation into the delivery tubing in the event of no 
fresh gas flow. When used with a tee-piece however, exhalation into the 
delivery tubing will result in CO2 rebreathing, and may result in asphyxia.
• If the fresh gas flow fails, the one-way valve will minimize the risk of 
asphyxia when there is no oxygen pressure. However, if there is no fresh 
gas flow, the patient will have to inhale at ambient pressure, though will 
still continue to exhale at the PEEP pressure (see Table 1); this will result 
in an increased work of breathing and may not be well tolerated by some 
patients. Therefore, when there is no oxygen flow from the WhisperFlow 
System, the mask should not be worn, and nor should the device be 
connected to a tracheal tube.
• External monitoring should be used to ensure that the WhisperFlow 
generator setting is suitable for the patient. An in-line pressure gauge or 
pressure monitor will show a constant pressure approximately the same as 
the PEEP valve specification. If the delivered flow is too low, the pressure 
exhibited will indicate a significant drop when the patient inhales. This 
inadequate flow can be corrected by increasing the flow from the 
WhisperFlow generator.
• The oxygen monitor with alarms is used in setting and monitoring the FIO2 
delivered by the unit. It may alert the user to the loss of oxygen flow if the 
patient continues to draw fresh gas without oxygen through the air inlet of 
the WhisperFlow generator.
• The safety PEEP valve is placed in the circuit line in the event that the 
PEEP valve attached to the face mask or endotracheal tube becomes 
occluded. Thus any excess circuit pressure above the prescribed PEEP 
pressure will be relieved.
WhisperFlow® CPAP System User’s Manual
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Figure 6. Installing a humidifier
Operating the WhisperFlow System
1. Turn all control valves off by turning fully clockwise (finger-tight only). 
2. Connect the oxygen supply, then listen for leaks: 
• Variable generator: Connect directly to the oxygen supply or connect an 
oxygen hose between the WhisperFlow System oxygen fitting and the 
oxygen supply.
• Fixed generator: Connect directly to flowmeter capable of delivering at 
least 13 L/min. at 60 psi (412 kPa). 
WARNING: Do not connect any gas supply other than oxygen to the Whisper-
Flow System.
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NOTE: The WhisperFlow should not be connected directly to oxygen tanks with 
pressures over 230 bar (3336 PSI).  Frost may form on the regulator and the 
device when FIO2 settings are higher than 30%.
3. Turn the ON/OFF valve fully on (one-half turn). Turn the flow adjustment valve 
fully on and check that the output flow from the patient outlet varies 
accordingly.
WARNING: The ON/OFF knob controls a continuous valve. Be sure to turn the 
knob fully counterclockwise, one half-turn, for the full ON position
4. For higher concentrations (variable generator only), turn the oxygen adjustment 
valve counter-clockwise until the oxygen analyzer displays the appropriate FIO2 
for 30 seconds. 
5. Leave the oxygen and flow controls as you have just set them, then turn the 
ON/OFF valve fully off (clockwise). Attach the circuit to the patient, and then 
turn the ON/OFF valve fully on (counter-clockwise).
6. Watch the PEEP valve to ensure that it remains open during inspiration. 
Gradually reduce the circuit flow by turning the flow adjustment valve down to 
point when you can still feel a slight flow at the CPAP valve when the patient 
inspires. Monitor the FIO2 as you reduce the circuit flow: as the circuit flow 
decreases, the FIO2 rises slightly. You can reduce the FIO2 by closing the 
oxygen adjustment valve.
7. Monitor the in-line pressure gauge or monitor. If the pressure drops 
significantly then the flow is inadequate.
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Monitoring the patient
During operation, be sure to check the following on regular basis:
• Ensure that there are no leaks at the patient connection.
• Ensure that there is flow from the PEEP valve during inspiration (which means 
that the generator is supplying adequate flow to meet patient demand).
• Monitor the in-line pressure gauge or monitor during inspiration. If the 
pressure drops significantly, then the flow is inadequate.
• Monitor the patient's arterial blood oxygen saturation (SaO2).
• Monitor the patient for signs of dehydration and discomfort in the upper 
airways.
• Monitor the patient’s delivered FIO2.
Maintenance
Under normal conditions, the WhisperFlow System does not require any special 
maintenance or sterilization. However, the WhisperFlow System generator can be 
gas-sterilized using ethylene oxide (EtO). Following sterilization, open all the valves 
fully, connect to an oxygen supply for five minutes, and verify performance before 
reuse.
CAUTION: Do not autoclave or immerse the WhisperFlow System or any of its 
components in any solution. The circuit, including the inlet filter, is for single 
patient use.
Follow these steps to test the WhisperFlow System's minimum FIO2 annually:
1. Variable generator only: set the flow adjustment to its maximum, and the 
oxygen adjustment valve to its minimum.
2. Attach a 10-cmH2O PEEP valve to the generator using a patient circuit.
3. Ensure that the FIO2 at a circuit pressure of 10 cmH2O does not exceed 30%.
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Environmental specifications
Temperature
• Operating: 5 to 45 °C at 15 to 95% relative humidity
• Storage: -40 to 60 °C at 95% relative humidity
Oxygen supply
• 40 to 80 psi (275 to 550 kPa)
• For flow requirements see Figure 10.
NOTE: The WhisperFlow should not be connected directly to oxygen tanks with 
pressures over 230 bar (3336 PSI).  Frost may form on the regulator and the 
device when FIO2 settings are higher than 30%.
Figure 7. Maximum flow and minimum oxygen versus pressure
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Figure 8. Minimum oxygen achievable at different flow settings for different PEEP values
Figure 9. Circuit pressure loss per meter of tubing
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Figure 10. Oxygen supply consumption at several flow and oxygen settings
Table 1: Pressure required to breathe through a system comprising a face mask, 
1.8m tubing, and a CPAP generator in the instance where oxygen supply is lost.
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Accessories
The following accessories are compatible with the WhisperFlow CPAP System:
• Mounting pole: Any pole with a clamp range of 10 to 40 mm.
• Humidifier: Fisher and Paykel MR730 and MR480. The MR410 
Humidifier can also be used when inspiratory flow rates are set to less than 
50 L/min.
• Oxygen monitor: You can use any in-line oxygen monitor with the 
WhisperFlow System. Some WhisperFlow procedure packs include a 
connector for attaching the oxygen monitors using a silicone tee or 15-mm 
probe.
Please contact your local dealer before using other accessories with the 
WhisperFlow System.
Customer Service and Product Support
Full service and repair is available from the manufacturer.
USA and Canada
Phone 1-800-345-6443 or 724-387-4000
Customer Service Fax 1-800-886-0245
Product Support Fax 1-724-387-5236
International Customer Service Phone 724-387-4000
International Customer Support Fax 724-387-5012
Europe/Africa/Middle East +33-1-47-52-30-00
Asia Pacific +852-3194-2280
service@respironics.com
clinical@respironics.com
www.respironics.com
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Manufacturer 
Approvals
The WhisperFlow System complies with the requirements of directive 
93/42/EEC concerning medical devices and therefore bears the CE mark.
Authorized Representative:
Respironics Deutschland
Gewerbestrasse 17
82211 Herrsching
Deutschland
Telephone: +49 8-152930640
Year of manufacture
The fifth and sixth digits of the serial number indicate the WhisperFlow System's 
year of manufacture.
Respironics Novametrix, LLC.
5 Technology Drive
Wallingford, CT 06492
USA
USA 800-345-6443 or 724-387-4000
Europe/Africa/Middle East +33-1-47-52-30-00
Asia Pacific +852-3194-2280
www.respironics.com
service@respironics.com
clinical@respironics.com
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Parts list
Description Part number
WhisperFlow CPAP System, variable generator (where x 
indicates the gas fitting, hose, and country). Contact 
your local dealer for further details.
8-20860x-00
WhisperFlow CPAP System, fixed generator 8-208530-00
CPAP valve, 2.5 cmH2O 8-208503-00
CPAP valve, 5 cmH2O 8-208505-00
CPAP valve, 7.5 cmH2O 8-208507-00
CPAP valve, 10 cmH2O 8-208510-00
CPAP valve, 12.5 cmH2O 8-208512-00
CPAP valve, 15 cmH2O 8-208515-00
CPAP valve, 20 cmH2O 8-208520-00
Filter, 22 mm 8-208570-00
Tee piece, safety valve, 22M/22F/22F ports 8-202502-00
Tee piece, oxygen analyzer, 22M/22M/(22M/15F) ports 8-202503-00
Connector, 22M/22F with Pressure Port 8-100327-00
Connector, 22F/22F ports 8-201009-00
Connector, 22M/22M ports 8-201007-00
Mask, dual-port, large 8-209000-00
Mask, dual-port, medium 8-209001-00
Mask, dual-port, small 8-209002-00
Head strap, four-point, latex 8-209102-00
Head strap, four-point, nonlatex 8-209103-00
WhisperFlow Mounting Kit 8-100068-00
Several CPAP procedure packs are available: please contact your local 
dealer for further details.
Notes:
WhisperFlow® CPAP System User’s Manual
8-100335-00 Rev E
ACCU-PEEP™
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COMPLETE RANGE OF THRESHOLD RESISTORSA
Vital Signs, Inc. introduces the ACCU-
PEEP™ threshold resistor. For use in
conjunction with CPAP Systems and
anesthesia/ventilation, the ACCU-PEEP™
has two main features:
Provides consistent levels of PEEP
irrespective of flow1
The unique design of the Vital Signs® valve
results in minimal deviation in expiratory
pressures at all flows. In both CPAP and
anesthesia/ventilation applications, the
clinician can be assured that the resistance
levels will be maintained regardless of flow.
The design of the valve makes it particularly
well suited for the high flows associated
with CPAP.
Allows for exhalation if valve is
incorrectly positioned and provides
entrainment if flow is insufficient in
a CPAP application.
This unique feature of the Vital Signs® PEEP
valve reduces the risks associated with flows
delivered below the patient’s peak
inspiratory demand.
The standard connections of the valve allows
for its use in anesthesia and other respiratory
applications.
ORDERING INFORMATION
CODE DESCRIPTION PER CASE
9003B ACCU-PEEP™ Valve 2.5 cm H2O 10
9005B ACCU-PEEP™ Valve 5.0 cm H2O 10
9007B ACCU-PEEP™ Valve 7.5 cm H2O 10
9010B ACCU-PEEP™ Valve 10.0 cm H2O 10
9012B ACCU-PEEP™ Valve 12.5 cm H2O 10
9015B ACCU-PEEP™ Valve 15.0 cm H2O 10
9022B ACCU-PEEP™ Valve 20.0 cm H2O 10
9005A PEEP Valve Adapter 10
vital
ACCU-PEEP™
Caution: Federal law restricts this device to sale by or on the order of a physician
   B721-083099   © 1999 Vital Signs, Inc.     All Rights Reserved
1 Banner MJ, Lampotang S, Boysen PG, et al. Flow resistance of
expiratory positive pressure valve systems. Chest, 1986; 90:212
The ACCU-PEEP™ valve is available in
pressure ratings to suit a wide range of
clinical applications and is an integral part of
the Vital Signs®  CPAP system.
Shorten the Time 
from Assessment to Action
Vigileo Monitor
The Vigileo monitor allows for the continuous 
monitoring of essential hemodynamic information, 
providing rapid insight on a minimally invasive, 
easy-to-use platform. The Vigileo monitor works 
with the FloTrac sensor to measure and display 
key fl ow parameters and the PreSep catheter to 
provide central venous oxygen saturation (ScvO2).
Act Early
• Provides immediate hemodynamic insight that 
may be missed using traditional vital signs alone
• The FloTrac sensor quickly connects to an 
existing arterial line
• The PreSep catheter provides real-time insight 
into tissue perfusion
Easy to Use and Less Invasive
• Simply requires patient age, gender, height and 
weight to initiate CCO monitoring
• Provides the same utility as continuous SvO2 
monitoring from a Swan-Ganz catheter but 
on a central line
• Requires no additional catheters, boluses 
or chemical indicators
Parameters
**Available when used with appropriate Edwards oximetry catheters.
Edwards Lifesciences LLC · One Edwards Way · Irvine, CA 92614 USA · 949.250.2500 · 800.424.3278 · www.edwards.com
Edwards Lifesciences (Canada) Inc. · 1290 Central Pkwy West, Suite 300 · Mississauga, Ontario · Canada L5C 4R3 · 905.566.4220 · 800.268.3993
Edwards Lifesciences Europe S.A. · Ch. du Glapin 6 · 1162 Saint-Prex · Switzerland · 41.21.823.4300
Edwards Lifesciences Japan · 2-8 Rokubancho · Chiyoda-ku, Tokyo 102-0085 · Japan · 81.3.5213.5700 · www.edwards.com/Japan
A Single Monitor Solution for Fluid Optimization and Tissue Oxygenation
Rx only. See instructions for use for full prescribing information.
Edwards Lifesciences devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.
Edwards and Vigileo are trademarks of Edwards Lifesciences Corporation. Edwards Lifesciences, the stylized E logo, FloTrac, PreSep and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are 
registered in the US Patent and Trademark Office.
© 2007 Edwards Lifesciences LLC.
All rights reserved. AR02484
Vigileo Monitor 
Product Specifications
Power/Electrical
• AC Mains: 100-240 VAC, 50/60 Hz, 1A maximum consumption
Color Display
• 5.2 in. (132.5 mm) x 3.9 in. (99.4 mm) TFT
• 640 x 480 pixels
Measuring Time
• CCO: display updated every 20 seconds or 5 minutes
• ScvO2/SvO2: display updated every 2 seconds
Startup Time
• Initial display in 60 seconds
Trend Range
• 0.1-72 hours
Display Capacity
• 2 trend lines, 2 numerical displays
Size
• Height: 7.3 in. (185.4 mm)
• Width: 10.7 in. (271.8 mm)
• Depth: 8.4 in. (213.4 mm)
Weight
• 6.0 lbs. (2.76 Kg)
• IV pole mount capability
Bi-directional Patient Monitor Communications
Analog Input/Output (Selectable Voltage)
• Input: 0 to 1 V, 0 to 5 V, 0 to 10 V
• Output: 0 to 1 V, 0 to 10 V
Digital I/O, Serial Communication Interface (RS232)
• Maximum data rate = 57.6 kilo baud
CVP Slave Compatible for Continuous SVR
• Pressure slave cables available for select physiologic 
   bedside monitors
Printer Communications
• USB Port: V1.1-compatible type A connector
Label Parameter Range/Units
CO Arterial Pressure Cardiac Output 1.0 – 20.0 L/min
CI Cardiac Index 1.0 – 20.0 L/min/m2
ScvO2** Central Venous Oxygen Saturation 0 – 99%
SvO2** Mixed Venous Oxygen Saturation 0 – 99%
DO2 Oxygen Delivery Derived Value mL/min
DO2I Oxygen Delivery Index Derived Value mL/min/m
2
SV Stroke Volume 0 – 300 mL/beat
SVI Stroke Volume Index 0 – 200 mL/beat/m2
SVV Stroke Volume Variation 0 – 99%
SVR Systemic Vascular Resistance 0 – 3,000 dynes-sec/cm5
(0 – 300.0 kPa-sec/l)
SVRI Systemic Vascular Resistance Index 0 – 6,000 dynes-sec-m2/cm5
(0 – 600.0 kPa-sec-m2/l)
Model No. Description 
MHM1 Vigileo monitor (110 V) 
MHM1E Vigileo monitor (220 V) 
MHD6 FloTrac sensor with 60” (152 cm) pressure line 
MHD6AZ FloTrac sensor with 60” (152 cm) pressure line and VAMP adult 
MHD8 FloTrac sensor with 84” (213 cm) pressure line 
MHAPLMNT Vigileo pole mount kit 
APCO9 FloTrac connecting cable 9’ (274 cm) 
For additional educational information visit: www.Edwards.com/FloTrac
L i D C O ™
CONTINUOUS, REAL-TIME
CARDIOVASCULAR MONITORING
The Cardiovascular
Monitoring Companywww.lidco.com
T H E P R I N C I P L E
2 LiDCO™plus CONTINUOUS, REAL-TIME CARDIOVASCULAR MONITORING
Introducing the LiDCOplus Hemodynamic Monitor
CON T I N UOU S , R E A L - T I M E MON I TO R I NG O F C A R D I A C OU T P U T
• LiDCO Ltd’s starting point for its products is with the
requirements of the clinician, nurse and hospital patient for
advanced minimally invasive cardiovascular monitoring.
• LiDCO Ltd’s products result from the consolidation of a
physiological knowledge base and leading physiological
software and sensor technology.
• LiDCO Ltd’s minimally invasive monitoring products
improve hospital standards of care, improve patient
outcome and reduce costs 88.
• LiDCO Ltd’s products provide medical staff with essential
hemodynamic information, not just data, in an ‘easy to
interpret’ manner.
I N T R O D U C I N G L i D C O LT D
Monitoring of the key cardiovascular parameters of blood pressure, cardiac output and oxygen delivery
is essential for many major surgical and acutely ill patients. In addition, there are many other patients
that could benefit from real-time cardiovascular monitoring if it were available in a safe and easy to
apply manner. This was the philosophy that resulted in the development, design and manufacture of the
unique LiDCOplus Hemodynamic Monitor.
The LiDCOplus system is a combination of the two innovative and novel monitors - the LiDCO System
indicator dilution cardiac output monitor and the PulseCO System real time, continuous arterial
waveform monitor, produced by LiDCO Ltd.
This unique combination provides beat-to-beat measurement of cardiac output with lower risk
and high precision 68.
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The LiDCOplus System combines the LiDCO & PulseCO Systems software and provides a real-time and
continuous assessment of a patient’s hemodynamic status.
The LiDCO™ System cardiac output method provides a bolus indicator dilution method of measuring cardiac output.
A small dose of lithium chloride is injected via a central or peripheral venous line; the resulting arterial lithium
concentration-time curve is recorded by withdrawing blood past a lithium sensor attached to the patient’s existing
arterial line. In terms of accuracy, clinical studies have demonstrated that over a wide range of cardiac outputs the
LiDCO method is at least as accurate as thermodilution and even in patients with varying cardiac outputs 7-12. In one
study LiDCO and thermodilution cardiac output were compared with an electromagnetic flow probe. The results of
this study indicated that LiDCO had a higher precision compared with conventional bolus thermodilution cardiac
output 12. The dose of lithium needed (0.15 - 0.3 mmol for an average adult) is very small and has no known
pharmacological effects 74.
The PulseCO™ System software (incorporated in the LiDCO™plus Monitor) calculates continuous beat-to-beat cardiac
output by analysis of the arterial blood pressure trace following calibration with an absolute LiDCO cardiac output
value. This method has been shown to be accurate and reliable in various clinical settings. It has also been shown
that recalibration is unnecessary for at least eight hours 2-6, 79, 80 and more recently for 24 hours94.
P U L S E CO S Y S T EM A U TOCO R R E L AT I ON A LGO R I T HM
The analogue arterial blood pressure trace is slaved from the conventional blood pressure monitor and undergoes a
three step transformation
• Step 1 Arterial pressure transformation
into a volume-time waveform
(incorporating arterial
tree compliance)
• Step 2 Deriving nominal
stroke volume and
heartbeat duration
• Step 3 Actual stroke volume via
calibration with an absolute
cardiac output value
L i D C O ™
Components of the LiDCOplus Monitor
The PulseCO software calculates continuous beat-to-beat cardiac output by analysis of the arterial blood
pressure trace following calibration with an absolute cardiac output value. This absolute cardiac output
value is accurately and precisely measured using the innovative LiDCO lithium chloride bolus indicator
dilution method.
The PulseCO software calculates the pulse power
and derived stroke volume from the arterial waveform.
This avoids the necessity for detection of any particular
waveform features such as the dichrotic notch.
Furthermore, arterial wave reflection does not have to be
estimated. Due to this innovative and patented method of
calculation, the PulseCO remains accurate and reliable
over a wide range of hemodynamic states in surgical,
post operative and intensive care settings 2. Studies have
demonstrated that re-calibration is unnecessary for at
least eight hours 2-6 and more recently 24 hours 94.
The LiDCOplus serves as a reliable alternative to
continuous cardiac output monitoring with the pulmonary
artery catheter and can easily be used intraoperatively,
in the ICU/HDU, trauma or burns unit, and cath lab.
LiDCOplus ’s accuracy is ensured with the proven
LiDCOplus lithium indicator dilution calibration procedure
that uses existing venous and arterial access, making it
fast, cost effective and minimally invasive.
The LiDCOplus calculates cardiac output continuously by
analysis of the arterial blood pressure trace following
calibration with the absolute LiDCO cardiac output value.
The concept of estimating cardiac output from the arterial
pressure waveform has been extensively researched with the
first researchers (Erlanger and Hooker) publishing in 1904 1.
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Intra-Thoracic Blood Volume (ITBV) - the innovation is the use of lithium chloride as the indicator. A small
dose of lithium chloride is injected via a central or peripheral venous line (Fig 1); the resulting arterial
lithium concentration-time curve is recorded by withdrawing blood past a lithium sensor attached to the
patient’s existing arterial line (Fig 2); the Monitor then calculates the cardiac output from the area of the
primary dilution curve (Fig 3). The mean transit time of the lithium is derived for calculation of the ITBV.
The signal to noise ratio and hence accuracy for lithium is better than that seen with thermodilution - due to the fact
that the lithium dose can be scaled to the size and cardiac output of the patient. Thermal noise from fluid infusion,
respiration and patient warming has little, if any, effect on the lithium curve. The precision of the LiDCO System method
means that only one lithium injection is required to accurately determine the cardiac output. In terms of accuracy,
clinical studies have demonstrated that the single bolus LiDCO System method is at least as accurate as triplicate
bolus thermodilution over a wide range of cardiac outputs and even in patients with varying cardiac outputs 7-12.
5
The l i th ium chlor ide indicator di lu t ion
method of measur ing cardiac output
and in t ra - thoracic blood volume ( ITBV)
Fig 2
Fig 1 Fig 3
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Arterial Pressure
The arterial pressure waveform is slaved from your conventional blood pressure monitor via an analogue
cable link. At the touch of a button the arterial pressure waveform is displayed on the LiDCOplus screen.
This can be viewed on the screen whenever the Trend, Graph and Chart screens are in use.
This Blood Pressure Waveform window is used to check the patient’s systolic, diastolic and mean pressure. The
pressure waveform shape and values should equate to those displayed on the primary blood pressure monitor.
This window also provides you with access to preload response values or volume status indicators of: Systolic
Pressure Variation (SPV), Pulse Pressure Variation (PPV%), Stroke Volume Variation (SVV%) as well as Heart Rate
Varation (HRV%).
SVV % = (SV max - SV min)/[(SV max + SV min)/2] x 100
Patient with SVV less than 10% are unlikely to be preload responsive.
DYNAM IC VOLUME STATUS IND ICATORS FOR VENT I LAT ED PAT I ENTS
Thoracic pressure changes caused by mechanical ventilation induces cyclic changes in Left Ventricular Stroke Volume. These
changes can provide an indication of the patient’s ventricular preload status (see figure of Frank-Starling curve)18, 20, 26, 66, 81-83.
By superimposing the Preload Response Parameters Window onto the Trend, Graph, or Chart screens, a continuous
measurement of Stroke Volume, Systolic Pressure and Pulse Pressure Variation is displayed numerically and graphically.
For closed chest ventilated patients these volume status measurements provide a way of predicting fluid volume
status and likely response to volume infusions. A fluid imbalance can have an adverse effect on a patient’s cardiac
performance and, in turn, oxygen delivery to key organs 13-35, 50, 56, 66, 67, 81.
D
CB
A
SV
PRELOAD
A + C = Volume e.g. 500ml
B = Patient is preload responsive
D = Patient not preload responsive
Frank-Starling Curve: Patient Preload Status
7Event Response
P R E - L O A D R E S PON S I V EN E S S V I A T H E E V EN T R E S PON S E D I S P L AY
The Event Response display allows the user to view up to 2 hemodynamic variables in a higher
resolution during a specific period (e.g. fluid challenge, inotrope change). The LiDCOplus will also
display percent change from start for each variable as a numeric value. Trend lines can also be added
to the graphical display.
This feature is very useful when evaluating the patient’s response to targeted interventions such as a fluid challenges
or changes in inotrope therapy. The advantage this screen brings is in averaging the data display to smooth any
noise and magnifying the display of changes so that they are easily viewed at a glance from a distance.
The Trend line is
switched on
Baseline value
Target Variable data:
Starting baseline
Current value and
% Change from
baseline
Press to Restart
Press to Stop
Press to Exit
Press to minimize
Elapsed time until a
new point is plotted
Press to capture screen image as JPG
Press the event button to reveal the submenu below.
Then press to open the Event Response Window.
Press to configure Event
Response
Press to
select
target
variable(s)
Press to
select
display
interval
A new data point is plotted
every 10, 20 or 30 seconds.
8Benefits to you and your patient
B EN E F I T S O F L I D CO p l u s CON T I N UOU S C A R D I A C OU T P U T
MON I TO R I NG I NC L U D E :
• Provides early warning of patient deterioration
• Optimisation of oxygen delivery
• Optimisation of fluid management
• Rational drug administration (e.g. Inotropes)
• The patient’s condition is clearly communicated to clinical staff
• Reduces the work of health care staff
• Decrease the procedural complications
• Is minimally invasive and therefore widely applicable
• Is accurate
• Can be nurse driven
• Provides real time, beat-to-beat cardiac output and oxygen delivery
• Provides real time preload and afterload values
• Provides indexed values
• Provides easy data interpretation
• Provides bedside information management
• Has easy to use event markers
• Provides information not simply data
• Can be linked to most commonly found BP monitors
• Records historical data
• Provides an absolute cardiac output value via a novel and proven indicator dilution technique
• Provides ITBV
• Requires no additional invasive catheters to insert into the patient
• Is safe – using non-toxic bolus dosages
• Is simple and quick to set up
• Can be used with a range of LiCl dosages
• Is as accurate as meaned triplicate thermodilution
• Is not temperature dependent
• Is less invasive monitoring
• Utilises existing peripheral or central venous and arterial lines
• Can be set up and used by nursing staff
• Is a well studied and validated technique
B EN E F I T S O F T H E L I D CO – L I T H I UM CH LO R I D E I N D I C ATO R
D I L U T I ON CA R D I A C OU T P U T M E T HOD :
L i D C O ™
The Trend Screen
A C L E A R CON T I N UOU S D I S P L AY
The Trend screen provides a continuous record of the patients hemodynamics. This large, clear and continuously
updating screen displays the actual and indexed values for Cardiac Output, Systemic Vascular Resistance, Mean
Arterial Pressure, Heart Rate and Left Ventricle Stoke Volume. Oxygen Delivery and Venous Oxygen Saturation can
also be displayed if selected. The clinician can accurately track the patients’ trend over several hours or minutes.
This screen facilitates intraoperative patient management allowing assessment of the immediate response to fluid
challenge, drugs or other therapeutic interventions.
E V EN T MA R K E R
Mark any number of events, such as initiation of inotropic agent or start of fluid infusion, using the event
marker button. There are several standard descriptions that can be selected and additional detail added.
The marked event will appear as a small flag on the Trend and History screens and will be recorded in the LiDCOplus data file
as the patient data is downloaded from the history screen. The event history window will allow selection of any events from the
past 24 hours and take the user to the area on the hemodynamic history screen where the event was marked.
Oxygen deliveryActual or Average data available
Heart Rate
Left Ventricle
Stroke Volume
Mean Arterial
Pressure
Systemic Vascular
Resistance
Cardiac Index
Cardiac Output
Venous Oxygen
Saturation
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L i D C O ™
The Chart Screen
PA R AM E T E R R E L AT I ON SH I P S AT A G L ANC E
Showing the relationship between pressure, flow and resistance in an integral bar chart display. This screen
simplifies the recognition and diagnosis of hemodynamic imbalance at the bedside. This means that potentially
complex hemodynamic data can be easily interpreted and the necessary corrective actions taken quickly.
OX YG EN D E L I V E R Y TA RG E T S AND S c vO 2 / S vO 2 D I S P L AY
Oxygen delivery optimisation has been demonstrated to be a key factor in the reduction in both length of stay and
complications for post surgical patients in the ICU88. Oxygen delivery targets can now be set in the patient limits.
These will be used on both the Graph and Chart screens to enhance the display of data. Venous Oxygen Saturation
can now be inputted to allow tracking as well as calculation of estimated oxygen consumption.
P r e s s u r e = F l o w x R e s i s t a n c e
Patients ideal status line
Indexed value
enables this easy
to interpret format
Patient optimal CO/CI or DO2/DO2I target, set by clinician
Patients optimal
MAP target, set
by the clinician
Oxygen
consumption
Venous oxygen
saturation
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The goal of monitoring cardiac output is to maximise the delivery of oxygen to the tissue
beds. The LiDCOplus monitor displays the parameter of oxygen delivery (and oxygen
delivery index) in real time. The ability to have these two parameters monitored
simultaneously on a real-time basis by the LiDCOplus can have a major impact on patient
care and outcomes. There is mounting evidence that monitoring oxygen delivery and cardiac
output in at-risk patients can significantly reduce mortality and length of hospital stay 50.
In a recent study utilizing the LiDCOplus it was shown that optimising oxygen delivery
index (DO2I) to a target of 600ml/min/m2 reduced morbidity by 50% and mean length
of stay per patient by 12.3 days88. Use of the LiDCOplus facilitates the perioperative
optimisation of patients.
H EMOD YNAM I C P R E - O P T I M I S AT I ON I N H I GH - R I S K PAT I E N T S
‘High risk’ surgery patients subjected to a reduction in global oxygen delivery are known to have increased
levels of morbidity and mortality. Increasing global oxygen delivery has been reported to result in a dramatic
improvement in outcome in these patients 36-67. For example in the USA there are over 30 million operations
performed annually, 10-15% of which (approximately 3 million operations) are deemed to be ‘high risk’. These
‘high risk’ patients have an increased risk of death. A recent review of 21 randomised controlled trials with
various approaches to treatment revealed statistically significant mortality reductions when patients with acute
critical illness were treated early to achieve optimal goals before the development of organ failure 58. There is
convincing evidence that measurement and manipulation of cardiac output, and therefore oxygen delivery, in
selected patients reduces the risk of mortality 59, 68, 69, 70.
MOR TA L I T Y O U T COM E S FO L L OW ING GOA L D I R E C T E D S T U D I E S :
Type of Surgery Study Author (Year) Mortality of Mortality of Goal Directed
Control Group (%) Treatment Group (%)
Vascular Shultz et al (1985) 44 29.0 2.9
General Shoemaker at al (1988) 45 33.0 4.0
Vascular Berlauk et al (1991) 46 9.5 1.5
Trauma Fleming et al (1992) 47 44.0 24.0
General & Vascular Boyd et al (1993) 67 22.2 5.7
Trauma Bishop et al (1995) 48 37.0 18.0
Hip Fracture Sinclair et al (1997) 51 10.0 5.0
Peripheral Vascular Ziegler et al (1997) 84 9.0 5.0
Elective General Wilson et al (1999) 50 17.0 3.0
Elective Cardiac Polonen et al (2000) 85 3.0 1.0
General & Vascular Lobo et al (2000) 86 50.0 15.7
L i D C O ™
The Graph Screen
K E E P I N G PA T I E N T C A R E O N TA R G E T
Allows easy assessment of the patients status at a glance and from a distance from the Monitor - useful in busy
ICU’s or high dependency units, as an early warning system to avoid adverse events. The graph screen is also
ideal for the implementation of goal directed protocols that target oxygen delivery. The graph screen is the ideal
“bedside” mode providing clear, easy-to-read feedback on changes to pressure, flow, and resistance. A patient
specific “target zone” for Cardiac Output or Oxygen Delivery, Mean Arterial Pressure and thereby Systemic
Vascular Resistance is defined specifically for each patient. The continuous display of the patient’s last 12
heartbeats provides a ready reference to how well the therapeutic/hemodynamic targets are being maintained.
The LiDCOplus Monitor provides point of care information, not just more patient data.
12 LiDCO™plus CONTINUOUS, REAL-TIME CARDIOVASCULAR MONITORING
Patients preferred
hemodynamic
status presented
as a window or
‘target zone’, set
by the clinician.
Patients current
Hemodynamic
status, presented
as a series of 12
colour coded
dots in real-time
updated for every
heart beat.
CON T I N UOU S , R E A L - T I M E MON I TO R I NG O F C A R D I A C OU T P U T
The History Screen
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KEEPING PATIENT RECORDS, FOR AUDIT, TEACHING, ANALYSIS AND RESEARCH
The History Screen can be used to look back over the last 24 hours of the patient’s hemodynamic data. The
display is similar to the display of the Trend Screen. Touch anywhere on the screen to see the parameter
readings, at that time, or track back through the hours of data as required.
This screen is designed to aid in data collection: for clinical studies or simply to have a complete record of the
patient’s treatment you can record the patient’s critical parameters at the touch of a button. The beat-to-beat patient
data, event markers and calibrations are recorded either as a file for LiDCOview or as an Excel file on a USB
memory stick. This powerful tool for data collection provides you with the ability to review, research and train
using Historical data. Record several patients or several days of a single patient onto one easy to use USB
memory stick.
A picture can be taken of the entire history screen. This can be stored on the hard drive or immediately
downloaded to a USB memory stick as a JPEG file.
13
Adjust timeline
viewing
Calibration
History
Event History
Scroll through
historical data
Download data
for LiDCOview
or Excel
Capture screens
as JPEG files
L i D C O ™
PulseCO Validation
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One study at the University of Texas evaluated the change/drift in calibration factor across a post operative
period of 8 hours in a group of 20 cardiac surgery patients 80.
The results of the study found:
• that the range of cardiac outputs was 3.33 to 8.47 litres per minute;
• that, once calibrated, the PulseCO tracked the cardiac output continuously through the post
surgery period without changes in calibration factor;
• that no significant differences were noted between the LiDCO, the thermodilution control and
the PulseCO reading.
A study in intensive care patients 94 has shown good correlation of LiDCO and PulseCO without recalibration over 24hrs.
Differences in CO measurements by technique (Liters/min).
0hours 2hours 4hours 6hours 8hours all times
TLdiff -0.1±0.1 0.0±0.1 0.1±0.1 0.0±0.2 -0.2±0.2 0.0±0.1
PLdiff 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0
PTdiff 0.1±0.1 0.0±0.1 0.0±0.1 0.0±0.2 0.2±0.2 0.0±0.1
I N T R A O P E R AT I V E P E R F O RMANC E
Conclusion:
‘This technique appears to offer a safe, reliable and less invasive alternative to the traditional PA catheter for
cardiac output monitoring in the immediate post-operative period after surgery.’
A number of studies have been completed in various centres in Europe and the USA demonstrating the
accuracy and precision of the PulseCO software (hosted within the LiDCOplus Hemodynamic Monitor)
when used in cardiothoracic surgery, major surgery and the ICU 2-6, 79, 80, 94.
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The results of the study found:
• that the range of cardiac outputs was 3.45 to 10.47 litres per minute;
• that there were acceptable bias and limits of agreement throughout the study with a correlation of r2 = 0.89;
• that 68% of catheters had an undesirable dynamic response but that this did not affect the agreement between
the measurements of cardiac output obtained by the PulseCO software and the Lithium dilution (p = 0.976)
P O S T O P E R AT I V E P E R F O RMANC E AND T H E E F F E C T O F D AM P I NG
A further study was undertaken at Duke University to examine the effects of arterial damping in a group
of 22 patients in a surgical intensive care unit 2. The study was designed to evaluate the change/drift in
calibration factor across a 24 hour period and in addition to examine whether the dynamic response
(damping) of the arterial pressure monitoring system has an effect on the accuracy of the PulseCO software.
PulseCO vs LiDCO Arterial Pressure Measurement Systems
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Dynamic response characteristics of the 21 arterial catheter/transducer systems at each
measurement interval, time = 0, 4, 8, 16, and 24 hours
Conclusion:
‘Technical limitations of arterial catheter monitoring systems, such as low natural frequency or under or over
damping, do not appear to influence the accuracy of the PulseCO measurement.’
‘The pulse contour algorithm appears accurate despite a wide variety of arterial pressure waveform contours
that are seen in clinical practice.’
‘Re-calibration of the PulseCO software is recommended every four hours, but we have extended the period
between calibrations to eight hours and demonstrated that the PulseCO software is still accurate after this time.’
1) A bolus of Lithium is
flushed through a
central or venous line
2) A Lithium sensitive sensor, attached to a
peripheral arterial line, detects the concentration
of Lithium ions in the arterial blood
3) The Lithium indicator dilution ‘wash-out’
curve on the LiDCOplus provides an
accurate absolute cardiac output value
4) This value is then used to calibrate the LiDCOplus
to give continuous cardiac output and derived
variables from arterial waveform analysis.
L i D C O ™
The LiDCOplus - Lithium Indicator Dilution
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The bolus indicator dilution method of measuring cardiac output was first described by Henriques and developed
by Hamilton et al in 1932 71. This became widely adopted - the original technique using indocyanine green (ICG)
as the marker. However, as this technique required frequent blood sampling and manual analysis of the dilution
curve, it proved to be technically difficult and time consuming. The use of Lithium as an indicator of cardiac output
was first described in 1993 72 and has since been extensively validated 73. Lithium like ICG, is a non-diffusible
indicator 92. The method of using bolus indicator dilution to measure volume was described by Stewart93 and the
method of ITBV calculation is simply ITBV=C0xMTt. MTt is the mean transit time of the lithium indicator from
injection to detection.
The LiDCOplus Monitor provides a lithium bolus indicator dilution method of measuring cardiac output. A small
dose of lithium chloride is injected via a central or peripheral venous line; the resulting arterial lithium concentration-
time curve is recorded by withdrawing blood past a lithium sensor.
T H E P R I NC I P L E
The LiDCOplus bolus lithium indicator dilution method is used to provide an accurate actual cardiac output
value for the patient. The lithium indicator dilution method is a very accurate and minimally invasive
indicator dilution cardiac output measurement method. This is used to calibrate the PulseCO arterial
waveform stroke volume value. It can also be used to calculate intra thoracic blood volume (ITBV).
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A D VAN TAG E S O F T H E L i D CO p l u s L I T H I UM
I N D I C ATO R D I L U T I ON M E T HOD
The advantages of the LiDCOplus method are that it is safe, accurate and simple to use:
• Safe - Central/peripheral venous and arterial catheters are usually already in place in patients needing
cardiac output measurements. No further catheter is needed, so the method avoids the risks associated
with pulmonary artery catheterisation. The method requires withdrawal of approximately 5 ml blood per
determination; for an adult this is an insignificant amount. The injectate is a solution of lithium chloride. The dose
needed (0.15 - 0.30 mmol for an average adult) is very small and has no known pharmacological effect 74.
The dosage regimen recommended is very conservative, making worst case assumptions on volume of
distribution of lithium, patient weight (assumes 40kg) and absence of renal function.
• Accurate - Clinical trials have been completed that demonstrate that the LiDCO System is at least as accurate
as thermodilution 11,12.
• Simple to use - The method is simple and quick to use. It has the advantage that there is no unpleasant
procedure for a conscious patient to undergo (such as insertion of a pulmonary artery catheter) and the time
taken to set up and apply is between 5 and 10 minutes 68.
T H E S EN SO R
The sensor consists of a lithium-selective
electrode in a flow-through cell. It is
disposable, sterilised by gamma irradiation
and foil packed. The sensor is connected
to a three-way tap on the arterial line and
a small peristaltic pump restricts the flow
through it to 4.5 ml/min. The flow-through
cell is made of polycarbonate and
designed with an eccentric inlet so that the
blood swirls past the tip of the electrode.
The lithium-selective electrode is made of polyurethane with a central lumen. Silver chloride paint coats the inside
and the outside. A wick, which is soaked in saline when the cell is first primed, makes the electrical connection
between the blood in the cell in the vicinity of the tip of the electrode and the remote reference. This arrangement
ensures adequate constancy of the voltage of the reference which is far enough from the blood to avoid a significant
temperature effect. The electrode is filled with a reference material which provides a constant ionic environment and
supports the membrane which is dip cast. The membrane is made of polyvinyl chloride and contains a lithium ionophore
to make it selectively permeable to lithium ions.
The LiDCO lithium- selective
electrode in a flow through cell.
Inlet
Wick
Membrane
Electrode
L i D C O ™
Indicator Dilution Screen
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G R E AT E R P R E C I S I ON T H AN A S I NG L E BO L U S T H E RMOD I L U T I ON
D E R I VA T I O N O F A B S O L U T E C A R D I A C O U T P U T VA L U E
The voltage across the sensor membrane is related via the Nernst equation to the plasma [Li+.] A correction is
applied for plasma sodium concentration because in the absence of lithium the baseline voltage is determined
by the sodium concentration. The voltage is measured using an amplifier optically isolated from the patient, then
digitised on-line and analysed by the LiDCOplus Monitor software.
Indicator dilution curves recorded in arterial blood consist of primary and secondary curves due to the initial
circulation and then re-circulation of the indicator. Cardiac output is calculated as:
Cardiac Output = (Lithium Dose x 60)/(Area x (1-PCV))
Where lithium dose is in mmol; Area is the integral of the primary curve (mM.s); PCV is packed cell volume which
may be calculated as hemoglobin concentration (g/dl) / 34: this correction is needed because lithium is distributed
in the plasma and not into the red or white cells on the first pass to the arterial circulation.
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L I T H I U M C H L O R I D E :
T H E FA C T S
Multiple dosages of Lithium have been
extensively investigated and the safety
profile is well established. The
pharmacokinetics of intravenous lithium
chloride in man (and animals) has been
documented 74, Lithium chloride has been
used extensively in medicine for
prophylactic and therapeutic treatment of
unipolar and bipolar manic-depressive
disorders 75, 76. The lithium chloride is
distributed throughout the total body water
and excreted almost entirely by the kidneys.
The half-life of lithium chloride in humans is
19.8 - 41.3 hrs 77, 78. The recommended
maximum total dose for a Lithium indicator
dilution would have to be exceeded many
times before toxic levels are reached. In fact,
a single lithium chloride LiDCO indicator
dilution determination at 0.3mmol is the
equivalent to a steady state plasma lithium
concentration of 1/240th of the therapeutic
level. Lithium has been used for the
measurement of cardiac output in thousands
of patients over many years without a single
side effect being reported.
(For warnings, contraindications and side-effect
please refer to LiDCO Ltd Lithium Chloride Data
Sheet and/or LiDCOplus manual)
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LiDCO = 0.97 thermodilution -0.14 l/min (r = 0.98)
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40 adult n = 200
6 Horse n = 70  
Figure 8. X-Y plot and Bland-Altman plot of 40 patients comparing LiDCO (average of 5
measurements) with bolus thermodilution (BTD) in 40 patients. X-Y plot: LiDCO = 0.31 + 0.89 BTD
(L/minute) r2 = 0.94. Bland-Altman plot: Mean differences BTD -LiDCO 0.25 L/minute, SD of the
difference was 0.46 L/minute.
Figure 9. Comparisons (n = 318) of LiDCO vs bolus thermodilution in adults, paediatrics and horses.
*The use of LiDCOplus is unlicensed in patients <40kg (88lb).
Validation comparing the LiDCO System with bolus pulmonary
artery catheter thermodilution technique (Figure 8)
demonstrated a good overall agreement between the two
methods (see Figure 8 r2= 0.94) 11. The conclusions were that
a single bolus of lithium was at least as accurate as meaned
triplicate bolus thermodilution. In another study where
thermodilution and lithium dilution were compared to an aortic
electromagnetic flow probe the LiDCO results showed less
variability and therefore the LiDCO System was found to have
a greater precision than single bolus thermodilution 12.
Larger animals (horses) and paediatric subjects have also been
studied to ensure that the lithium dilution technique remained
valid at extremes of flows (Figure 9). The body weight studied
ranged from as small as a 2kg baby* up to a 550kg horse 10 95.
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Performance of six types of oxygen delivery devices
at varying respiratory rates*
T. A. J. Wagstaff1 and N. Soni2
1 Clinical Research Fellow, 2 Director Intensive Care, Magill Department of Anaesthesia, Intensive Care and Pain
Management, Chelsea and Westminster Hospital, 369, Fulham Road, London SW10 9NH, UK
Summary
The administration of a known concentration of oxygen is an important part of routine care of
the sick patient. Many devices are currently available. The actual concentration of oxygen that
can be delivered by these devices can be affected by several factors, both from the patient as well as
the device itself. Measuring the FiO2 delivered to the lungs in vivo can be both difficult and
potentially uncomfortable for the subjects. We constructed a model using a resuscitation manikin,
a ventilator and a set of bellows to simulate ventilation. With this model we tested a series of
devices – variable performance, fixed performance and high flow – at two fixed tidal volumes.
The respiratory rate was increased and its effect on the oxygen concentration assessed. Variable
performance systems such as the Hudson mask deliver a significantly reduced oxygen concentration
at high respiratory rates. Fixed performance systems delivering 24–40% oxygen deliver appropriate
oxygen concentrations across the range of respiratory rates, whereas those delivering 60% show
a reduction in performance. High flow systems show no failure of performance at increased
respiratory rates.
.......................................................................................................
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Modern management of the sick patient involves the
administration of oxygen in supposedly known concen-
trations. There are a many delivery systems commercially
available whose performances are documented in the
literature [1–8]. This is usually reported as the actual
delivery from the system [3], the resultant inspired
concentration of oxygen [1, 2, 4–9], or the arterial
oxygenation achieved [9].
From a physics perspective, the actual concentration
of oxygen delivered is determined by the interaction
between the delivery system and the patient’s breathing
pattern [4]. In contrast, most of the in vivo measure-
ments that have been reported were carried out in
normal subjects breathing at rest or trained to vary
their tidal volumes [1–5, 7–18]. Several of these studies
do point out that there are multiple factors which may
compromise the performance of these devices and
result in an effective FiO2 that is less, or occasionally
more, than that expected [4,7]. The factors that
influence the concentration actually inspired by the
patient are summarised in Table 1.
Few studies have tried to evaluate delivery system
performance in the adverse circumstances in which the
systems are commonly used [19–21]. Practical difficulties
include the instantaneous and simultaneous measurement
of FiO2 and gas flow. This is compounded by the
problems of identifying and accessing a suitable sampling
site [8]. The predominant problem is the relationship of
the oxygen flow into the mask, the size of the reservoir
effect of the mask and the peak inspiratory flow rate, the
combination of which will determine air entrainment and
therefore oxygen dilution.
An alternative approach is to devise a model that could
mimic spontaneous breathing patterns and to collect the
mixed inspired gas from the model lungs. The mixed
inspired gas would, to a certain degree, represent the final
concentration of inspired oxygen. This could be des-
cribed as the ‘effective inspired oxygen concentration’
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(EIOC), as it represents the resultant oxygen concentra-
tion in the model over the inspiratory phase of ventila-
tion. This avoids many of the measurement problems of
the previous methods, but remains only a model. As the
oxygen delivery from these systems is largely determined
by the physics of the system, the model should lend itself
to providing useful information about the relative per-
formance of oxygen delivery systems.
The intention of this study was to devise such a model
and to use it to assess the effective inspired oxygen
delivery of several commonly used systems with changing
respiratory patterns.
Methods
The concept behind the model that was devised is that by
collecting the ‘exhaled ‘gas from the model, the mean
oxygen concentration that had arrived in the lung could
be measured easily. It is this mean concentration, derived
from the entirety of inspiration, that represents the actual
or effective oxygen delivery. This system is considerably
simpler than trying to measure simultaneously the oxygen
concentration and flow.
The model
An experimental rig was constructed as shown in Fig. 1. A
Laerdal Airway Management Trainer manikin (Laerdal,
Orpington, UK), was used to simulate the nasopharynx,
larynx and trachea. The manikin’s ‘bronchi’ were attached
via a Y-piece to a set of ‘slave’ bellows. These were driven
by a second set of ‘driving’ bellows by way of a connecting
rod. The driving bellows were connected to a Dra¨ger Evita
ventilator (Dra¨ger Medical, Hemel Hempstead, UK),
set to deliver a square wave. This would allow changes
in respiratory rate, tidal volume, inspired : expired (I : E)
ratio and maximum inspiratory flow rate. As the driving
bellows expand, a reciprocal negative pressure is produced
in the slave bellows. This acts as ‘inspiration’. Gas is thus
‘inhaled’ into the slave bellows. Expiration is passive byway
of a return spring. This spring conferred a more sinusoidal
profile to the square wave ventilation delivered by the
ventilator. Unidirectional valves block gas return to the
manikin and conduct expired gas via a T-piece to a 10-l
airtight canister to allow adequate mixing of ‘exhaled’ gas.
This mixed gas represents the mean inspired concentration
in the model and for the purpose of this study is called the
EIOC. This gas was then piped past a Datex-OhmedaTM
5120 oxygen analyser (GE Healthcare, Chalfont St. Giles,
UK), and the oxygen percentages recorded. All connecting
tubes were 22-mm Intersurgical Elephant Tubing (Inter-
surgical Ltd., Wokingham, UK).
Dräger 1st Bellows 2nd Bellows
A
V/T
Wright’s
respirometer 
B C
Figure 1 The experimental rig: The
two sets of bellows are demonstrated.
Diagram A. Positive pressure from the
Dra¨ger Evita ventilator ( ) inflates the
first set of bellows and via the connect-
ing rod, causes the second set of bellows
to open and draw in gas (solid arrows,
diagram B). The negative pressure
derived from the second set of bellows
draws gas from the manikin (dashed
arrows, diagram B). During the expira-
tory cycle of the ventilator the gas
within the second set of bellows is
expelled by a return spring (solid arrows,
diagram C) into a 10-l mixing chamber
and then out to the environment past a
Datex-Ohmeda 5120 Oxygen analyser
(dashed arrows, diagram C). Direction
of gas movement around the apparatus
was controlled by unidirectional flow
valves ( ).
Table 1 Factors that influence the FiO2 delivered to a patient by
oxygen delivery devices. (After Leigh [4]).
Patient factors Device factors
Inspiratory flow rate Oxygen flow rate
Presence of a respiratory pause Volume of mask
Vent resistance
Tightness of fit
Anaesthesia, 2007, 62, pages 492–503 T. A. J. Wagstaff and N. Soni Æ Oxygen delivery system performance.....................................................................................................................................................................................................................
 2007 The Authors
Journal compilation  2007 The Association of Anaesthetists of Great Britain and Ireland 493
Calibration
Control measurements were performed by intubating the
manikin with a 7.0-mm cuffed tracheal tube. Ventilating
at a tidal volume of 300 and 500 ml, with a respiratory
rate of 10 breaths.min)1, an I : E ratio of 1 : 2 and no
positive end-expiratory pressure (PEEP), the manikin
‘breathed’ firstly air and then 100% oxygen via a
Mapleson C system. The oxygen analyser was thus
calibrated to 21% and 100%, respectively. The time taken
to reach concentrations of 100% from 21% was assessed
and found to have a mean of 4 min 12.3 s and 3 min 5.8 s
for 300 and 500 ml, respectively. Tidal volume measures
were achieved using a Wright’s respirometer inserted in
the expiratory limb of the slave system. Its reflection of
inspiratory volume was assessed by attaching a second
respirometer to the end of the tracheal tube. There was
concordance between the two at tidal volumes of 100,
250, 500, 750 and 1000 ml at respiratory rates of 10, 20
and 30 breaths.min)1.
Devices
The devices selected for study are those commonly used
for oxygen delivery in our institution (Table 2).
The Vapotherm system (Vapotherm Inc., Stevens-
ville, MD) is a new method of delivering oxygen by nasal
cannulae. It consists of a high flow air ⁄ oxygen mixer
(0–50 l.min)1). It requires connection to oxygen and air
supplies by way of Schra¨eder valves. The gas mix is
humidified and warmed as it passes through the device
and its warmth is maintained by a warm water jacket
surrounding the piping that delivers the gases to the
patient. Data provided by Vapotherm Inc. suggest that the
high flow nasal delivery system is better tolerated than
conventional nasal cannulae (usually to a maximum flow
of 8 l.min)1) because of the warming and humidification
of the gas mix.
The Thermovent T2 HME (Smiths Medical, Hythe,
UK) is designed for use with a tracheostomy. To examine
this device, the manikin was intubated orally, as we were
not permitted to perform a tracheostomy on the manikin.
Assessment
A standard regimen was executed for each of the above
devices. The first sets of measurements were performed at a
measured tidal volume that was fixed at 500 ml. The I : E
ratio remained constant at 1 : 2. The value of the
inspiratory flow rate delivered by the ventilator was set at
the minimum required to generate the appropriate tidal
volume at each respiratory rate while maintaining the I : E
ratio at 1 : 2. For each change in respiratory rate, the
manikin was ventilated for 5 min to ensure that equilib-
rium had been reached at the oxygen analyser. On
completion of each cycle, a further period of 5 min
‘washout’ on air was performed before the next alteration
in respiratory rate. The maximum oxygen concentrations
were recorded for the devices at 10, 15, 20 and 30
breaths.min)1. The variable performance devices were
tested at oxygen flow rates of 2, 4, 6, 8, 10 and 15 l.min)1 as
delivered by an AHE ball flow meter. The fixed perform-
ance devices were assessed using the oxygen flow rates for
the appropriate inserts, as recommended by the manufac-
turer. The high flow system, the Vapotherm, was analysed
at two fresh gas flow rates (15 and 30 l.min)1) and four
oxygen concentrations (30, 60, 80 and 100%).
The measurements were then repeated in the same
manner, but with a measured tidal volume fixed at
300 ml. Each assessment was repeated three times to
ensure reproducibility. Ventilator adjustments, application
of the oxygen system to the mannequin, and measure-
ments were done by the same investigator, and repeated
on different days using the same equipment.
Results
Variable performance systems
The variable performance systems that were analysed
were the Hudson mask with and without the non-
rebreathing reservoir bag attachment, nasal cannulae, and
the Thermovent HME.
Hudson mask
The Hudson mask showed evidence of deterioration of
performance as the respiratory rate increased both at tidal
volumes of 300 ml and 500 ml. At a respiratory rate of
10 breaths.min)1, the mask delivered a mean EIOC of
94.67% and 88.33% at 15 l.min)1 oxygen flow rate for
tidal volumes of 300 and 500 ml, respectively. This was
reduced to a mean of 75.67% and 63.33% when the
respiratory rate was raised to 30 breaths.min)1. The
reduction in performance was greater at 500 ml tidal
volume (38.30%) than at 300 ml (20.07%) (Fig. 2).
Table 2 Devices selected for study (manufacturer).
Variable performance devices Fixed performance devices
Nasal Cannula (Teleflex Medical) Fixed Performance mask
with Venturi inserts
(Intersurgical)
Variable Performance Hudson-type mask
(Teleflex Medical)
Variable Performance mask with reservoir
bag and safety vent (Teleflex Medical)
Vapotherm
Thermovent T2 HME (Smiths Medical)
Teleflex Medical, High Wycombe, UK. Smiths Medical, Hythe, UK.
Intersurgical Ltd, Wokingham, UK.
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Hudson non-rebreathing mask
The addition of a reservoir bag and flap valves over the
orifices does not improve the performance of the Hudson
mask. The mean EIOC delivered by the non-rebreathing
system at 15 l.min)1 oxygen flow rate and 10 breaths.min)1
respiratory rate was 85.67% and 79.33% for 300 ml and
500 ml tidal volume, respectively. In fact, for all oxygen
flow rates, the non-rebreathing system failed to perform as
well as the standardHudsonmask, across all respiratory rates
and at both tidal volumes. It also showed deterioration in
performance as the respiratory rate increased. For example,
at an oxygen flow rate of 15 l min)1, the mean EIOC fell
from 85.67% to 68.33% (20.2%) and 79.33% to 59.67%
(24.78%) at 300 ml and 500 ml tidal volume, respectively
(Fig. 3).
Nasal cannulae
Of interest, the nasal cannulae achieved the highest EIOC
of all the variable performance systems. This was main-
tained across all oxygen flow rates and both tidal vol-
umes. In particular, at 15 l.min)1, a respiratory rate of
10 breaths.min)1 and a tidal volume of 300 ml, the mean
EIOC was 97.33%, approaching the holy grail of 100%
in a self-ventilating patient. However, the cannulae also
demonstrated deterioration in performance as the respir-
atory rate increased at both tidal volumes. At an oxygen
flow rate of 6 l.min)1, oxygen concentrations fell from
87.67% to 69.33% (20.92%) and from 81.33% to 54.67%
(14.75%) at 300 ml and 500 ml, respectively (Fig. 4).
Thermovent H2 HME
As with the above oxygen delivery systems, the Thermo-
vent system in the intubated manikin showed deterioration
in performance at higher respiratory rates. Unlike the
previous systems, at lower oxygen flow rates the perform-
ance was more consistent (2 l.min)1 oxygen flow
rate, Vt 500 ml: 10 breaths.min
)1 oxygen ¼ 31.67%,
30 breaths.min)1; oxygen ¼ 25.67%), and also the change
in tidal volume had less of an influence on the EIOC
(at 4 l min)1 oxygen flow rate and 30 breaths.min)1: with
Vt 300 ml, oxygen ¼ 32%; Vt 500 ml oxygen ¼ 31.33%)
(Fig. 5).
Fixed performance system
The fixed performance system that was tested was the
Venturi mask and inserts supplied by Intersurgical.
Venturi system
The Venturi system showed consistent performance at the
lower oxygen concentration inserts at both tidal volumes
examined. The mean EIOC measured was close to that
expected by the insert. For example, at 30 breaths.min)1
with a tidal volume of 500 ml, the 24% and 28% inserts
delivered a mean EIOC of 23.67% and 26%, respectively.
There was, however, some reduction in the EIOC at
the higher oxygen concentration inserts, particularly at
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Figure 2 Effective inspired oxygen concentration (EIOC) achi-
eved by a Hudson mask at four oxygen flow rates: 2 l.min)1 (u),
6 l.min)1 (e), 10 l.min)1 (n) and 15 l.min)1 (s), across a range
of respiratory rates at tidal volumes of 300 ml (A) and 500 ml (B).
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500 ml tidal volume. (Vt 300 ml, 60% insert, 10 breaths.
min)1 oxygen¼ 59.67%; 30 breaths.min)1 oxygen¼
53.33%. Vt 500 ml, 60% insert, 10 breaths.min
)1 oxygen ¼
57.33%, 30 breaths.min)1 oxygen ¼ 50.33%) (Fig. 6).
High flow, high concentration system
The high flow, high concentration system that was tested
was the Vapotherm system.
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Figure 3 Effective inspired oxygen concentration (EIOC) achi-
eved by a Hudson non-rebreathing mask at four oxygen flow
rates: 2 l.min)1 (u), 6 l.min)1 (e), 10 l.min)1 (n) and
15 l.min)1 (s), across a range of respiratory rates at tidal volumes
of 300 ml (A) and 500 ml (B).
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Figure 4 Effective inspired oxygen concentration (EIOC) achi-
eved by nasal cannulae at four oxygen flow rates: 2 l.min)1 (u),
6 l.min)1 (e), 10 l.min)1 (n) and 15 l.min)1 (s), across a
range of respiratory rates at tidal volumes of 300 ml (A) and
500 ml (B).
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Vapotherm
The Vapotherm system was additionally analysed at two
gas flow rates, 15 and 30 l.min)1. The oxygen conc-
entration was selected on the dial on the system. In terms
of consistent performance, this system showed very little
reduction in EIOC as the respiratory rate changed. At
tidal volumes of 300 ml, there was no change in EIOC at
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Figure 5 Effective inspired oxygen concentration (EIOC) achi-
eved by a Thermovent T2 HME at four oxygen flow rates:
2 l.min)1 (u), 6 l.min)1 (e), 10 l.min)1 (n) and 15 l.min)1 (s),
across a range of respiratory rates at tidal volumes of 300 ml (A)
and 500 ml (B).
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Figure 6 Effective inspired oxygen concentration (EIOC) achi-
eved by a each Venturi Mask insert: 24% (·), 28% (u), 35% (e),
40% (n) and 60% (s), across a range of respiratory rates at tidal
volumes of 300 ml (A) and 500 ml (B).
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all oxygen concentrations as the respiratory rate increased.
Doubling of the gas flow rate also had little influence on
the EIOC. With the tidal volume set at 500 ml, however,
there was a slight reduction in EIOC at 15 l.min)1 gas
flow (FiO2 100%, 10 breaths.min
)1 71.67, 30 breaths.
min)1 oxygen ¼ 67.67%). This, however, was abolished
when the gas flow rate was increased to 30 l.min)1. Of
greatest interest was that in this model the Vapotherm is
not able to deliver the dialled FiO2. For example, at both
300 ml and 500 ml tidal volume, the maximum EIOC
achieved for ‘100%’ FiO2 was 78.67% and 76.67%,
respectively. Increasing the gas flow rate did improve
delivery, particularly in the 500 ml assessment, but only
by a maximum of 7% (30 breaths.min)1 100% FiO2 Vt
500 ml) (Fig. 7).
Discussion
The model clearly demonstrates a reduction in the
effective inspired oxygen concentration (the mixed
oxygen concentration from the entire inspiratory phase)
with the variable performance masks as the respiratory
rate increases while at a fixed tidal volume. This varied
between delivery systems. With nasal cannulae and an
oxygen flow rate of 4 l.min)1, EIOC falls from 69.67%
to 48% when the respiratory rate increases from 10 to
30 breaths.min)1 and the tidal volume is 500 ml.
With the fixed performance systems, the impact of
altered ventilation is substantially diminished. The 24%
Venturi mask shows no reduction in performance,
whereas the 60% mask deteriorates from 57.33% oxygen
at 10 breaths per minute and a tidal volume of 500 ml, to
50.33% oxygen at 30 breaths per minute.
The Vapotherm, which is a high flow rate system, shows
minimal change across the range of respiratory rates.
Interestingly, changing the gas flow rate from 15 to
30 l.min)1 has only a minimal effect on EIOC and neither
produces the value that is selected on the oxygen : air mix
dial, particularly at the higher FiO2. The system is known to
achieve 99% humidity and this would compromise the
EIOC; however, this could only account for a drop of
approximately 5% with fully saturated air.
Table 3 summarises the manufacturers’ recommenda-
tions for oxygen flow rates for their variable performance
devices tested, and the resultant oxygen concentration to
be expected. The studies we have performed indicate that
with many of the currently used oxygen delivery systems
this predicted performance is unpredictable. To com-
pound the potential problem, the delivery deteriorates
with the increased rate of breathing, and presumably
increasing peak inspiratory flow rate (PIFR), which
is characteristic of sick patients. The actual FiO2 that is
inspired by the patient and reaches the distal airways is
difficult to predict for several reasons (see Table 1). The
entrainment of environmental air will be influenced by
the relationship between oxygen gas flow through the
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Figure 7 Effective inspired oxygen concentration (EIOC) achi-
eved by the Vapotherm for four different oxygen concentrations
at 30 l.min)1 gas flow: 30% (u), 60% (e), 80% (n) and 100% (s)
across a range of respiratory rates at tidal volumes of 300 ml (A)
and 500 ml (B).
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system, the inspiratory pattern of the patient and to some
degree the dead space of the mask and pharynx. The
single most important factor is probably the relationship
between the tidal volume and the PIFR, and at what
point this exceeds the available volume of undiluted
oxygen within the mask and pharynx. In sick patients, the
respiratory pattern is often altered and tends towards
relatively lower tidal volumes at an increased respiratory
rate and hence a high PIFR. Respiratory rates in excess
of 30 breaths.min)1 are not uncommon and may be
associated with PIFRs of greater than 30 l.min)1 and loss
or diminution of the respiratory pause. This will increase
entrainment of environmental air which, combined with
rebreathing of dead space gases, will dilute the inspired
oxygen concentration.
Attempts to measure this in the past have focused upon
trying to measure instantaneously FiO2 and gas flow. This
has been hampered by the sampling site, flow and oxygen
concentration measurement, and aligning these electron-
ically. Sampling in patients needs to be as far down the
airway as possible, which again poses a difficulty. The
accuracy of the pneumotachograph is problematic and
its presence will invariably alter the mechanics of the
delivery system itself. Rapid, real time oxygen concen-
tration analysis has been difficult, and even now, when
available, would have to synchronise with flow measure-
ment to provide the amount of oxygen delivered.
An alternative approach is this model that mimics
spontaneous breathing patterns. It may produce a more
realistic indication of how these delivery systems function
in adverse circumstances. This contrasts with most
previous models which have evaluated the concentration
of the oxygen flowing through the delivery system
without looking at the interplay between delivery and
respiratory pattern [3].
There are problems with the model. Firstly, there is the
absence of the contribution that carbon dioxide and water
vapour (with the exception of the Vapotherm) make to the
concentration of oxygen in the exhaled gas. The rebreath-
ing of any exhaled gas is prevented by the effects of the
unidirectional valves passing ‘inhaled’ gas to the oxygen
analyser. The contribution of the dead space gases to FiO2
can, however, be estimated by making assumptions about
the proportion that dead space contributes to tidal volume,
oxygen uptake and carbon dioxide production. A relatively
simple formula can be derived to predict further reduction
in the measured EIOC values caused by the presence of
dead space gases (see Appendix). These are, however, only
estimates and can not accurately predict FiO2 based on this
model’s data because of the complexity of pulmonary
physiology. The variation in anatomical and physiological
dead space and changes in oxygen consumption and carbon
dioxide production, particularly in acute illness, make the
derived values in the Appendix only approximations.
Secondly, the action of the valves also prevents ongoing
entrainment of delivered oxygen during the end of the
expiratory phase and respiratory pause. If the results are to
be extrapolated to the clinical setting, the limitations
noted above would be more likely to cause the device to
perform even less well than we have demonstrated, owing
to the presence of gases and vapours other than oxygen
and air and the rebreathing of a proportion of dead space
derived from both the device and upper airway.
In only one of the delivery systems did the model
produce an unexpected result. When the nasal cannulae
were used, the effective inspired oxygen was higher than
with the Hudson mask, which was not an intuitively
sound result. In the model, the oxygen is delivered into
the nose of the manikin, and even though the mouth was
open, it is possible that it effectively produces a pharynx
full of oxygen resulting in a high inspired oxygen value.
It is impossible to say if this represents the clinical
situation.
Conclusion
Using this model, an indication of the performance of
different oxygen delivery systems has been achieved. The
variable performance systems, including those with a
rebreathing bag, appear to function poorly under adverse
conditions. The fixed performance systems are predict-
ably better, but only up to 60% oxygen, which may be
inadequate. The high flow systems perform well across
the circumstances tested. Anxieties about comfort and
airway drying may be misplaced [22]. This model could
Table 3 Manufacturers’ recommendations for oxygen flow rates
and resultant oxygen concentrations for the variable perform-
ance device (Teleflex Medical. Hudson RCI Therapy Products.
Personal communication 2006). The fixed performance devices
Venturi and Vapotherm have been omitted as their correct use
implies a resultant oxygen concentration.
Oxygen delivery device
Oxygen flow
rate; l.min)1
Resultant oxygen
concentration; %
Nasal cannulae
(Teleflex Medica)
1 24
2 28
3 32
4 36
5 40
6 44
Hudson mask
(Teleflex Medical)
5–6 40
7–8 50
9–10 60
Hudson Nonrebreather
(Teleflex Medical)
10–12* 80–100
*May require higher flows. The flow should be adjusted so that the
reservoir bag does not deflate more than one third during inspiration.
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be used to produce realistic tables of oxygen delivery
system performance.
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Appendix: Mathematical derivation
of the possible contribution of dead space
gases to the EIOC
This is a mechanical model and as such permits the
application of simple physical principles to allow the
estimation of the possible further detrimental effect that
the inclusion of dead space gases and vapours might have
on the EIOC obtained from measurement. For this
mathematical formula, we have selected the Hudson mask
as the example, although the calculations could be used
with data from any of the oxygen delivery systems tested.
A. Derivation of formula for EIOC corrected
(EIOCcorr)
Tidal volume (Vt) in an average 70 kg male: 500 ml [23]
Dead space; both anatomical and physiological (VD): 30%
of Vt [23].
Oxygen consumption: 250 ml.min)1 [23]
Respiratory quotient (R): 0.8 [23]
The data that we have derived from the model requires
correction factors for the effect of dead space to be added in.
Carbon dioxide
For each breath, at the end of expiration we can assume
that VD contains gas from the alveolus (VA). The oxygen
concentration of VA at end expiration (VA[O2]) is the
original oxygen concentration at end inspiration (Vi[O2])
minus the proportion of oxygen consumed and is reflec-
ted in the value of EtO2. If R is assumed to be 0.8,
then it can be assumed that the 80% of the difference
between Vi[O2] and VD[O2] is made up of carbon
dioxide. Resting oxygen consumption is approxima-
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tely 250 ml.min)1, thus carbon dioxide production is
0.8 · 250 ¼ 200 ml.min)1.
At a respiratory rate of 10 breaths.min)1, the contri-
bution of carbon dioxide per breath would be 200 ‚
10 ¼ 20 ml.
This carbon dioxide would be distributed in a VA of
VA ¼ Vt – VD (¼ 500 – 150 ¼ 350).
The carbon dioxide would contribute (20 ‚ 350) ·
100 ¼ 5.7% of the value of VD gas at end-expiration.
The value contribution of carbon dioxide at a respir-
atory rate of 30 would have a value of approximately 2%
assuming a constant oxygen consumption, Respiratory
quotient, Vt and VD : VA ratio. These assumptions may
not be applicable in pathology that results in such a high
respiratory rate.
Water vapour
Fully saturated air contains water vapour at a partial
pressure of 47 mmHg [23]. If atmospheric pressure is
assumed to be 760 mmHg, then water vapour will con-
tribute (47 ‚ 760) · 100 ¼ 6.18%.
So this could be added as a correction factor to the
EIOC as the model results for the non-humidified
systems (all except the Vapotherm).
If it is assumed that both inhaled and exhaled gases are
fully saturated and that the water vapour is distributed
evenly through all gases, then the correction required
for the oxygen concentrations as a percentage is ¼
0.0618 · EIOC. For example, for an EIOC of 40% we
must subtract ¼ 0.0618 · 40 (¼ 2.47%).
The additional contribution of carbon dioxide of
between approximately 2% and 5.7% would mean
between approximately 8% and 13% of the VD would
contain water vapour and carbon dioxide.
Dead space
If we assume that VD contributes 30% to the value of Vt,
and that the EtO2 reflects the concentration of oxygen in
the dead space, then it can be said that the contribution of
this gas to Vi[O2] is: ¼ 0.3 · EtO2, i.e. 30% of the gas
inhaled has an oxygen concentration of the EtO2.
This is added to the concentration of oxygen deliv-
ered by the oxygen system in the rest of Vt (70%): 0.7 ·
EIOC ¼ (0.3 · EtO2) + (0.7 · EIOC).
Now add in the contribution of water vapour for a
final formula that approximates the FiO2 for VD of 30%:
EIOCcorr ¼ [(0.3 · EtO2) + (0.7 · EIOC)] – (0.0618 ·
EIOC).
Example
From the data for a Hudson Mask:
Vt: 500 ml
Respiratory rate: 10 breaths.min)1
Oxygen flow rate: 2 l.min)1
Assuming the EtO2 is 30% and a VD of 30%, EIOCcorr ¼
[(0.3 · 30) + (0.7 · 42)] – (0.0618 · 42) ¼ 35.80%.
The estimation of the EtO2 and proportions of VD and
VA, make this method only an approximation of the
contribution of dead space to the EIOC derived from the
model, but it does allow the plotting of families of curves
for both increasing VD at the same tidal volume, as well as
variation in the EtO2 (see below).
B. Example 1: Hudson mask Vt 500 ml. Effect of
varying the proportion of Vt that is VD
Table A1 shows the EIOC measured for the Hudson
mask across the range of respiratory rates when the Vt was
set at 500 ml. We can calculate the EIOCcorr for a
VD : VA ratio of 30 : 70 by putting the values of EIOC
into the formula and assume that the EtO2 remains fixed
at 30%: EIOCcorr ¼ [(0.3 · EtO2) + (0.7 · EIOC)] –
(0.0618 · EIOC).
This results in Table A2.
There is increasing reduction in EIOCcorr as the
oxygen flow rate and respiratory rate increases. This is,
in part, due to the assumption that the EtO2 is fixed at
30% and therefore has a greater influence on the EIOCcorr
at higher EIOCs. Estimation of EtO2 is difficult in vivo
as it is dependent on oxygen uptake, which can vary
significantly, particularly in respiratory pathology.
Table A2 EIOCcorr for a Hudson mask at 500 ml assuming an
EtO2 of 0.3 and a VD : VA ratio of 30 : 70.
Oxygen flow
rate; l.min)1
Respiratory rate; breaths.min)1
10 15 20 30
2 35.80 31.34 30.06 28.15
4 46.87 41.34 37.51 34.74
6 50.70 45.16 41.12 37.51
8 56.44 50.48 46.02 41.76
10 61.33 54.52 49.63 44.53
15 65.37 59.84 55.38 49.42
Table A1 Effective inspired oxygen concentration (EIOC) val-
ues for a Hudson mask at a tidal volume of 500 ml.
Oxygen flow
rate; l.min)1
Respiratory rate; breaths.min)1
10 15 20 30
2 42.00 35.00 33.00 30.00
4 59.33 50.67 44.67 40.33
6 65.33 56.67 50.33 44.67
8 74.33 65.00 58.00 51.33
10 82.00 71.33 63.67 55.67
15 88.33 79.67 72.67 63.33
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If we consider only the EIOCcorr for the Hudson mask
at Vt 500 ml and oxygen flow rate of 4 l.min
)1, we can
use the derived formula to approximate the effect of
altering the ratio of VD and VA assuming that EtO2 is
maintained at 30%. This is summarised in Table A3 and
shown graphically in Fig. A1.
The results of the calculations confirm that introduc-
tion of a correction factor further reduces the EIOC that
the mask delivers. Also, increasing the contribution of the
dead space gases and vapours by increasing the proportion
of Vt that is VD reduces the EIOC still further. This
simplistic view of mixing of gases in the model relies
on significant assumptions and the values derived for
EIOCcorr can only be viewed as a guide for the real mask
performance in vivo.
C. Example 2: Hudson mask Vt 500 ml.
Effect of varying the value of EtO2
The derived formula for calculating EIOCcorr to allow for
the effect of dead space gases and vapours relies on an
approximation of EtO2 as a reflection of oxygen con-
sumption and carbon dioxide production. The value of
EtO2 is predominantly dependent upon the FiO2 and
oxygen consumption. Oxygen consumption can vary
widely in pathology and so for the purpose of this
example we present calculations based on a spectrum of
Table A4 Hudson mask at 500 ml delivering 4 l.min)1 oxygen
flow rate. Effect of varying the EtO2 on the EIOCcorr if the
VD : VA ratio is constant at 30 : 70.
EtO2; %
Respiratory rate; breaths.min)1
10 20 30 40
No correction 59.33 50.67 44.67 40.33
15 42.37 36.84 33.01 30.24
20 43.87 38.34 34.51 31.74
25 45.37 39.84 36.01 33.24
30 46.87 41.34 37.51 34.74
35 48.37 42.84 39.01 36.24
40 49.87 44.34 40.51 37.74
Table A3 The Hudson mask with oxygen flow rate of
4 l.min)1 and a Vt of 500 ml. The effect on EIOCcorr of altering
the VD : VA ratio assuming a constant EtO2 of 30%.
VD : VA ratio
Respiratory rate; breaths.min)1
10 15 20 30
No correction 59.33 50.67 44.67 40.33
20 : 80 49.80 43.40 38.97 35.77
30 : 70 46.87 41.34 37.51 34.74
40 : 60 43.93 39.27 36.04 33.71
50 : 50 41.00 37.20 34.57 32.67
60 : 40 38.07 35.14 33.11 31.64
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Figure A1 The effect of varying the VD : VA ratio on the
EIOCcorr for a Hudson mask delivering oxygen at 4 l.min
)1 to a
Vt of 500 ml with an assumed EtO2 of 30%. 60 : 40 (·), 50 : 50
(u), 40 : 60 (e), 30 : 70 (n), 20 : 80 (s) and no correction (d).
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Figure A2 The effect of varying the EtO2 on the EIOCcorr for a
Hudson mask delivering oxygen at 4 l.min)1 to a Vt of 500 ml
with an fixed VD : VA ratio of 30 : 70. 0.15 (+), 0.2 (·), 0.25
(u), 0.3 (e), 0.35 (n), 0.4 (s) and no correction (d).
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possible EtO2 values. This represents the best and worse
case scenarios depending upon the value of EtO2 as a
representation of oxygen consumption, and its contribu-
tion to the concentration of oxygen in the dead space
gases.
Using the Hudson mask again at 500 ml and 4 l.min)1
oxygen flow rate, the EIOCcorr values obtained with the
EtO2 varying between 40% and 15% are represented in
Table A4 and Fig. A2.
Table A4 and Fig. A2 also confirm that assuming a
lower oxygen concentration in the expired gas will
produce a further reduction in delivery by the oxygen
systems, and that the greater the difference between the
oxygen concentration delivered and the EtO2, the lower
the corrected EIOC. Once again, we caution that the
above calculations only represent true values in vivo, as
their derivation depends upon assumptions about EtO2
and VA : VD ratio, both of which are potentially
extremely variable in the patient population. However,
the above tables and figures do demonstrate the possible
effects of the dead space on the delivery of oxygen to
the alveoli and how that would further undermine the
performance of the mask in reality as opposed to this
bench model.
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